AUNA 0001193125-25-114989 20-F/A as filed: May 7, 2025

20-F/A

true0001799207FYIt is dedicated to the production and commercialization of radiopharmaceuticals used for diagnostic images of PET (positron emission tomography) and scintigraphy and its fiscal address is Calle 30 N 46 - 25 Medellín – Colombia.It is dedicated to the production of radiopharmaceuticals used for diagnostic images of PET (positron emission tomography).It is dedicated to providing medical diagnostic imaging services and cancer treatment, using PET / CT molecular imaging technology.In 2024, the net exchange difference includes an effect for S/ 9,249 thousand (S/ 32,100 thousand and S/ 53,400 thousand in 2023 and 2022, respectively) for the cash flow hedges reclassified from OCI (note 8.A).For years 2024, 2023 and 2022, this includes S/ 256 thousand, S/ 339 thousand and S/ 304 thousand related to government grants of interest expenses (note 3.O), respectively.The movement of contingent consideration is the following:For years 2024, 2023 and 2022, this includes mainly cost of factoring for S/ 19,132 thousand, S/ 14,465 thousand and S/ 5,191 thousand, respectively.Mainly dedicated to providing oncologic healthcare services.Mainly dedicated to providing services through health centers (inpatients and outpatients).Mainly dedicated to providing the Group with internal administrative, commercial, real estate and management services. Outstanding claims reserve represent the Group’s outstanding third-party obligations and do not include amounts related to the Group’s customers that are part of the insurance premium program.In June 2023, the Group adjusted the purchase price of the acquisition of Hospital y Clínica OCA performed in October 2022 in accordance with the acquisition Share Purchase Agreement for S/ 8,193 thousand.Non-current assets exclude deferred tax assets and derivatives.Corresponds to the administration, parking and valet parking services provided by the clinics. Income for parking is recognized once the service has been rendered.Mainly corresponds to recoveries of receivables that were expected as uncollectable at the acquisition date of Oncomedica S.A.This caption includes S/ 46,613 thousand for the derecognition of a portion of other account payables to former shareholders of Hospital y Clínica OCA, S.A. de C.V. (OCA). These other account payable corresponds to the Holdback at the acquisition of OCA to compensate to Group for any subsequent indemnification (note 17).Mainly corresponds to income from food services (cafeteria), income from teaching services and other miscellaneous income of the Mexican Component.Holdings of the Group. Auna Colombia is a holding located in the Republic of Colombia and Grupo Salud Auna México, S.A. de C.V. is a holding located in the Republic of Mexico.They do not include taxes payable, prepayments and labor liabilities.As of December 31, 2024, 2023 and 2022, it includes the tax credit (net) of value added tax (VAT).As of December 31, 2022, it includes the payment as an advance for the acquisition of shares of the OCA Hospital through Auna Mexico, which was agreed with the former shareholder as a deposit representing the amount of S/ 11,592 thousand and decreased on this balance by S/ 219 thousand as a lower exchange difference. In January 2023, this amount was recovered in cash.It corresponds to the deposit of S/ 95,201 thousand (COP 100,000 million) in a trust fund to guarantee the payment of the contingent consideration in accordance with the acquisition of shares of the Oncomedica S.A. (note 1.C.iii). In June 2023, this amount was recovered in cash. It corresponds to insurance paid in advance, annual licenses of software and the incremental cost of obtaining a contract with a supplier for selling oncological healthcare plans.It corresponds to payments in advance of income tax, which will be offset with future income tax in the next fiscal year. It includes a receivable for salaries of employees on leave that is to be refunded by the government for S/ 793 thousand for December 31, 2024 (S/ 1,199 thousand and S/ 1,124 thousand for December 31, 2023 and 2022, respectively). As of December 31, 2024, 2023 and 2022, it corresponds to account receivables from former shareholders for tax and labor liabilities contingencies that were determined in the acquisition of Patología Oncológica for S/ 209 thousand. As of December 31, 2024, 2023 and 2022, it includes the account receivables from former shareholders for medical liabilities contingencies that were determined in the acquisition of PMLA. In 2024, the amount of account receivables from former shareholders is S/ 549 thousand. (S/ 940 thousand and S/ 726 thousand for December 31, 2023 and 2022, respectively). It corresponds to funds under restriction in financial institutions mainly for the compliance with debts and guarantees for real estate rentals. It includes accounts receivable from Consorcio Trecca for S/ 16,033 thousand for December 31, 2024 (S/ 12,395 thousand and S/ 11,301 thousand for December 31, 2023 and 2022, respectively) which corresponds to preoperative activities defined in the concession arrangement, that represents a contractual right to receive cash and the accounts receivable is accumulated when the preoperative activities are incurred. They do not include taxes receivable and prepayments. 0001799207 2024-01-01 2024-12-31 0001799207 2024-12-31 0001799207 2023-12-31 0001799207 2022-12-31 0001799207 2023-01-01 2023-12-31 0001799207 2022-01-01 2022-12-31 0001799207 2024-09-30 0001799207 2024-09-30 2024-09-30 0001799207 2024-03-04 0001799207 2023-07-06 0001799207 2022-04-25 0001799207 2024-03-21 0001799207 2024-03-21 2024-03-21 0001799207 2023-06-01 2023-06-30 0001799207 2024-12-18 2024-12-18 0001799207 2024-03-19 0001799207 2024-04-25 0001799207 2020-11-20 0001799207 2020-11-20 2020-11-20 0001799207 2025-03-31 0001799207 2025-06-30 0001799207 2021-12-31 0001799207 dei:BusinessContactMember 2024-01-01 2024-12-31 0001799207 auna:AtwellSarlMember 2024-01-01 2024-12-31 0001799207 ifrs-full:RestrictedShareUnitsMember auna:Award2024GrantToDirectorsOnJanuary12024Member 2024-01-01 2024-12-31 0001799207 ifrs-full:RestrictedShareUnitsMember auna:Award2023GrantToDirectorsOnDecember82023Member 2024-01-01 2024-12-31 0001799207 ifrs-full:RestrictedShareUnitsMember 2024-01-01 2024-12-31 0001799207 auna:OptionAndRestrictedStockUnitPlansMember 2024-01-01 2024-12-31 0001799207 auna:PerformanceBasedOptionAgreementOnMarchTwentyFirstTwoThousandAndTwentyFourMember 2024-01-01 2024-12-31 0001799207 auna:LongTermIncentiveManagementOnMarchTwentyFirstTwoThousandAndTwentyFourMember 2024-01-01 2024-12-31 0001799207 auna:RestrictedStockUnitOnMarchTwentyFirstTwoThousandAndTwentyFourMember 2024-01-01 2024-12-31 0001799207 auna:CiclotronColombiaSasMember 2024-01-01 2024-12-31 0001799207 auna:CiclotrnPeruSaMember 2024-01-01 2024-12-31 0001799207 auna:PetCtPeruSaMember 2024-01-01 2024-12-31 0001799207 ifrs-full:RestrictedShareUnitsMember auna:MarketValueMember 2024-01-01 2024-12-31 0001799207 auna:PerformanceBasedOptionAgreementMember auna:BinomialMember 2024-01-01 2024-12-31 0001799207 auna:LongTermIncentiveManagementMember auna:BlackScholesMember 2024-01-01 2024-12-31 0001799207 ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember 2024-01-01 2024-12-31 0001799207 ifrs-full:ReserveOfCashFlowHedgesMember 2024-01-01 2024-12-31 0001799207 auna:HedgingReserveMember 2024-01-01 2024-12-31 0001799207 ifrs-full:MergerReserveMember 2024-01-01 2024-12-31 0001799207 ifrs-full:RetainedEarningsMember 2024-01-01 2024-12-31 0001799207 ifrs-full:EquityAttributableToOwnersOfParentMember 2024-01-01 2024-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember 2024-01-01 2024-12-31 0001799207 ifrs-full:IssuedCapitalMember 2024-01-01 2024-12-31 0001799207 ifrs-full:SharePremiumMember 2024-01-01 2024-12-31 0001799207 ifrs-full:MiscellaneousOtherReservesMember 2024-01-01 2024-12-31 0001799207 ifrs-full:ReserveOfSharebasedPaymentsMember 2024-01-01 2024-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember 2024-01-01 2024-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:BuildingsMember 2024-01-01 2024-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember auna:MedicalEquipmentMember 2024-01-01 2024-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:VehiclesMember 2024-01-01 2024-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:FixturesAndFittingsMember 2024-01-01 2024-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:BuildingsMember 2024-01-01 2024-12-31 0001799207 ifrs-full:GrossCarryingAmountMember auna:MedicalEquipmentMember 2024-01-01 2024-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:VehiclesMember 2024-01-01 2024-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:FixturesAndFittingsMember 2024-01-01 2024-12-31 0001799207 ifrs-full:GrossCarryingAmountMember auna:WorksInProgressMember 2024-01-01 2024-12-31 0001799207 ifrs-full:GrossCarryingAmountMember 2024-01-01 2024-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:LandMember 2024-01-01 2024-12-31 0001799207 auna:OncomedicaSAMember 2024-01-01 2024-12-31 0001799207 auna:EntitiesMember 2024-01-01 2024-12-31 0001799207 auna:DentegraSegurosDentalesSAMember 2024-01-01 2024-12-31 0001799207 ifrs-full:BuildingsMember 2024-01-01 2024-12-31 0001799207 auna:MedicalEquipmentMember 2024-01-01 2024-12-31 0001799207 ifrs-full:LandMember 2024-01-01 2024-12-31 0001799207 ifrs-full:VehiclesMember 2024-01-01 2024-12-31 0001799207 ifrs-full:FixturesAndFittingsMember 2024-01-01 2024-12-31 0001799207 ifrs-full:CostOfSalesMember 2024-01-01 2024-12-31 0001799207 auna:SellingExpensesMember 2024-01-01 2024-12-31 0001799207 auna:AdministrativeExpenseMember 2024-01-01 2024-12-31 0001799207 auna:commercialOfficesAndEquipmentMember 2024-01-01 2024-12-31 0001799207 auna:AdjustmentForTaxLossesMember 2024-01-01 2024-12-31 0001799207 auna:AdjustmentForLossForImpairmentOfTradeReceivablesMember 2024-01-01 2024-12-31 0001799207 auna:AdjustmentForProvisionForUnpaidVacationsAndAnnualPerformanceBonusesMember 2024-01-01 2024-12-31 0001799207 auna:AdjustmentForTradeAccountsPayableMember 2024-01-01 2024-12-31 0001799207 auna:AdjustmentForDerivativeFinancialInstrumentsMember 2024-01-01 2024-12-31 0001799207 auna:AdjustmentOfProvisionsMember 2024-01-01 2024-12-31 0001799207 ifrs-full:IntangibleAssetsOtherThanGoodwillMember 2024-01-01 2024-12-31 0001799207 auna:AdjustmentForInvestmentsInAssociatesAndOthersMember 2024-01-01 2024-12-31 0001799207 ifrs-full:LongtermBorrowingsMember 2024-01-01 2024-12-31 0001799207 ifrs-full:PropertyPlantAndEquipmentMember 2024-01-01 2024-12-31 0001799207 auna:AdjustmentForOthersMember 2024-01-01 2024-12-31 0001799207 auna:InmueblesJrd2000SaDeCvMember 2024-01-01 2024-12-31 0001799207 auna:TovlejaHgSaMember 2024-01-01 2024-12-31 0001799207 auna:DentegraSegurosDentalesSAMember 2024-01-01 2024-12-31 0001799207 auna:OncomedicaSAMember 2024-01-01 2024-12-31 0001799207 auna:ImatSasMember 2024-01-01 2024-12-31 0001799207 auna:ClnicaPortoazulSaMember 2024-01-01 2024-12-31 0001799207 auna:GspTrujilloSacClnicaCaminoRealMember 2024-01-01 2024-12-31 0001799207 auna:MedicserSacClnicaDelgadoMember 2024-01-01 2024-12-31 0001799207 auna:PatologaOncolgicaSacMember 2024-01-01 2024-12-31 0001799207 auna:OncogenomicsSacMember 2024-01-01 2024-12-31 0001799207 auna:HospitalYClnicaOcaSaDeCvMember 2024-01-01 2024-12-31 0001799207 auna:DrjInmueblesSaDeCvMember 2024-01-01 2024-12-31 0001799207 auna:ServimdicosSacMember 2024-01-01 2024-12-31 0001799207 auna:ClnicaBellavistaSacMember 2024-01-01 2024-12-31 0001799207 auna:LaboratorioClnicaInmunolgicoCantellaSacMember 2024-01-01 2024-12-31 0001799207 auna:ClnicaMirafloresSaMember 2024-01-01 2024-12-31 0001799207 auna:RrPatologosAsociadosSacMember 2024-01-01 2024-12-31 0001799207 auna:ClnicaVallesurSaMember 2024-01-01 2024-12-31 0001799207 auna:PromotoraMdicaLasAmricasSaMember 2024-01-01 2024-12-31 0001799207 auna:LaboratorioMdicoLasAmricasLtdaMember 2024-01-01 2024-12-31 0001799207 auna:InstitutoDeCancerologaSaMember 2024-01-01 2024-12-31 0001799207 auna:OncosaludSacMember 2024-01-01 2024-12-31 0001799207 auna:OncocenterPerSacMember 2024-01-01 2024-12-31 0001799207 auna:LasAmricasFarmaStoreSasMember 2024-01-01 2024-12-31 0001799207 auna:CardioImatSaMember 2024-01-01 2024-12-31 0001799207 auna:IntensivosImatSaMember 2024-01-01 2024-12-31 0001799207 auna:ConsorcioTreccaSacMember 2024-01-01 2024-12-31 0001799207 auna:SociedadRadiooncolgicaDeMonteraSaMember 2024-01-01 2024-12-31 0001799207 auna:InversionesMercurioSacMember 2024-01-01 2024-12-31 0001799207 auna:GrupoSaludAunaMxicoSaDeCvMember 2024-01-01 2024-12-31 0001799207 auna:AunaColombiaSasMember 2024-01-01 2024-12-31 0001799207 auna:AunaSaludSacMember 2024-01-01 2024-12-31 0001799207 auna:GspInversionesSacMember 2024-01-01 2024-12-31 0001799207 auna:OperadorEstratgicoSacMember 2024-01-01 2024-12-31 0001799207 auna:GspServiciosGeneralesSacMember 2024-01-01 2024-12-31 0001799207 auna:GspServiciosComercialesSacMember 2024-01-01 2024-12-31 0001799207 auna:ProMedLasAmricasLlcMember 2024-01-01 2024-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:ComputerSoftwareMember 2024-01-01 2024-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:ServiceConcessionRightsMember 2024-01-01 2024-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:ComputerSoftwareMember 2024-01-01 2024-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:CustomerrelatedIntangibleAssetsMember 2024-01-01 2024-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:GoodwillMember 2024-01-01 2024-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:BrandNamesMember 2024-01-01 2024-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:CustomerrelatedIntangibleAssetsMember 2024-01-01 2024-12-31 0001799207 auna:DentegraSegurosDentalesSAMember auna:TrademarkMember 2024-01-01 2024-12-31 0001799207 auna:EntitiesMember ifrs-full:CustomerrelatedIntangibleAssetsMember 2024-01-01 2024-12-31 0001799207 auna:EntitiesMember auna:PropertyFurnitureAndEquipmentAndInvestmentPropertiesMember 2024-01-01 2024-12-31 0001799207 auna:EntitiesMember auna:TrademarkMember 2024-01-01 2024-12-31 0001799207 auna:OncomedicaSAMember auna:TrademarkMember 2024-01-01 2024-12-31 0001799207 auna:OncomedicaSAMember ifrs-full:PropertyPlantAndEquipmentMember 2024-01-01 2024-12-31 0001799207 auna:OncomedicaSAMember auna:LoansAndBorrowingsMember 2024-01-01 2024-12-31 0001799207 ifrs-full:InsuranceRiskMember 2024-01-01 2024-12-31 0001799207 auna:FivePercentFrequencyBottomMember ifrs-full:InsuranceRiskMember 2024-01-01 2024-12-31 0001799207 auna:TenPercentFrequencyTopMember ifrs-full:InsuranceRiskMember 2024-01-01 2024-12-31 0001799207 auna:FivePercentAverageCostBottomMember ifrs-full:InsuranceRiskMember 2024-01-01 2024-12-31 0001799207 auna:TenPercentAverageCostTopMember ifrs-full:InsuranceRiskMember 2024-01-01 2024-12-31 0001799207 auna:FivePercentCombinedBottomMember ifrs-full:InsuranceRiskMember 2024-01-01 2024-12-31 0001799207 auna:TenPercentCombinedTopMember ifrs-full:InsuranceRiskMember 2024-01-01 2024-12-31 0001799207 auna:AunaSAMember 2024-01-01 2024-12-31 0001799207 ifrs-full:ParentMember 2024-01-01 2024-12-31 0001799207 ifrs-full:NetLiabilitiesOrAssetsForRemainingCoverageExcludingLossComponentMember 2024-01-01 2024-12-31 0001799207 ifrs-full:EstimatesOfPresentValueOfFutureCashFlowsMember 2024-01-01 2024-12-31 0001799207 ifrs-full:RiskAdjustmentForNonfinancialRiskMember 2024-01-01 2024-12-31 0001799207 ifrs-full:JointVenturesWhereEntityIsVenturerMember 2024-01-01 2024-12-31 0001799207 ifrs-full:OtherRelatedPartiesMember 2024-01-01 2024-12-31 0001799207 ifrs-full:AssociatesMember 2024-01-01 2024-12-31 0001799207 ifrs-full:RelatedPartiesMember 2024-01-01 2024-12-31 0001799207 auna:OtherManagementChargesMember 2024-01-01 2024-12-31 0001799207 country:PE srt:SubsidiariesMember 2024-01-01 2024-12-31 0001799207 country:CO srt:SubsidiariesMember 2024-01-01 2024-12-31 0001799207 auna:BoardOfDirectorsMember 2024-01-01 2024-12-31 0001799207 country:MX srt:SubsidiariesMember 2024-01-01 2024-12-31 0001799207 auna:NonExecutiveMember 2024-01-01 2024-12-31 0001799207 auna:EnfocaMember 2024-01-01 2024-12-31 0001799207 auna:ClassACommonShareMember 2024-01-01 2024-12-31 0001799207 ifrs-full:BottomOfRangeMember auna:ClassBCommonStockMember auna:RangeTwoMember 2024-01-01 2024-12-31 0001799207 ifrs-full:TopOfRangeMember auna:ClassBCommonStockMember auna:RangeTwoMember 2024-01-01 2024-12-31 0001799207 ifrs-full:BottomOfRangeMember auna:ClassBCommonStockMember auna:RangeThreeMember 2024-01-01 2024-12-31 0001799207 ifrs-full:TopOfRangeMember auna:ClassBCommonStockMember auna:RangeThreeMember 2024-01-01 2024-12-31 0001799207 ifrs-full:BottomOfRangeMember auna:ClassBCommonStockMember auna:RangeFourMember 2024-01-01 2024-12-31 0001799207 ifrs-full:TopOfRangeMember auna:ClassBCommonStockMember auna:RangeFourMember 2024-01-01 2024-12-31 0001799207 ifrs-full:BottomOfRangeMember auna:ClassBCommonStockMember auna:RangeOneMember 2024-01-01 2024-12-31 0001799207 ifrs-full:TopOfRangeMember auna:ClassBCommonStockMember auna:RangeOneMember 2024-01-01 2024-12-31 0001799207 auna:ClassBCommonStockMember auna:NumberOfShareholdersMember auna:RangeFourMember 2024-01-01 2024-12-31 0001799207 auna:ClassBCommonStockMember auna:NumberOfShareholdersMember 2024-01-01 2024-12-31 0001799207 auna:ClassBCommonStockMember auna:NumberOfShareholdersMember auna:RangeOneMember 2024-01-01 2024-12-31 0001799207 auna:ClassBCommonStockMember auna:NumberOfShareholdersMember auna:RangeTwoMember 2024-01-01 2024-12-31 0001799207 auna:ClassBCommonStockMember auna:NumberOfShareholdersMember auna:RangeThreeMember 2024-01-01 2024-12-31 0001799207 auna:ClassBCommonStockMember auna:PercentageOfParticipationMember auna:RangeThreeMember 2024-01-01 2024-12-31 0001799207 auna:ClassBCommonStockMember auna:PercentageOfParticipationMember auna:RangeTwoMember 2024-01-01 2024-12-31 0001799207 auna:ClassBCommonStockMember auna:PercentageOfParticipationMember auna:RangeOneMember 2024-01-01 2024-12-31 0001799207 auna:ClassBCommonStockMember auna:PercentageOfParticipationMember 2024-01-01 2024-12-31 0001799207 auna:ClassBCommonStockMember auna:PercentageOfParticipationMember auna:RangeFourMember 2024-01-01 2024-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:ClinicaVallesurMember 2024-01-01 2024-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:ClinicaMirafloresMember 2024-01-01 2024-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:PmlaMember 2024-01-01 2024-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:ClinicaPortoazulMember 2024-01-01 2024-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:OncomedicaMember 2024-01-01 2024-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember ifrs-full:SubsidiariesMember 2024-01-01 2024-12-31 0001799207 auna:OncosaludPeruMember ifrs-full:OperatingSegmentsMember 2024-01-01 2024-12-31 0001799207 auna:HealthcareServicesInPeruMember ifrs-full:OperatingSegmentsMember 2024-01-01 2024-12-31 0001799207 auna:HealthcareServicesInColombiaMember ifrs-full:OperatingSegmentsMember 2024-01-01 2024-12-31 0001799207 auna:HealthcareServicesInMexicoMember ifrs-full:OperatingSegmentsMember 2024-01-01 2024-12-31 0001799207 ifrs-full:MiscellaneousOtherProvisionsMember 2024-01-01 2024-12-31 0001799207 auna:OutstandingClaimsReserveMember 2024-01-01 2024-12-31 0001799207 auna:FxOperationAgreementsPurchasedCollarLongPut2025Member auna:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-01-01 2024-12-31 0001799207 auna:FxOperationAgreementsPurchasedCollarShortCall2025Member auna:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-01-01 2024-12-31 0001799207 auna:FxOperationAgreementCallSpread2028TwoMember ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-01-01 2024-12-31 0001799207 auna:FxOperationAgreementPurchasedCollar2028Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-01-01 2024-12-31 0001799207 auna:FxOperationAgreementSingleCall2028Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-01-01 2024-12-31 0001799207 auna:InterestRateSwapTiie2028Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-01-01 2024-12-31 0001799207 auna:InterestRateSwapTiie2028Member auna:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-01-01 2024-12-31 0001799207 auna:InterestRateSwapSofr2028Member auna:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-01-01 2024-12-31 0001799207 auna:FxOperationAgreementCallSpreadLongPut2025Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-01-01 2024-12-31 0001799207 auna:FxOperationAgreementCallSpreadShortCall2025Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-01-01 2024-12-31 0001799207 auna:FxOperationAgreementsPurchasedCollarLongPut2025Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-01-01 2024-12-31 0001799207 auna:FxOperationAgreementsPurchasedCollarShortCall2025Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-01-01 2024-12-31 0001799207 auna:FxOperationAgreementCallSpread2026Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-01-01 2024-12-31 0001799207 auna:FxOperationAgreementCallSpread2028OneMember ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-01-01 2024-12-31 0001799207 auna:FxOperationAgreementPurchasedCollar2026Member ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember 2024-01-01 2024-12-31 0001799207 auna:FxOperationAgreementPurchasedCollar2024Member ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember 2024-01-01 2024-12-31 0001799207 auna:FxOperationAgreementsLongForward2023Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-01-01 2024-12-31 0001799207 auna:FxOperationAgreementsPurchasedCollarLongPut2023Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-01-01 2024-12-31 0001799207 auna:FxOperationAgreementsPurchasedCollarShortCall2023Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-01-01 2024-12-31 0001799207 auna:FxOperationAgreementCallSpread2029Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-01-01 2024-12-31 0001799207 ifrs-full:CurrencyRiskMember 2024-01-01 2024-12-31 0001799207 ifrs-full:CurrencyRiskMember auna:FivePercentFrequencyWeakeningBottomMember 2024-01-01 2024-12-31 0001799207 ifrs-full:CurrencyRiskMember auna:TenPercentFrequencyWeakeningTopMember 2024-01-01 2024-12-31 0001799207 ifrs-full:CurrencyRiskMember auna:FivePercentFrequencyStrengtheningBottomMember 2024-01-01 2024-12-31 0001799207 ifrs-full:CurrencyRiskMember auna:TenPercentFrequencyStrengtheningTopMember 2024-01-01 2024-12-31 0001799207 country:MX 2024-01-01 2024-12-31 0001799207 country:PE 2024-01-01 2024-12-31 0001799207 country:CO 2024-01-01 2024-12-31 0001799207 auna:HealthcareServicesMember 2024-01-01 2024-12-31 0001799207 auna:SaleOfMedicinesMember 2024-01-01 2024-12-31 0001799207 auna:OncologyPlansMember 2024-01-01 2024-12-31 0001799207 auna:GeneralHealthcareServicesPlansMember 2024-01-01 2024-12-31 0001799207 ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember 2024-01-01 2024-12-31 0001799207 ifrs-full:GoodsOrServicesTransferredOverTimeMember 2024-01-01 2024-12-31 0001799207 ifrs-full:InterestRateRiskMember auna:FivePercentageOfDecreaseInInterestRateMember 2024-01-01 2024-12-31 0001799207 ifrs-full:InterestRateRiskMember auna:TenPercentageOfDecreaseInInterestRateMember 2024-01-01 2024-12-31 0001799207 ifrs-full:InterestRateRiskMember auna:FivePercentageOfIncreaseInInterestRateMember 2024-01-01 2024-12-31 0001799207 ifrs-full:InterestRateRiskMember auna:TenPercentageOfIncreaseInInterestRateMember 2024-01-01 2024-12-31 0001799207 ifrs-full:ComputerSoftwareMember ifrs-full:BottomOfRangeMember 2024-01-01 2024-12-31 0001799207 ifrs-full:ComputerSoftwareMember ifrs-full:TopOfRangeMember 2024-01-01 2024-12-31 0001799207 ifrs-full:CustomerrelatedIntangibleAssetsMember ifrs-full:BottomOfRangeMember 2024-01-01 2024-12-31 0001799207 ifrs-full:CustomerrelatedIntangibleAssetsMember ifrs-full:TopOfRangeMember 2024-01-01 2024-12-31 0001799207 auna:SurfaceRightsAgreementMember 2024-01-01 2024-12-31 0001799207 auna:MedicalEquipmentMember ifrs-full:TopOfRangeMember 2024-01-01 2024-12-31 0001799207 ifrs-full:VehiclesMember ifrs-full:BottomOfRangeMember 2024-01-01 2024-12-31 0001799207 ifrs-full:VehiclesMember ifrs-full:TopOfRangeMember 2024-01-01 2024-12-31 0001799207 ifrs-full:FixturesAndFittingsMember ifrs-full:BottomOfRangeMember 2024-01-01 2024-12-31 0001799207 ifrs-full:FixturesAndFittingsMember ifrs-full:TopOfRangeMember 2024-01-01 2024-12-31 0001799207 auna:ITEquipmentMember ifrs-full:BottomOfRangeMember 2024-01-01 2024-12-31 0001799207 ifrs-full:BuildingsMember ifrs-full:BottomOfRangeMember 2024-01-01 2024-12-31 0001799207 ifrs-full:BuildingsMember ifrs-full:TopOfRangeMember 2024-01-01 2024-12-31 0001799207 auna:MedicalEquipmentMember ifrs-full:BottomOfRangeMember 2024-01-01 2024-12-31 0001799207 auna:ITEquipmentMember ifrs-full:TopOfRangeMember 2024-01-01 2024-12-31 0001799207 auna:HospitalyClinicaOCASAdeCVMember 2024-01-01 2024-12-31 0001799207 auna:PagologaOncologicaSACMember 2024-01-01 2024-12-31 0001799207 auna:OncogenomicsSacMember 2024-01-01 2024-12-31 0001799207 auna:PromotoraMedicaLasAmericasSAMember 2024-01-01 2024-12-31 0001799207 auna:ConsorcioTreccaMember 2024-01-01 2024-12-31 0001799207 auna:PeruvianSubsidiariesMember 2024-01-01 2024-12-31 0001799207 auna:MexicanSubsidiariesMember 2024-01-01 2024-12-31 0001799207 auna:HealthcareServicesMember 2024-01-01 2024-12-31 0001799207 auna:HealthcareServicesMember ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMember 2024-01-01 2024-12-31 0001799207 auna:SaleOfMedicinesMember ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMember 2024-01-01 2024-12-31 0001799207 auna:PeruvianFinancialEntitiesMember 2024-01-01 2024-12-31 0001799207 auna:ColombianFinancialEntitiesMember 2024-01-01 2024-12-31 0001799207 auna:MexicanFinancialEntitiesMember 2024-01-01 2024-12-31 0001799207 auna:LuxembourgFinancialEntitiesMember 2024-01-01 2024-12-31 0001799207 auna:CorporateCustomersMember 2024-01-01 2024-12-31 0001799207 auna:IndividualCustomersMember 2024-01-01 2024-12-31 0001799207 ifrs-full:InsuranceRiskMember ifrs-full:BottomOfRangeMember 2024-01-01 2024-12-31 0001799207 ifrs-full:InsuranceRiskMember ifrs-full:TopOfRangeMember 2024-01-01 2024-12-31 0001799207 ifrs-full:InterestRateRiskMember 2024-01-01 2024-12-31 0001799207 auna:CostOfSalesAndServicesMember 2024-01-01 2024-12-31 0001799207 ifrs-full:BottomOfRangeMember country:CO 2024-01-01 2024-12-31 0001799207 ifrs-full:TopOfRangeMember country:CO 2024-01-01 2024-12-31 0001799207 auna:HealthcareServicesInColombiaMember 2024-01-01 2024-12-31 0001799207 auna:HealthcareServicesInMexicoMember 2024-01-01 2024-12-31 0001799207 ifrs-full:ReportableSegmentsMember 2024-01-01 2024-12-31 0001799207 auna:HoldingAndEliminationsMember 2024-01-01 2024-12-31 0001799207 auna:InterSegmentMember auna:OncosaludPeruMember 2024-01-01 2024-12-31 0001799207 auna:InterSegmentMember auna:HealthcareServicesInPeruMember 2024-01-01 2024-12-31 0001799207 auna:InterSegmentMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-12-31 0001799207 auna:OncosaludPeruMember 2024-01-01 2024-12-31 0001799207 auna:HealthcareServicesInPeruMember 2024-01-01 2024-12-31 0001799207 auna:ExternalMember auna:OncosaludPeruMember 2024-01-01 2024-12-31 0001799207 auna:ExternalMember auna:HealthcareServicesInPeruMember 2024-01-01 2024-12-31 0001799207 auna:ExternalMember auna:HealthcareServicesInColombiaMember 2024-01-01 2024-12-31 0001799207 auna:ExternalMember auna:HealthcareServicesInMexicoMember 2024-01-01 2024-12-31 0001799207 auna:ExternalMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-12-31 0001799207 auna:ExternalMember 2024-01-01 2024-12-31 0001799207 auna:ExternalMember auna:HoldingAndEliminationsMember 2024-01-01 2024-12-31 0001799207 auna:CorporateCustomersMember auna:HealthcareServicesInMexicoMember 2024-01-01 2024-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-12-31 0001799207 auna:CorporateCustomersMember auna:HoldingAndEliminationsMember 2024-01-01 2024-12-31 0001799207 auna:CorporateCustomersMember 2024-01-01 2024-12-31 0001799207 auna:InterSegmentMember auna:HoldingAndEliminationsMember 2024-01-01 2024-12-31 0001799207 auna:CorporateCustomersMember auna:OncosaludPeruMember 2024-01-01 2024-12-31 0001799207 auna:CorporateCustomersMember auna:HealthcareServicesInPeruMember 2024-01-01 2024-12-31 0001799207 auna:CorporateCustomersMember auna:HealthcareServicesInColombiaMember 2024-01-01 2024-12-31 0001799207 auna:InterSegmentMember 2024-01-01 2024-12-31 0001799207 country:CO auna:HealthcareServicesSegmentsMember 2024-01-01 2024-12-31 0001799207 country:MX auna:HealthcareServicesSegmentsMember 2024-01-01 2024-12-31 0001799207 country:PE auna:OncosaludPeruMember 2024-01-01 2024-12-31 0001799207 country:PE auna:HealthcareServicesSegmentsMember 2024-01-01 2024-12-31 0001799207 auna:AdministrativeExpensesMember 2024-01-01 2024-12-31 0001799207 country:LU 2024-01-01 2024-12-31 0001799207 auna:BonusesMember 2024-01-01 2024-12-31 0001799207 auna:SeverancePaymentsMember 2024-01-01 2024-12-31 0001799207 auna:LegalBonusesMember 2024-01-01 2024-12-31 0001799207 auna:HealthInsuranceForEmployeesMember 2024-01-01 2024-12-31 0001799207 auna:TrainingMember 2024-01-01 2024-12-31 0001799207 auna:VacationsMember 2024-01-01 2024-12-31 0001799207 auna:EmployeesProfitSharingMember 2024-01-01 2024-12-31 0001799207 auna:RemunerationsMember 2024-01-01 2024-12-31 0001799207 auna:CompensationToPersonnelMember 2024-01-01 2024-12-31 0001799207 auna:OtherBenefitsMember 2024-01-01 2024-12-31 0001799207 auna:BoardOfDirectorsRemunerationMember 2024-01-01 2024-12-31 0001799207 auna:EquitysettledSharebasedPaymentExpensesMember 2024-01-01 2024-12-31 0001799207 auna:TwentyTwentyFiveMember auna:BancognbBankLoan20255900PercentageMember currency:PEN 2024-01-01 2024-12-31 0001799207 auna:TwentyTwentyThreeMember auna:BancoSantanderMxicoHsbcMexicoMultivaAndGenaroLevinsonMarcovichLoan2023Tiie650PercentageMember currency:MXN 2024-01-01 2024-12-31 0001799207 auna:TwentyTwentyEightMember auna:BancoSantanderMxicoHsbcAndCitibankBankLoan2028Sofr4875PercentageTwoMember currency:USD 2024-01-01 2024-12-31 0001799207 auna:TwentyTwentyFiveMember auna:BbvaBancomerBankloan2023Tiie0900PercentageMember currency:USD 2024-01-01 2024-12-31 0001799207 auna:TwentyTwentyNineMember auna:SecuredBondsIssuesSeniorNotes202910000PercentageMember currency:USD 2024-01-01 2024-12-31 0001799207 currency:USD auna:TwentyTwentyEightMember auna:BancoSantanderMexicoHsbcAndCitibankBankLoan2028Sofr4875PercentageMember 2024-01-01 2024-12-31 0001799207 auna:TwentyTwentyFiveMember auna:HsbcMxicoBankLoan202512430PercentageMember currency:MXN 2024-01-01 2024-12-31 0001799207 auna:TwentyTwentyEightMember auna:BancoSantanderMxicoHsbcAndCitibankBankLoan2028Tiie4500PercentageMember currency:MXN 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoCitibankColombiaBankLoan2025FourteenPointSixThreeZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoCitibankColombiaBankLoan2025FourteenPointSixThreeZeroPercentageOneMember currency:COP 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025ThirtyThreePointZeroEightPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:TermDepositRateMember currency:COP auna:TwentyThirtyThreeMember auna:BancolombiaOtherFinancing2033DtfPlusThreePointNineFiveZeroPercentageMember 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyThreeMember auna:BancoCitibankColombiaBankLoan2023TwelvePointThreeOneZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:COP auna:TwentyTwentyThreeMember auna:BancoCitibankColombiaBankLoan2023FifteenPointZeroEightZeroPercentageMember 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoCitibankColombiaBankLoan2025FifteenPointThreeTwoZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoCitibankColombiaBankLoan2025FifteenPointThreeSevenZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:TwentyTwentyFourMember auna:BancolombiaBankLoan2024IbrPlusSixPointFourThreeZeroPercentageMember 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025ThirtyNinePointSixFourZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025IbrPlusSixPointSixSevenTwoPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025IbrPlusSevenPointZeroFourTwoPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFourMember auna:BancolombiaBankLoan2024IbrPlusSixPointSixZeroZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:TermDepositRateMember auna:TwentyTwentySixMember auna:BancolombiaBankLoan2026DtfPlusThreePointZeroOneZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyThirtyThreeMember auna:BancolombiaBankLoan2033IbrPlusThreePointTwoZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyThirtyThreeMember auna:BancolombiaBankLoan2033IbrPlusSixPointFourZeroZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentySixMember auna:BancolombiaBankLoan2026IbrPlusTwoPointNineTwoZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025IbrPlusTwoPointNineZeroZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025IbrPlusThreePointThreeZeroZeroPercentageMember 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025IbrPlusTwoPointZeroTwoFourPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025FortySixPointTwoOneZeroPercentageThreeMember currency:COP 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025TwoPointNineOneZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025IbrPlusFourPointTwoOneZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025IbrPlusFourPointSixTwoZeroPercentageMember 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025IbrPlusFivePointFiveTwoZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:USD auna:BancoCitibank202410060PercentageMember 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoCitibank20248800PercentageMember currency:PEN 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoPichincha20255900PercentageMember 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025FortySixPointTwoOneZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025FortySixPointTwoOneZeroPercentageOneMember currency:COP 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025FortySixPointTwoOneZeroPercentageTwoMember currency:COP 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoInteramericanoDeFinanzas20256200PercentageMember currency:PEN 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoInternacionalDelPerSaaBankLoan20247380PercentageMember currency:USD 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoInternacionalDelPerSaaBankLoan20246000PercentageMember currency:USD 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoInternacionalDelPerSaa20246830PercentageMember currency:PEN 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:USD auna:BancoCitibank20256400PercentageMember 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoCitibank20255790PercentageMember currency:USD 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoInteramericanoDeFinanzas20248450PercentageMember currency:PEN 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoInteramericanoDeFinanzas20247610PercentageMember currency:USD 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoInteramericanoDeFinanzas20248150PercentageMember currency:PEN 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:BancoInteramericanoDeFinanzas20248300PercentageMember 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoInteramericanoDeFinanzas20247200PercentageMember currency:PEN 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:BancoInteramericanoDeFinanzas20256650PercentageMember 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:ScotiabankPerSaaBankLoan20256230PercentageMember 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:ScotiabankPerSaaBankLoan20255950PercentageMember currency:PEN 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:TwentyTwentyFourMember auna:ScotiabankPerSAABankloan20248700PercentageMember 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoBbvaContinentalBankLoan20258200PercentageMember currency:USD 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoBbvaContinentalBankLoan20256530PercentageMember currency:USD 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoBbvaContinentalBankLoan20256950PercentageMember currency:USD 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoDaviviendaBankLoan2025FortyFivePointNineThreeZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancoDaviviendaGovernmentGuaranteedLoan2025IBRPlusOnePointFiveZeroZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyNineMember auna:BancoDaviviendaGovernmentGuaranteedLoan2029IBRPlusOnePointFiveZeroZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:BancoDaviviendaGovernmentGuaranteedLoan2025IBRPlusFivePointFiveFiveZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:BancoDaviviendaBankLoan2025IBRPlusFivePointTwoZeroZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:BancoDaviviendaBankLoan2025IBRPlusFourPointFiveZeroZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:BancoDaviviendaBankLoan2025IBRPlusThreePointFiveZeroZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:BancoDaviviendaBankLoan2025IBRPlusFourPointSixZeroZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:BancoDaviviendaBankLoan2025IBRPlusFourPointSixZeroZeroPercentageOneMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BancoDaviviendaGovernmentGuaranteedLoan2025IBRPlusThreePointFiveZeroZeroPercentageMember auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BancoDaviviendaGovernmentGuaranteedLoan2028IBRPlusSixPointEightZeroZeroPercentageMember auna:BankReferenceIndicatorMember auna:TwentyTwentyEightMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BancoDaviviendaBankLoan2026IBRPlusThreePointFiveZeroZeroPercentageOneMember auna:BankReferenceIndicatorMember auna:TwentyTwentySixMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:BancoDaviviendaBankLoan2025IBRPlusFourPointSevenZeroZeroPercentageMember 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancodeBogotaBankloan2025IBRPlusTwoPointTwoZeroZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:TwentyTwentyFiveMember auna:BancodeOccidenteBankloan2025IBRPlusTwoPointThreeThreeZeroPercentageMember 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentySevenMember auna:BancoDaviviendaGovernmentGuaranteedLoan2027IBRPlusThreePointSevenFiveZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancodeBogotaBankloan2025IBRPlusSevenPointZeroZeroZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:TwentyTwentySixMember auna:BancodeBogotaBankloan2026IBRPlusFivePointFiveZeroZeroPercentageMember 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFourMember auna:BancodeOccidenteBankloan2024ThirtyEightPointFiveTwoZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:TwentyTwentyFourMember auna:BancodeOccidenteBankloan2024IBRPlusThreePointSevenThreeZeroPercentageMember 2024-01-01 2024-12-31 0001799207 auna:BancodeOccidenteBankloan2028IBRPlusFourPointNineNineZeroPercentageMember auna:BankReferenceIndicatorMember auna:TwentyTwentyEightMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:BancodeOccidenteBankloan2025IBRPlusOnePointSixTwoZeroPercentageMember 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:BancodeOccidenteBankloan2025IBRPlusTwoPointNineSevenZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyThreeMember auna:BancoPichincha20247350PercentageMember 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoPichincha20246100PercentageMember 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoCitibank20249650PercentageMember currency:PEN 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoBbvaContinentalBankLoan20247500PercentageMember currency:USD 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoBbvaContinentalBankLoan20246500PercentageMember currency:USD 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoItau20244850PercentageMember currency:USD 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoInteramericanoDeFinanzas20246000PercentageMember currency:PEN 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:USD auna:BancoInternacionalDelPerSaa20257750PercentageMember 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyThreeMember auna:BancoDeCreditoDelPeruGovernmentGuaranteedLoan2023ZeroPointEightNineZeroPercentageMember currency:PEN 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyThreeMember auna:BancoDeCreditoDelPeruGovernmentGuaranteedLoan2023OnePointNineNineZeroPercentageMember currency:PEN 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:TwentyTwentyFourMember auna:ScotiabankPeruSaaBankLoan20248500PercentageMember 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:USD auna:TwentyTwentyThreeMember auna:ScotiabankPerSaaBankLoan20234200PercentageMember 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:ScotiabankPerSaaOtherfinancing20276300PercentageMember 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:ScotiabankPerSaaOtherfinancing20275900PercentageMember 2024-01-01 2024-12-31 0001799207 auna:SecuredOvernightFinancingRateMember auna:TwentyTwentyThreeMember auna:JPMorganBank2023SOFRPlusFourPointZeroZeroZeroPercentageMember currency:USD 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:TwentyTwentyFourMember auna:BancoDeCreditoDelPeruBankLoan2024NinePointSevenZeroZeroPercentageMember 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:USD auna:TwentyTwentyFourMember auna:BancoDeCreditoDelPeruBankLoan2024SixPointNineThreeZeroPercentageOneMember 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:USD auna:TwentyTwentyThreeMember auna:BancoDeCreditoDelPeruBankLoan2023EightPointFourEightZeroPercentageMember 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoDeCreditoDelPeruBankLoan2025SevenPointEightFiveZeroPercentageMember currency:USD 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoDeCreditoDelPeruBankLoan2025SevenPointTwoZeroZeroPercentageMember currency:PEN 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:COP auna:TwentyTwentyFiveMember auna:BancoCitibankColombiaBankLoan2025TwelvePointSixZeroZeroPercentageMember 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:COP auna:TwentyTwentyFiveMember auna:ItauCorpbancaColombiaSABankLoan2025FortyFivePointTwoFourZeroPercentageMember 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:COP auna:TwentyTwentyFourMember auna:ItauCorpbancaColombiaSABankLoan2024EightPointSixFourZeroPercentageMember 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFourMember auna:ItauCorpbancaColombiaSABankLoan2024IBRPlusThreePointSixFiveZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyThirtyFiveMember auna:ItauCorpbancaColombiaSABankLoan2024IBRPlusThreePointFourNineZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyEightMember auna:BostonScientificColombiaLt2028TenPointSevenEightZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoCitibank20258380PercentageMember currency:USD 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:ScotiabankPerSaaOtherfinancing20276000PercentageMember currency:PEN 2024-01-01 2024-12-31 0001799207 currency:MXN auna:TwentyTwentyThreeMember auna:BbvaBancomerBankloan2023Tiie0900PercentageMember 2024-01-01 2024-12-31 0001799207 auna:TwentyTwentyEightMember auna:BancoSantanderMxicoHsbcAndCitibankBankLoan2028Sofr4875PercentageTwoMember currency:MXN 2024-01-01 2024-12-31 0001799207 auna:TwentyTwentyEightMember auna:HsbcMxicoBankLoan202512430PercentageMember currency:USD 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:BancodeBogotaBankloan2026IBRPlusFivePointFiveZeroZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:BancoDaviviendaBankLoan2026IBRPlusThreePointFiveZeroZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:BancodeBogotaBankloan2025IBRPlusSevenPointZeroZeroZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:BancoDaviviendaGovernmentGuaranteedLoan2029IBRPlusOnePointFiveZeroZeroPercentageMember 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:BancoDaviviendaGovernmentGuaranteedLoan2025IBRPlusThreePointFiveZeroZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:BancoDaviviendaGovernmentGuaranteedLoan2027IBRPlusThreePointSevenFiveZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:BancoDaviviendaGovernmentGuaranteedLoan2028IBRPlusSixPointEightZeroZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:BancodeOccidenteBankloan2025IBRPlusTwoPointThreeThreeZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:BancodeOccidenteBankloan2024IBRPlusThreePointSevenThreeZeroPercentageMember 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:BancodeOccidenteBankloan2028IBRPlusFourPointNineNineZeroPercentageMember 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:BancoDaviviendaGovernmentGuaranteedLoan2025IBRPlusOnePointFiveZeroZeroPercentageMember 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:BancodeBogotaBankloan2025IBRPlusTwoPointTwoZeroZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:BancodeBogotaBankloan2025IBRPlusOnePointSixEightZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:BancodeBogotaBankloan2025IBRPlusFourPointZeroZeroZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:BancoDeBogotaBankLoan2025FortySixPointTwoThreeZeroPercentageMember currency:COP 2024-01-01 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:BancoDeBogotaBankLoan2025FortySixPointTwoThreeZeroPercentageOneMember currency:COP 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:ScotiabankPeruSaaBankLoan20248500PercentageMember currency:PEN 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:ScotiabankPerSAABankloan20248700PercentageMember 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:USD auna:ScotiabankPerSaaBankLoan20234200PercentageMember 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:BancoInternacionalDelPerSaaBankLoan20255950PercentageMember 2024-01-01 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:BancoCitibank202410060PercentageMember 2024-01-01 2024-12-31 0001799207 auna:TwentyTwentyThreeMember auna:BancoSantanderMxicoHsbcMexicoMultivaAndGenaroLevinsonMarcovichLoan2023Tiie650PercentageMember 2024-01-01 2024-12-31 0001799207 auna:TwentyTwentyThreeMember auna:BbvaBancomerBankloan2023Tiie0900PercentageMember 2024-01-01 2024-12-31 0001799207 auna:TwentyTwentyFiveMember auna:SecuredBondsIssuesSeniornotes20256500PercentageMember currency:USD 2024-01-01 2024-12-31 0001799207 auna:TwentyTwentyFiveMember auna:SecuredBondsIssuesSeniorNotes202910000PercentageMember currency:USD 2024-01-01 2024-12-31 0001799207 ifrs-full:SharePremiumMember 2024-01-01 2024-12-31 0001799207 auna:SeniorityPremiumMember 2024-01-01 2024-12-31 0001799207 auna:FinancialLoanMember 2024-01-01 2024-12-31 0001799207 auna:AccountsPayableRelatedwithExchangeMember 2024-01-01 2024-12-31 0001799207 ifrs-full:LeaseLiabilitiesMember 2024-01-01 2024-12-31 0001799207 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2024-01-01 2024-12-31 0001799207 auna:MergeReserveMember 2024-01-01 2024-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember 2024-01-01 2024-12-31 0001799207 auna:DerivativesPremiumsPayableMember 2024-01-01 2024-12-31 0001799207 auna:DeferredIncomeMember 2024-01-01 2024-12-31 0001799207 ifrs-full:RetainedEarningsMember 2024-01-01 2024-12-31 0001799207 auna:OtherFinancingDebtsMember auna:ScotiaBankMember 2024-01-01 2024-12-31 0001799207 auna:ClassACommonStockMember 2024-12-31 0001799207 auna:ClassBCommonStockMember 2024-12-31 0001799207 ifrs-full:CurrentMember 2024-12-31 0001799207 auna:NonCurrentMember 2024-12-31 0001799207 auna:CiclotronColombiaSasMember 2024-12-31 0001799207 auna:CiclotrnPeruSaMember 2024-12-31 0001799207 auna:PetCtPeruSaMember 2024-12-31 0001799207 auna:AdjustmentForProvisionForUnpaidVacationsAndAnnualPerformanceBonusesMember 2024-12-31 0001799207 auna:AdjustmentForTradeAccountsPayableMember 2024-12-31 0001799207 auna:AdjustmentForDerivativeFinancialInstrumentsMember 2024-12-31 0001799207 auna:AdjustmentOfProvisionsMember 2024-12-31 0001799207 auna:AdjustmentForLossForImpairmentOfTradeReceivablesMember 2024-12-31 0001799207 auna:AdjustmentForTaxLossesMember 2024-12-31 0001799207 ifrs-full:IntangibleAssetsOtherThanGoodwillMember 2024-12-31 0001799207 ifrs-full:LongtermBorrowingsMember 2024-12-31 0001799207 auna:AdjustmentForInvestmentsInAssociatesAndOthersMember 2024-12-31 0001799207 auna:AdjustmentForOthersMember 2024-12-31 0001799207 ifrs-full:PropertyPlantAndEquipmentMember 2024-12-31 0001799207 ifrs-full:CurrencyRiskMember 2024-12-31 0001799207 ifrs-full:JointVenturesWhereEntityIsVenturerMember 2024-12-31 0001799207 ifrs-full:OtherRelatedPartiesMember 2024-12-31 0001799207 ifrs-full:AssociatesMember 2024-12-31 0001799207 ifrs-full:RelatedPartiesMember 2024-12-31 0001799207 auna:OtherManagementChargesMember 2024-12-31 0001799207 ifrs-full:FinancialGuaranteeContractsMember 2024-12-31 0001799207 auna:ScotiabankPerSAAMember 2024-12-31 0001799207 auna:BancoInteramericanoDeFinanzasMember 2024-12-31 0001799207 auna:BancoInterbankMember 2024-12-31 0001799207 auna:BancoDeCreditoDelPeruMember 2024-12-31 0001799207 auna:CitibankMember 2024-12-31 0001799207 country:MX 2024-12-31 0001799207 auna:MexicanMember 2024-12-31 0001799207 auna:OncomedicaSAMember 2024-12-31 0001799207 auna:ClassACommonShareMember 2024-12-31 0001799207 auna:ClassBCommonShareMember 2024-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:ClinicaVallesurMember 2024-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:ClinicaMirafloresMember 2024-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:PmlaMember 2024-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:ClinicaPortoazulMember 2024-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:OncomedicaMember 2024-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember ifrs-full:SubsidiariesMember 2024-12-31 0001799207 auna:FxOperationAgreementCallSpread2028TwoMember ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-12-31 0001799207 auna:FxOperationAgreementPurchasedCollar2028Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-12-31 0001799207 auna:FxOperationAgreementSingleCall2028Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-12-31 0001799207 auna:InterestRateSwapTiie2028Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-12-31 0001799207 auna:InterestRateSwapTiie2028Member auna:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-12-31 0001799207 auna:InterestRateSwapSofr2028Member auna:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-12-31 0001799207 auna:FxOperationAgreementCallSpreadLongPut2025Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-12-31 0001799207 auna:FxOperationAgreementCallSpreadShortCall2025Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-12-31 0001799207 auna:FxOperationAgreementsPurchasedCollarLongPut2025Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-12-31 0001799207 auna:FxOperationAgreementsPurchasedCollarShortCall2025Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-12-31 0001799207 auna:FxOperationAgreementCallSpread2026Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-12-31 0001799207 auna:FxOperationAgreementCallSpread2028OneMember ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-12-31 0001799207 auna:FxOperationAgreementPurchasedCollar2026Member ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember 2024-12-31 0001799207 auna:FxOperationAgreementPurchasedCollar2024Member ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember 2024-12-31 0001799207 auna:FxOperationAgreementsLongForward2023Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-12-31 0001799207 auna:FxOperationAgreementsPurchasedCollarLongPut2023Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-12-31 0001799207 auna:FxOperationAgreementsPurchasedCollarShortCall2023Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-12-31 0001799207 auna:FxOperationAgreementCallSpread2029Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-12-31 0001799207 auna:FxOperationAgreementsPurchasedCollarLongPut2025Member auna:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-12-31 0001799207 auna:FxOperationAgreementsPurchasedCollarShortCall2025Member auna:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2024-12-31 0001799207 country:CO 2024-12-31 0001799207 country:PE 2024-12-31 0001799207 auna:DentegraSegurosDentalesSAMember 2024-12-31 0001799207 auna:OncomedicaSAMember 2024-12-31 0001799207 auna:HospitalYClnicaOcaSaDeCvMember 2024-12-31 0001799207 auna:InstitutoDeCancerologiaSAMember 2024-12-31 0001799207 auna:LaboratorioMedicoLasAmericasLtdaMember 2024-12-31 0001799207 auna:OncogenomicsSacMember 2024-12-31 0001799207 auna:PromotoraMedicaLasAmericasSAMember 2024-12-31 0001799207 auna:ClinicaBellavistaSacBellavistaMember 2024-12-31 0001799207 auna:PatologiaOncologicaSACMember 2024-12-31 0001799207 auna:RRPatologosAsociadosSACRrMember 2024-12-31 0001799207 auna:ServimedicosSACServimedicosMember 2024-12-31 0001799207 auna:RadioncologiaSACRadioncologiaMember 2024-12-31 0001799207 auna:LaboratorioCantellaSACCantellaMember 2024-12-31 0001799207 country:CO ifrs-full:BottomOfRangeMember 2024-12-31 0001799207 country:CO ifrs-full:TopOfRangeMember 2024-12-31 0001799207 country:PE ifrs-full:BottomOfRangeMember 2024-12-31 0001799207 country:PE ifrs-full:TopOfRangeMember 2024-12-31 0001799207 country:MX ifrs-full:BottomOfRangeMember 2024-12-31 0001799207 country:MX ifrs-full:TopOfRangeMember 2024-12-31 0001799207 ifrs-full:CreditRiskMember currency:MXN 2024-12-31 0001799207 ifrs-full:CreditRiskMember 2024-12-31 0001799207 ifrs-full:CreditRiskMember currency:PEN 2024-12-31 0001799207 ifrs-full:CreditRiskMember currency:COP 2024-12-31 0001799207 ifrs-full:LiquidityRiskMember ifrs-full:CarryingAmountMember 2024-12-31 0001799207 ifrs-full:LiquidityRiskMember 2024-12-31 0001799207 ifrs-full:LiquidityRiskMember ifrs-full:NotLaterThanOneYearMember 2024-12-31 0001799207 ifrs-full:LiquidityRiskMember ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember 2024-12-31 0001799207 ifrs-full:LiquidityRiskMember ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember 2024-12-31 0001799207 ifrs-full:LiquidityRiskMember ifrs-full:LaterThanFiveYearsMember 2024-12-31 0001799207 ifrs-full:BottomOfRangeMember auna:RadioncologiaSACRadioncologiaMember 2024-12-31 0001799207 ifrs-full:TopOfRangeMember auna:RadioncologiaSACRadioncologiaMember 2024-12-31 0001799207 ifrs-full:BottomOfRangeMember auna:LaboratorioCantellaSACCantellaMember 2024-12-31 0001799207 ifrs-full:TopOfRangeMember auna:LaboratorioCantellaSACCantellaMember 2024-12-31 0001799207 ifrs-full:BottomOfRangeMember auna:RrPatologosAsociadosSacMember 2024-12-31 0001799207 ifrs-full:TopOfRangeMember auna:DentegraSegurosDentalesSAMember 2024-12-31 0001799207 ifrs-full:TopOfRangeMember auna:InstitutoDeCancerologiaSAMember 2024-12-31 0001799207 ifrs-full:BottomOfRangeMember auna:OncomedicaSAMember 2024-12-31 0001799207 ifrs-full:TopOfRangeMember auna:OncomedicaSAMember 2024-12-31 0001799207 ifrs-full:BottomOfRangeMember auna:HospitalYClnicaOcaSaDeCvMember 2024-12-31 0001799207 ifrs-full:TopOfRangeMember auna:HospitalYClnicaOcaSaDeCvMember 2024-12-31 0001799207 ifrs-full:BottomOfRangeMember auna:DentegraSegurosDentalesSAMember 2024-12-31 0001799207 ifrs-full:TopOfRangeMember auna:PatologiaOncologicaSACMember 2024-12-31 0001799207 ifrs-full:BottomOfRangeMember auna:OncogenomicsSacMember 2024-12-31 0001799207 ifrs-full:TopOfRangeMember auna:OncogenomicsSacMember 2024-12-31 0001799207 ifrs-full:BottomOfRangeMember auna:PromotoraMedicaLasAmericasSAMember 2024-12-31 0001799207 ifrs-full:TopOfRangeMember auna:PromotoraMedicaLasAmericasSAMember 2024-12-31 0001799207 ifrs-full:BottomOfRangeMember auna:InstitutoDeCancerologiaSAMember 2024-12-31 0001799207 ifrs-full:TopOfRangeMember auna:RrPatologosAsociadosSacMember 2024-12-31 0001799207 ifrs-full:BottomOfRangeMember auna:ServimedicosSACServimedicosMember 2024-12-31 0001799207 ifrs-full:TopOfRangeMember auna:ServimedicosSACServimedicosMember 2024-12-31 0001799207 ifrs-full:BottomOfRangeMember auna:ClinicaBellavistaSacBellavistaMember 2024-12-31 0001799207 ifrs-full:TopOfRangeMember auna:ClinicaBellavistaSacBellavistaMember 2024-12-31 0001799207 ifrs-full:BottomOfRangeMember auna:PatologiaOncologicaSACMember 2024-12-31 0001799207 auna:CapitalRiskMember 2024-12-31 0001799207 auna:ClinicaPortoazulSaMember 2024-12-31 0001799207 auna:HospitalyClinicaOCASAdeCVMember 2024-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialAssetsAtFairValueMember auna:FairValueOtherComprehensiveIncomeDebtInstrumentsMember 2024-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialAssetsAtFairValueMember 2024-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:Level1OfFairValueHierarchyMember auna:FairValueMember 2024-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialAssetsAtFairValueMember auna:FairValueMember 2024-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialLiabilitiesAtFairValueMember 2024-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialLiabilitiesAtFairValueMember ifrs-full:Level2OfFairValueHierarchyMember auna:FairValueMember 2024-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialLiabilitiesAtFairValueMember auna:FairValueMember 2024-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialAssetsAtFairValueMember auna:FairValueHedgingInstrumentsMember 2024-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:Level2OfFairValueHierarchyMember auna:FairValueMember 2024-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialLiabilitiesAtFairValueMember auna:FairValueHedgingInstrumentsMember 2024-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialAssetsAtAmortisedCostMember 2024-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialAssetsAtAmortisedCostMember auna:FinancialAssetsAtAmortizedCostMember 2024-12-31 0001799207 auna:CapitalRiskMember ifrs-full:Level2OfFairValueHierarchyMember auna:FairValueMember 2024-12-31 0001799207 auna:CapitalRiskMember auna:FairValueMember 2024-12-31 0001799207 auna:CapitalRiskMember auna:OtherFinancialLiabilitiesMember 2024-12-31 0001799207 auna:PeruvianFinancialEntitiesMember 2024-12-31 0001799207 auna:PeruvianFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AMinusMember 2024-12-31 0001799207 auna:PeruvianFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AMember 2024-12-31 0001799207 auna:PeruvianFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:APlusMember 2024-12-31 0001799207 auna:PeruvianFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AAPlusMember 2024-12-31 0001799207 auna:MexicanFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:BBBMember 2024-12-31 0001799207 auna:MexicanFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:BBBPlusMember 2024-12-31 0001799207 auna:MexicanFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AMember 2024-12-31 0001799207 auna:MexicanFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AAMember 2024-12-31 0001799207 auna:ColombianFinancialEntitiesMember 2024-12-31 0001799207 auna:MexicanFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AAAMember 2024-12-31 0001799207 auna:ColombianFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AAPlusMember 2024-12-31 0001799207 auna:ColombianFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AAMinusMember 2024-12-31 0001799207 auna:LuxembourgFinancialEntitiesMember 2024-12-31 0001799207 auna:ColombianFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AAAMember 2024-12-31 0001799207 auna:LuxembourgFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AAMember 2024-12-31 0001799207 auna:LuxembourgFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AAAMember 2024-12-31 0001799207 auna:MexicanFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:BBBMinusMember 2024-12-31 0001799207 auna:MexicanFinancialEntitiesMember 2024-12-31 0001799207 auna:LuxembourgFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:APlusMember 2024-12-31 0001799207 auna:TerminalValueGrowthRateMember auna:DentegraSegurosDentalesSAMember 2024-12-31 0001799207 auna:TerminalValueGrowthRateMember auna:HospitalyClinicaOCASAdeCVMember 2024-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:DentegraSegurosDentalesSAMember 2024-12-31 0001799207 auna:TerminalValueGrowthRateMember auna:OncomedicaSAMember 2024-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:HospitalyClinicaOCASAdeCVMember 2024-12-31 0001799207 auna:TerminalValueGrowthRateMember auna:InstitutoDeCancerologiaSAMember 2024-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:OncomedicaSAMember 2024-12-31 0001799207 auna:TerminalValueGrowthRateMember auna:PromotoraMedicaLasAmericasSAMember 2024-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:InstitutoDeCancerologiaSAMember 2024-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:OncogenomicsSacMember 2024-12-31 0001799207 auna:TerminalValueGrowthRateMember auna:OncogenomicsSacMember 2024-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:PromotoraMedicaLasAmericasSAMember 2024-12-31 0001799207 auna:TerminalValueGrowthRateMember auna:ClinicaBellavistaSacBellavistaMember 2024-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:PatologiaOncologicaSACMember 2024-12-31 0001799207 auna:TerminalValueGrowthRateMember auna:PatologiaOncologicaSACMember 2024-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:ClinicaBellavistaSacBellavistaMember 2024-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:RRPatologosAsociadosSACRrMember 2024-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:ServimedicosSACServimedicosMember 2024-12-31 0001799207 auna:TerminalValueGrowthRateMember auna:RadioncologiaSACRadioncologiaMember 2024-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:LaboratorioCantellaSACCantellaMember 2024-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:RadioncologiaSACRadioncologiaMember 2024-12-31 0001799207 auna:FactoringAgreementsWithCitibankDelPeruSAMember 2024-12-31 0001799207 auna:HealthcareServicesMember 2024-12-31 0001799207 auna:HealthcareServicesMember country:PE 2024-12-31 0001799207 auna:HealthcareServicesMember country:CO 2024-12-31 0001799207 auna:HealthcareServicesMember country:MX 2024-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember country:MX 2024-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember 2024-12-31 0001799207 ifrs-full:TradeReceivablesMember country:PE 2024-12-31 0001799207 ifrs-full:TradeReceivablesMember country:CO 2024-12-31 0001799207 ifrs-full:TradeReceivablesMember country:MX 2024-12-31 0001799207 ifrs-full:TradeReceivablesMember 2024-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember country:PE 2024-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember country:CO 2024-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember country:MX 2024-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember 2024-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember country:PE 2024-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember country:CO 2024-12-31 0001799207 ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember country:MX 2024-12-31 0001799207 ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember 2024-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember country:PE 2024-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember country:CO 2024-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember country:MX 2024-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember 2024-12-31 0001799207 ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember country:PE 2024-12-31 0001799207 ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember country:CO 2024-12-31 0001799207 ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember country:MX 2024-12-31 0001799207 ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember 2024-12-31 0001799207 ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember country:PE 2024-12-31 0001799207 ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember country:CO 2024-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember 2024-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember 2024-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember 2024-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember 2024-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember 2024-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember ifrs-full:AllowanceForCreditLossesMember 2024-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember ifrs-full:AllowanceForCreditLossesMember 2024-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:GrossCarryingAmountMember 2024-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:AllowanceForCreditLossesMember 2024-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember ifrs-full:GrossCarryingAmountMember 2024-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember ifrs-full:GrossCarryingAmountMember 2024-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember ifrs-full:AllowanceForCreditLossesMember 2024-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember ifrs-full:GrossCarryingAmountMember 2024-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember ifrs-full:AllowanceForCreditLossesMember 2024-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember ifrs-full:GrossCarryingAmountMember 2024-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember ifrs-full:AllowanceForCreditLossesMember 2024-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember ifrs-full:GrossCarryingAmountMember 2024-12-31 0001799207 ifrs-full:LiquidityRiskMember country:PE auna:SantanderMember ifrs-full:FixedInterestRateMember 2024-12-31 0001799207 ifrs-full:LiquidityRiskMember country:PE auna:GnbMember ifrs-full:FixedInterestRateMember 2024-12-31 0001799207 ifrs-full:LiquidityRiskMember country:CO ifrs-full:FixedInterestRateMember 2024-12-31 0001799207 ifrs-full:LiquidityRiskMember country:MX ifrs-full:FloatingInterestRateMember 2024-12-31 0001799207 ifrs-full:LiquidityRiskMember country:PE auna:BanbifMember ifrs-full:FixedInterestRateMember 2024-12-31 0001799207 ifrs-full:LiquidityRiskMember country:PE auna:BbvaMember ifrs-full:FixedInterestRateMember 2024-12-31 0001799207 ifrs-full:LiquidityRiskMember country:PE auna:BcpMember ifrs-full:FixedInterestRateMember 2024-12-31 0001799207 ifrs-full:LiquidityRiskMember country:PE auna:InterbankMember ifrs-full:FixedInterestRateMember 2024-12-31 0001799207 ifrs-full:LiquidityRiskMember country:PE auna:CitibankMember ifrs-full:FixedInterestRateMember 2024-12-31 0001799207 ifrs-full:LiquidityRiskMember country:PE auna:PichinchaMember ifrs-full:FixedInterestRateMember 2024-12-31 0001799207 ifrs-full:LiquidityRiskMember country:PE auna:ScotiaBankMember ifrs-full:FixedInterestRateMember 2024-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember 2024-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember 2024-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember 2024-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember 2024-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember 2024-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:AllowanceForCreditLossesMember 2024-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember ifrs-full:AllowanceForCreditLossesMember 2024-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember ifrs-full:GrossCarryingAmountMember 2024-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember ifrs-full:AllowanceForCreditLossesMember 2024-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember ifrs-full:GrossCarryingAmountMember 2024-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember ifrs-full:AllowanceForCreditLossesMember 2024-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:GrossCarryingAmountMember 2024-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember ifrs-full:GrossCarryingAmountMember 2024-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember ifrs-full:AllowanceForCreditLossesMember 2024-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember ifrs-full:GrossCarryingAmountMember 2024-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember ifrs-full:AllowanceForCreditLossesMember 2024-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember ifrs-full:GrossCarryingAmountMember 2024-12-31 0001799207 auna:CapitalRiskMember ifrs-full:BottomOfRangeMember 2024-12-31 0001799207 auna:PatologaOncolgicaMember 2024-12-31 0001799207 auna:PromotoraMedicaLasAmericasSAMember 2024-12-31 0001799207 auna:ConsorcioTreccaMember 2024-12-31 0001799207 auna:SuppliesAndPackagingMember 2024-12-31 0001799207 auna:MedicinesMember 2024-12-31 0001799207 auna:MedicalSuppliesMember 2024-12-31 0001799207 currency:MXN 2024-12-31 0001799207 currency:USD 2024-12-31 0001799207 currency:COP 2024-12-31 0001799207 currency:PEN 2024-12-31 0001799207 auna:HealthcareServicesInPeruMember 2024-12-31 0001799207 auna:HealthcareServicesInColombiaMember 2024-12-31 0001799207 auna:HealthcareServicesInMexicoMember 2024-12-31 0001799207 ifrs-full:ReportableSegmentsMember 2024-12-31 0001799207 auna:HoldingAndEliminationsMember 2024-12-31 0001799207 auna:OncosaludPeruMember 2024-12-31 0001799207 ifrs-full:UnusedTaxCreditsMember 2024-12-31 0001799207 auna:OnePointSixSevenMember auna:Citibank1Member auna:TwoThousandAndTwentyFiveMember auna:PayableOneMember 2024-12-31 0001799207 auna:OnePointThreeZeroMember auna:Citibank2Member auna:TwoThousandAndTwentyEightMember auna:PayableTwoMember 2024-12-31 0001799207 auna:OnePointSixSevenMember auna:Citibank3Member auna:TwoThousandAndTwentySixMember auna:PayableThreeMember 2024-12-31 0001799207 auna:OnePointThreeZeroMember auna:Citibank4Member auna:TwoThousandAndTwentyEightMember auna:PayableFourMember 2024-12-31 0001799207 auna:TenPointEightEightMember auna:DeutscheBankMember auna:TwoThousandAndTwentyNineMember auna:PayableFiveMember 2024-12-31 0001799207 auna:TwoPointFiveThreeMember auna:SantanderBankMember auna:TwoThousandAndTwentySixMember auna:PayableSixMember 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyThirtyFiveMember auna:ItauCorpbancaColombiaSABankLoan2024IBRPlusThreePointFourNineZeroPercentageMember currency:COP 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyEightMember auna:BostonScientificColombiaLt2028TenPointSevenEightZeroPercentageMember currency:COP 2024-12-31 0001799207 auna:SecuredOvernightFinancingRateMember auna:TwentyTwentyThreeMember auna:JPMorganBank2023SOFRPlusFourPointZeroZeroZeroPercentageMember currency:USD 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFourMember auna:BancoDeCreditoDelPeruBankLoan2024NinePointSevenZeroZeroPercentageMember currency:PEN 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:USD auna:TwentyTwentyFourMember auna:BancoDeCreditoDelPeruBankLoan2024SixPointNineThreeZeroPercentageOneMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyThreeMember auna:BancoDeCreditoDelPeruBankLoan2023EightPointFourEightZeroPercentageMember currency:USD 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoCitibankColombiaBankLoan2025FourteenPointSixThreeZeroPercentageMember currency:COP 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoCitibankColombiaBankLoan2025TwelvePointSixZeroZeroPercentageMember currency:COP 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:COP auna:TwentyTwentyFiveMember auna:BancoCitibankColombiaBankLoan2025FourteenPointSixThreeZeroPercentageOneMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:ItauCorpbancaColombiaSABankLoan2025FortyFivePointTwoFourZeroPercentageMember currency:COP 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:COP auna:TwentyTwentyFourMember auna:ItauCorpbancaColombiaSABankLoan2024EightPointSixFourZeroPercentageMember 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFourMember auna:ItauCorpbancaColombiaSABankLoan2024IBRPlusThreePointSixFiveZeroPercentageMember currency:COP 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025ThirtyThreePointZeroEightPercentageMember currency:COP 2024-12-31 0001799207 auna:TermDepositRateMember auna:TwentyThirtyThreeMember auna:BancolombiaOtherFinancing2033DtfPlusThreePointNineFiveZeroPercentageMember currency:COP 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyThreeMember auna:BancoCitibankColombiaBankLoan2023TwelvePointThreeOneZeroPercentageMember currency:COP 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:COP auna:TwentyTwentyThreeMember auna:BancoCitibankColombiaBankLoan2023FifteenPointZeroEightZeroPercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoCitibankColombiaBankLoan2025FifteenPointThreeTwoZeroPercentageMember currency:COP 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoCitibankColombiaBankLoan2025FifteenPointThreeSevenZeroPercentageMember currency:COP 2024-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:TwentyTwentyFourMember auna:BancolombiaBankLoan2024IbrPlusSixPointFourThreeZeroPercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:COP auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025ThirtyNinePointSixFourZeroPercentageMember 2024-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025IbrPlusSixPointSixSevenTwoPercentageMember 2024-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025IbrPlusSevenPointZeroFourTwoPercentageMember 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFourMember auna:BancolombiaBankLoan2024IbrPlusSixPointSixZeroZeroPercentageMember currency:COP 2024-12-31 0001799207 auna:TermDepositRateMember auna:TwentyTwentySixMember auna:BancolombiaBankLoan2026DtfPlusThreePointZeroOneZeroPercentageMember currency:COP 2024-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:TwentyThirtyThreeMember auna:BancolombiaBankLoan2033IbrPlusThreePointTwoZeroPercentageMember 2024-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:TwentyThirtyThreeMember auna:BancolombiaBankLoan2033IbrPlusSixPointFourZeroZeroPercentageMember 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentySixMember auna:BancolombiaBankLoan2026IbrPlusTwoPointNineTwoZeroPercentageMember currency:COP 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025IbrPlusTwoPointNineZeroZeroPercentageMember currency:COP 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025IbrPlusThreePointThreeZeroZeroPercentageMember currency:COP 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025IbrPlusTwoPointZeroTwoFourPercentageMember currency:COP 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025FortySixPointTwoOneZeroPercentageThreeMember currency:COP 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025TwoPointNineOneZeroPercentageMember currency:COP 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025IbrPlusFourPointTwoOneZeroPercentageMember currency:COP 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025IbrPlusFourPointSixTwoZeroPercentageMember currency:COP 2024-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025IbrPlusFivePointFiveTwoZeroPercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoCitibank20249650PercentageMember currency:PEN 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoCitibank20248800PercentageMember currency:PEN 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoCitibank20258380PercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:COP auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025FortySixPointTwoOneZeroPercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:COP auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025FortySixPointTwoOneZeroPercentageOneMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:COP auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025FortySixPointTwoOneZeroPercentageTwoMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyThreeMember auna:BancoPichincha20247350PercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoPichincha20246100PercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoPichincha20255900PercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:USD auna:BancoCitibank20256400PercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:USD auna:BancoCitibank20255790PercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:USD auna:BancoCitibank202410060PercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:BancoInteramericanoDeFinanzas20256200PercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:USD auna:BancoInternacionalDelPerSaa20257750PercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:USD auna:BancoInternacionalDelPerSaaBankLoan20247380PercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoInternacionalDelPerSaaBankLoan20246000PercentageMember currency:USD 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoInternacionalDelPerSaa20246830PercentageMember currency:PEN 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoInternacionalDelPerSaaBankLoan20255950PercentageMember currency:PEN 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:BancoInteramericanoDeFinanzas20248450PercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoInteramericanoDeFinanzas20247610PercentageMember currency:USD 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoInteramericanoDeFinanzas20248150PercentageMember currency:PEN 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoInteramericanoDeFinanzas20248300PercentageMember currency:PEN 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoInteramericanoDeFinanzas20247200PercentageMember currency:PEN 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:BancoInteramericanoDeFinanzas20256650PercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoBbvaContinentalBankLoan20246500PercentageMember currency:USD 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoBbvaContinentalBankLoan20258200PercentageMember currency:USD 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoBbvaContinentalBankLoan20256530PercentageMember currency:USD 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:USD auna:BancoBbvaContinentalBankLoan20256950PercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:USD auna:BancoItau20244850PercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:BancoInteramericanoDeFinanzas20246000PercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:ScotiabankPerSaaOtherfinancing20276300PercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:ScotiabankPerSaaOtherfinancing20275900PercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:ScotiabankPerSaaOtherfinancing20276000PercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:ScotiabankPerSaaBankLoan20256230PercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:ScotiabankPerSaaBankLoan20255950PercentageMember currency:PEN 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:BancoBbvaContinentalBankLoan20247500PercentageMember currency:USD 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFourMember auna:ScotiabankPeruSaaBankLoan20248500PercentageMember currency:PEN 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFourMember auna:ScotiabankPerSAABankloan20248700PercentageMember currency:PEN 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyThreeMember auna:ScotiabankPerSaaBankLoan20234200PercentageMember currency:USD 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentySixMember auna:BancodeBogotaBankloan2026IBRPlusFivePointFiveZeroZeroPercentageMember currency:COP 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:BancoDaviviendaBankLoan2025IBRPlusFourPointSevenZeroZeroPercentageMember currency:COP 2024-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:TwentyTwentyFiveMember auna:BancoDaviviendaBankLoan2025IBRPlusFourPointFiveZeroZeroPercentageMember 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancoDaviviendaBankLoan2025IBRPlusThreePointFiveZeroZeroPercentageMember currency:COP 2024-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:TwentyTwentyFiveMember auna:BancoDaviviendaBankLoan2025IBRPlusFourPointSixZeroZeroPercentageMember 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentySixMember auna:BancoDaviviendaBankLoan2026IBRPlusThreePointFiveZeroZeroPercentageMember currency:COP 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancodeBogotaBankloan2025IBRPlusSevenPointZeroZeroZeroPercentageMember currency:COP 2024-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:TwentyTwentyNineMember auna:BancoDaviviendaGovernmentGuaranteedLoan2029IBRPlusOnePointFiveZeroZeroPercentageMember 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancoDaviviendaGovernmentGuaranteedLoan2025IBRPlusFivePointFiveFiveZeroPercentageMember currency:COP 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancoDaviviendaGovernmentGuaranteedLoan2025IBRPlusThreePointFiveZeroZeroPercentageMember currency:COP 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentySevenMember auna:BancoDaviviendaGovernmentGuaranteedLoan2027IBRPlusThreePointSevenFiveZeroPercentageMember currency:COP 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyEightMember auna:BancoDaviviendaGovernmentGuaranteedLoan2028IBRPlusSixPointEightZeroZeroPercentageMember currency:COP 2024-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:TwentyTwentyEightMember auna:BancoDaviviendaBankLoan2025IBRPlusFivePointTwoZeroZeroPercentageMember 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFourMember auna:BancodeOccidenteBankloan2025IBRPlusOnePointSixTwoZeroPercentageMember currency:COP 2024-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:TwentyTwentyFiveMember auna:BancodeOccidenteBankloan2025IBRPlusTwoPointThreeThreeZeroPercentageMember 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancodeOccidenteBankloan2025IBRPlusTwoPointNineSevenZeroPercentageMember currency:COP 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFourMember auna:BancodeOccidenteBankloan2024IBRPlusThreePointSevenThreeZeroPercentageMember currency:COP 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyEightMember auna:BancodeOccidenteBankloan2028IBRPlusFourPointNineNineZeroPercentageMember currency:COP 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancoDaviviendaGovernmentGuaranteedLoan2025IBRPlusOnePointFiveZeroZeroPercentageMember currency:COP 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoDaviviendaBankLoan2025FortyFivePointNineThreeZeroPercentageMember currency:COP 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFourMember auna:BancodeOccidenteBankloan2024ThirtyEightPointFiveTwoZeroPercentageMember currency:COP 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:COP auna:TwentyTwentyFiveMember auna:BancoDeBogotaBankLoan2025FortySixPointTwoThreeZeroPercentageMember 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancodeBogotaBankloan2025IBRPlusTwoPointTwoZeroZeroPercentageMember currency:COP 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancodeBogotaBankloan2025IBRPlusOnePointSixEightZeroPercentageMember currency:COP 2024-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:TwentyTwentyFiveMember auna:BancodeBogotaBankloan2025IBRPlusFourPointZeroZeroZeroPercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:USD auna:TwentyTwentyFiveMember auna:BancoDeCreditoDelPeruBankLoan2025SevenPointEightFiveZeroPercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoDeCreditoDelPeruBankLoan2025SevenPointTwoZeroZeroPercentageMember currency:PEN 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyThreeMember auna:BancoDeCreditoDelPeruGovernmentGuaranteedLoan2023ZeroPointEightNineZeroPercentageMember currency:PEN 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyThreeMember auna:BancoDeCreditoDelPeruGovernmentGuaranteedLoan2023OnePointNineNineZeroPercentageMember currency:PEN 2024-12-31 0001799207 auna:TwentyTwentyEightMember auna:BancoSantanderMexicoHsbcAndCitibankBankLoan2028Sofr4875PercentageMember currency:USD 2024-12-31 0001799207 auna:TwentyTwentyEightMember auna:BancoSantanderMxicoHsbcAndCitibankBankLoan2028Tiie4500PercentageMember currency:MXN 2024-12-31 0001799207 currency:USD auna:TwentyTwentyEightMember auna:BancoSantanderMxicoHsbcAndCitibankBankLoan2028Sofr4875PercentageTwoMember 2024-12-31 0001799207 currency:MXN auna:TwentyTwentyFiveMember auna:HsbcMxicoBankLoan202512430PercentageMember 2024-12-31 0001799207 currency:PEN auna:TwentyTwentyFiveMember auna:BancognbBankLoan20255900PercentageMember 2024-12-31 0001799207 currency:MXN auna:TwentyTwentyThreeMember auna:BancoSantanderMxicoHsbcMexicoMultivaAndGenaroLevinsonMarcovichLoan2023Tiie650PercentageMember 2024-12-31 0001799207 auna:TwentyTwentyThreeMember auna:BbvaBancomerBankloan2023Tiie0900PercentageMember currency:MXN 2024-12-31 0001799207 auna:TwentyTwentyFiveMember auna:SecuredBondsIssuesSeniornotes20256500PercentageMember currency:USD 2024-12-31 0001799207 auna:TwentyTwentyNineMember auna:SecuredBondsIssuesSeniorNotes202910000PercentageMember currency:USD 2024-12-31 0001799207 auna:SeniorityPremiumMember 2024-12-31 0001799207 ifrs-full:ActuarialAssumptionOfDiscountRatesMember ifrs-full:BottomOfRangeMember 2024-12-31 0001799207 ifrs-full:ActuarialAssumptionOfDiscountRatesMember ifrs-full:TopOfRangeMember 2024-12-31 0001799207 auna:ActuarialAssumptionOfSalaryGrowthRatesMember ifrs-full:BottomOfRangeMember 2024-12-31 0001799207 auna:ActuarialAssumptionOfSalaryGrowthRatesMember ifrs-full:TopOfRangeMember 2024-12-31 0001799207 auna:ActuarialAssumptionOfMinimumWageRatesMember ifrs-full:TopOfRangeMember 2024-12-31 0001799207 auna:ActuarialAssumptionOfMinimumWageRatesMember ifrs-full:BottomOfRangeMember 2024-12-31 0001799207 auna:IncreaseInDicountRateMember auna:CurrentServiceCostImpactMember ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember 2024-12-31 0001799207 auna:DecreaseInDicountRateMember auna:DefinedBenefitObligationImpactMember ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember 2024-12-31 0001799207 auna:DecreaseInDicountRateMember auna:CurrentServiceCostImpactMember ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember 2024-12-31 0001799207 auna:IncreaseInDicountRateMember auna:DefinedBenefitObligationImpactMember ifrs-full:ActuarialAssumptionOfDiscountRatesMember 2024-12-31 0001799207 auna:IncreaseInDicountRateMember auna:CurrentServiceCostImpactMember ifrs-full:ActuarialAssumptionOfDiscountRatesMember 2024-12-31 0001799207 auna:DecreaseInDicountRateMember auna:DefinedBenefitObligationImpactMember ifrs-full:ActuarialAssumptionOfDiscountRatesMember 2024-12-31 0001799207 auna:DecreaseInDicountRateMember auna:CurrentServiceCostImpactMember ifrs-full:ActuarialAssumptionOfDiscountRatesMember 2024-12-31 0001799207 auna:IncreaseInDicountRateMember auna:DefinedBenefitObligationImpactMember ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember 2024-12-31 0001799207 ifrs-full:ActuarialAssumptionOfDiscountRatesMember 2024-12-31 0001799207 ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember 2024-12-31 0001799207 auna:MexicanSubsidiariesMember 2024-12-31 0001799207 auna:CitibankDelPeruSAAMember 2024-12-31 0001799207 ifrs-full:BottomOfRangeMember auna:NotesPurchaseAgreementMember 2024-12-31 0001799207 ifrs-full:TopOfRangeMember auna:NotesPurchaseAgreementMember 2024-12-31 0001799207 ifrs-full:RestrictedShareUnitsMember auna:Award2024GrantToDirectorsOnJanuary12024Member 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoBbvaContinentalBankLoan20246500PercentageMember currency:USD 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoBbvaContinentalBankLoan20258200PercentageMember currency:USD 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:USD auna:TwentyTwentyFiveMember auna:BancoBbvaContinentalBankLoan20256530PercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:TwentyTwentySevenMember auna:ScotiabankPerSaaOtherfinancing20275900PercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:TwentyTwentyFiveMember auna:ScotiabankPerSaaOtherfinancing20276000PercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:TwentyTwentyFiveMember auna:ScotiabankPerSaaBankLoan20256230PercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:ScotiabankPerSaaBankLoan20255950PercentageMember currency:PEN 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoCitibank20248800PercentageMember currency:PEN 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:USD auna:TwentyTwentyFiveMember auna:BancoCitibank20258380PercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentySevenMember auna:ScotiabankPerSaaOtherfinancing20276300PercentageMember currency:PEN 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoPichincha20246100PercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoPichincha20255900PercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:TwentyTwentyFourMember auna:BancoInternacionalDelPerSaa20246830PercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoInternacionalDelPerSaaBankLoan20255950PercentageMember currency:PEN 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:TwentyTwentyFiveMember auna:BancoInteramericanoDeFinanzas20256650PercentageMember 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoInteramericanoDeFinanzas20256200PercentageMember currency:PEN 2024-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoDeBogotaBankLoan2025FortySixPointTwoThreeZeroPercentageOneMember currency:COP 2024-12-31 0001799207 auna:BancoDaviviendaBankLoan2025IBRPlusFourPointSixZeroZeroPercentageOneMember auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember currency:COP 2024-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:TwentyTwentySixMember auna:BancoDaviviendaBankLoan2026IBRPlusThreePointFiveZeroZeroPercentageOneMember 2024-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:TwentyTwentyFiveMember auna:BancoDaviviendaBankLoan2025IBRPlusFivePointTwoZeroZeroPercentageMember 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancoDaviviendaBankLoan2025IBRPlusFourPointSevenZeroZeroPercentageMember currency:COP 2024-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancodeOccidenteBankloan2025IBRPlusOnePointSixTwoZeroPercentageMember currency:COP 2024-12-31 0001799207 auna:TwentyTwentyFiveMember auna:HsbcMxicoBankLoan202512430PercentageMember currency:PEN 2024-12-31 0001799207 auna:PerformanceBasedOptionAgreementOnMarchTwentyFirstTwoThousandAndTwentyFourMember 2024-12-31 0001799207 auna:LongTermIncentiveManagementOnMarchTwentyFirstTwoThousandAndTwentyFourMember 2024-12-31 0001799207 auna:RestrictedStockUnitOnMarchTwentyFirstTwoThousandAndTwentyFourMember 2024-12-31 0001799207 ifrs-full:BottomOfRangeMember 2024-12-31 0001799207 ifrs-full:TopOfRangeMember 2024-12-31 0001799207 ifrs-full:LandMember 2024-12-31 0001799207 ifrs-full:BuildingsMember 2024-12-31 0001799207 auna:MedicalEquipmentMember 2024-12-31 0001799207 ifrs-full:VehiclesMember 2024-12-31 0001799207 ifrs-full:FixturesAndFittingsMember 2024-12-31 0001799207 auna:WorksInProgressMember 2024-12-31 0001799207 ifrs-full:CurrentMember 2023-12-31 0001799207 auna:NonCurrentMember 2023-12-31 0001799207 auna:CiclotronColombiaSasMember 2023-12-31 0001799207 auna:CiclotrnPeruSaMember 2023-12-31 0001799207 auna:PetCtPeruSaMember 2023-12-31 0001799207 auna:AdjustmentForInvestmentsInAssociatesAndOthersMember 2023-12-31 0001799207 ifrs-full:PropertyPlantAndEquipmentMember 2023-12-31 0001799207 ifrs-full:LongtermBorrowingsMember 2023-12-31 0001799207 auna:AdjustmentForOthersMember 2023-12-31 0001799207 auna:AdjustmentOfProvisionsMember 2023-12-31 0001799207 auna:AdjustmentForTaxLossesMember 2023-12-31 0001799207 auna:AdjustmentForProvisionForUnpaidVacationsAndAnnualPerformanceBonusesMember 2023-12-31 0001799207 auna:AdjustmentForLossForImpairmentOfTradeReceivablesMember 2023-12-31 0001799207 auna:AdjustmentForDerivativeFinancialInstrumentsMember 2023-12-31 0001799207 auna:AdjustmentForTradeAccountsPayableMember 2023-12-31 0001799207 auna:EntitiesMember 2023-12-31 0001799207 auna:DentegraSegurosDentalesSAMember 2023-12-31 0001799207 ifrs-full:CurrencyRiskMember 2023-12-31 0001799207 ifrs-full:JointVenturesWhereEntityIsVenturerMember 2023-12-31 0001799207 ifrs-full:OtherRelatedPartiesMember 2023-12-31 0001799207 ifrs-full:AssociatesMember 2023-12-31 0001799207 ifrs-full:RelatedPartiesMember 2023-12-31 0001799207 auna:OtherManagementChargesMember 2023-12-31 0001799207 ifrs-full:FinancialGuaranteeContractsMember 2023-12-31 0001799207 auna:ScotiabankPerSAAMember 2023-12-31 0001799207 auna:BancoInteramericanoDeFinanzasMember 2023-12-31 0001799207 auna:BancoDeCreditoDelPeruMember 2023-12-31 0001799207 country:MX 2023-12-31 0001799207 auna:ClassACommonShareMember 2023-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:ClinicaVallesurMember 2023-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:ClinicaMirafloresMember 2023-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:PmlaMember 2023-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:ClinicaPortoazulMember 2023-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:OncomedicaMember 2023-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:AunaSaludMember 2023-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember ifrs-full:SubsidiariesMember 2023-12-31 0001799207 auna:FxOperationAgreementsPurchasedCollarLongPut2025Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2023-12-31 0001799207 auna:FxOperationAgreementsPurchasedCollarShortCall2025Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2023-12-31 0001799207 auna:FxOperationAgreementCallSpread2026Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2023-12-31 0001799207 auna:FxOperationAgreementCallSpread2028OneMember ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2023-12-31 0001799207 auna:FxOperationAgreementCallSpread2028TwoMember ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2023-12-31 0001799207 auna:FxOperationAgreementPurchasedCollar2028Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2023-12-31 0001799207 auna:FxOperationAgreementPurchasedCollar2024Member ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember 2023-12-31 0001799207 country:CO 2023-12-31 0001799207 country:PE 2023-12-31 0001799207 auna:DentegraSegurosDentalesSAMember 2023-12-31 0001799207 auna:OncomedicaSAMember 2023-12-31 0001799207 auna:HospitalYClnicaOcaSaDeCvMember 2023-12-31 0001799207 auna:InstitutoDeCancerologiaSAMember 2023-12-31 0001799207 auna:LaboratorioMedicoLasAmericasLtdaMember 2023-12-31 0001799207 auna:OncogenomicsSacMember 2023-12-31 0001799207 auna:PromotoraMedicaLasAmericasSAMember 2023-12-31 0001799207 auna:ClinicaBellavistaSacBellavistaMember 2023-12-31 0001799207 auna:PatologiaOncologicaSACMember 2023-12-31 0001799207 auna:RRPatologosAsociadosSACRrMember 2023-12-31 0001799207 auna:ServimedicosSACServimedicosMember 2023-12-31 0001799207 auna:RadioncologiaSACRadioncologiaMember 2023-12-31 0001799207 auna:LaboratorioCantellaSACCantellaMember 2023-12-31 0001799207 country:CO ifrs-full:BottomOfRangeMember 2023-12-31 0001799207 country:CO ifrs-full:TopOfRangeMember 2023-12-31 0001799207 country:PE ifrs-full:BottomOfRangeMember 2023-12-31 0001799207 country:PE ifrs-full:TopOfRangeMember 2023-12-31 0001799207 country:MX ifrs-full:BottomOfRangeMember 2023-12-31 0001799207 country:MX ifrs-full:TopOfRangeMember 2023-12-31 0001799207 ifrs-full:CreditRiskMember currency:MXN 2023-12-31 0001799207 ifrs-full:CreditRiskMember 2023-12-31 0001799207 ifrs-full:CreditRiskMember currency:PEN 2023-12-31 0001799207 ifrs-full:CreditRiskMember currency:COP 2023-12-31 0001799207 ifrs-full:LiquidityRiskMember ifrs-full:NotLaterThanOneYearMember 2023-12-31 0001799207 ifrs-full:LiquidityRiskMember ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember 2023-12-31 0001799207 ifrs-full:LiquidityRiskMember ifrs-full:CarryingAmountMember 2023-12-31 0001799207 ifrs-full:LiquidityRiskMember 2023-12-31 0001799207 ifrs-full:LiquidityRiskMember ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember 2023-12-31 0001799207 ifrs-full:LiquidityRiskMember ifrs-full:LaterThanFiveYearsMember 2023-12-31 0001799207 auna:CapitalRiskMember 2023-12-31 0001799207 auna:ClinicaPortoazulSaMember 2023-12-31 0001799207 auna:HospitalyClinicaOCASAdeCVMember 2023-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialAssetsAtFairValueMember auna:FairValueOtherComprehensiveIncomeDebtInstrumentsMember 2023-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialAssetsAtFairValueMember 2023-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:Level1OfFairValueHierarchyMember auna:FairValueMember 2023-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialAssetsAtFairValueMember auna:FairValueMember 2023-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialAssetsAtFairValueMember auna:FairValueHedgingInstrumentsMember 2023-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:Level2OfFairValueHierarchyMember auna:FairValueMember 2023-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialAssetsAtAmortisedCostMember auna:FinancialAssetsAtAmortizedCostMember 2023-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialAssetsAtAmortisedCostMember 2023-12-31 0001799207 auna:CapitalRiskMember auna:OtherFinancialLiabilitiesMember 2023-12-31 0001799207 auna:CapitalRiskMember ifrs-full:Level2OfFairValueHierarchyMember auna:FairValueMember 2023-12-31 0001799207 auna:CapitalRiskMember auna:FairValueMember 2023-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialLiabilitiesAtFairValueMember auna:OtherFinancialLiabilitiesMember 2023-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialLiabilitiesAtFairValueMember 2023-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialLiabilitiesAtFairValueMember ifrs-full:Level3OfFairValueHierarchyMember auna:FairValueMember 2023-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialLiabilitiesAtFairValueMember auna:FairValueMember 2023-12-31 0001799207 auna:PeruvianFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AMinusMember 2023-12-31 0001799207 auna:PeruvianFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AMember 2023-12-31 0001799207 auna:PeruvianFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:APlusMember 2023-12-31 0001799207 auna:PeruvianFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AAPlusMember 2023-12-31 0001799207 auna:MexicanFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AAMember 2023-12-31 0001799207 auna:MexicanFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:BBBMember 2023-12-31 0001799207 auna:MexicanFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AAAMember 2023-12-31 0001799207 auna:MexicanFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AMember 2023-12-31 0001799207 auna:ColombianFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AAMinusMember 2023-12-31 0001799207 auna:ColombianFinancialEntitiesMember 2023-12-31 0001799207 auna:ColombianFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AAAMember 2023-12-31 0001799207 auna:ColombianFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AAPlusMember 2023-12-31 0001799207 auna:LuxembourgFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AAAMember 2023-12-31 0001799207 auna:LuxembourgFinancialEntitiesMember 2023-12-31 0001799207 auna:PeruvianFinancialEntitiesMember 2023-12-31 0001799207 auna:LuxembourgFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AAMember 2023-12-31 0001799207 auna:MexicanFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:BBBPlusMember 2023-12-31 0001799207 auna:MexicanFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:BBBMinusMember 2023-12-31 0001799207 auna:MexicanFinancialEntitiesMember 2023-12-31 0001799207 auna:LuxembourgFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:APlusMember 2023-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:DentegraSegurosDentalesSAMember 2023-12-31 0001799207 auna:TerminalValueGrowthRateMember auna:DentegraSegurosDentalesSAMember 2023-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:HospitalyClinicaOCASAdeCVMember 2023-12-31 0001799207 auna:TerminalValueGrowthRateMember auna:HospitalyClinicaOCASAdeCVMember 2023-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:OncomedicaSAMember 2023-12-31 0001799207 auna:TerminalValueGrowthRateMember auna:OncomedicaSAMember 2023-12-31 0001799207 auna:TerminalValueGrowthRateMember auna:InstitutoDeCancerologiaSAMember 2023-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:PromotoraMedicaLasAmericasSAMember 2023-12-31 0001799207 auna:TerminalValueGrowthRateMember auna:PromotoraMedicaLasAmericasSAMember 2023-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:InstitutoDeCancerologiaSAMember 2023-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:OncogenomicsSacMember 2023-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:PatologiaOncologicaSACMember 2023-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:ServimedicosSACServimedicosMember 2023-12-31 0001799207 auna:TerminalValueGrowthRateMember auna:ServimedicosSACServimedicosMember 2023-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:ClinicaBellavistaSacBellavistaMember 2023-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:RRPatologosAsociadosSACRrMember 2023-12-31 0001799207 auna:TerminalValueGrowthRateMember auna:RRPatologosAsociadosSACRrMember 2023-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:RadioncologiaSACRadioncologiaMember 2023-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:LaboratorioCantellaSACCantellaMember 2023-12-31 0001799207 ifrs-full:IntangibleAssetsOtherThanGoodwillMember 2023-12-31 0001799207 ifrs-full:ContingentConsiderationMember ifrs-full:TopOfRangeMember 2023-12-31 0001799207 ifrs-full:ContingentConsiderationMember ifrs-full:BottomOfRangeMember 2023-12-31 0001799207 auna:PutLiabilityMember ifrs-full:TopOfRangeMember 2023-12-31 0001799207 auna:PutLiabilityMember ifrs-full:BottomOfRangeMember 2023-12-31 0001799207 ifrs-full:ContingentConsiderationMember 2023-12-31 0001799207 auna:PutLiabilityMember 2023-12-31 0001799207 auna:FactoringAgreementsWithCitibankDelPeruSAMember 2023-12-31 0001799207 auna:HealthcareServicesMember 2023-12-31 0001799207 auna:HealthcareServicesMember country:MX 2023-12-31 0001799207 auna:HealthcareServicesMember country:PE 2023-12-31 0001799207 auna:HealthcareServicesMember country:CO 2023-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember country:MX 2023-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember 2023-12-31 0001799207 ifrs-full:TradeReceivablesMember country:PE 2023-12-31 0001799207 ifrs-full:TradeReceivablesMember country:CO 2023-12-31 0001799207 ifrs-full:TradeReceivablesMember country:MX 2023-12-31 0001799207 ifrs-full:TradeReceivablesMember 2023-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember country:PE 2023-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember country:CO 2023-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember country:MX 2023-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember 2023-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember country:PE 2023-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember country:CO 2023-12-31 0001799207 ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember country:MX 2023-12-31 0001799207 ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember 2023-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember country:PE 2023-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember country:CO 2023-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember country:MX 2023-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember 2023-12-31 0001799207 ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember country:PE 2023-12-31 0001799207 ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember country:CO 2023-12-31 0001799207 ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember country:MX 2023-12-31 0001799207 ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember 2023-12-31 0001799207 ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember country:PE 2023-12-31 0001799207 ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember country:CO 2023-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember 2023-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember 2023-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember 2023-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember 2023-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember 2023-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:GrossCarryingAmountMember 2023-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:AllowanceForCreditLossesMember 2023-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember ifrs-full:GrossCarryingAmountMember 2023-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember ifrs-full:AllowanceForCreditLossesMember 2023-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember ifrs-full:GrossCarryingAmountMember 2023-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember ifrs-full:AllowanceForCreditLossesMember 2023-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember ifrs-full:GrossCarryingAmountMember 2023-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember ifrs-full:AllowanceForCreditLossesMember 2023-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember ifrs-full:GrossCarryingAmountMember 2023-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember ifrs-full:AllowanceForCreditLossesMember 2023-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember ifrs-full:GrossCarryingAmountMember 2023-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember ifrs-full:AllowanceForCreditLossesMember 2023-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember 2023-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember 2023-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember 2023-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember 2023-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember 2023-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:AllowanceForCreditLossesMember 2023-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember ifrs-full:AllowanceForCreditLossesMember 2023-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember ifrs-full:GrossCarryingAmountMember 2023-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember ifrs-full:AllowanceForCreditLossesMember 2023-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember ifrs-full:GrossCarryingAmountMember 2023-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember ifrs-full:AllowanceForCreditLossesMember 2023-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:GrossCarryingAmountMember 2023-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember ifrs-full:GrossCarryingAmountMember 2023-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember ifrs-full:AllowanceForCreditLossesMember 2023-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember ifrs-full:GrossCarryingAmountMember 2023-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember ifrs-full:AllowanceForCreditLossesMember 2023-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember ifrs-full:GrossCarryingAmountMember 2023-12-31 0001799207 auna:CapitalRiskMember ifrs-full:BottomOfRangeMember 2023-12-31 0001799207 ifrs-full:DiscountedCashFlowMember ifrs-full:ContingentConsiderationMember 2023-12-31 0001799207 ifrs-full:BottomOfRangeMember auna:PutLiabilityMember ifrs-full:DiscountRateMeasurementInputMember 2023-12-31 0001799207 ifrs-full:TopOfRangeMember auna:PutLiabilityMember ifrs-full:DiscountRateMeasurementInputMember 2023-12-31 0001799207 ifrs-full:BottomOfRangeMember ifrs-full:DiscountedCashFlowMember ifrs-full:ContingentConsiderationMember ifrs-full:DiscountRateMeasurementInputMember 2023-12-31 0001799207 ifrs-full:TopOfRangeMember ifrs-full:DiscountedCashFlowMember ifrs-full:ContingentConsiderationMember ifrs-full:DiscountRateMeasurementInputMember 2023-12-31 0001799207 auna:PatologaOncolgicaMember 2023-12-31 0001799207 auna:PromotoraMedicaLasAmericasSAMember 2023-12-31 0001799207 auna:ConsorcioTreccaMember 2023-12-31 0001799207 auna:MedicalSuppliesMember 2023-12-31 0001799207 auna:SuppliesAndPackagingMember 2023-12-31 0001799207 auna:MedicinesMember 2023-12-31 0001799207 currency:EUR 2023-12-31 0001799207 currency:MXN 2023-12-31 0001799207 currency:USD 2023-12-31 0001799207 currency:COP 2023-12-31 0001799207 currency:PEN 2023-12-31 0001799207 ifrs-full:ReportableSegmentsMember 2023-12-31 0001799207 auna:HoldingAndEliminationsMember 2023-12-31 0001799207 auna:OncosaludPeruMember 2023-12-31 0001799207 auna:HealthcareServicesInPeruMember 2023-12-31 0001799207 auna:HealthcareServicesInColombiaMember 2023-12-31 0001799207 auna:HealthcareServicesInMexicoMember 2023-12-31 0001799207 ifrs-full:UnusedTaxCreditsMember 2023-12-31 0001799207 auna:OnePointSixSevenMember auna:Citibank3Member auna:TwoThousandAndTwentySixMember auna:PayableThreeMember 2023-12-31 0001799207 auna:OnePointThreeZeroMember auna:Citibank4Member auna:TwoThousandAndTwentyEightMember auna:PayableFourMember 2023-12-31 0001799207 auna:ZeroPointSevenTwoMember auna:Citibank5Member auna:TwoThousandAndTwentyFourMember auna:PayableFiveMember 2023-12-31 0001799207 auna:TwoPointFiveThreeMember auna:SantanderBankMember auna:TwoThousandAndTwentySixMember auna:PayableSixMember 2023-12-31 0001799207 auna:OnePointSixSevenMember auna:Citibank1Member auna:TwoThousandAndTwentyFiveMember auna:PayableOneMember 2023-12-31 0001799207 auna:OnePointThreeZeroMember auna:Citibank2Member auna:TwoThousandAndTwentyEightMember auna:PayableTwoMember 2023-12-31 0001799207 auna:SeniorityPremiumMember 2023-12-31 0001799207 auna:RetirementBenefitsMember 2023-12-31 0001799207 ifrs-full:ActuarialAssumptionOfDiscountRatesMember ifrs-full:BottomOfRangeMember 2023-12-31 0001799207 ifrs-full:ActuarialAssumptionOfDiscountRatesMember ifrs-full:TopOfRangeMember 2023-12-31 0001799207 auna:ActuarialAssumptionOfSalaryGrowthRatesMember ifrs-full:BottomOfRangeMember 2023-12-31 0001799207 auna:ActuarialAssumptionOfSalaryGrowthRatesMember ifrs-full:TopOfRangeMember 2023-12-31 0001799207 auna:ActuarialAssumptionOfMinimumWageRatesMember ifrs-full:TopOfRangeMember 2023-12-31 0001799207 auna:ActuarialAssumptionOfMinimumWageRatesMember ifrs-full:BottomOfRangeMember 2023-12-31 0001799207 auna:DecreaseInDicountRateMember auna:CurrentServiceCostImpactMember ifrs-full:ActuarialAssumptionOfDiscountRatesMember 2023-12-31 0001799207 auna:IncreaseInDicountRateMember auna:DefinedBenefitObligationImpactMember ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember 2023-12-31 0001799207 auna:IncreaseInDicountRateMember auna:DefinedBenefitObligationImpactMember ifrs-full:ActuarialAssumptionOfDiscountRatesMember 2023-12-31 0001799207 auna:IncreaseInDicountRateMember auna:CurrentServiceCostImpactMember ifrs-full:ActuarialAssumptionOfDiscountRatesMember 2023-12-31 0001799207 auna:DecreaseInDicountRateMember auna:DefinedBenefitObligationImpactMember ifrs-full:ActuarialAssumptionOfDiscountRatesMember 2023-12-31 0001799207 auna:IncreaseInDicountRateMember auna:CurrentServiceCostImpactMember ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember 2023-12-31 0001799207 auna:DecreaseInDicountRateMember auna:DefinedBenefitObligationImpactMember ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember 2023-12-31 0001799207 auna:DecreaseInDicountRateMember auna:CurrentServiceCostImpactMember ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember 2023-12-31 0001799207 ifrs-full:ActuarialAssumptionOfDiscountRatesMember 2023-12-31 0001799207 ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember 2023-12-31 0001799207 auna:MexicanSubsidiariesMember 2023-12-31 0001799207 auna:CitibankDelPeruSAAMember 2023-12-31 0001799207 auna:NotesPurchaseAgreementMember ifrs-full:BottomOfRangeMember 2023-12-31 0001799207 ifrs-full:TopOfRangeMember auna:NotesPurchaseAgreementMember 2023-12-31 0001799207 ifrs-full:RestrictedShareUnitsMember auna:Award2023GrantToDirectorsOnDecember82023Member 2023-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFourMember auna:BancodeOccidenteBankloan2024IBRPlusThreePointSevenThreeZeroPercentageMember currency:COP 2023-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyEightMember auna:BancodeOccidenteBankloan2028IBRPlusFourPointNineNineZeroPercentageMember currency:COP 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoDaviviendaBankLoan2025FortyFivePointNineThreeZeroPercentageMember currency:COP 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025FortySixPointTwoOneZeroPercentageThreeMember currency:COP 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:COP auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025FortySixPointTwoOneZeroPercentageOneMember 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025FortySixPointTwoOneZeroPercentageTwoMember currency:COP 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoInteramericanoDeFinanzas20248450PercentageMember currency:PEN 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoInteramericanoDeFinanzas20247610PercentageMember currency:USD 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoInteramericanoDeFinanzas20248150PercentageMember currency:PEN 2023-12-31 0001799207 auna:BancolombiaBankLoan2025FortySixPointTwoOneZeroPercentageMember ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember currency:COP 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:USD auna:TwentyTwentyFiveMember auna:BancoBbvaContinentalBankLoan20256950PercentageMember 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentySevenMember auna:ScotiabankPerSaaOtherfinancing20276300PercentageMember currency:PEN 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:TwentyTwentyFourMember auna:ScotiabankPeruSaaBankLoan20248500PercentageMember 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFourMember auna:ScotiabankPerSAABankloan20248700PercentageMember currency:PEN 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFourMember auna:BancoCitibank202410060PercentageMember currency:PEN 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFourMember auna:BancoInternacionalDelPerSaaBankLoan20247380PercentageMember currency:USD 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyThreeMember auna:BancoPichincha20247350PercentageMember 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:TwentyTwentyFiveMember auna:BancoInteramericanoDeFinanzas20248300PercentageMember 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFourMember auna:BancoInternacionalDelPerSaa20257750PercentageMember currency:USD 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:TwentyTwentyFourMember auna:BancoDeCreditoDelPeruBankLoan2024NinePointSevenZeroZeroPercentageMember 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFourMember auna:BancoDeCreditoDelPeruBankLoan2024SixPointNineThreeZeroPercentageOneMember currency:USD 2023-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyThirtyFiveMember auna:ItauCorpbancaColombiaSABankLoan2024IBRPlusThreePointFourNineZeroPercentageMember currency:COP 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyEightMember auna:BostonScientificColombiaLt2028TenPointSevenEightZeroPercentageMember currency:COP 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:ItauCorpbancaColombiaSABankLoan2025FortyFivePointTwoFourZeroPercentageMember currency:COP 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFourMember auna:ItauCorpbancaColombiaSABankLoan2024EightPointSixFourZeroPercentageMember currency:COP 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoCitibankColombiaBankLoan2025FourteenPointSixThreeZeroPercentageMember currency:COP 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:COP auna:TwentyTwentyFiveMember auna:BancoCitibankColombiaBankLoan2025TwelvePointSixZeroZeroPercentageMember 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoCitibankColombiaBankLoan2025FifteenPointThreeTwoZeroPercentageMember currency:COP 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoCitibankColombiaBankLoan2025FifteenPointThreeSevenZeroPercentageMember currency:COP 2023-12-31 0001799207 auna:TermDepositRateMember auna:TwentyTwentySixMember auna:BancolombiaBankLoan2026DtfPlusThreePointZeroOneZeroPercentageMember currency:COP 2023-12-31 0001799207 auna:TermDepositRateMember auna:TwentyThirtyThreeMember auna:BancolombiaOtherFinancing2033DtfPlusThreePointNineFiveZeroPercentageMember currency:COP 2023-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:TwentyTwentyFourMember auna:BancolombiaBankLoan2024IbrPlusSixPointFourThreeZeroPercentageMember 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:COP auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025ThirtyNinePointSixFourZeroPercentageMember 2023-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025IbrPlusSixPointSixSevenTwoPercentageMember currency:COP 2023-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025IbrPlusSevenPointZeroFourTwoPercentageMember 2023-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFourMember auna:BancolombiaBankLoan2024IbrPlusSixPointSixZeroZeroPercentageMember currency:COP 2023-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyThirtyThreeMember auna:BancolombiaBankLoan2033IbrPlusSixPointFourZeroZeroPercentageMember currency:COP 2023-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentySixMember auna:BancodeBogotaBankloan2026IBRPlusFivePointFiveZeroZeroPercentageMember currency:COP 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoDeBogotaBankLoan2025FortySixPointTwoThreeZeroPercentageMember currency:COP 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:COP auna:TwentyTwentyFiveMember auna:BancoDeBogotaBankLoan2025FortySixPointTwoThreeZeroPercentageOneMember 2023-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:TwentyTwentyFiveMember auna:BancodeBogotaBankloan2025IBRPlusSevenPointZeroZeroZeroPercentageMember 2023-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyEightMember auna:BancoDaviviendaGovernmentGuaranteedLoan2028IBRPlusSixPointEightZeroZeroPercentageMember currency:COP 2023-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:TwentyTwentyFiveMember auna:BancoDaviviendaGovernmentGuaranteedLoan2025IBRPlusThreePointFiveZeroZeroPercentageMember 2023-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentySevenMember auna:BancoDaviviendaGovernmentGuaranteedLoan2027IBRPlusThreePointSevenFiveZeroPercentageMember currency:COP 2023-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyNineMember auna:BancoDaviviendaGovernmentGuaranteedLoan2029IBRPlusOnePointFiveZeroZeroPercentageMember currency:COP 2023-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancoDaviviendaGovernmentGuaranteedLoan2025IBRPlusFivePointFiveFiveZeroPercentageMember currency:COP 2023-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFourMember auna:BancodeOccidenteBankloan2024ThirtyEightPointFiveTwoZeroPercentageMember currency:COP 2023-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancoDaviviendaGovernmentGuaranteedLoan2025IBRPlusOnePointFiveZeroZeroPercentageMember currency:COP 2023-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancodeBogotaBankloan2025IBRPlusFourPointZeroZeroZeroPercentageMember currency:COP 2023-12-31 0001799207 currency:USD auna:TwentyTwentyEightMember auna:BancoSantanderMxicoHsbcAndCitibankBankLoan2028Sofr4875PercentageTwoMember 2023-12-31 0001799207 auna:TwentyTwentyNineMember auna:SecuredBondsIssuesSeniorNotes202910000PercentageMember currency:USD 2023-12-31 0001799207 auna:TwentyTwentyEightMember auna:BancoSantanderMexicoHsbcAndCitibankBankLoan2028Sofr4875PercentageMember currency:USD 2023-12-31 0001799207 auna:TwentyTwentyEightMember auna:BancoSantanderMxicoHsbcAndCitibankBankLoan2028Tiie4500PercentageMember currency:MXN 2023-12-31 0001799207 currency:USD auna:TwentyTwentyFiveMember auna:SecuredBondsIssuesSeniornotes20256500PercentageMember 2023-12-31 0001799207 ifrs-full:BottomOfRangeMember 2023-12-31 0001799207 ifrs-full:TopOfRangeMember 2023-12-31 0001799207 ifrs-full:BuildingsMember 2023-12-31 0001799207 auna:MedicalEquipmentMember 2023-12-31 0001799207 ifrs-full:VehiclesMember 2023-12-31 0001799207 ifrs-full:FixturesAndFittingsMember 2023-12-31 0001799207 auna:WorksInProgressMember 2023-12-31 0001799207 ifrs-full:LandMember 2023-12-31 0001799207 auna:CiclotronColombiaSasMember 2022-12-31 0001799207 auna:CiclotrnPeruSaMember 2022-12-31 0001799207 auna:PetCtPeruSaMember 2022-12-31 0001799207 auna:AdjustmentForOthersMember 2022-12-31 0001799207 auna:AdjustmentForTaxLossesMember 2022-12-31 0001799207 auna:AdjustmentForProvisionForUnpaidVacationsAndAnnualPerformanceBonusesMember 2022-12-31 0001799207 auna:AdjustmentForTradeAccountsPayableMember 2022-12-31 0001799207 auna:AdjustmentForLossForImpairmentOfTradeReceivablesMember 2022-12-31 0001799207 ifrs-full:LongtermBorrowingsMember 2022-12-31 0001799207 auna:AdjustmentForInvestmentsInAssociatesAndOthersMember 2022-12-31 0001799207 ifrs-full:PropertyPlantAndEquipmentMember 2022-12-31 0001799207 auna:AdjustmentOfProvisionsMember 2022-12-31 0001799207 auna:AdjustmentForDerivativeFinancialInstrumentsMember 2022-12-31 0001799207 auna:EntitiesMember 2022-12-31 0001799207 ifrs-full:CurrencyRiskMember 2022-12-31 0001799207 auna:OncomedicaSAMember 2022-12-31 0001799207 ifrs-full:JointVenturesWhereEntityIsVenturerMember 2022-12-31 0001799207 ifrs-full:OtherRelatedPartiesMember 2022-12-31 0001799207 ifrs-full:AssociatesMember 2022-12-31 0001799207 ifrs-full:RelatedPartiesMember 2022-12-31 0001799207 auna:OtherManagementChargesMember 2022-12-31 0001799207 ifrs-full:FinancialGuaranteeContractsMember 2022-12-31 0001799207 auna:ScotiabankPerSAAMember 2022-12-31 0001799207 auna:BancoInteramericanoDeFinanzasMember 2022-12-31 0001799207 auna:BancoInterbankMember 2022-12-31 0001799207 auna:BancoDeCreditoDelPeruMember 2022-12-31 0001799207 auna:CitibankMember 2022-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:ClinicaVallesurMember 2022-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:ClinicaMirafloresMember 2022-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:PmlaMember 2022-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:ClinicaPortoazulMember 2022-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:OncomedicaMember 2022-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:AunaSaludMember 2022-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember ifrs-full:SubsidiariesMember 2022-12-31 0001799207 ifrs-full:OtherReservesMember 2022-12-31 0001799207 auna:FxOperationAgreementsLongForward2023Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2022-12-31 0001799207 auna:FxOperationAgreementsPurchasedCollarLongPut2023Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2022-12-31 0001799207 auna:FxOperationAgreementsPurchasedCollarShortCall2023Member ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2022-12-31 0001799207 auna:FxOperationAgreementPurchasedCollar2026Member ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember 2022-12-31 0001799207 country:CO 2022-12-31 0001799207 country:PE 2022-12-31 0001799207 country:MX 2022-12-31 0001799207 auna:OncomedicaSAMember 2022-12-31 0001799207 auna:HospitalYClnicaOcaSaDeCvMember 2022-12-31 0001799207 auna:InstitutoDeCancerologiaSAMember 2022-12-31 0001799207 auna:LaboratorioMedicoLasAmericasLtdaMember 2022-12-31 0001799207 auna:OncogenomicsSacMember 2022-12-31 0001799207 auna:PromotoraMedicaLasAmericasSAMember 2022-12-31 0001799207 auna:ClinicaBellavistaSacBellavistaMember 2022-12-31 0001799207 auna:PatologiaOncologicaSACMember 2022-12-31 0001799207 auna:RRPatologosAsociadosSACRrMember 2022-12-31 0001799207 auna:ServimedicosSACServimedicosMember 2022-12-31 0001799207 auna:RadioncologiaSACRadioncologiaMember 2022-12-31 0001799207 auna:LaboratorioCantellaSACCantellaMember 2022-12-31 0001799207 country:PE ifrs-full:BottomOfRangeMember 2022-12-31 0001799207 country:PE ifrs-full:TopOfRangeMember 2022-12-31 0001799207 country:CO ifrs-full:BottomOfRangeMember 2022-12-31 0001799207 country:CO ifrs-full:TopOfRangeMember 2022-12-31 0001799207 ifrs-full:CreditRiskMember currency:MXN 2022-12-31 0001799207 ifrs-full:CreditRiskMember 2022-12-31 0001799207 ifrs-full:CreditRiskMember currency:PEN 2022-12-31 0001799207 ifrs-full:CreditRiskMember currency:COP 2022-12-31 0001799207 ifrs-full:LiquidityRiskMember ifrs-full:CarryingAmountMember 2022-12-31 0001799207 ifrs-full:LiquidityRiskMember 2022-12-31 0001799207 ifrs-full:LiquidityRiskMember ifrs-full:NotLaterThanOneYearMember 2022-12-31 0001799207 ifrs-full:LiquidityRiskMember ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember 2022-12-31 0001799207 ifrs-full:LiquidityRiskMember ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember 2022-12-31 0001799207 ifrs-full:LiquidityRiskMember ifrs-full:LaterThanFiveYearsMember 2022-12-31 0001799207 auna:CapitalRiskMember 2022-12-31 0001799207 auna:ClinicaPortoazulSaMember 2022-12-31 0001799207 auna:HospitalyClinicaOCASAdeCVMember 2022-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialAssetsAtFairValueMember auna:FairValueHedgingInstrumentsMember 2022-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialAssetsAtFairValueMember 2022-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:Level2OfFairValueHierarchyMember auna:FairValueMember 2022-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialAssetsAtFairValueMember auna:FairValueMember 2022-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialAssetsAtAmortisedCostMember auna:FinancialAssetsAtAmortizedCostMember 2022-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialAssetsAtAmortisedCostMember 2022-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialLiabilitiesAtFairValueMember auna:FairValueHedgingInstrumentsMember 2022-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialLiabilitiesAtFairValueMember 2022-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialLiabilitiesAtFairValueMember ifrs-full:Level2OfFairValueHierarchyMember auna:FairValueMember 2022-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialLiabilitiesAtFairValueMember auna:FairValueMember 2022-12-31 0001799207 auna:CapitalRiskMember auna:OtherFinancialLiabilitiesMember 2022-12-31 0001799207 auna:CapitalRiskMember ifrs-full:Level2OfFairValueHierarchyMember auna:FairValueMember 2022-12-31 0001799207 auna:CapitalRiskMember auna:FairValueMember 2022-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialLiabilitiesAtFairValueMember auna:OtherFinancialLiabilitiesMember 2022-12-31 0001799207 auna:CapitalRiskMember ifrs-full:FinancialLiabilitiesAtFairValueMember ifrs-full:Level3OfFairValueHierarchyMember auna:FairValueMember 2022-12-31 0001799207 auna:PeruvianFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AMinusMember 2022-12-31 0001799207 auna:PeruvianFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AMember 2022-12-31 0001799207 auna:PeruvianFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:APlusMember 2022-12-31 0001799207 auna:PeruvianFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AAPlusMember 2022-12-31 0001799207 auna:MexicanFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AAMember 2022-12-31 0001799207 auna:MexicanFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:BBBMember 2022-12-31 0001799207 auna:MexicanFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AAAMember 2022-12-31 0001799207 auna:MexicanFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AMember 2022-12-31 0001799207 auna:ColombianFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AAMinusMember 2022-12-31 0001799207 auna:ColombianFinancialEntitiesMember 2022-12-31 0001799207 auna:ColombianFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AAAMember 2022-12-31 0001799207 auna:ColombianFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AAPlusMember 2022-12-31 0001799207 auna:LuxembourgFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:AAAMember 2022-12-31 0001799207 auna:LuxembourgFinancialEntitiesMember 2022-12-31 0001799207 auna:PeruvianFinancialEntitiesMember 2022-12-31 0001799207 auna:LuxembourgFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:APlusMember 2022-12-31 0001799207 auna:MexicanFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:BBBPlusMember 2022-12-31 0001799207 auna:MexicanFinancialEntitiesMember auna:BankDepositsAndAccountsMember auna:BBBMinusMember 2022-12-31 0001799207 auna:MexicanFinancialEntitiesMember 2022-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:HospitalyClinicaOCASAdeCVMember 2022-12-31 0001799207 auna:TerminalValueGrowthRateMember auna:HospitalyClinicaOCASAdeCVMember 2022-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:OncomedicaSAMember 2022-12-31 0001799207 auna:TerminalValueGrowthRateMember auna:OncomedicaSAMember 2022-12-31 0001799207 auna:TerminalValueGrowthRateMember auna:InstitutoDeCancerologiaSAMember 2022-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:LaboratorioMedicoLasAmericasLtdaMember 2022-12-31 0001799207 auna:TerminalValueGrowthRateMember auna:LaboratorioMedicoLasAmericasLtdaMember 2022-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:InstitutoDeCancerologiaSAMember 2022-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:OncogenomicsSacMember 2022-12-31 0001799207 auna:TerminalValueGrowthRateMember auna:OncogenomicsSacMember 2022-12-31 0001799207 auna:TerminalValueGrowthRateMember auna:ClinicaBellavistaSacBellavistaMember 2022-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:PatologiaOncologicaSACMember 2022-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:ServimedicosSACServimedicosMember 2022-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:ClinicaBellavistaSacBellavistaMember 2022-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:LaboratorioCantellaSACCantellaMember 2022-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:RRPatologosAsociadosSACRrMember 2022-12-31 0001799207 auna:AfterTaxDiscountRateMember auna:RadioncologiaSACRadioncologiaMember 2022-12-31 0001799207 auna:TerminalValueGrowthRateMember auna:RadioncologiaSACRadioncologiaMember 2022-12-31 0001799207 ifrs-full:IntangibleAssetsOtherThanGoodwillMember 2022-12-31 0001799207 auna:PutLiabilityMember ifrs-full:BottomOfRangeMember 2022-12-31 0001799207 ifrs-full:ContingentConsiderationMember ifrs-full:TopOfRangeMember 2022-12-31 0001799207 ifrs-full:ContingentConsiderationMember ifrs-full:BottomOfRangeMember 2022-12-31 0001799207 auna:PutLiabilityMember ifrs-full:TopOfRangeMember 2022-12-31 0001799207 ifrs-full:ContingentConsiderationMember 2022-12-31 0001799207 auna:PutLiabilityMember 2022-12-31 0001799207 auna:FactoringAgreementsWithCitibankDelPeruSAMember 2022-12-31 0001799207 auna:HealthcareServicesMember 2022-12-31 0001799207 auna:HealthcareServicesMember country:PE 2022-12-31 0001799207 auna:HealthcareServicesMember country:CO 2022-12-31 0001799207 auna:HealthcareServicesMember country:MX 2022-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember country:MX 2022-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember 2022-12-31 0001799207 ifrs-full:TradeReceivablesMember country:PE 2022-12-31 0001799207 ifrs-full:TradeReceivablesMember country:CO 2022-12-31 0001799207 ifrs-full:TradeReceivablesMember country:MX 2022-12-31 0001799207 ifrs-full:TradeReceivablesMember 2022-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember country:PE 2022-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember country:CO 2022-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember country:MX 2022-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember 2022-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember country:PE 2022-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember country:CO 2022-12-31 0001799207 ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember country:MX 2022-12-31 0001799207 ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember 2022-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember country:PE 2022-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember country:CO 2022-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember country:MX 2022-12-31 0001799207 ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember 2022-12-31 0001799207 ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember country:PE 2022-12-31 0001799207 ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember country:CO 2022-12-31 0001799207 ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember country:MX 2022-12-31 0001799207 ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember 2022-12-31 0001799207 ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember country:PE 2022-12-31 0001799207 ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember country:CO 2022-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember 2022-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember 2022-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember 2022-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember 2022-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember 2022-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember ifrs-full:GrossCarryingAmountMember 2022-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember ifrs-full:AllowanceForCreditLossesMember 2022-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember ifrs-full:GrossCarryingAmountMember 2022-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember ifrs-full:AllowanceForCreditLossesMember 2022-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember ifrs-full:GrossCarryingAmountMember 2022-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember ifrs-full:AllowanceForCreditLossesMember 2022-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember ifrs-full:GrossCarryingAmountMember 2022-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember ifrs-full:AllowanceForCreditLossesMember 2022-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:GrossCarryingAmountMember 2022-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember ifrs-full:GrossCarryingAmountMember 2022-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember ifrs-full:AllowanceForCreditLossesMember 2022-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:AllowanceForCreditLossesMember 2022-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember 2022-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember 2022-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember 2022-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember 2022-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember 2022-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember ifrs-full:AllowanceForCreditLossesMember 2022-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember ifrs-full:GrossCarryingAmountMember 2022-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanSixMonthAndNotLaterThanTwelveMonthsMember ifrs-full:AllowanceForCreditLossesMember 2022-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember ifrs-full:GrossCarryingAmountMember 2022-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanTwelveMonthsMember ifrs-full:AllowanceForCreditLossesMember 2022-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:GrossCarryingAmountMember 2022-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember ifrs-full:GrossCarryingAmountMember 2022-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember ifrs-full:AllowanceForCreditLossesMember 2022-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember ifrs-full:GrossCarryingAmountMember 2022-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanThreeMonthsMember ifrs-full:AllowanceForCreditLossesMember 2022-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember auna:LaterThanThreeMonthAndNotLaterThanSixMonthsMember ifrs-full:GrossCarryingAmountMember 2022-12-31 0001799207 auna:IndividualCustomersMember ifrs-full:TradeReceivablesMember ifrs-full:AllowanceForCreditLossesMember 2022-12-31 0001799207 auna:CapitalRiskMember ifrs-full:BottomOfRangeMember 2022-12-31 0001799207 auna:PatologaOncolgicaMember 2022-12-31 0001799207 auna:PromotoraMedicaLasAmericasSAMember 2022-12-31 0001799207 auna:ConsorcioTreccaMember 2022-12-31 0001799207 auna:MedicalSuppliesMember 2022-12-31 0001799207 auna:SuppliesAndPackagingMember 2022-12-31 0001799207 auna:MedicinesMember 2022-12-31 0001799207 currency:MXN 2022-12-31 0001799207 currency:USD 2022-12-31 0001799207 currency:COP 2022-12-31 0001799207 currency:PEN 2022-12-31 0001799207 auna:HealthcareServicesInMexicoMember 2022-12-31 0001799207 ifrs-full:ReportableSegmentsMember 2022-12-31 0001799207 auna:HoldingAndEliminationsMember 2022-12-31 0001799207 auna:OncosaludPeruMember 2022-12-31 0001799207 auna:HealthcareServicesInPeruMember 2022-12-31 0001799207 auna:HealthcareServicesInColombiaMember 2022-12-31 0001799207 ifrs-full:UnusedTaxCreditsMember 2022-12-31 0001799207 auna:GoldmanSachsBankOneMember auna:PayableTenMember 2022-12-31 0001799207 auna:PayableSevenMember 2022-12-31 0001799207 auna:PayableEightMember 2022-12-31 0001799207 auna:PayableNineMember 2022-12-31 0001799207 auna:SeniorityPremiumMember 2022-12-31 0001799207 auna:RetirementBenefitsMember 2022-12-31 0001799207 ifrs-full:ActuarialAssumptionOfDiscountRatesMember 2022-12-31 0001799207 auna:ActuarialAssumptionOfSalaryGrowthRatesMember 2022-12-31 0001799207 auna:ActuarialAssumptionOfMinimumWageRatesMember 2022-12-31 0001799207 auna:DecreaseInDicountRateMember auna:CurrentServiceCostImpactMember ifrs-full:ActuarialAssumptionOfDiscountRatesMember 2022-12-31 0001799207 auna:IncreaseInDicountRateMember auna:DefinedBenefitObligationImpactMember ifrs-full:ActuarialAssumptionOfDiscountRatesMember 2022-12-31 0001799207 auna:IncreaseInDicountRateMember auna:CurrentServiceCostImpactMember ifrs-full:ActuarialAssumptionOfDiscountRatesMember 2022-12-31 0001799207 auna:DecreaseInDicountRateMember auna:DefinedBenefitObligationImpactMember ifrs-full:ActuarialAssumptionOfDiscountRatesMember 2022-12-31 0001799207 auna:MexicanSubsidiariesMember 2022-12-31 0001799207 auna:CitibankDelPeruSAAMember 2022-12-31 0001799207 auna:FxOperationAgreementsPurchasedCollarLongPut2025Member auna:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2022-12-31 0001799207 auna:FxOperationAgreementsPurchasedCollarShortCall2025Member auna:FinancialLiabilitiesMeasuredAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2022-12-31 0001799207 ifrs-full:BottomOfRangeMember auna:NotesPurchaseAgreementMember 2022-12-31 0001799207 ifrs-full:BottomOfRangeMember auna:BancoSantanderHsbcMxicoAndGenaroLevinsonMarcovichMember 2022-12-31 0001799207 auna:NotesPurchaseAgreementMember ifrs-full:TopOfRangeMember 2022-12-31 0001799207 ifrs-full:TopOfRangeMember auna:JpmorganChaseBankSaMember 2022-12-31 0001799207 ifrs-full:BottomOfRangeMember auna:JpmorganChaseBankSaMember 2022-12-31 0001799207 ifrs-full:TopOfRangeMember auna:BancoSantanderHsbcMxicoAndGenaroLevinsonMarcovichMember 2022-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025FortySixPointTwoOneZeroPercentageThreeMember currency:COP 2022-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025TwoPointNineOneZeroPercentageMember currency:COP 2022-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025IbrPlusFourPointTwoOneZeroPercentageMember 2022-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025IbrPlusFourPointSixTwoZeroPercentageMember currency:COP 2022-12-31 0001799207 auna:BancolombiaBankLoan2025FortySixPointTwoOneZeroPercentageMember ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember currency:COP 2022-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025FortySixPointTwoOneZeroPercentageOneMember currency:COP 2022-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025FortySixPointTwoOneZeroPercentageTwoMember currency:COP 2022-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoInteramericanoDeFinanzas20246000PercentageMember currency:PEN 2022-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFourMember auna:BancoBbvaContinentalBankLoan20247500PercentageMember currency:USD 2022-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:USD auna:TwentyTwentyFourMember auna:BancoItau20244850PercentageMember 2022-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:TwentyTwentySevenMember auna:ScotiabankPerSaaOtherfinancing20276300PercentageMember 2022-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyThreeMember currency:USD 2022-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFourMember auna:BancoCitibank20256400PercentageMember currency:USD 2022-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFourMember auna:BancoCitibank20255790PercentageMember currency:USD 2022-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:PEN auna:TwentyTwentyFourMember auna:BancoCitibank20249650PercentageMember 2022-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFourMember auna:BancoInternacionalDelPerSaaBankLoan20246000PercentageMember currency:USD 2022-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyThreeMember auna:BancoPichincha20247350PercentageMember 2022-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyThreeMember auna:BancoDeCreditoDelPeruGovernmentGuaranteedLoan2023OnePointNineNineZeroPercentageMember currency:PEN 2022-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoInteramericanoDeFinanzas20247200PercentageMember currency:PEN 2022-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:USD auna:TwentyTwentyThreeMember auna:BancoDeCreditoDelPeruBankLoan2023EightPointFourEightZeroPercentageMember 2022-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyThreeMember auna:BancoDeCreditoDelPeruGovernmentGuaranteedLoan2023ZeroPointEightNineZeroPercentageMember currency:PEN 2022-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyThirtyFiveMember auna:ItauCorpbancaColombiaSABankLoan2024IBRPlusThreePointFourNineZeroPercentageMember currency:COP 2022-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyEightMember auna:BostonScientificColombiaLt2028TenPointSevenEightZeroPercentageMember currency:COP 2022-12-31 0001799207 auna:SecuredOvernightFinancingRateMember currency:USD auna:TwentyTwentyThreeMember auna:JPMorganBank2023SOFRPlusFourPointZeroZeroZeroPercentageMember 2022-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:ItauCorpbancaColombiaSABankLoan2025FortyFivePointTwoFourZeroPercentageMember currency:COP 2022-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:COP auna:TwentyTwentyFourMember auna:ItauCorpbancaColombiaSABankLoan2024EightPointSixFourZeroPercentageMember 2022-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFourMember auna:ItauCorpbancaColombiaSABankLoan2024IBRPlusThreePointSixFiveZeroPercentageMember currency:COP 2022-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyThreeMember auna:BancoCitibankColombiaBankLoan2023TwelvePointThreeOneZeroPercentageMember currency:COP 2022-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:COP auna:TwentyTwentyThreeMember auna:BancoCitibankColombiaBankLoan2023FifteenPointZeroEightZeroPercentageMember 2022-12-31 0001799207 auna:TermDepositRateMember currency:COP auna:TwentyThirtyThreeMember auna:BancolombiaOtherFinancing2033DtfPlusThreePointNineFiveZeroPercentageMember 2022-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:TwentyTwentyFiveMember auna:BancolombiaBankLoan2025IbrPlusFivePointFiveTwoZeroPercentageMember 2022-12-31 0001799207 auna:BancolombiaBankLoan2026DtfPlusThreePointZeroOneZeroPercentageMember auna:TermDepositRateMember auna:TwentyTwentySixMember currency:COP 2022-12-31 0001799207 ifrs-full:FixedInterestRateMember auna:TwentyTwentyFiveMember auna:BancoDeBogotaBankLoan2025FortySixPointTwoThreeZeroPercentageOneMember currency:COP 2022-12-31 0001799207 auna:BankReferenceIndicatorMember currency:COP auna:TwentyTwentyFiveMember auna:BancoDaviviendaGovernmentGuaranteedLoan2025IBRPlusOnePointFiveZeroZeroPercentageMember 2022-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:COP auna:TwentyTwentyFiveMember auna:BancoDeBogotaBankLoan2025FortySixPointTwoThreeZeroPercentageMember 2022-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancoDaviviendaGovernmentGuaranteedLoan2025IBRPlusThreePointFiveZeroZeroPercentageMember currency:COP 2022-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentySevenMember auna:BancoDaviviendaGovernmentGuaranteedLoan2027IBRPlusThreePointSevenFiveZeroPercentageMember currency:COP 2022-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyNineMember auna:BancoDaviviendaGovernmentGuaranteedLoan2029IBRPlusOnePointFiveZeroZeroPercentageMember currency:COP 2022-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancoDaviviendaGovernmentGuaranteedLoan2025IBRPlusFivePointFiveFiveZeroPercentageMember currency:COP 2022-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancodeBogotaBankloan2025IBRPlusFourPointZeroZeroZeroPercentageMember currency:COP 2022-12-31 0001799207 ifrs-full:FixedInterestRateMember currency:COP auna:TwentyTwentyFourMember auna:BancodeOccidenteBankloan2024ThirtyEightPointFiveTwoZeroPercentageMember 2022-12-31 0001799207 auna:BankReferenceIndicatorMember auna:TwentyTwentyFiveMember auna:BancodeBogotaBankloan2025IBRPlusTwoPointTwoZeroZeroPercentageMember currency:COP 2022-12-31 0001799207 auna:TwentyTwentyThreeMember auna:BancoSantanderMxicoHsbcMexicoMultivaAndGenaroLevinsonMarcovichLoan2023Tiie650PercentageMember currency:MXN 2022-12-31 0001799207 auna:TwentyTwentyThreeMember auna:BbvaBancomerBankloan2023Tiie0900PercentageMember currency:MXN 2022-12-31 0001799207 auna:TwentyTwentyFiveMember auna:SecuredBondsIssuesSeniornotes20256500PercentageMember currency:USD 2022-12-31 0001799207 ifrs-full:LandMember 2022-12-31 0001799207 ifrs-full:BuildingsMember 2022-12-31 0001799207 auna:MedicalEquipmentMember 2022-12-31 0001799207 ifrs-full:VehiclesMember 2022-12-31 0001799207 ifrs-full:FixturesAndFittingsMember 2022-12-31 0001799207 auna:WorksInProgressMember 2022-12-31 0001799207 ifrs-full:RestrictedShareUnitsMember 2023-01-01 2023-12-31 0001799207 auna:CiclotronColombiaSasMember 2023-01-01 2023-12-31 0001799207 auna:CiclotrnPeruSaMember 2023-01-01 2023-12-31 0001799207 auna:PetCtPeruSaMember 2023-01-01 2023-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember 2023-01-01 2023-12-31 0001799207 ifrs-full:RetainedEarningsMember 2023-01-01 2023-12-31 0001799207 ifrs-full:EquityAttributableToOwnersOfParentMember 2023-01-01 2023-12-31 0001799207 ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember 2023-01-01 2023-12-31 0001799207 ifrs-full:ReserveOfCashFlowHedgesMember 2023-01-01 2023-12-31 0001799207 auna:HedgingReserveMember 2023-01-01 2023-12-31 0001799207 ifrs-full:MergerReserveMember 2023-01-01 2023-12-31 0001799207 ifrs-full:MiscellaneousOtherReservesMember 2023-01-01 2023-12-31 0001799207 ifrs-full:IssuedCapitalMember 2023-01-01 2023-12-31 0001799207 ifrs-full:SharePremiumMember 2023-01-01 2023-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:BuildingsMember 2023-01-01 2023-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember auna:MedicalEquipmentMember 2023-01-01 2023-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:VehiclesMember 2023-01-01 2023-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:FixturesAndFittingsMember 2023-01-01 2023-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember 2023-01-01 2023-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:VehiclesMember 2023-01-01 2023-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:FixturesAndFittingsMember 2023-01-01 2023-12-31 0001799207 ifrs-full:GrossCarryingAmountMember auna:WorksInProgressMember 2023-01-01 2023-12-31 0001799207 ifrs-full:GrossCarryingAmountMember 2023-01-01 2023-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:BuildingsMember 2023-01-01 2023-12-31 0001799207 ifrs-full:GrossCarryingAmountMember auna:MedicalEquipmentMember 2023-01-01 2023-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:LandMember 2023-01-01 2023-12-31 0001799207 ifrs-full:BuildingsMember 2023-01-01 2023-12-31 0001799207 auna:MedicalEquipmentMember 2023-01-01 2023-12-31 0001799207 ifrs-full:LandMember 2023-01-01 2023-12-31 0001799207 ifrs-full:VehiclesMember 2023-01-01 2023-12-31 0001799207 ifrs-full:FixturesAndFittingsMember 2023-01-01 2023-12-31 0001799207 ifrs-full:CostOfSalesMember 2023-01-01 2023-12-31 0001799207 auna:SellingExpensesMember 2023-01-01 2023-12-31 0001799207 auna:AdministrativeExpenseMember 2023-01-01 2023-12-31 0001799207 auna:commercialOfficesAndEquipmentMember 2023-01-01 2023-12-31 0001799207 ifrs-full:AccumulatedImpairmentMember 2023-01-01 2023-12-31 0001799207 auna:AdjustmentOfProvisionsMember 2023-01-01 2023-12-31 0001799207 ifrs-full:IntangibleAssetsOtherThanGoodwillMember 2023-01-01 2023-12-31 0001799207 auna:AdjustmentForInvestmentsInAssociatesAndOthersMember 2023-01-01 2023-12-31 0001799207 ifrs-full:LongtermBorrowingsMember 2023-01-01 2023-12-31 0001799207 ifrs-full:PropertyPlantAndEquipmentMember 2023-01-01 2023-12-31 0001799207 auna:AdjustmentForOthersMember 2023-01-01 2023-12-31 0001799207 auna:AdjustmentForTaxLossesMember 2023-01-01 2023-12-31 0001799207 auna:AdjustmentForLossForImpairmentOfTradeReceivablesMember 2023-01-01 2023-12-31 0001799207 auna:AdjustmentForProvisionForUnpaidVacationsAndAnnualPerformanceBonusesMember 2023-01-01 2023-12-31 0001799207 auna:AdjustmentForTradeAccountsPayableMember 2023-01-01 2023-12-31 0001799207 auna:AdjustmentForDerivativeFinancialInstrumentsMember 2023-01-01 2023-12-31 0001799207 auna:ClnicaBellavistaSacMember 2023-01-01 2023-12-31 0001799207 auna:LaboratorioClnicaInmunolgicoCantellaSacMember 2023-01-01 2023-12-31 0001799207 auna:ClnicaMirafloresSaMember 2023-01-01 2023-12-31 0001799207 auna:ClnicaVallesurSaMember 2023-01-01 2023-12-31 0001799207 auna:RrPatologosAsociadosSacMember 2023-01-01 2023-12-31 0001799207 auna:GspTrujilloSacClnicaCaminoRealMember 2023-01-01 2023-12-31 0001799207 auna:MedicserSacClnicaDelgadoMember 2023-01-01 2023-12-31 0001799207 auna:PatologaOncolgicaSacMember 2023-01-01 2023-12-31 0001799207 auna:HospitalYClnicaOcaSaDeCvMember 2023-01-01 2023-12-31 0001799207 auna:DrjInmueblesSaDeCvMember 2023-01-01 2023-12-31 0001799207 auna:OncogenomicsSacMember 2023-01-01 2023-12-31 0001799207 auna:InmueblesJrd2000SaDeCvMember 2023-01-01 2023-12-31 0001799207 auna:TovlejaHgSaMember 2023-01-01 2023-12-31 0001799207 auna:DentegraSegurosDentalesSAMember 2023-01-01 2023-12-31 0001799207 auna:OncomedicaSAMember 2023-01-01 2023-12-31 0001799207 auna:ImatSasMember 2023-01-01 2023-12-31 0001799207 auna:ClnicaPortoazulSaMember 2023-01-01 2023-12-31 0001799207 auna:PromotoraMdicaLasAmricasSaMember 2023-01-01 2023-12-31 0001799207 auna:InstitutoDeCancerologaSaMember 2023-01-01 2023-12-31 0001799207 auna:LaboratorioMdicoLasAmricasLtdaMember 2023-01-01 2023-12-31 0001799207 auna:OncosaludSacMember 2023-01-01 2023-12-31 0001799207 auna:OncocenterPerSacMember 2023-01-01 2023-12-31 0001799207 auna:ServimdicosSacMember 2023-01-01 2023-12-31 0001799207 auna:CardioImatSaMember 2023-01-01 2023-12-31 0001799207 auna:LasAmricasFarmaStoreSasMember 2023-01-01 2023-12-31 0001799207 auna:ConsorcioTreccaSacMember 2023-01-01 2023-12-31 0001799207 auna:SociedadRadiooncolgicaDeMonteraSaMember 2023-01-01 2023-12-31 0001799207 auna:IntensivosImatSaMember 2023-01-01 2023-12-31 0001799207 auna:InversionesMercurioSacMember 2023-01-01 2023-12-31 0001799207 auna:AunaColombiaSasMember 2023-01-01 2023-12-31 0001799207 auna:AunaSaludSacMember 2023-01-01 2023-12-31 0001799207 auna:GspInversionesSacMember 2023-01-01 2023-12-31 0001799207 auna:OperadorEstratgicoSacMember 2023-01-01 2023-12-31 0001799207 auna:GrupoSaludAunaMxicoSaDeCvMember 2023-01-01 2023-12-31 0001799207 auna:GspServiciosGeneralesSacMember 2023-01-01 2023-12-31 0001799207 auna:GspServiciosComercialesSacMember 2023-01-01 2023-12-31 0001799207 auna:ProMedLasAmricasLlcMember 2023-01-01 2023-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:ComputerSoftwareMember 2023-01-01 2023-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:ServiceConcessionRightsMember 2023-01-01 2023-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:GoodwillMember 2023-01-01 2023-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:BrandNamesMember 2023-01-01 2023-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:ComputerSoftwareMember 2023-01-01 2023-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:CustomerrelatedIntangibleAssetsMember 2023-01-01 2023-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:CustomerrelatedIntangibleAssetsMember 2023-01-01 2023-12-31 0001799207 auna:FivePercentFrequencyBottomMember ifrs-full:InsuranceRiskMember 2023-01-01 2023-12-31 0001799207 auna:TenPercentFrequencyTopMember ifrs-full:InsuranceRiskMember 2023-01-01 2023-12-31 0001799207 auna:FivePercentAverageCostBottomMember ifrs-full:InsuranceRiskMember 2023-01-01 2023-12-31 0001799207 auna:TenPercentAverageCostTopMember ifrs-full:InsuranceRiskMember 2023-01-01 2023-12-31 0001799207 auna:FivePercentCombinedBottomMember ifrs-full:InsuranceRiskMember 2023-01-01 2023-12-31 0001799207 auna:TenPercentCombinedTopMember ifrs-full:InsuranceRiskMember 2023-01-01 2023-12-31 0001799207 ifrs-full:InsuranceRiskMember 2023-01-01 2023-12-31 0001799207 auna:DentegraSegurosDentalesSAMember 2023-01-01 2023-12-31 0001799207 ifrs-full:NetLiabilitiesOrAssetsForRemainingCoverageExcludingLossComponentMember 2023-01-01 2023-12-31 0001799207 ifrs-full:EstimatesOfPresentValueOfFutureCashFlowsMember 2023-01-01 2023-12-31 0001799207 ifrs-full:RiskAdjustmentForNonfinancialRiskMember 2023-01-01 2023-12-31 0001799207 ifrs-full:JointVenturesWhereEntityIsVenturerMember 2023-01-01 2023-12-31 0001799207 ifrs-full:OtherRelatedPartiesMember 2023-01-01 2023-12-31 0001799207 ifrs-full:AssociatesMember 2023-01-01 2023-12-31 0001799207 ifrs-full:RelatedPartiesMember 2023-01-01 2023-12-31 0001799207 auna:OtherManagementChargesMember 2023-01-01 2023-12-31 0001799207 country:PE srt:SubsidiariesMember 2023-01-01 2023-12-31 0001799207 auna:BoardOfDirectorsMember 2023-01-01 2023-12-31 0001799207 country:CO srt:SubsidiariesMember 2023-01-01 2023-12-31 0001799207 country:MX srt:SubsidiariesMember 2023-01-01 2023-12-31 0001799207 auna:NonExecutiveMember 2023-01-01 2023-12-31 0001799207 auna:EnfocaMember 2023-01-01 2023-12-31 0001799207 auna:ClassACommonShareMember 2023-01-01 2023-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:PmlaMember 2023-01-01 2023-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:ClinicaPortoazulMember 2023-01-01 2023-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:OncomedicaMember 2023-01-01 2023-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:AunaSaludMember 2023-01-01 2023-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:ClinicaVallesurMember 2023-01-01 2023-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:ClinicaMirafloresMember 2023-01-01 2023-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember ifrs-full:SubsidiariesMember 2023-01-01 2023-12-31 0001799207 ifrs-full:MiscellaneousOtherProvisionsMember 2023-01-01 2023-12-31 0001799207 auna:OutstandingClaimsReserveMember 2023-01-01 2023-12-31 0001799207 ifrs-full:CurrencyRiskMember 2023-01-01 2023-12-31 0001799207 ifrs-full:CurrencyRiskMember auna:FivePercentFrequencyWeakeningBottomMember 2023-01-01 2023-12-31 0001799207 ifrs-full:CurrencyRiskMember auna:TenPercentFrequencyWeakeningTopMember 2023-01-01 2023-12-31 0001799207 ifrs-full:CurrencyRiskMember auna:TenPercentFrequencyStrengtheningTopMember 2023-01-01 2023-12-31 0001799207 ifrs-full:CurrencyRiskMember auna:FivePercentFrequencyStrengtheningBottomMember 2023-01-01 2023-12-31 0001799207 country:MX 2023-01-01 2023-12-31 0001799207 country:PE 2023-01-01 2023-12-31 0001799207 country:CO 2023-01-01 2023-12-31 0001799207 auna:HealthcareServicesMember 2023-01-01 2023-12-31 0001799207 auna:SaleOfMedicinesMember 2023-01-01 2023-12-31 0001799207 auna:OncologyPlansMember 2023-01-01 2023-12-31 0001799207 auna:GeneralHealthcareServicesPlansMember 2023-01-01 2023-12-31 0001799207 ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember 2023-01-01 2023-12-31 0001799207 ifrs-full:GoodsOrServicesTransferredOverTimeMember 2023-01-01 2023-12-31 0001799207 auna:HealthcareServicesMember 2023-01-01 2023-12-31 0001799207 ifrs-full:ContingentConsiderationMember ifrs-full:TopOfRangeMember 2023-01-01 2023-12-31 0001799207 ifrs-full:ContingentConsiderationMember ifrs-full:BottomOfRangeMember 2023-01-01 2023-12-31 0001799207 ifrs-full:InsuranceRiskMember ifrs-full:BottomOfRangeMember 2023-01-01 2023-12-31 0001799207 ifrs-full:InsuranceRiskMember ifrs-full:TopOfRangeMember 2023-01-01 2023-12-31 0001799207 auna:CostOfSalesAndServicesMember 2023-01-01 2023-12-31 0001799207 ifrs-full:DiscountedCashFlowMember auna:PutLiabilityMember 2023-01-01 2023-12-31 0001799207 ifrs-full:BottomOfRangeMember country:CO 2023-01-01 2023-12-31 0001799207 ifrs-full:TopOfRangeMember country:CO 2023-01-01 2023-12-31 0001799207 auna:HoldingAndEliminationsMember 2023-01-01 2023-12-31 0001799207 auna:InterSegmentMember auna:HoldingAndEliminationsMember 2023-01-01 2023-12-31 0001799207 auna:OncosaludPeruMember 2023-01-01 2023-12-31 0001799207 auna:HealthcareServicesInPeruMember 2023-01-01 2023-12-31 0001799207 auna:HealthcareServicesInColombiaMember 2023-01-01 2023-12-31 0001799207 auna:HealthcareServicesInMexicoMember 2023-01-01 2023-12-31 0001799207 ifrs-full:ReportableSegmentsMember 2023-01-01 2023-12-31 0001799207 auna:ExternalMember auna:HealthcareServicesInMexicoMember 2023-01-01 2023-12-31 0001799207 auna:ExternalMember ifrs-full:ReportableSegmentsMember 2023-01-01 2023-12-31 0001799207 auna:ExternalMember 2023-01-01 2023-12-31 0001799207 auna:InterSegmentMember auna:OncosaludPeruMember 2023-01-01 2023-12-31 0001799207 auna:InterSegmentMember auna:HealthcareServicesInPeruMember 2023-01-01 2023-12-31 0001799207 auna:InterSegmentMember ifrs-full:ReportableSegmentsMember 2023-01-01 2023-12-31 0001799207 auna:ExternalMember auna:OncosaludPeruMember 2023-01-01 2023-12-31 0001799207 auna:ExternalMember auna:HealthcareServicesInPeruMember 2023-01-01 2023-12-31 0001799207 auna:ExternalMember auna:HealthcareServicesInColombiaMember 2023-01-01 2023-12-31 0001799207 auna:ExternalMember auna:HoldingAndEliminationsMember 2023-01-01 2023-12-31 0001799207 auna:CorporateCustomersMember auna:HoldingAndEliminationsMember 2023-01-01 2023-12-31 0001799207 auna:CorporateCustomersMember 2023-01-01 2023-12-31 0001799207 auna:CorporateCustomersMember auna:OncosaludPeruMember 2023-01-01 2023-12-31 0001799207 auna:CorporateCustomersMember auna:HealthcareServicesInPeruMember 2023-01-01 2023-12-31 0001799207 auna:CorporateCustomersMember auna:HealthcareServicesInColombiaMember 2023-01-01 2023-12-31 0001799207 auna:CorporateCustomersMember auna:HealthcareServicesInMexicoMember 2023-01-01 2023-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:ReportableSegmentsMember 2023-01-01 2023-12-31 0001799207 country:PE auna:HealthcareServicesSegmentsMember 2023-01-01 2023-12-31 0001799207 country:CO auna:HealthcareServicesSegmentsMember 2023-01-01 2023-12-31 0001799207 country:MX auna:HealthcareServicesSegmentsMember 2023-01-01 2023-12-31 0001799207 country:PE auna:OncosaludPeruMember 2023-01-01 2023-12-31 0001799207 auna:AdministrativeExpensesMember 2023-01-01 2023-12-31 0001799207 auna:BonusesMember 2023-01-01 2023-12-31 0001799207 auna:SeverancePaymentsMember 2023-01-01 2023-12-31 0001799207 auna:LegalBonusesMember 2023-01-01 2023-12-31 0001799207 auna:HealthInsuranceForEmployeesMember 2023-01-01 2023-12-31 0001799207 auna:RemunerationsMember 2023-01-01 2023-12-31 0001799207 auna:TrainingMember 2023-01-01 2023-12-31 0001799207 auna:VacationsMember 2023-01-01 2023-12-31 0001799207 auna:OtherBenefitsMember 2023-01-01 2023-12-31 0001799207 auna:EquitysettledSharebasedPaymentExpensesMember 2023-01-01 2023-12-31 0001799207 auna:CompensationToPersonnelMember 2023-01-01 2023-12-31 0001799207 auna:EmployeesProfitSharingMember 2023-01-01 2023-12-31 0001799207 auna:BoardOfDirectorsRemunerationMember 2023-01-01 2023-12-31 0001799207 auna:SeniorityPremiumMember 2023-01-01 2023-12-31 0001799207 auna:RetirementBenefitsMember 2023-01-01 2023-12-31 0001799207 auna:FinancialLoanMember 2023-01-01 2023-12-31 0001799207 ifrs-full:LeaseLiabilitiesMember 2023-01-01 2023-12-31 0001799207 auna:TrustFundsMember 2023-01-01 2023-12-31 0001799207 auna:MergeReserveMember 2023-01-01 2023-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember 2023-01-01 2023-12-31 0001799207 auna:DerivativesPremiumsPayableMember 2023-01-01 2023-12-31 0001799207 auna:DeferredIncomeMember 2023-01-01 2023-12-31 0001799207 ifrs-full:SharePremiumMember 2023-01-01 2023-12-31 0001799207 ifrs-full:RetainedEarningsMember 2023-01-01 2023-12-31 0001799207 auna:OtherFinancingDebtsMember auna:ScotiaBankMember 2023-01-01 2023-12-31 0001799207 auna:CiclotronColombiaSasMember 2022-01-01 2022-12-31 0001799207 auna:CiclotrnPeruSaMember 2022-01-01 2022-12-31 0001799207 auna:PetCtPeruSaMember 2022-01-01 2022-12-31 0001799207 ifrs-full:RetainedEarningsMember 2022-01-01 2022-12-31 0001799207 ifrs-full:EquityAttributableToOwnersOfParentMember 2022-01-01 2022-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember 2022-01-01 2022-12-31 0001799207 ifrs-full:ReserveOfCashFlowHedgesMember 2022-01-01 2022-12-31 0001799207 auna:HedgingReserveMember 2022-01-01 2022-12-31 0001799207 ifrs-full:MergerReserveMember 2022-01-01 2022-12-31 0001799207 ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember 2022-01-01 2022-12-31 0001799207 ifrs-full:MiscellaneousOtherReservesMember 2022-01-01 2022-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember 2022-01-01 2022-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:BuildingsMember 2022-01-01 2022-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember auna:MedicalEquipmentMember 2022-01-01 2022-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:VehiclesMember 2022-01-01 2022-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:FixturesAndFittingsMember 2022-01-01 2022-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:LandMember 2022-01-01 2022-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:BuildingsMember 2022-01-01 2022-12-31 0001799207 ifrs-full:GrossCarryingAmountMember auna:MedicalEquipmentMember 2022-01-01 2022-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:VehiclesMember 2022-01-01 2022-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:FixturesAndFittingsMember 2022-01-01 2022-12-31 0001799207 ifrs-full:GrossCarryingAmountMember auna:WorksInProgressMember 2022-01-01 2022-12-31 0001799207 ifrs-full:GrossCarryingAmountMember 2022-01-01 2022-12-31 0001799207 ifrs-full:BuildingsMember 2022-01-01 2022-12-31 0001799207 auna:MedicalEquipmentMember 2022-01-01 2022-12-31 0001799207 ifrs-full:VehiclesMember 2022-01-01 2022-12-31 0001799207 ifrs-full:FixturesAndFittingsMember 2022-01-01 2022-12-31 0001799207 ifrs-full:LandMember 2022-01-01 2022-12-31 0001799207 ifrs-full:CostOfSalesMember 2022-01-01 2022-12-31 0001799207 auna:SellingExpensesMember 2022-01-01 2022-12-31 0001799207 auna:AdministrativeExpenseMember 2022-01-01 2022-12-31 0001799207 auna:commercialOfficesAndEquipmentMember 2022-01-01 2022-12-31 0001799207 auna:AdjustmentForLossForImpairmentOfTradeReceivablesMember 2022-01-01 2022-12-31 0001799207 auna:AdjustmentForProvisionForUnpaidVacationsAndAnnualPerformanceBonusesMember 2022-01-01 2022-12-31 0001799207 auna:AdjustmentForTradeAccountsPayableMember 2022-01-01 2022-12-31 0001799207 ifrs-full:LongtermBorrowingsMember 2022-01-01 2022-12-31 0001799207 ifrs-full:PropertyPlantAndEquipmentMember 2022-01-01 2022-12-31 0001799207 auna:AdjustmentForOthersMember 2022-01-01 2022-12-31 0001799207 auna:AdjustmentForTaxLossesMember 2022-01-01 2022-12-31 0001799207 auna:AdjustmentForDerivativeFinancialInstrumentsMember 2022-01-01 2022-12-31 0001799207 auna:AdjustmentOfProvisionsMember 2022-01-01 2022-12-31 0001799207 ifrs-full:IntangibleAssetsOtherThanGoodwillMember 2022-01-01 2022-12-31 0001799207 auna:AdjustmentForInvestmentsInAssociatesAndOthersMember 2022-01-01 2022-12-31 0001799207 auna:ClnicaBellavistaSacMember 2022-01-01 2022-12-31 0001799207 auna:LaboratorioClnicaInmunolgicoCantellaSacMember 2022-01-01 2022-12-31 0001799207 auna:ClnicaMirafloresSaMember 2022-01-01 2022-12-31 0001799207 auna:ClnicaVallesurSaMember 2022-01-01 2022-12-31 0001799207 auna:RrPatologosAsociadosSacMember 2022-01-01 2022-12-31 0001799207 auna:GspTrujilloSacClnicaCaminoRealMember 2022-01-01 2022-12-31 0001799207 auna:MedicserSacClnicaDelgadoMember 2022-01-01 2022-12-31 0001799207 auna:HospitalYClnicaOcaSaDeCvMember 2022-01-01 2022-12-31 0001799207 auna:DrjInmueblesSaDeCvMember 2022-01-01 2022-12-31 0001799207 auna:OncogenomicsSacMember 2022-01-01 2022-12-31 0001799207 auna:PatologaOncolgicaSacMember 2022-01-01 2022-12-31 0001799207 auna:InmueblesJrd2000SaDeCvMember 2022-01-01 2022-12-31 0001799207 auna:TovlejaHgSaMember 2022-01-01 2022-12-31 0001799207 auna:DentegraSegurosDentalesSAMember 2022-01-01 2022-12-31 0001799207 auna:OncomedicaSAMember 2022-01-01 2022-12-31 0001799207 auna:ImatSasMember 2022-01-01 2022-12-31 0001799207 auna:ClnicaPortoazulSaMember 2022-01-01 2022-12-31 0001799207 auna:PromotoraMdicaLasAmricasSaMember 2022-01-01 2022-12-31 0001799207 auna:InstitutoDeCancerologaSaMember 2022-01-01 2022-12-31 0001799207 auna:LaboratorioMdicoLasAmricasLtdaMember 2022-01-01 2022-12-31 0001799207 auna:OncosaludSacMember 2022-01-01 2022-12-31 0001799207 auna:OncocenterPerSacMember 2022-01-01 2022-12-31 0001799207 auna:ServimdicosSacMember 2022-01-01 2022-12-31 0001799207 auna:CardioImatSaMember 2022-01-01 2022-12-31 0001799207 auna:LasAmricasFarmaStoreSasMember 2022-01-01 2022-12-31 0001799207 auna:ConsorcioTreccaSacMember 2022-01-01 2022-12-31 0001799207 auna:SociedadRadiooncolgicaDeMonteraSaMember 2022-01-01 2022-12-31 0001799207 auna:IntensivosImatSaMember 2022-01-01 2022-12-31 0001799207 auna:InversionesMercurioSacMember 2022-01-01 2022-12-31 0001799207 auna:AunaColombiaSasMember 2022-01-01 2022-12-31 0001799207 auna:AunaSaludSacMember 2022-01-01 2022-12-31 0001799207 auna:GspInversionesSacMember 2022-01-01 2022-12-31 0001799207 auna:OperadorEstratgicoSacMember 2022-01-01 2022-12-31 0001799207 auna:GrupoSaludAunaMxicoSaDeCvMember 2022-01-01 2022-12-31 0001799207 auna:GspServiciosGeneralesSacMember 2022-01-01 2022-12-31 0001799207 auna:GspServiciosComercialesSacMember 2022-01-01 2022-12-31 0001799207 auna:ProMedLasAmricasLlcMember 2022-01-01 2022-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:ComputerSoftwareMember 2022-01-01 2022-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:ServiceConcessionRightsMember 2022-01-01 2022-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:GoodwillMember 2022-01-01 2022-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:BrandNamesMember 2022-01-01 2022-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:CustomerrelatedIntangibleAssetsMember 2022-01-01 2022-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:ComputerSoftwareMember 2022-01-01 2022-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:CustomerrelatedIntangibleAssetsMember 2022-01-01 2022-12-31 0001799207 auna:TenPercentCombinedTopMember ifrs-full:InsuranceRiskMember 2022-01-01 2022-12-31 0001799207 ifrs-full:InsuranceRiskMember 2022-01-01 2022-12-31 0001799207 auna:FivePercentFrequencyBottomMember ifrs-full:InsuranceRiskMember 2022-01-01 2022-12-31 0001799207 auna:TenPercentFrequencyTopMember ifrs-full:InsuranceRiskMember 2022-01-01 2022-12-31 0001799207 auna:FivePercentAverageCostBottomMember ifrs-full:InsuranceRiskMember 2022-01-01 2022-12-31 0001799207 auna:TenPercentAverageCostTopMember ifrs-full:InsuranceRiskMember 2022-01-01 2022-12-31 0001799207 auna:FivePercentCombinedBottomMember ifrs-full:InsuranceRiskMember 2022-01-01 2022-12-31 0001799207 auna:OncomedicaSAMember 2022-01-01 2022-12-31 0001799207 auna:EntitiesMember 2022-01-01 2022-12-31 0001799207 auna:OncomedicaSAMember ifrs-full:BottomOfRangeMember 2022-01-01 2022-12-31 0001799207 auna:OncomedicaSAMember ifrs-full:TopOfRangeMember 2022-01-01 2022-12-31 0001799207 ifrs-full:JointVenturesWhereEntityIsVenturerMember 2022-01-01 2022-12-31 0001799207 ifrs-full:OtherRelatedPartiesMember 2022-01-01 2022-12-31 0001799207 ifrs-full:AssociatesMember 2022-01-01 2022-12-31 0001799207 ifrs-full:RelatedPartiesMember 2022-01-01 2022-12-31 0001799207 auna:OtherManagementChargesMember 2022-01-01 2022-12-31 0001799207 country:PE srt:SubsidiariesMember 2022-01-01 2022-12-31 0001799207 auna:BoardOfDirectorsMember 2022-01-01 2022-12-31 0001799207 country:CO srt:SubsidiariesMember 2022-01-01 2022-12-31 0001799207 auna:EnfocaMember 2022-01-01 2022-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:PmlaMember 2022-01-01 2022-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:ClinicaPortoazulMember 2022-01-01 2022-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:OncomedicaMember 2022-01-01 2022-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:AunaSaludMember 2022-01-01 2022-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:ClinicaVallesurMember 2022-01-01 2022-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember auna:ClinicaMirafloresMember 2022-01-01 2022-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember ifrs-full:SubsidiariesMember 2022-01-01 2022-12-31 0001799207 ifrs-full:MiscellaneousOtherProvisionsMember 2022-01-01 2022-12-31 0001799207 ifrs-full:CurrencyRiskMember 2022-01-01 2022-12-31 0001799207 ifrs-full:CurrencyRiskMember auna:FivePercentFrequencyWeakeningBottomMember 2022-01-01 2022-12-31 0001799207 ifrs-full:CurrencyRiskMember auna:TenPercentFrequencyWeakeningTopMember 2022-01-01 2022-12-31 0001799207 ifrs-full:CurrencyRiskMember auna:FivePercentFrequencyStrengtheningBottomMember 2022-01-01 2022-12-31 0001799207 ifrs-full:CurrencyRiskMember auna:TenPercentFrequencyStrengtheningTopMember 2022-01-01 2022-12-31 0001799207 country:MX 2022-01-01 2022-12-31 0001799207 country:PE 2022-01-01 2022-12-31 0001799207 country:CO 2022-01-01 2022-12-31 0001799207 auna:HealthcareServicesMember 2022-01-01 2022-12-31 0001799207 auna:SaleOfMedicinesMember 2022-01-01 2022-12-31 0001799207 auna:OncologyPlansMember 2022-01-01 2022-12-31 0001799207 auna:GeneralHealthcareServicesPlansMember 2022-01-01 2022-12-31 0001799207 ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember 2022-01-01 2022-12-31 0001799207 ifrs-full:GoodsOrServicesTransferredOverTimeMember 2022-01-01 2022-12-31 0001799207 auna:HealthcareServicesMember 2022-01-01 2022-12-31 0001799207 ifrs-full:ContingentConsiderationMember ifrs-full:TopOfRangeMember 2022-01-01 2022-12-31 0001799207 ifrs-full:ContingentConsiderationMember ifrs-full:BottomOfRangeMember 2022-01-01 2022-12-31 0001799207 auna:PutLiabilityMember ifrs-full:TopOfRangeMember 2022-01-01 2022-12-31 0001799207 auna:PutLiabilityMember ifrs-full:BottomOfRangeMember 2022-01-01 2022-12-31 0001799207 ifrs-full:InsuranceRiskMember ifrs-full:BottomOfRangeMember 2022-01-01 2022-12-31 0001799207 ifrs-full:InsuranceRiskMember ifrs-full:TopOfRangeMember 2022-01-01 2022-12-31 0001799207 auna:CostOfSalesAndServicesMember 2022-01-01 2022-12-31 0001799207 ifrs-full:BottomOfRangeMember country:CO 2022-01-01 2022-12-31 0001799207 ifrs-full:TopOfRangeMember country:CO 2022-01-01 2022-12-31 0001799207 auna:OncosaludPeruMember 2022-01-01 2022-12-31 0001799207 auna:HealthcareServicesInPeruMember 2022-01-01 2022-12-31 0001799207 auna:HealthcareServicesInColombiaMember 2022-01-01 2022-12-31 0001799207 auna:HealthcareServicesInMexicoMember 2022-01-01 2022-12-31 0001799207 ifrs-full:ReportableSegmentsMember 2022-01-01 2022-12-31 0001799207 auna:HoldingAndEliminationsMember 2022-01-01 2022-12-31 0001799207 auna:ExternalMember ifrs-full:ReportableSegmentsMember 2022-01-01 2022-12-31 0001799207 auna:ExternalMember 2022-01-01 2022-12-31 0001799207 auna:InterSegmentMember auna:OncosaludPeruMember 2022-01-01 2022-12-31 0001799207 auna:InterSegmentMember auna:HealthcareServicesInPeruMember 2022-01-01 2022-12-31 0001799207 auna:InterSegmentMember ifrs-full:ReportableSegmentsMember 2022-01-01 2022-12-31 0001799207 auna:InterSegmentMember auna:HoldingAndEliminationsMember 2022-01-01 2022-12-31 0001799207 auna:ExternalMember auna:OncosaludPeruMember 2022-01-01 2022-12-31 0001799207 auna:ExternalMember auna:HealthcareServicesInPeruMember 2022-01-01 2022-12-31 0001799207 auna:ExternalMember auna:HealthcareServicesInColombiaMember 2022-01-01 2022-12-31 0001799207 auna:ExternalMember auna:HealthcareServicesInMexicoMember 2022-01-01 2022-12-31 0001799207 auna:ExternalMember auna:HoldingAndEliminationsMember 2022-01-01 2022-12-31 0001799207 auna:CorporateCustomersMember ifrs-full:ReportableSegmentsMember 2022-01-01 2022-12-31 0001799207 auna:CorporateCustomersMember auna:HoldingAndEliminationsMember 2022-01-01 2022-12-31 0001799207 auna:CorporateCustomersMember 2022-01-01 2022-12-31 0001799207 auna:CorporateCustomersMember auna:OncosaludPeruMember 2022-01-01 2022-12-31 0001799207 auna:CorporateCustomersMember auna:HealthcareServicesInPeruMember 2022-01-01 2022-12-31 0001799207 auna:CorporateCustomersMember auna:HealthcareServicesInColombiaMember 2022-01-01 2022-12-31 0001799207 country:PE auna:OncosaludPeruMember 2022-01-01 2022-12-31 0001799207 country:PE auna:HealthcareServicesSegmentsMember 2022-01-01 2022-12-31 0001799207 country:CO auna:HealthcareServicesSegmentsMember 2022-01-01 2022-12-31 0001799207 auna:AdministrativeExpensesMember 2022-01-01 2022-12-31 0001799207 auna:BonusesMember 2022-01-01 2022-12-31 0001799207 auna:SeverancePaymentsMember 2022-01-01 2022-12-31 0001799207 auna:LegalBonusesMember 2022-01-01 2022-12-31 0001799207 auna:HealthInsuranceForEmployeesMember 2022-01-01 2022-12-31 0001799207 auna:RemunerationsMember 2022-01-01 2022-12-31 0001799207 auna:VacationsMember 2022-01-01 2022-12-31 0001799207 auna:OtherBenefitsMember 2022-01-01 2022-12-31 0001799207 auna:CompensationToPersonnelMember 2022-01-01 2022-12-31 0001799207 auna:TrainingMember 2022-01-01 2022-12-31 0001799207 auna:EmployeesProfitSharingMember 2022-01-01 2022-12-31 0001799207 auna:BoardOfDirectorsRemunerationMember 2022-01-01 2022-12-31 0001799207 auna:SeniorityPremiumMember 2022-01-01 2022-12-31 0001799207 auna:RetirementBenefitsMember 2022-01-01 2022-12-31 0001799207 auna:FinancialLoanMember 2022-01-01 2022-12-31 0001799207 ifrs-full:LeaseLiabilitiesMember 2022-01-01 2022-12-31 0001799207 auna:MergeReserveMember 2022-01-01 2022-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember 2022-01-01 2022-12-31 0001799207 auna:DerivativesPremiumsPayableMember 2022-01-01 2022-12-31 0001799207 auna:DeferredIncomeMember 2022-01-01 2022-12-31 0001799207 ifrs-full:RetainedEarningsMember 2022-01-01 2022-12-31 0001799207 auna:OtherFinancingDebtsMember auna:ScotiaBankMember 2022-01-01 2022-12-31 0001799207 auna:CallSpreadMember auna:NonAdjustingEventsAfterReportingPeriodMember 2025-01-31 0001799207 auna:CallSpreadMember auna:NonAdjustingEventsAfterReportingPeriodMember ifrs-full:BottomOfRangeMember 2025-01-31 0001799207 auna:CallSpreadMember auna:NonAdjustingEventsAfterReportingPeriodMember ifrs-full:TopOfRangeMember 2025-01-31 0001799207 ifrs-full:RestrictedShareUnitsMember auna:Award2023GrantToDirectorsOnDecember82023Member 2023-12-08 2023-12-08 0001799207 ifrs-full:BottomOfRangeMember auna:LaterThanSeptember302025Member auna:TwoThousandTwentyNineNotesMember 2023-12-08 2023-12-08 0001799207 ifrs-full:TopOfRangeMember auna:NotLaterThanSeptember302024Member auna:TwoThousandTwentyNineNotesMember 2023-12-08 2023-12-08 0001799207 ifrs-full:BottomOfRangeMember auna:NotLaterThanSeptember302024Member auna:TwoThousandTwentyNineNotesMember 2023-12-08 2023-12-08 0001799207 ifrs-full:BottomOfRangeMember auna:NotLaterThanSeptember302025Member auna:TwoThousandTwentyNineNotesMember 2023-12-08 2023-12-08 0001799207 ifrs-full:TopOfRangeMember auna:LaterThanSeptember302025Member auna:TwoThousandTwentyNineNotesMember 2023-12-08 2023-12-08 0001799207 auna:InterestRateSwapTiie2028Member 2024-09-30 0001799207 ifrs-full:BottomOfRangeMember auna:NotesPurchaseAgreementMember 2024-09-30 0001799207 auna:NotesPurchaseAgreementMember ifrs-full:TopOfRangeMember 2024-09-30 0001799207 auna:InitialPublicOfferingMember auna:SeriesAOrdinarySharesMember 2024-03-21 0001799207 auna:HerediaInvestmentsSACMember 2024-03-21 0001799207 auna:ClassACommonShareMember 2024-03-21 0001799207 ifrs-full:TopOfRangeMember auna:ClassACommonShareMember 2024-03-21 0001799207 auna:SeriesACommonStockMember 2024-03-21 0001799207 auna:InitialPublicOfferingMember auna:SeriesAOrdinarySharesMember 2024-03-21 2024-03-21 0001799207 auna:DentegraSegurosDentalesSAMember 2021-09-03 0001799207 auna:DentegraSegurosDentalesSAMember auna:SharePurchaseAgreementMember 2021-09-03 2021-09-03 0001799207 auna:DentegraSegurosDentalesSAMember 2021-09-03 2021-09-03 0001799207 auna:DentegraSegurosDentalesSAMember 2023-01-01 2023-01-01 0001799207 auna:EntitiesMember 2022-10-05 2022-10-05 0001799207 auna:EntitiesMember auna:SharePurchaseAgreementMember 2022-10-05 2022-10-05 0001799207 auna:EntitiesMember 2022-10-05 0001799207 auna:EntitiesMember auna:LoanAgreementWithSantanderMexicoBankAndHsbcMexicoBankMember 2022-10-05 0001799207 auna:EntitiesMember auna:LoanAgreementwithJPMorganChaseBankSAMember 2022-10-05 0001799207 ifrs-full:BrandNamesMember auna:OcaHospitalMember 2022-10-05 0001799207 ifrs-full:ComputerSoftwareMember auna:OcaHospitalMember 2022-10-05 0001799207 auna:OcaHospitalMember 2022-10-05 0001799207 auna:EntitiesMember 2024-09-01 2024-09-30 0001799207 auna:OncomedicaSAMember 2022-01-01 2022-01-01 0001799207 auna:EntitiesMember 2022-01-01 2022-01-01 0001799207 auna:OncomedicaSAMember auna:SharePurchaseAgreementMember 2022-01-18 2022-01-18 0001799207 auna:OncomedicaSAMember 2022-01-18 2022-01-18 0001799207 auna:OncomedicaSAMember 2022-01-18 0001799207 auna:OncomedicaSAMember auna:LoanAgreementwithJPMorganChaseBankSAMember 2022-01-18 0001799207 auna:OncomedicaSAMember auna:SharePurchaseAgreementMember 2022-01-18 0001799207 auna:OncomedicaSAMember 2022-12-31 2022-12-31 0001799207 auna:AunaSaludSacMember ifrs-full:TopOfRangeMember 2022-09-28 0001799207 auna:AunaSaludSacMember ifrs-full:BottomOfRangeMember 2022-09-28 0001799207 auna:AunaSaludSacMember 2022-09-28 0001799207 auna:ClassBCommonShareMember 2024-03-04 0001799207 ifrs-full:TopOfRangeMember 2024-03-04 0001799207 ifrs-full:TopOfRangeMember 2024-08-29 0001799207 auna:DentegraSegurosDentalesSAMember 2023-02-01 0001799207 ifrs-full:BrandNamesMember auna:DentegraMember 2023-02-01 0001799207 auna:DentegraMember 2023-02-01 0001799207 ifrs-full:TopOfRangeMember ifrs-full:NotLaterThanOneYearMember 2020-11-20 0001799207 ifrs-full:BottomOfRangeMember ifrs-full:NotLaterThanOneYearMember 2020-11-20 0001799207 ifrs-full:TopOfRangeMember ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember 2020-11-20 0001799207 ifrs-full:TopOfRangeMember ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember 2020-11-20 0001799207 ifrs-full:BottomOfRangeMember ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember 2020-11-20 0001799207 ifrs-full:BottomOfRangeMember ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember 2020-11-20 0001799207 ifrs-full:TopOfRangeMember ifrs-full:LaterThanThreeYearsMember 2020-11-20 0001799207 ifrs-full:BottomOfRangeMember ifrs-full:LaterThanThreeYearsMember 2020-11-20 0001799207 auna:OtherFinancingDebtsMember auna:ScotiaBankMember 2020-11-20 0001799207 ifrs-full:TopOfRangeMember 2020-11-20 2020-11-20 0001799207 ifrs-full:BottomOfRangeMember 2020-11-20 2020-11-20 0001799207 auna:TermLoanMember 2023-12-18 0001799207 auna:TwoThousandTwentyNineNotesMember 2023-12-18 0001799207 auna:TwoThousandTwentyFiveSeniorNotesMember 2023-12-18 0001799207 auna:NotesPurchaseAgreementMember 2023-12-18 0001799207 auna:TwoThousandTwentyNineNotesOneMember 2023-12-18 0001799207 auna:TwoThousandTwentyFiveSeniorNotesOneMember 2023-12-18 0001799207 ifrs-full:TopOfRangeMember ifrs-full:NotLaterThanOneYearMember auna:TwoThousandTwentyNineNotesMember 2023-12-18 0001799207 ifrs-full:TopOfRangeMember ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember auna:TwoThousandTwentyNineNotesMember 2023-12-18 0001799207 ifrs-full:BottomOfRangeMember ifrs-full:NotLaterThanOneYearMember auna:TwoThousandTwentyNineNotesMember 2023-12-18 0001799207 auna:TwoThousandTwentyNineNotesMember ifrs-full:BottomOfRangeMember ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember 2023-12-18 0001799207 auna:TwoThousandTwentyNineNotesMember ifrs-full:TopOfRangeMember ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember 2023-12-18 0001799207 auna:TwoThousandTwentyNineNotesMember ifrs-full:BottomOfRangeMember ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember 2023-12-18 0001799207 auna:TwoThousandTwentyNineNotesOneMember 2023-12-18 2023-12-18 0001799207 auna:NotesPurchaseAgreementMember 2023-12-18 2023-12-18 0001799207 auna:TwoThousandTwentyNineNotesMember 2023-12-18 2023-12-18 0001799207 auna:TwoThousandTwentyNineNotesMember ifrs-full:TopOfRangeMember auna:NotLaterThanSeptember302025Member 2023-12-18 2023-12-18 0001799207 auna:TermLoanMember 2023-12-18 2023-12-18 0001799207 auna:JpmorganChaseBankSaMember 2022-04-20 0001799207 auna:JpmorganChaseBankSaMember ifrs-full:FloatingInterestRateMember auna:OneToThreeMonthsMember 2022-04-20 0001799207 auna:JpmorganChaseBankSaMember ifrs-full:FloatingInterestRateMember auna:FourToSixMonthsMember 2022-04-20 0001799207 auna:JpmorganChaseBankSaMember ifrs-full:FloatingInterestRateMember auna:SevenToNineMonthsMember 2022-04-20 0001799207 auna:JpmorganChaseBankSaMember ifrs-full:FloatingInterestRateMember auna:TenToTwelveMonthsMember 2022-04-20 0001799207 auna:JpmorganChaseBankSaMember 2022-04-20 2022-04-20 0001799207 ifrs-full:TopOfRangeMember auna:JpmorganChaseBankSaMember 2022-04-20 2022-04-20 0001799207 ifrs-full:BottomOfRangeMember auna:JpmorganChaseBankSaMember 2022-04-20 2022-04-20 0001799207 auna:JpmorganChaseBankSaMember auna:SecuredOvernightFinancingRateMember 2022-04-20 2022-04-20 0001799207 auna:FxOperationAgreementsLongForward2023Member 2022-11-29 0001799207 auna:FxOperationAgreementsPurchasedCollarLongPut2023Member 2022-11-29 0001799207 auna:FxOperationAgreementCallSpread2026Member 2022-11-29 0001799207 auna:FxOperationAgreementCallSpread2026Member ifrs-full:BottomOfRangeMember 2022-11-29 2022-11-29 0001799207 auna:FxOperationAgreementCallSpread2026Member ifrs-full:TopOfRangeMember 2022-11-29 2022-11-29 0001799207 auna:FxOperationAgreementsLongForward2023Member ifrs-full:BottomOfRangeMember 2022-11-29 2022-11-29 0001799207 auna:FxOperationAgreementsLongForward2023Member ifrs-full:TopOfRangeMember 2022-11-29 2022-11-29 0001799207 auna:FxOperationAgreementsPurchasedCollarLongPut2023Member ifrs-full:BottomOfRangeMember 2022-11-29 2022-11-29 0001799207 auna:FxOperationAgreementsPurchasedCollarLongPut2023Member ifrs-full:TopOfRangeMember 2022-11-29 2022-11-29 0001799207 auna:FxOperationAgreementsLongForward2023Member 2022-11-29 2022-11-29 0001799207 auna:FxOperationAgreementCallSpread2026Member 2022-11-29 2022-11-29 0001799207 auna:BancoSantanderHsbcMxicoAndGenaroLevinsonMarcovichMember 2022-09-30 0001799207 ifrs-full:TopOfRangeMember auna:JpmorganChaseBankSaMember 2022-09-30 0001799207 ifrs-full:BottomOfRangeMember auna:JpmorganChaseBankSaMember 2022-09-30 0001799207 ifrs-full:BottomOfRangeMember auna:NotesPurchaseAgreementMember 2023-03-31 0001799207 ifrs-full:TopOfRangeMember auna:BancoSantanderHsbcMxicoAndGenaroLevinsonMarcovichMember 2023-03-31 0001799207 ifrs-full:BottomOfRangeMember auna:BancoSantanderHsbcMxicoAndGenaroLevinsonMarcovichMember 2023-03-31 0001799207 auna:NotesPurchaseAgreementMember ifrs-full:TopOfRangeMember 2023-03-31 0001799207 ifrs-full:TopOfRangeMember auna:JpmorganChaseBankSaMember 2023-03-31 0001799207 ifrs-full:BottomOfRangeMember auna:JpmorganChaseBankSaMember 2023-03-31 0001799207 auna:FxOperationAgreementCallSpread2029Member 2024-03-22 0001799207 auna:BancoSantanderHsbcMxicoAndGenaroLevinsonMarcovichMember 2022-09-30 2022-09-30 0001799207 ifrs-full:BottomOfRangeMember auna:BancoSantanderHsbcMxicoAndGenaroLevinsonMarcovichMember 2022-09-30 2022-09-30 0001799207 ifrs-full:TopOfRangeMember auna:BancoSantanderHsbcMxicoAndGenaroLevinsonMarcovichMember 2022-09-30 2022-09-30 0001799207 auna:FxOperationAgreementCallSpreadLongPut2025Member 2024-12-18 0001799207 auna:FxOperationAgreementCallSpreadShortCall2025Member 2024-12-18 0001799207 auna:FxOperationAgreementPurchasedCollar2028Member 2023-05-05 0001799207 auna:FxOperationAgreementSingleCall2028Member 2024-04-25 0001799207 auna:FxOperationAgreementSingleCall2028Member 2024-04-25 2024-04-25 0001799207 auna:FxOperationAgreementCallSpreadWithCitibankMember 2023-06-01 0001799207 auna:FxOperationAgreementCallSpreadWithCitibankMember ifrs-full:BottomOfRangeMember 2023-12-01 2023-12-31 0001799207 auna:FxOperationAgreementCallSpreadWithCitibankMember ifrs-full:TopOfRangeMember 2023-12-01 2023-12-31 0001799207 auna:FxOperationAgreementPurchasedCollar2024Member 2023-07-21 0001799207 auna:FxOperationAgreementPurchasedCollar2024Member 2023-07-21 2023-07-21 0001799207 auna:InterestRateSwapTiie2028Member 2024-04-30 0001799207 auna:InterestRateSwapSofr2028Member 2024-04-30 0001799207 auna:NotesPurchaseAgreementMember 2023-04-11 2023-04-11 0001799207 auna:BancoSantanderHsbcMxicoAndGenaroLevinsonMarcovichMember 2023-04-11 2023-04-11 0001799207 auna:NotesPurchaseAgreementMember 2023-04-11 0001799207 ifrs-full:BottomOfRangeMember auna:NotesPurchaseAgreementMember 2023-06-30 0001799207 auna:NotesPurchaseAgreementMember ifrs-full:TopOfRangeMember 2023-06-30 0001799207 auna:TermLoanMember auna:JointLeadArrangersAndJointBookrunnersMember 2024-03-31 0001799207 auna:NotesPurchaseAgreementMember ifrs-full:BottomOfRangeMember 2024-03-31 0001799207 ifrs-full:TopOfRangeMember auna:NotesPurchaseAgreementMember 2024-03-31 0001799207 auna:NotesPurchaseAgreementMember ifrs-full:BottomOfRangeMember 2024-06-30 0001799207 ifrs-full:TopOfRangeMember auna:NotesPurchaseAgreementMember 2024-06-30 0001799207 ifrs-full:TopOfRangeMember auna:NotesPurchaseAgreementMember 2025-12-31 0001799207 auna:NotesPurchaseAgreementMember ifrs-full:BottomOfRangeMember 2025-12-31 0001799207 ifrs-full:BottomOfRangeMember auna:NotesPurchaseAgreementMember 2025-03-31 0001799207 auna:NotesPurchaseAgreementMember ifrs-full:BottomOfRangeMember 2025-06-30 0001799207 auna:OtherFinancingDebtsMember auna:ScotiaBankMember 2020-12-01 0001799207 auna:OtherFinancingDebtsMember auna:ScotiaBankMember 2020-12-01 2020-12-01 0001799207 auna:OtherFinancingDebtsMember auna:ScotiaBankMember 2021-10-01 0001799207 auna:OtherFinancingDebtsMember auna:ScotiaBankMember 2021-06-30 0001799207 auna:OtherFinancingDebtsMember auna:ScotiaBankMember 2021-12-01 0001799207 auna:ScotiaBankMember auna:OtherFinancingDebtsMember 2022-12-01 0001799207 auna:ScotiaBankMember auna:OtherFinancingDebtsMember 2023-12-01 0001799207 auna:ScotiaBankMember auna:OtherFinancingDebtsMember 2024-12-01 0001799207 auna:NotesPurchaseAgreementMember ifrs-full:BottomOfRangeMember 2024-01-01 2024-03-31 0001799207 ifrs-full:TopOfRangeMember auna:NotesPurchaseAgreementMember 2024-01-01 2024-03-31 0001799207 ifrs-full:TopOfRangeMember auna:NotesPurchaseAgreementMember 2024-04-01 2024-06-30 0001799207 auna:NotesPurchaseAgreementMember ifrs-full:BottomOfRangeMember 2024-04-01 2024-06-30 0001799207 auna:NotesPurchaseAgreementMember ifrs-full:BottomOfRangeMember 2024-07-01 2024-09-30 0001799207 ifrs-full:TopOfRangeMember auna:NotesPurchaseAgreementMember 2024-07-01 2024-09-30 0001799207 auna:NotesPurchaseAgreementMember ifrs-full:BottomOfRangeMember 2024-10-01 2024-12-31 0001799207 auna:NotesPurchaseAgreementMember ifrs-full:TopOfRangeMember 2024-10-01 2024-12-31 0001799207 auna:NotesPurchaseAgreementMember 2024-10-01 2024-12-31 0001799207 auna:NotesPurchaseAgreementMember ifrs-full:BottomOfRangeMember 2023-01-01 2023-03-31 0001799207 ifrs-full:TopOfRangeMember auna:NotesPurchaseAgreementMember 2023-01-01 2023-03-31 0001799207 auna:NotesPurchaseAgreementMember ifrs-full:BottomOfRangeMember 2023-04-01 2023-06-30 0001799207 ifrs-full:TopOfRangeMember auna:NotesPurchaseAgreementMember 2023-04-01 2023-06-30 0001799207 auna:NotesPurchaseAgreementMember ifrs-full:TopOfRangeMember 2023-07-01 2023-09-30 0001799207 ifrs-full:BottomOfRangeMember auna:NotesPurchaseAgreementMember 2023-07-01 2023-09-30 0001799207 ifrs-full:TopOfRangeMember auna:NotesPurchaseAgreementMember 2023-10-01 2023-12-31 0001799207 auna:NotesPurchaseAgreementMember ifrs-full:BottomOfRangeMember 2023-10-01 2023-12-31 0001799207 auna:NotesPurchaseAgreementMember ifrs-full:BottomOfRangeMember 2022-10-01 2022-12-31 0001799207 ifrs-full:TopOfRangeMember auna:NotesPurchaseAgreementMember 2022-10-01 2022-12-31 0001799207 auna:NotesPurchaseAgreementMember ifrs-full:BottomOfRangeMember 2025-01-01 2025-03-31 0001799207 ifrs-full:TopOfRangeMember auna:NotesPurchaseAgreementMember 2025-01-01 2025-03-31 0001799207 auna:NotesPurchaseAgreementMember ifrs-full:BottomOfRangeMember 2025-04-01 2025-06-30 0001799207 ifrs-full:TopOfRangeMember auna:NotesPurchaseAgreementMember 2025-04-01 2025-06-30 0001799207 ifrs-full:BottomOfRangeMember auna:NotesPurchaseAgreementMember 2025-07-01 2025-09-30 0001799207 ifrs-full:TopOfRangeMember auna:NotesPurchaseAgreementMember 2025-07-01 2025-09-30 0001799207 ifrs-full:TopOfRangeMember auna:NotesPurchaseAgreementMember 2025-10-01 2025-12-31 0001799207 auna:NotesPurchaseAgreementMember ifrs-full:BottomOfRangeMember 2025-10-01 2025-12-31 0001799207 ifrs-full:BottomOfRangeMember auna:NotesPurchaseAgreementMember 2025-09-30 0001799207 ifrs-full:TopOfRangeMember auna:NotesPurchaseAgreementMember 2025-09-30 0001799207 ifrs-full:TopOfRangeMember auna:NotesPurchaseAgreementMember 2026-03-31 0001799207 auna:NotesPurchaseAgreementMember ifrs-full:BottomOfRangeMember 2026-03-31 0001799207 auna:NotesPurchaseAgreementMember ifrs-full:BottomOfRangeMember 2026-06-30 0001799207 ifrs-full:TopOfRangeMember auna:NotesPurchaseAgreementMember 2026-06-30 0001799207 auna:NotesPurchaseAgreementMember ifrs-full:BottomOfRangeMember 2026-09-30 0001799207 auna:NotesPurchaseAgreementMember ifrs-full:TopOfRangeMember 2026-09-30 0001799207 ifrs-full:TopOfRangeMember auna:NotesPurchaseAgreementMember 2026-10-01 2026-12-31 0001799207 ifrs-full:BottomOfRangeMember auna:NotesPurchaseAgreementMember 2026-10-01 2026-12-31 0001799207 ifrs-full:BottomOfRangeMember auna:NotesPurchaseAgreementMember 2026-12-31 0001799207 ifrs-full:TopOfRangeMember auna:NotesPurchaseAgreementMember 2026-12-31 0001799207 ifrs-full:OtherReservesMember 2023-07-06 0001799207 auna:DentegraSegurosDentalesSAMember 2023-07-24 0001799207 auna:DentegraSegurosDentalesSAMember 2023-02-01 2023-02-01 0001799207 auna:EntitiesMember 2023-12-31 2023-12-31 0001799207 auna:OncomedicaSAMember 2022-04-21 0001799207 ifrs-full:BrandNamesMember auna:ImatMember 2022-04-21 0001799207 ifrs-full:ComputerSoftwareMember auna:ImatMember 2022-04-21 0001799207 auna:ImatMember 2022-04-21 0001799207 auna:OncomedicaSAMember 2022-04-21 2022-04-21 0001799207 ifrs-full:IssuedCapitalMember 2023-12-31 0001799207 ifrs-full:RetainedEarningsMember 2023-12-31 0001799207 ifrs-full:EquityAttributableToOwnersOfParentMember 2023-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember 2023-12-31 0001799207 ifrs-full:MiscellaneousOtherReservesMember 2023-12-31 0001799207 ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember 2023-12-31 0001799207 ifrs-full:ReserveOfCashFlowHedgesMember 2023-12-31 0001799207 auna:HedgingReserveMember 2023-12-31 0001799207 ifrs-full:MergerReserveMember 2023-12-31 0001799207 ifrs-full:ReserveOfSharebasedPaymentsMember 2023-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:VehiclesMember 2023-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:FixturesAndFittingsMember 2023-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember 2023-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:BuildingsMember 2023-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember auna:MedicalEquipmentMember 2023-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:BuildingsMember 2023-12-31 0001799207 ifrs-full:GrossCarryingAmountMember auna:MedicalEquipmentMember 2023-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:VehiclesMember 2023-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:FixturesAndFittingsMember 2023-12-31 0001799207 ifrs-full:GrossCarryingAmountMember auna:WorksInProgressMember 2023-12-31 0001799207 ifrs-full:GrossCarryingAmountMember 2023-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:LandMember 2023-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:BuildingsMember 2024-12-31 0001799207 ifrs-full:GrossCarryingAmountMember 2024-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:LandMember 2024-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:BuildingsMember 2024-12-31 0001799207 ifrs-full:GrossCarryingAmountMember auna:MedicalEquipmentMember 2024-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:VehiclesMember 2024-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:FixturesAndFittingsMember 2024-12-31 0001799207 ifrs-full:GrossCarryingAmountMember auna:WorksInProgressMember 2024-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember auna:MedicalEquipmentMember 2024-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:VehiclesMember 2024-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:FixturesAndFittingsMember 2024-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember 2024-12-31 0001799207 ifrs-full:LandMember 2023-12-31 0001799207 ifrs-full:BuildingsMember 2023-12-31 0001799207 auna:MedicalEquipmentMember 2023-12-31 0001799207 ifrs-full:VehiclesMember 2023-12-31 0001799207 ifrs-full:FixturesAndFittingsMember 2023-12-31 0001799207 ifrs-full:LandMember 2024-12-31 0001799207 ifrs-full:BuildingsMember 2024-12-31 0001799207 auna:MedicalEquipmentMember 2024-12-31 0001799207 ifrs-full:VehiclesMember 2024-12-31 0001799207 ifrs-full:FixturesAndFittingsMember 2024-12-31 0001799207 ifrs-full:EquityAttributableToOwnersOfParentMember 2024-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember 2024-12-31 0001799207 ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember 2024-12-31 0001799207 ifrs-full:ReserveOfCashFlowHedgesMember 2024-12-31 0001799207 auna:HedgingReserveMember 2024-12-31 0001799207 ifrs-full:MergerReserveMember 2024-12-31 0001799207 ifrs-full:ReserveOfSharebasedPaymentsMember 2024-12-31 0001799207 ifrs-full:RetainedEarningsMember 2024-12-31 0001799207 ifrs-full:IssuedCapitalMember 2024-12-31 0001799207 ifrs-full:SharePremiumMember 2024-12-31 0001799207 ifrs-full:MiscellaneousOtherReservesMember 2024-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:CustomerrelatedIntangibleAssetsMember 2023-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:ComputerSoftwareMember 2023-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:BrandNamesMember 2023-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:CustomerrelatedIntangibleAssetsMember 2023-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:ComputerSoftwareMember 2023-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:ServiceConcessionRightsMember 2023-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:GoodwillMember 2023-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:ServiceConcessionRightsMember 2024-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:GoodwillMember 2024-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:BrandNamesMember 2024-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:CustomerrelatedIntangibleAssetsMember 2024-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:ComputerSoftwareMember 2024-12-31 0001799207 ifrs-full:BrandNamesMember 2024-12-31 0001799207 ifrs-full:CustomerrelatedIntangibleAssetsMember 2024-12-31 0001799207 ifrs-full:ComputerSoftwareMember 2024-12-31 0001799207 ifrs-full:ServiceConcessionRightsMember 2024-12-31 0001799207 ifrs-full:GoodwillMember 2024-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:CustomerrelatedIntangibleAssetsMember 2024-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:ComputerSoftwareMember 2024-12-31 0001799207 ifrs-full:NetLiabilitiesOrAssetsForRemainingCoverageExcludingLossComponentMember 2023-12-31 0001799207 ifrs-full:EstimatesOfPresentValueOfFutureCashFlowsMember 2023-12-31 0001799207 ifrs-full:RiskAdjustmentForNonfinancialRiskMember 2023-12-31 0001799207 auna:OutstandingClaimsReserveMember 2023-12-31 0001799207 ifrs-full:MiscellaneousOtherProvisionsMember 2023-12-31 0001799207 auna:OutstandingClaimsReserveMember 2024-12-31 0001799207 ifrs-full:MiscellaneousOtherProvisionsMember 2024-12-31 0001799207 auna:AccountsPayableRelatedwithExchangeMember 2023-12-31 0001799207 ifrs-full:SharePremiumMember 2023-12-31 0001799207 ifrs-full:RetainedEarningsMember 2023-12-31 0001799207 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2023-12-31 0001799207 auna:MergeReserveMember 2023-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember 2023-12-31 0001799207 auna:FinancialLoanMember 2023-12-31 0001799207 auna:DeferredIncomeMember 2023-12-31 0001799207 ifrs-full:LeaseLiabilitiesMember 2023-12-31 0001799207 auna:DerivativesPremiumsPayableMember 2023-12-31 0001799207 auna:FinancialLoanMember 2024-12-31 0001799207 auna:DeferredIncomeMember 2024-12-31 0001799207 auna:MergeReserveMember 2024-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember 2024-12-31 0001799207 ifrs-full:LeaseLiabilitiesMember 2024-12-31 0001799207 auna:DerivativesPremiumsPayableMember 2024-12-31 0001799207 auna:AccountsPayableRelatedwithExchangeMember 2024-12-31 0001799207 ifrs-full:SharePremiumMember 2024-12-31 0001799207 ifrs-full:RetainedEarningsMember 2024-12-31 0001799207 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2024-12-31 0001799207 ifrs-full:NetLiabilitiesOrAssetsForRemainingCoverageExcludingLossComponentMember 2024-12-31 0001799207 ifrs-full:EstimatesOfPresentValueOfFutureCashFlowsMember 2024-12-31 0001799207 ifrs-full:RiskAdjustmentForNonfinancialRiskMember 2024-12-31 0001799207 ifrs-full:EquityAttributableToOwnersOfParentMember 2022-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember 2022-12-31 0001799207 ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember 2022-12-31 0001799207 ifrs-full:ReserveOfCashFlowHedgesMember 2022-12-31 0001799207 auna:HedgingReserveMember 2022-12-31 0001799207 ifrs-full:MergerReserveMember 2022-12-31 0001799207 ifrs-full:ReserveOfSharebasedPaymentsMember 2022-12-31 0001799207 ifrs-full:RetainedEarningsMember 2022-12-31 0001799207 ifrs-full:IssuedCapitalMember 2022-12-31 0001799207 ifrs-full:SharePremiumMember 2022-12-31 0001799207 ifrs-full:MiscellaneousOtherReservesMember 2022-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:BuildingsMember 2022-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember auna:MedicalEquipmentMember 2022-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:VehiclesMember 2022-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:FixturesAndFittingsMember 2022-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember 2022-12-31 0001799207 ifrs-full:GrossCarryingAmountMember auna:MedicalEquipmentMember 2022-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:VehiclesMember 2022-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:FixturesAndFittingsMember 2022-12-31 0001799207 ifrs-full:GrossCarryingAmountMember auna:WorksInProgressMember 2022-12-31 0001799207 ifrs-full:GrossCarryingAmountMember 2022-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:LandMember 2022-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:BuildingsMember 2022-12-31 0001799207 ifrs-full:LandMember 2022-12-31 0001799207 ifrs-full:BuildingsMember 2022-12-31 0001799207 auna:MedicalEquipmentMember 2022-12-31 0001799207 ifrs-full:VehiclesMember 2022-12-31 0001799207 ifrs-full:FixturesAndFittingsMember 2022-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:CustomerrelatedIntangibleAssetsMember 2022-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:ComputerSoftwareMember 2022-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:ServiceConcessionRightsMember 2022-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:GoodwillMember 2022-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:BrandNamesMember 2022-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:CustomerrelatedIntangibleAssetsMember 2022-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:ComputerSoftwareMember 2022-12-31 0001799207 ifrs-full:BrandNamesMember 2023-12-31 0001799207 ifrs-full:CustomerrelatedIntangibleAssetsMember 2023-12-31 0001799207 ifrs-full:ComputerSoftwareMember 2023-12-31 0001799207 ifrs-full:ServiceConcessionRightsMember 2023-12-31 0001799207 ifrs-full:GoodwillMember 2023-12-31 0001799207 ifrs-full:RiskAdjustmentForNonfinancialRiskMember 2022-12-31 0001799207 ifrs-full:NetLiabilitiesOrAssetsForRemainingCoverageExcludingLossComponentMember 2022-12-31 0001799207 ifrs-full:EstimatesOfPresentValueOfFutureCashFlowsMember 2022-12-31 0001799207 auna:OutstandingClaimsReserveMember 2022-12-31 0001799207 ifrs-full:MiscellaneousOtherProvisionsMember 2022-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember 2022-12-31 0001799207 ifrs-full:LeaseLiabilitiesMember 2022-12-31 0001799207 auna:DerivativesPremiumsPayableMember 2022-12-31 0001799207 auna:TrustFundsMember 2022-12-31 0001799207 ifrs-full:SharePremiumMember 2022-12-31 0001799207 ifrs-full:RetainedEarningsMember 2022-12-31 0001799207 auna:MergeReserveMember 2022-12-31 0001799207 auna:FinancialLoanMember 2022-12-31 0001799207 auna:DeferredIncomeMember 2022-12-31 0001799207 ifrs-full:IssuedCapitalMember 2021-12-31 0001799207 ifrs-full:SharePremiumMember 2021-12-31 0001799207 ifrs-full:MiscellaneousOtherReservesMember 2021-12-31 0001799207 ifrs-full:EquityAttributableToOwnersOfParentMember 2021-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember 2021-12-31 0001799207 ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember 2021-12-31 0001799207 ifrs-full:ReserveOfCashFlowHedgesMember 2021-12-31 0001799207 auna:HedgingReserveMember 2021-12-31 0001799207 ifrs-full:MergerReserveMember 2021-12-31 0001799207 ifrs-full:ReserveOfSharebasedPaymentsMember 2021-12-31 0001799207 ifrs-full:RetainedEarningsMember 2021-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:BuildingsMember 2021-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember auna:MedicalEquipmentMember 2021-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:VehiclesMember 2021-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:FixturesAndFittingsMember 2021-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember 2021-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:LandMember 2021-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:BuildingsMember 2021-12-31 0001799207 ifrs-full:GrossCarryingAmountMember auna:MedicalEquipmentMember 2021-12-31 0001799207 ifrs-full:GrossCarryingAmountMember auna:WorksInProgressMember 2021-12-31 0001799207 ifrs-full:GrossCarryingAmountMember 2021-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:VehiclesMember 2021-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:FixturesAndFittingsMember 2021-12-31 0001799207 ifrs-full:BuildingsMember 2021-12-31 0001799207 auna:MedicalEquipmentMember 2021-12-31 0001799207 ifrs-full:VehiclesMember 2021-12-31 0001799207 ifrs-full:FixturesAndFittingsMember 2021-12-31 0001799207 ifrs-full:LandMember 2021-12-31 0001799207 auna:AdjustmentForProvisionForUnpaidVacationsAndAnnualPerformanceBonusesMember 2021-12-31 0001799207 auna:AdjustmentForTradeAccountsPayableMember 2021-12-31 0001799207 auna:AdjustmentForDerivativeFinancialInstrumentsMember 2021-12-31 0001799207 ifrs-full:LongtermBorrowingsMember 2021-12-31 0001799207 ifrs-full:PropertyPlantAndEquipmentMember 2021-12-31 0001799207 auna:AdjustmentForOthersMember 2021-12-31 0001799207 auna:AdjustmentForTaxLossesMember 2021-12-31 0001799207 auna:AdjustmentForLossForImpairmentOfTradeReceivablesMember 2021-12-31 0001799207 auna:AdjustmentOfProvisionsMember 2021-12-31 0001799207 ifrs-full:IntangibleAssetsOtherThanGoodwillMember 2021-12-31 0001799207 auna:AdjustmentForInvestmentsInAssociatesAndOthersMember 2021-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:GoodwillMember 2021-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:CustomerrelatedIntangibleAssetsMember 2021-12-31 0001799207 ifrs-full:AccumulatedDepreciationAndAmortisationMember ifrs-full:ComputerSoftwareMember 2021-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:BrandNamesMember 2021-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:CustomerrelatedIntangibleAssetsMember 2021-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:ComputerSoftwareMember 2021-12-31 0001799207 ifrs-full:GrossCarryingAmountMember ifrs-full:ServiceConcessionRightsMember 2021-12-31 0001799207 ifrs-full:BrandNamesMember 2022-12-31 0001799207 ifrs-full:CustomerrelatedIntangibleAssetsMember 2022-12-31 0001799207 ifrs-full:ComputerSoftwareMember 2022-12-31 0001799207 ifrs-full:ServiceConcessionRightsMember 2022-12-31 0001799207 ifrs-full:GoodwillMember 2022-12-31 0001799207 auna:OutstandingClaimsReserveMember 2021-12-31 0001799207 ifrs-full:MiscellaneousOtherProvisionsMember 2021-12-31 0001799207 auna:DerivativesPremiumsPayableMember 2021-12-31 0001799207 ifrs-full:SharePremiumMember 2021-12-31 0001799207 ifrs-full:RetainedEarningsMember 2021-12-31 0001799207 auna:MergeReserveMember 2021-12-31 0001799207 ifrs-full:NoncontrollingInterestsMember 2021-12-31 0001799207 auna:FinancialLoanMember 2021-12-31 0001799207 auna:DeferredIncomeMember 2021-12-31 0001799207 ifrs-full:LeaseLiabilitiesMember 2021-12-31 xbrli:shares iso4217:PEN iso4217:USD utr:Year xbrli:pure iso4217:MXN iso4217:COP utr:Day utr:Month iso4217:EUR iso4217:PEN xbrli:shares iso4217:USD xbrli:shares auna:Shareholder

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM

20-F/A

Amendment No. 1

(Mark One)

☐	REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

☒	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2024

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

☐	SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of event requiring this shell company report

Commission file number:

001-41982

Auna S.A.

(Exact name of Registrant as specified in its charter)

Auna Inc.

(Translation of Registrant’s name into English)

Grand Duchy of Luxembourg

(Jurisdiction of incorporation or organization)

6, rue Jean Monnet

L-2180

Luxembourg

Grand Duchy of Luxembourg

+51

1-205-3500

(Address of principal executive offices)

Gisele Remy Ferrero

Chief Financial Officer and Executive Vice President

+51

1-205-3500

6, rue Jean Monnet

L-2180

Luxembourg

Grand Duchy of Luxembourg

(Name, Telephone,

E-mail

and/or Facsimile number and Address of Company Contact Person)

Securities registered or to be registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Ordinary Shares, par value US$0.01 per share	AUNA	New York Stock Exchange

Securities registered or to be registered pursuant to Section 12(g) of the Act:

None

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:

None

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report. 30,052,722 class A ordinary shares, and 43,917,577 class B ordinary shares as of December 31, 2024.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ☐ No ☒

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Yes ☐ No ☒

Note

– Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a

non-accelerated

filer or an emerging growth company. See definition of “large accelerated filer,” accelerated filer,” and “emerging growth company” in Rule

12b-2

of the Exchange Act.:


Large Accelerated Filer ☐		Accelerated Filer ☐		Non-accelerated Filer ☐		Emerging growth company ☒

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

†	The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b) by the registered public accounting firm that prepared or issued its audit report. ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to

§240.10D-1(b). ☐

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

☐

U.S. GAAP

☒

International Financial Reporting Standards as issued by the International Accounting Standards Board

☐

Other

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.

☐ Item 17 ☐ Item 18

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule

12b-2

of the Exchange Act).

Yes ☐ No ☒


PCAOB ID: 2282		Auditors Name: Emmerich, Córdova y Asociados S. Civil de R.L .		Location: Lima, Peru

EXPLANATORY N

OTE

This Amendment No. 1 to the Annual Report on Form 20-F of Auna S.A. (the “Company”) amends the Co

mpan

y’s Annual Report on Form 20-F for the year ended December 31, 2024 (the “Original 20-F”), which was filed with the Securities and Exchange Commission on April 10, 2025. The Company is filing this Amendment No. 1 solely to update Item 16J and Item 16K, as well as to furnish Exhibit 101, in each case, in eXtensible Business Reporting Language (XBRL).

Except as described above, this Amendment No. 1 does not amend any information set forth in the Original 20-F, and the Company has not u

pdate

d disclosures included therein to reflect any events that occurred subsequent to April 10, 2025.

Item 16J. Insider Trading Policies.

We have adopted insider trading policies and procedures applicable to our directors, officers and em

ploy

ees, and have implemented processes for the Company that we believe are reasonably designed to promote compliance with insider trading laws, rules and regulations, and the NYSE Corporate Governance Standards. Our Insider Trading Policy prohibits our directors, officers, employees and related persons and entities from (i) trading in securities of Auna and other companies while in possession of material, nonpublic information, (ii) disclosing material, nonpublic information of Auna, or another publicly traded company, to others who may trade on the basis of that information. Our Insider Trading Policy also requires that our directors, officers, certain employees and related persons only transact in Auna securities during an open window period, subject to limited exceptions. Our executive officers and directors must also comply with additional trading restrictions and disclosure requirements. The foregoing summary of our insider trading policies and procedures does not purport to be complete and is qualified by reference to our Insider Trading Policy, a copy of which can be found as Exhibit 11.2 to this annual report on Form

20-F.

Item 16K. Cybersecurity.

We have implemented an Information Security and Cybersecurity

(IS-C)

framework that is aligned with industry best practices and standards, including ISO 27001, ISO 27031 and the NIST Cybersecurity Framework, with the objective of systematically addressing cyber risks across our organization. Cybersecurity is a core component of our overall business strategy, and our approach ensures that cybersecurity processes are integrated into the broader operational framework of the company, by fostering collaboration among departments and utilizing corporate and intra-company communication tools to mitigate risks. These processes are incorporated into our enterprise-wide risk management system.

Our board of directors has overall responsibility for our risk management, including cybersecurity risks, and delegates specific oversight of cybersecurity risk management to the dedicated cybersecurity manager. The board receives regular updates on cybersecurity risks and incidents from the cybersecurity manager. The board receives cybersecurity reports annually, with additional updates as necessary following significant incidents or developments. The Audit and Risk Committee receives detailed annual reports from both the cybersecurity manager and the board of directors, which include information regarding our

IS-C

maturity level, emerging cyber risks, and the status of ongoing projects to strengthen our cybersecurity defenses. Our cybersecurity manager and the team of dedicated personnel are highly experienced information systems security professionals. The cybersecurity manager has over 20 years of experience in managing and designing processes and systems to detect, assess, and remediate cybersecurity threats. As of April 1, 2025, our cybersecurity management team will consist of 10 individuals, with 3 located in Peru, 3 in Mexico, and 4 in Colombia, all reporting directly to the cybersecurity manager.

Technology and process

To enhance our cybersecurity capabilities, we rely on third-party providers that offer preventive and protective solutions, including Security Operations Centers (SOC), firewall protection, Web Application Firewalls (WAF), Anti-DDoS measures, mail filtering, antimalware and vulnerability and penetration testing of our core systems. In addition, we have implemented a robust set of internal security controls, including password policies, access controls, and backup and restoration processes. We regularly conduct internal assessments of third-party tools and evaluate security controls through reports from key providers, such as Service Organization Control (SOC) reports (e.g., SOC 1 Type II). We conduct internal assessments and periodically engage external consultants to review our cybersecurity strategy and provide feedback on its effectiveness.

Awareness

To further strengthen our cybersecurity posture, we have implemented a comprehensive

IS-C

aren

ess program designed to educate employees on identifying, mitigating, and preventing cybersecurity risks. This program includes monthly training sessions, with all employees required to participate in periodic training focused on confidentiality, security practices, and evolving threat landscapes. Despite our proactive efforts, we recognize that cybersecurity threats remain a constant and evolving challenge, and we are committed to continually enhancing our defenses to address these risks effectively.

Incidents

In 2024, we did not identify any cybersecurity incidents that materially affected or are reasonably likely to materially affect our business strategy, results of operations, or financial condition. Materiality is determined by evaluating the severity of any potential breach and its ability to significantly affect our organization’s financial results or operations. However, despite our best efforts, we cannot eliminate all risks from cybersecurity threats and cannot provide assurance that no undetected cybersecurity incidents have occurred. For more information about these risks, please refer to “Item 3. Key Information—D. Risk Factors—Risks Related to Our Business—A failure of our IT systems could adversely impact our business.”

PART III

ITEM 19. EXHIBITS


Exhibit No.		Exhibit

101.INS		Inline XBRL Instance Document

101.SCH		Inline XBRL Taxonomy Extension Schema Document

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

SIGNATURES

The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this Amendment No. 1 to the annual report on Form 20-F on its behalf.


AUNA S.A.

May 7, 2025

By:		/s/ Gisele Remy Ferrero
		Name: Gisele Remy Ferrero
		Title: Chief Financial Officer and Executive Vice President

Auna S.A. and Subsidiaries

Consolidated Financial Statements

December 31, 2024

(Including Independent Auditors’ Report)

F-1

Report of Independent Registered Public

Accounting Firm

To the Stockholders and Board of Directors

Auna S.A.

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated statements of financial position of Auna S.A. and subsidiaries (the “Company”) as of December 31, 2024, 2023 and 2022, and the related consolidated statements of profit or loss and other comprehensive income, changes in equity and cash flows for each of the years in the three-year period ended December 31, 2024, and the related notes (collectively, the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024, 2023 and 2022, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2024, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board (IFRS Accounting Standards).

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ Emmerich, Córdova y Asociados S. Civil de R.L.

We have served as the Company’s auditor since 2016.

Lima, Peru

April 10, 2025

F-2

Auna S.A. and Subsidiaries

Consolidated Financial Statements

December 31, 2024


Contents	Page

Consolidated Statement of Financial Position		F-4

Consolidated Statement of Profit or Loss and Other Comprehensive Income		F-5

Consolidated Statement of Changes in Equity		F-6

Consolidated Statement of Cash Flows		F-7

Notes to the Consolidated Financial Statements		F-8 -F-121

F-3

Auna S.A. and Subsidiaries

Consolidated Statement of Financial Position

As of December 31, 2024, 2023 and 2022


In thousands of soles	Note		2024		2023		2022
Assets
Current assets
Cash and cash equivalents		4		235,745		241,133		208,694
Trade accounts receivable		5		961,886		860,916		574,166
Other assets		6		253,283		222,728		255,595
Inventories		7		143,764		130,521		87,578
Derivative financial instruments		8		8,962		721		69,064
Other investments		9		100,228		93,132		—

Total current assets				1,703,868		1,549,151		1,195,097

Non-current assets
Trade accounts receivable		5		571		420		551
Other assets		6		24,433		21,573		19,806
Investments in associates and joint venture		10		25,405		20,584		13,096
Property, furniture, and equipment		11		2,280,123		2,573,140		2,320,144
Intangible assets		12		2,656,888		3,129,187		2,758,917
Right-of-use assets		13		131,062		139,386		144,317
Investment properties				6,058		6,959		5,982
Derivative financial instruments		8		58,510		81,492		13,542
Deferred tax assets		14		193,520		167,371		122,211
Other investments		9		282		289		—

Total non-current assets				5,376,852		6,140,401		5,398,566

Total assets				7,080,720		7,689,552		6,593,663


In thousands of soles	Note		2024			2023			2022
Liabilities
Current liabilities
Loans and borrowings		15		654,233			385,300			2,040,980
Lease liabilities		13		32,459			31,867			28,084
Trade accounts payable		16		931,265			749,349			512,587
Other accounts payable		17		289,563			463,600			216,163
Provisions		18		12,246			19,074			19,974
Derivative financial instruments		8		15,273			—			15,317
Insurance contract liabilities		32		10,098			39,853			11,699
Deferred income				138			267			313

Total current liabilities				1,945,275			1,689,310			2,845,117

Non-current liabilities
Loans and borrowings		15		2,965,541			3,376,282			1,307,667
Lease liabilities		13		115,429			126,178			134,838
Trade accounts payable		16		2,741			3,906			73
Other accounts payable		17		73,150			221,132			277,181
Derivative financial instruments		8		27,097			—			—
Deferred tax liabilities		14		328,370			495,826			470,159
Deferred income				177			352			567

Total non-current liabilities				3,512,505			4,223,676			2,190,485

Total liabilities				5,457,780			5,912,986			5,035,602

Equity		19
Share capital				17,387			8,820			236,547
Share premium				1,208,586			—			386,045
Reserves				524,776			1,823,364			533,369
Retained losses				(273,533	)		(366,899	)		(90,982	)

Equity attributable to the owner of the Company				1,477,216			1,465,285			1,064,979

Non-controlling interest				145,724			311,281			493,082

Total equity				1,622,940			1,776,566			1,558,061

Total liabilities and equity				7,080,720			7,689,552			6,593,663

The accompanying notes on pages 8 to 121 are an integral part of these consolidated financial statements.

F-

Auna S.A. and Subsidiaries

Consolidated Statement of Profit or Loss and Other Comprehensive Income

For the years ended December 31, 2024, 2023 and 2022


In thousands of soles	Note		2024			2023			2022
Revenue
Insurance revenue		20		1,052,958			914,182			716,064
Healthcare services revenue		20		3,012,454			2,695,860			1,514,639
Sales of medicines		20		320,700			265,865			220,905

Total revenue from contracts with customers				4,386,112			3,875,907			2,451,608

Cost of sales and services		21		(2,660,819	)		(2,440,561	)		(1,571,904	)

Gross profit				1,725,293			1,435,346			879,704

Selling expenses		21		(197,475	)		(193,943	)		(169,803	)
Administrative expenses		21		(788,677	)		(704,565	)		(477,524	)
(Loss) reversal for impairment of trade receivables		5		(40,855	)		(5,684	)		1,580
Other expenses		23		(2,112	)		(20,927	)		(1,028	)
Other income		22		87,586			50,113			21,658

Operating profit				783,760			560,340			254,587

Finance income		24		24,810			17,126			6,910
Finance income from exchange difference		24		—			75,852			—
Finance costs		24		(591,884	)		(783,782	)		(254,930	)
Finance costs from exchange difference		24		(41,709	)		—			(57,771	)

Net finance cost				(608,783	)		(690,804	)		(305,791	)

Share of profit of equity-accounted investees		10		8,800			6,290			3,757

Income (loss) before tax				183,777			(124,174	)		(47,447	)
Income tax expense		27		(59,819	)		(90,170	)		(29,383	)

Profit (loss) for the year				123,958			(214,344	)		(76,830	)

Other comprehensive income
Items that are or may be reclassified subsequently to profit or loss
Cash flow hedges				3,768			13,762			10,154
Foreign operations – Foreign currency translation differences				(409,746	)		390,180			(217,832	)
Remeasurements of defined benefit liability		17		1,523			(2,202	)		(437	)
Change in fair value of put liability				—			40,430			(9,666	)
Other investments at FVOCI – net change in fair value				1,072			188			—
Equity-accounted investees – share of OCI		10		—			(42	)		(77	)
Income tax				(1,744	)		(4,305	)		(2,996	)

Other comprehensive income (loss) for the year, net of tax				(405,127	)		438,011			(220,854	)

Total comprehensive income (loss) for the year				(281,169	)		223,667			(297,684	)

Income (loss) attributable to:
Owner of the Company				110,271			(253,921	)		(85,606	)
Non-controlling interest		19.G		13,687			39,577			8,776

				123,958			(214,344	)		(76,830	)

Total comprehensive income (loss) attributable to:
Owner of the Company				(276,855	)		84,292			(264,389	)
Non-controlling interest		19.G		(4,314	)		139,375			(33,295	)

				(281,169	)		223,667			(297,684	)

Earnings per share
Basic earnings per share		19 - 25		1.64			(5.78	)		(1.95	)
Diluted earnings per share		19 - 25		1.63			(5.78	)		(1.95	)

The accompanying notes on pages 8 to 121 are an integral part of these consolidated financial statements.

F-

Auna S.A. and Subsidiaries

Consolidated Statement of Changes in Equity

For the years ended December 31, 2024, 2023 and 2022


		Equity attributable to the owner of the Company
In thousands of soles	Note	Share capital (note 19.A)			Share premium			Other capital reserve (note 19.B)		Translation reserve (note 19.C)			Cost of hedging reserve (note 19.D)			Hedging reserve (note 19.E)			Merger and other reserves (note 19.F)			Shared- based payment reserve (note 33)			Retained earnings (losses)			Total			Non- controlling interest (note19.G)			Total equity
Balances as of January 1, 2022			236,547			386,045			51,240		(13,714	)		(18,873	)		(20,174	)		(79,764	)		—			(302	)		541,005			50,094			591,099

Loss for the year			—			—			—		—			—			—			—			—			(85,606	)		(85,606	)		8,776			(76,830	)
Other comprehensive loss for the year			—			—			—		(176,675	)		3,740			3,418			(9,266	)		—			—			(178,783	)		(42,071	)		(220,854	)

Total comprehensive loss for the year			—			—			—		(176,675	)		3,740			3,418			(9,266	)		—			(85,606	)		(264,389	)		(33,295	)		(297,684	)

Contributions from non-controlling shareholder			—			—			—		—			—			—			950,228			—			—			950,228			402,382			1,352,610
Acquisition of subsidiary with NCI			—			—			—		—			—			—			(161,915	)		—			—			(161,915	)		73,901			(88,014	)
Transfer to legal reserve			—			—			5,074		—			—			—			—			—			(5,074	)		—			—			—
Shareholder’s downstream merger			—			—			—		—			—			—			50			—			—			50			—			50

Total transactions with the owners of the Company			—			—			5,074		—			—			—			788,363			—			(5,074	)		788,363			476,283			1,264,646

Balances as of December 31, 2022			236,547			386,045			56,314		(190,389	)		(15,133	)		(16,756	)		699,333			—			(90,982	)		1,064,979			493,082			1,558,061

Balances as of January 1, 2023			236,547			386,045			56,314		(190,389	)		(15,133	)		(16,756	)		699,333			—			(90,982	)		1,064,979			493,082			1,558,061
Loss for the year			—			—			—		—			—			—			—			—			(253,921	)		(253,921	)		39,577			(214,344	)
Other comprehensive income for the year			—			—			—		302,095			28,839			(23,191	)		30,470			—			—			338,213			99,798			438,011

Total comprehensive income for the year			—			—			—		302,095			28,839			(23,191	)		30,470			—			(253,921	)		84,292			139,375			223,667

Transfer to legal reserve			—			—			23,468		—			—			—			—			—			(23,468	)		—			—			—
Changes of participation NCI in subsidiary	19.G		—			—			—		28,360			(7,284	)		10,399			283,892			—			—			315,367			(315,367	)		—
Contributions from non-controlling Shareholder			—			—			—		—			—			—			(1,016	)		—			—			(1,016	)		1,032			16
Shareholder’s downstream merger	19.A		(227,727	)		(386,045	)		—		—			—			—			613,963			—			(2,203	)		(2,012	)		—			(2,012	)
Dividend distribution			—			—			—		—			—			—			—			—			—			—			(6,841	)		(6,841	)
Equity-settled share-based payment	33		—			—			—		—			—			—			—			—			3,675			3,675			—			3,675

Total transactions with the owners of the Company			(227,727	)		(386,045	)		23,468		28,360			(7,284	)		10,399			896,839			—			(21,996	)		316,014			(321,176	)		(5,162	)

Balances as of December 31, 2023			8,820			—			79,782		140,066			6,422			(29,548	)		1,626,642			—			(366,899	)		1,465,285			311,281			1,776,566

Balances as of January 1, 2024			8,820			—			79,782		140,066			6,422			(29,548	)		1,626,642			—			(366,899	)		1,465,285			311,281			1,776,566
Profit for the year			—			—			—		—			—			—			—			—			110,271			110,271			13,687			123,958
Other comprehensive loss the year			—			—			—		(391,745	)		8,970			(6,946	)		2,595			—			—			(387,126	)		(18,001	)		(405,127	)

Total comprehensive loss for the year			—			—			—		(391,745	)		8,970			(6,946	)		2,595			—			110,271			(276,855	)		(4,314	)		(281,169	)

Issuance of common stock, net of issuance costs			1,112			1,204,913			—		—			—			—			—			—			—			1,206,025			—			1,206,025
Transfer to legal reserve			—			—			13,230		—			—			—			—			—			(13,230	)		—			—			—
Capitalization of merger reserve			7,453			—			—		—			—			—			(7,453	)		—			—			—			—			—
Reclassification of shared-based payment reserve			—			—			—		—			—			—			—			3,675			(3,675	)		—			—			—
Changes of participation NCI in subsidiary																				183									183			(183	)		—
Issuance of shares			2			3,673			—		—			—			—			—			(3,675	)		—			—			—			—
Acquisition of non-controlling interest	19.F		—			—			—		18,909			—			—			(1,076,628	)		—			—			(1,057,719	)		(159,910	)		(1,217,629	)
Derecognition of put liability			—			—			—		—			—			—			131,152			—			—			131,152			—			131,152
Dividend distribution			—			—			—		—			—			—			—			—			—			—			(1,150	)		(1,150	)
Equity-settled share-based payment	33		—			—			—		—			—			—			—			9,145			—			9,145			—			9,145

Total transactions with the owners of the Company			8,567			1,208,586			13,230		18,909			—			—			(952,746	)		9,145			(16,905	)		288,786			(161,243	)		127,543

Balances as of December 31, 2024			17,387			1,208,586			93,012		(232,770	)		15,392			(36,494	)		676,491			9,145			(273,533	)		1,477,216			145,724			1,622,940

The accompanying notes on pages 8 to 121 are an integral part of these consolidated financial statements.

F-

Auna S.A. and Subsidiaries

Consolidated Statement of Cash Flows

For the years ended December 31, 2024, 2023 and 2022


In thousands of soles	Note	2024			2023			2022
Cash flows from operating activities
Profit (loss) for the year			123,958			(214,344	)		(76,830	)
Adjustments for:
Depreciation	11		115,237			132,442			85,310
Depreciation of right-of-use assets	13		27,636			26,577			21,726
Amortization	12		76,273			76,731			31,055
Change in fair value of investment property			(161	)		(116	)		(173	)
(Reversal) Impairment of inventories			419			(1,927	)		4,655
Equity-settled share-based payment transactions			9,145			3,675			—
Gain (loss) on disposal of property, furniture, and equipment	11		4,491			(696	)		1,143
Loss on disposal of right-of-use assets net of leases	13		79			743			(32	)
Loss on disposal of intangibles	23		1,117			477			1,028
Other expenses for derecognition of other assets			2,112			—			—
Other expenses for changes in contingent consideration	23		—			20,927			—
Other income for reversal of contingent consideration	22		—			(4,095	)		—
Other income for reversal of others accounts payable to former shareholders	22		(46,613	)		—			—
Reversal (loss) for impairment of trade receivables	5		40,855			5,684			(1,580	)
Share of profit of equity-accounted investees	10		(8,800	)		(6,290	)		(3,757	)
Provisions	18		1,001			1,176			380
Finance income	24		(24,810	)		(92,978	)		(6,910	)
Finance costs	24		633,593			783,782			312,701
Tax expense	27		59,819			90,170			29,383
Net changes in assets and liabilities
Trade accounts receivable and other assets			(343,151	)		(316,000	)		(80,478	)
Inventories			(25,853	)		(30,107	)		(22,911	)
Trade accounts payable and other accounts payable			229,751			183,740			(63,168	)
Provisions and employee benefits	18		(5,718	)		(4,328	)		(2,145	)
Insurance contract liabilities			(28,602	)		25,068			(5,749	)

Cash generated from operating activities			841,778			680,311			223,648

Income tax paid			(194,322	)		(114,726	)		(67,767	)
Interest received			21,042			16,828			6,760

Net cash from operating activities			668,498			582,413			162,641

Cash flows from investing activities
Acquisition of subsidiary, net of cash acquired	1.C		—			(59,994	)		(2,952,721	)
Payment for accounts payable to former shareholder	1.C.i		(30,011	)		(1,368	)		—
Purchase of properties, furniture, and equipment	11		(90,857	)		(116,248	)		(102,497	)
Purchase of intangibles	12		(50,991	)		(48,917	)		(49,472	)
Dividends from equity-accounted investees	10		3,311			1,439			1,586
Other assets (Trust funds)	1.C.ii		—			94,539			(94,526	)
Purchase of other investments, net of sales			(21,312	)		(22,246	)		—
Proceeds from sale of property, furniture, and equipment			213			4,194			176
Payment for contingent consideration			(47,174	)		(36,143	)		(397	)
Proceeds from (payment in advance for) purchase of shares			—			11,592			(11,592	)

Net cash used in investing activities			(236,821	)		(173,152	)		(3,209,443	)

Cash flows from financing activities
Proceeds from issuance of common stock in initial public offering, net of issuance costs	15		1,267,794			—			—
Payments of initial public offering costs	15		(15,908	)		—			—
Proceeds from loans and borrowings	15		1,239,486			4,871,380			2,287,819
Payment for loans and borrowings	15		(1,125,622	)		(4,520,827	)		(340,113	)
Payment for lease liabilities	15		(45,593	)		(42,530	)		(34,758	)
Penalty paid for debt prepayment	15		—			(53,285	)		(9	)
Payment for derivatives premiums	15		(50,705	)		(51,141	)		(26,461	)
Payment for costs of extinguishment of debt	15		(16,607	)		—			—
Interest paid	15		(450,982	)		(566,774	)		(108,303	)
Proceeds from settlement of derivatives - interest rate swaps			(1,202	)		—			—
Dividends paid	19.G		(1,150	)		(6,841	)		(131	)
Contributions from non-controlling shareholders	15 & 19		—			16			1,352,610
Acquisition of non-controlling interest	19.F		(1,217,629	)		—			—

Net cash (used in) from financing activities			(418,118	)		(370,002	)		3,130,654

Net increase in cash and cash equivalents			13,559			39,259			83,852
Cash and cash equivalents at January 1			241,133			208,694			138,771
Cash and cash equivalents arising from shareholder’s downstream merger			—			—			145
Effect of movements in exchange rates on cash held			(18,947	)		(6,820	)		(14,074	)

Cash and cash equivalents at December 31			235,745			241,133			208,694

Transactions not representing cash flows
Assets acquired through finance lease and other financing	13		26,826			17,892			36,617
Assets acquired from suppliers in installments	11		10,060			16,834			(14,003	)

The accompanying notes on pages 8 to 121 are an integral part of these consolidated financial statements.

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

1.	Economic Activity

A.	Business activity

Auna S.A. (hereinafter the “Company” or “Auna”) is a subsidiary of Enfoca Group (ultimate controlling party), which holds a share capital of 68.26% acquired through different mechanisms. The Company is the controlling parent of a group of operating and

pre-operating

companies focused on the healthcare sector.

Auna S.A., as a Company, was incorporated on April 25, 2022, and organized under the laws of Luxembourg as a Société anonyme for an unlimited period.

Prior to July 6, 2023, the Company was incorporated in 2008 in Peru as an openly held corporation (sociedad anónima abierta) named Auna S.A.A. On July 6, 2023, the Company redomiciled to Luxembourg by way of a merger into Auna S.A., a limited liability company incorporated and existing under the laws of the Grand Duchy of Luxembourg, registered with the Luxembourg Trade and Companies Register under number B267590, with Auna S.A. continuing as the surviving entity.

The Company’s registered office is 6, rue Jean Monnet,

L-2180

Luxembourg, Grand Duchy of Luxembourg. The Company and its subsidiaries together are also referred to in these consolidated financial statements as the “Group”. The Group is a healthcare service provider primarily focused on services that provide cancer treatment through its subsidiary Oncosalud S.A.C., inpatient hospitals, outpatient care centers and specialized medical centers in Peru. Since the end of 2018 it has operated in Colombia through Promotora Médica Las Américas S.A. (hereinafter “PMLA”); since September 1, 2020 through Clínica Portoazul; and since April 21, 2022 through Oncomedica S.A. In February 2022, the Group established a holding company in Mexico, named Grupo Salud Auna Mexico S.A. de C.V. (hereinafter “Auna Mexico”), focused on healthcare investments. On October 5, 2022, the Group through Auna Mexico acquired Hospital y Clinica OCA S.A. de C.V., and on February 1, 2023 it acquired Dentegra Seguros Dentales, S.A. (hereinafter “Dentegra”). The structure of the Group is detailed in note 28.

Initial Public Offering

On March 21, 2024, the Group completed its initial public offering (the “IPO”) of 30,000,000 shares of Series A common stock at a price to the public of US$ 12.00 per share and the Company sold 30,000,000 of such shares. The Group received net proceeds from the IPO of S/ 1,267,794 thousand (equivalent to US$ 342,000 thousand), after deducting underwriting discounts and commissions, and S/ 61,769 thousand in offering-related expenses.

B.	Approval of the consolidated financial statements

The consolidated financial statements as of December 31, 2024, 2023 and 2022 were approved for issuance by the Board of Directors on April 10, 2025.

C.	Acquisition of subsidiaries

i.	Dentegra Seguros Dentales, S.A.

On September 3, 2021, Auna S.A. signed a share purchase agreement (hereinafter the “SPA”) with the shareholders of Dentegra for the acquisition of 100% of shares, obtaining control over the entity. The transaction closing date was on February 1, 2023.

Dentegra specializes in providing dental and vision ins

uran

ce in Mexico. The entity’s registered office is in Mexico City. The acquisition is expected to provide the Group with a presence in the insurance market in Mexico.

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

This acquisition was recorded using the acquisition method of accounting. Under this method, assets and liabilities were recorded at their estimated fair values at the date of purchase, including identifiable intangibles not recorded in the statement of financial position of the acquired entity. The transaction costs associated with the acquisition of S/ 1,709 thousand were recorded as an expense and presented under “administrative expenses” in the consolidated statement of income and other comprehensive income. The fair value of the acquired net assets are presented below:

Identifiable assets acquired and liabilities assumed


In thousands of soles	Note
Cash and cash equivalents		4,310
Other accounts receivables		1,868
Other investments		65,605
Intangible assets	12	3,411
Property, furniture and equipment	11	358
Deferred tax assets		1,484
Trade accounts payable and other accounts payable		(30,417	)
Insurance contract liabilities	32	(2,299	)

Total identifiable net assets acquired		44,320

Other accounts receivable include gross contractual amounts of S/ 1,868 thousand. As of the date of acquisition, there were no expected uncollectable amounts.

The other investments mainly correspond to investments in sovereign debt securities measured at FVOCI. As of December 31, 2023, other investments amounted to S/ 93,421 thousand.

The Group agreed to a price adjustment of S/ 1,347 thousand (equivalent to MXN 6,356 thousand) which was fully paid to the selling shareholders in July 2023 for an amount of S/ 1,368 thousand which includes an exchange difference of S/ 21 thousand.

The following table summarizes the fair value at the acquisition date of each major class of consideration transferred:


In thousands of soles
Cash			64,304
Account payables to former shareholder			1,347

Total consideration transferred			65,651

This acquisition resulted in goodwill, which has been determined as follows:


In thousands of soles
Consideration transferred	65,651
(Less)
Fair value of identifiable net assets	(44,320	)

Goodwill	21,331

The Group has recorded a goodwill on the acquisition of S/ 21,331 thousand in the Healthcare Services in Mexico segment as part of the “intangibles assets” account in the consolidated statement of financial position. None of the goodwill recognized is expected to be deductible for tax p

urp

oses.

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

Factors that explain the transaction and the goodwill are related to the business model of the acquired entity, which specializes in providing dental and vision insurance. According to Management, the Group intended to acquire an entity highly experienced in insurance, which would allow the Group to have a strategic position in the health insurance sector in Mexico. In addition, goodwill represents other synergies in operating efficiencies expected to be achieved from the mix of operations and other efficiencies not included in intangibles.

The purchase accounting as of the date of these financial statements is complete.

For the period ended December 31, 2023, the entity contributed revenues of S/ 102,916 thousand and profit before tax of S/ 30,882 thousand to the Group’s results.

If the acquisition had been made as of January 1, 2023, revenues would have amounted to S/ 3,884,448 thousand and loss before tax for the year would have amounted to S/ 123,032 thousand in the consolidated statement of income and other comprehensive income.

The net cash flows incurred as a result of the acquisition is presented below:


In thousands of soles
Consideration transferred in cash	64,304
Cash and cash equivalents from the entity	(4,310	)

Net cash flows incurred	59,994

Measurement of fair values

The valuation techniques used for measuring the fair value of material assets acquired were as follows:


Assets acquired		Valuation technique
Trademark		“Dentegra” is trademark of the acquired entity, for which a right to use the trademark was signed. This brand has a local presence and offers a broad portfolio of dental and vision insurance services. Of the three main approaches of value (income, market and cost) and the methods that include these approaches, the Group considered the relief from royalty (RFR) method within the income approach as the most appropriate to assess the value of the brand. The basic principle of the RFR method is that without ownership of the intangible in question, the user of such intangible would have to make a stream of payments to the asset owner in exchange for the rights to use that asset. By acquiring the intangible, the user avoids these payments. Based on the projections of the purchase model, the projected income and cash flow of the brand was estimated for the years 2023-2027. As of 2028, a growth of 9.6% was considered according to Management. This growth was used to calculate the terminal value of the brand that has an indefinite useful life. The royalty rate used for brand valuation is 0.4%. This royalty rate was obtained from comparable companies. Brand valuation found a nominal discount rate in MXN (WACC) by estimating a cost of debt (Kd) and equity (CoK).

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

ii.	Hospital y Clínica OCA, S.A. de C.V., DRJ Inmuebles, S.A. de C.V., Inmuebles JRD 2000, S.A. de C.V. and Tovleja HG, S.A. de C.V.

On October 5, 2022, Grupo Salud Auna México, S.A. de C.V. signed a share purchase agreement (hereinafter the “SPA”) with the shareholders of Hospital y Clínica OCA, S.A. de C.V., DRJ Inmuebles, S.A. de C.V., Inmuebles JRD 2000, S.A. de C.V. and Tovleja HG, S.A. (hereinafter the “entities”) for the acquisition of 100% of shares, obtaining control over the entities. Additionally, a group of properties was acquired as part of the acquisition. The transaction closing date was on October 5, 2022.

The entities are engaged in the direct provision of healthcare services. The entities registered office is in the city of Monterrey - Mexico. The acquisition is expected to provide the Group with an entry into the healthcare services market in Mexico.

Grupo Salud Auna México, S.A. de C.V. signed a loan agreement with Santander México, Bank and HSBC México Bank and a loan with the former shareholder for an amount of S/ 1,385,045 thousand (equivalent to US$ 350,000 thousand) and a capital contribution from shareholders, which were used to pay for the acquisition.

This acquisition was recorded using the acquisition method of accounting. Under this method, assets and liabilities were recorded at their estimated fair values at the date of purchase, including identifiable intangibles not recorded in the statement of financial position of the acquired entity. The transaction costs associated with the acquisition to S/ 24,481 thousand were recorded as an expense and presented under “administrative expenses” in the consolidated statement of income and other comprehensive income. The fair values of the acquired net assets are presented below:

Identifiable assets acquired and liabilities assumed


In thousands of soles	Note
Cash and cash equivalents			17,792
Trade accounts receivable and other accounts receivables			70,549
Inventory			10,009
Intangible assets		12	606,620
Property, furniture and equipment		11	1,083,894
Investment properties			4,647
Trade accounts payable and other accounts payable			(97,279	)
Loans and borrowings		15	(13,830	)
Contingent liabilities		18	(14,119	)
Deferred tax liability		14	(410,754	)

Total identifiable net assets acquired			1,257,529

Trade accounts receivable and other accounts receivable include gross contractual amounts due of S/ 80,749 thousand. As of the date of acquisition, S/ 10,200 thousand was expected to be uncollectable.

The Group has agreed with the selling shareholders to defer a portion of the purchase price (holdback) in an amount of S/ 93,317 thousand (e

quiv

alent to US$ 23,615 thousand) for a period of 450 days and subject to compensation for any indemnification claims at the date of payment. In June 2023, the Group adjusted the purchase price of the acquisition of Hospital y Clínica OCA consummated in October 2022 in accordance with the SPA for S/ 8,193 thousand (equivalent to US$ 1,933 thousand) as a lower holdback and goodwill. As of December 31, 2023, the deferred portion of the purchase price amounts to S/ 85,124 thousand (equivalent to US$ 21,682 thousand). This amount does not include interest accrued of S/ 5,018 thousand (equivalent to US$ 1,356 thousand) and a lower exchange difference of S/ 4,877 thousand. In September 2024 the Group derecognized of a portion of holdback at the acquisition of OCA to former shareholders of Hospital y Clínica OCA, S.A. de C.V. (OCA) of S/ 46,613 thousand (note 22(d)).

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

The following table summarizes the fair value as of the acquisition date of each major class of consideration transferred:


In thousands of soles
Cash			2,589,679
Holdback			93,317

Total consideration transferred / to be transferred			2,682,996

This acquisition resulted in goodwill, which has been determined as follows:


In thousands of soles
Consideration transferred	2,682,996
Purchase price adjustment	(8,193	)
(Less)
Fair value of identifiable net assets	(1,257,529	)

Goodwill	1,417,274

The Group, through its subsidiary Grupo Salud Auna México, S.A. de C.V., has recorded a goodwill on the acquisition of S/ 1,417,274 thousand in the Healthcare Services in Mexico segment as part of the “intangibles assets” account in the consolidated statement of financial position. None of the goodwill recognized is expected to be deductible for tax purposes.

Factors that explain the transaction and the goodwill are related to the business model of the acquired companies, which are a group of clinics that provide healthcare services. According to Management, the Group looked to acquire an entity highly experienced in healthcare services, which would allow the Group to have a strategic position in the health sector in Mexico. In addition, goodwill represents other synergies in operating efficiencies expected to be achieved from the mix of operations and other efficiencies not included in intangibles.

The purchase accounting as of the date of these financial statements is complete.

For the period ended December 31, 2022, the entities contributed revenues of S/ 216,121 thousand and profit before tax of S/ 34,206 thousand to the Group’s results.

If the acquisition had been made as of January 1, 2022, revenues would have amounted to S/ 3,030,375 thousand and profit before tax for the period 2022 would have amounted to S/ 101,852 thousand in the consolidated statement of income and other comprehensive income.

The net cash flows incurred as a result of the acquisition is presented below:


In thousands of soles
Consideration transferred in cash	2,589,679
Cash and cash equivalents from the entities	(17,792	)

Net cash flows incurred	2,571,887

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

Measurement of fair values

The valuation techniques used for measuring the fair value of material assets acquired were as follows:


Assets and liabilities acquired		Valuation technique
Trademarks		“Oca” and “Doctors” are trademarks of the acquired group. These brands have a local presence and offer a broad portfolio of healthcare services to their patients. Of the three main approaches of value (income, market and cost) and the methods that include these approaches, the Group considered the relief from royalty (RFR) method within the income approach as the most appropriate to assess the value of the brands. The basic principle of the RFR method is that without ownership of the intangible in question, the user of such intangible would have to make a stream of payments to the asset owner in exchange for the rights to use that asset. By acquiring the intangible, the user avoids these payments. Based on the projections of the purchase model, the projected income and cash flow of the brands was estimated for the years 2022-2027. As of 2028, a growth of 2.3% is estimated according to Management. This growth was used to calculate the terminal value of brands that have an indefinite useful life. The royalty rate used for brand valuation was 2.5%. This royalty rate was obtained from comparable companies. Brands valuation found a nominal discount rate in MXN (WACC) by estimating a cost of debt (Kd) and equity (CoK).
Customer relationship		Contracts agreed with doctors in connection with the healthcare services, mainly, in which a number of services are contracted for an established population. It is considered that they meet the criteria established for the recognition of said intangible asset. The multi-period excess earnings method (“MPEEM”) within the income approach is the most appropriate to value this asset. The MPEEM determines the value of an intangible as the present value of the incremental after-tax cash flows attributable only to the subject intangible after deducting the Contributory Asset Charges (CAC). The concept behind the CAC is that an intangible ‘rents’ or ‘leases’ from a hypothetical third party all the assets it requires to produce the cash flows resulting from its development, that each project leases only those assets it needs (including trading elements) and not those it does not need, and that each project pays to the owner of the assets a fair return (where appropriate) on the value of the leased assets.
Property, furniture and equipment and Investment properties		Market comparison technique and cost technique: The valuation model considers market prices quoted for similar items when they are available, and depreciated replacement cost when appropriate. Depreciated replacement cost reflects adjustments for physical deterioration, as well as functional and economic obsolescence.

iii.	Oncomedica S.A.

On January 18, 2022, Auna Colombia S.A.S. signed a share purchase agreement (hereinafter SPA) with the shareholders of On

comedic

a S.A. for the acquisition of 70% of shares (735,909,887 shares) of Oncomedica S.A., obtaining an interest of 70% and obtaining control. The transaction closing date was on April 21, 2022.

F-1

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

Oncomedica S.A. and its subsidiaries are engaged in the direct provision of healthcare services and other healthcare-related services. Oncomedica S.A.’s registered office is in the city of Montería, Colombia. The acquisition is expected to provide the Group with an increased share of the healthcare services market in Colombia.

Auna Colombia S.A.S. signed a loan agreement with JPMorgan Chase Bank, S.A. for an amount of S/ 205,628 thousand (equivalent to US$ 55,500 thousand) which was used to pay for the acquisition of Oncomedica S.A.

This acquisition was recorded using the acquisition method of accounting. Under this method, assets and liabilities were recorded at their estimated fair values at the date of purchase, including identifiable intangibles not recorded in the statement of financial position of the acquired entity. The transaction costs associated with the acquisition of S/ 1,195 thousand were recorded as an expense and presented under “administrative expenses” in the consolidated statement of income and other comprehensive income. The fair values of the acquired net assets are presented below:

Identifiable assets acquired and liabilities assumed


In thousands of soles	Note
Cash and cash equivalents		15,966
Trade accounts receivable and other accounts receivables		198,129
Inventory		5,324
Intangible assets	12	66,053
Property, furniture and equipment	11	168,501
Right-of-use assets	13	21,679
Trade accounts payable and other accounts payable		(126,372	)
Loans and borrowings	15	(48,440	)
Lease liabilities	13	(21,551	)
Deferred tax liability	14	(32,952	)

Total identifiable net assets acquired		246,337

Trade accounts receivable and other accounts receivable include gross contractual amounts due of S/ 286,465 thousand. As of the date of acquisition, S/ 88,336 thousand was expected to be uncollectable.

The Group has agreed to pay the selling shareholders a contingent consideration from S/ 73,439 thousand (equivalent to COP 74,031 million) to S/ 122,397 thousand (equivalent to COP 123,384 million) if the acquiree’s EBITDA for 2022 is between S/ 85,471 thousand (equivalent to COP 86,160 million) and S/ 116,355 thousand (equivalent to COP 117,203 million). As of the date of the acquisition, the Group has estimated the fair value of the consideration at S/ 79,461 thousand (COP 80,101,345 thousand). The Group is in the process of negotiating the payment date, which is expected to be made within the first quarter of 2024.

To guarantee the payment of the contingent consideration, on the closing date, the SPA established a bank guarantee to be provided by the acquirer to the sellers. In this regard, the Group has deposited S/ 94,526 thousand (COP 100,000 million) in a trust fund, which has been accounted for as other financial assets and included in other assets in the consolidated financial statement position. This amount has increased on this balance by S/ 675 thousand due to a higher exchange rate difference, see note 6(c).

F-1

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

The following table summarizes the fair value as of the acquisition date of each major class of consideration transferred:


In thousands of soles
Cash			396,800
Contingent consideration			79,461

Total consideration transferred			476,261

The SPA establishes put and call options for the shares owned by the

non-controlling

interest (NCI) (hereinafter “put and call”) that could be exercised if certain precedent conditions are met for:

•

The

non-controlling

shareholders with 10.89% interest during the three years after the closing date.

•

The

non-controlling

shareholders with 15.95% interest during the third year after closing date.

Considering the precedent conditions, the NCI still has access to the returns associated with the underlying ownership interest. Therefore, the Company used the present-access method to recognize the put liability at its fair value in “other accounts payable” for S/ 161,915 thousand against “merge and other reserves” in equity.

As of December 31, 2022, the balance of the put liability is S/ 136,938 thousand after recognizing the changes in fair value of S/ 9,666 thousand in “merger and other reserves” and the decrease in this balance due to changes in the COP exchange rate to soles of S/ 34,643 thousand. During 2024, the Group has determined that the precedent conditions of the put liability have not been and will not be exercised.

This acquisition resulted in a goodwill, which has been determined as follows:


In thousands of soles
Consideration transferred	476,261
Non-controlling interest	73,901
(Less)
Fair value of identifiable net assets	(246,337	)

Goodwill	303,825

The Group, through its subsidiary Auna Colombia S.A.S., has recorded goodwill on the acquisition of Oncomedica S.A. of S/ 303,825 thousand in the Healthcare Services in Colombia segment as part of the “intangibles assets” account in the consolidated statement of financial position. None of the goodwill recognized is expected to be deductible for tax purposes.

Factors that explain the transaction and the goodwill are related to the business model of the acquired company, which is a clinic that provides integral care to oncological patients. The Group looked to acquire an entity highly experienced in the specialty of oncology, which would allow the Group to have a strategic position in the health sector in this part of Colombia. In addition, goodwill represents other synergies in operating efficiencies that are expected to be achieved from the combination of operations and other efficiencies not included in intangibles.

The purchase accounting as of the date of these financial statements is complete.

According with the accounting policy choice used by Management for

non-controlling

interest measurement, the Group recognizes

non-controlling

interests in the acquiree based on the

non-controlling

interest’s pr

oportio

nate share of the acquired entity’s net identifiable assets.

F-1

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

For the period ended December 31, 2022, Oncomedica S.A. and its subsidiaries contributed revenues of S/ 210,323 thousand and profit before tax of S/ 55,233 thousand to the Group’s results.

If the acquisition had been made as of January 1, 2022, revenues would have amounted to S/ 2,533,991 thousand and losses before tax for the period 2022 would have amounted to S/ 34,394 thousand in the consolidated statement of income and other comprehensive income.

The net cash flows incurred as a result of the acquisition is presented below:


In thousands of soles
Consideration transferred	396,800
Cash and cash equivalents from Oncomedica S.A. and Subsidiaries	(15,966	)

Net cash flows incurred	380,834

Measurement of fair values

The valuation techniques used for measuring the fair value of material assets acquired were as follows:


Assets and liabilities acquired		Valuation technique
Trademarks		IMAT is the trademark of the acquired group. This brand has a local presence and offers a broad portfolio of healthcare services to patients. Of the three main approaches of value (income, market and cost) and the methods that include these approaches, the Company considered the relief from royalty (RFR) method within the income approach as the most appropriate to assess the value of the IMAT brand. The basic principle of the RFR method is that without ownership of the intangible in question, the user of such intangible would have to make a stream of payments to the asset owner in exchange for the rights to use that asset. By acquiring the intangible, the user avoids these payments. Based on the projections of the purchase model, the projected income and cash flow of IMAT was estimated for the years 2022-2027, and as of 2028, a growth of 2.93% is estimated according to Management. This growth was used to calculate the terminal value of brands that have an indefinite useful life. The royalty rate used for brand valuation is 2.70%. This royalty rate was obtained from comparable companies. Brand valuation found a nominal discount rate in COP (WACC) by estimating a cost of debt (Kd) and equity (CoK). Additionally, a premium of 1.0% will be considered on the WACC related to the lower liquidity of the intangible asset compared to other assets (considered discount rate of 14.03%).
Property, furniture and equipment		Market comparison technique: The valuation model considers market prices quoted for similar items when they are available.

Loans and borrowings		Oncomedica S.A. and its subsidiaries’ loans and borrowings are private debt. Due to this, Management has used a valuation technique that maximizes the use of relevant observable inputs and has considered the contractual cash flows of the remaining debt discounted at the rate that best represents Oncomedica S.A. and its subsidiaries’ credit risk at the acquisition date.

F-1

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

D.	Regulatory agency for private healthcare services

Oncosalud S.A.C. is an indirect subsidiary of the Company. It is supervised by the Superintendencia Nacional de Salud - SUSALUD (Peruvian Board of Health). SUSALUD authorizes, regulates and supervises the operations of entities that provide healthcare services.

In the case of PMLA, Clínica Portoazul and Oncomedica S.A. are regulated by the Superintendencia Nacional de Salud - Supersalud (Colombian Board of Health), an agency that authorizes, regulates and supervises the operation of entities providing healthcare services.

Also, since February 1, 2023, Dentegra Seguros Dentales, S.A. is a subsidiary of the Company, which is supervised by the Comisión Nacional de Seguros y Fianzas – CNSF (Mexican Commission of Insurers). CNSF authorizes, regulates and supervises the operations of entities that provide insurers services.

2.	Basis for the Preparation of Consolidated Financial Statements

A.	Basis of accounting

These consolidated financial statements of the Group have been prepared in accordance with IFRS Accounting Standards issued by the International Accounting Standards Board (IFRS Accounting Standards).

Details of the Group’s material accounting policies are included in note 3.

Comparative information

Since the focus in consolidated financial statements is the economic entity rather than the legal entity, and on the basis that Auna S.A. group continues to reflect the operations of the merged group Auna S.A.A (from Auna S.A.A’s point of view, there has simply been a change in jurisdiction), the Group is using Auna S.A.A. group’s consolidated figures as comparatives as if the Group existed before July 6, 2023 (note 1.A).

B.	Basis of measurement

The consolidated financial statements have been prepared on the historical cost principle, based on the accounting records maintained by the Group, except for the derivative financial instruments, other investments and investment properties which have been measured at fair value.

C.	Functional and presentation currency

These consolidated financial statements are presented in Soles (S/), which is the Company’s functional currency. All amounts have been rounded to the nearest thousand, unless otherwise indicated. The functional currency of the subsidiaries domicilied in Peru is S/ (Soles), the subsidiaries domiciled in Colombia is COP (Colombian Pesos) and the subsidiaries domiciled in Mexico is MXN (Mexican Pesos).

D.	Use of judgments and estimates

In preparing these consolidated financial statements, Management has made judgments and estimates that affect the application of the Group’s accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to estimates are re

cogniz

ed prospectively.

F-1

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

Judgments

Information about judgments made in applying accounting policies that have the most significant effects on the amounts recognized in the consolidated financial statements is included in the following notes:

•

CGU: whether a group of assets that generate cash flows and that are largely independent of the cash inflows of other assets or group of assets is a CGU (note 3.F);

•

leases: whether an arrangement contains a lease (note 3.J);

•

lease term: whether the Group is reasonably certain to exercise extension options (note 3.J); and

•

reverse factoring: presentation of amounts related to supplier finance arrangements in the statement of financial position and in the statement of cash flow.

ii.	Assumptions and estimation uncertainties

Information about assumptions and estimation uncertainties at December 31, 2024 that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities in the next financial year is included in the following notes:

•

Impairment test of intangible assets and goodwill: key assumptions underlying recoverable amounts (note 12);

•

Recognition of deferred tax asset: availability of future taxable profit against which deductible temporary differences and tax losses carried forward can be utilized (note 14);

•

Recognition and measurement of provisions: key assumptions about the likelihood and magnitude of an outflow of resources (note 18);

•

Measurement of defined benefit obligations: key actuarial assumptions (note 17);

•

Measurement of ECL allowance for trade receivables: key assumptions in determining the weighted-average loss rate (note 5); and

•

Acquisition of subsidiary: fair value of the consideration transferred and fair value of the assets acquired and liabilities (note 1.C).

The significant judgments made by management in applying the Group’s accounting policies and the key sources of estimation uncertainty related to the adoption of IFRS 17, Insurance contracts, were as follows:

Insurance contracts

PAA – Premium Allocation Approach

The PAA is an optional simplified measurement model in IFRS 17 that is available for insurance contracts that meet the eligibility criteria.

The Group determined it would apply the PAA to all insurance contracts because the coverage period of each contract in the Group is one year or less.

Liability for remaining coverage

The Group applies the PAA to simplify the measurement of insurance contracts.

Under IFRS 17, the Group’s insurance contracts issued are all eligible to be measured by applying the PAA, because the coverage period of each contract in the Group is one year or less. The PAA simplifies the measurement of insurance contracts in comparison with the General Measurement Model (GMM) in IFRS 17.

F-1

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

Liability for incurred claims

The methodologies analyzed are: Chain-Ladder, Expected Trend and Bornhuetter – Ferguson (BF), using various types of factor averaging, namely simple, median, truncated average or weighted average. From the methodologies analyzed, the result is selected at the discretion of the actuary considering the context and expectations at the valuation date.

The Group estimates the liability for incurred claims as the fulfillment of cash flows related to incurred claims.

The fulfillment of cash flows incorporates, in an unbiased way, all reasonable and supportable information available without undue cost or effort about the amount, timing and uncertainty of those future cash flows, which reflect current estimates from the perspective of the entity and include an explicit adjustment for

non-financial

risk (the risk adjustment).

Discount rates

The Group does not adjust the future cash flows for the time value of money and the effect of financial risk for the measurement of liability for incurred claims that are expected to be paid within one year of being incurred.

Risk adjustment for

non-financial

risk

The risk adjustment for

non-financial

risk is the compensation that the Group requires for bearing the uncertainty about the amount and timing of the cash flows of groups of insurance contracts. The risk adjustment reflects an amount that an insurer would rationally pay to remove the uncertainty that future cash flows will exceed the expected value amount.

The estimation error is calculated as the standard deviation of the mean square error using the deterministic method suggested by Thomas Mack (Distribution Free). This method seeks to determine the Standard Error of estimation as the aggregation of the error associated with the process, and the error associated with the calculation of the parameter.

From the total loss triangle, the amount of the MOCE (Margin over current estimation) is calculated and a factor is obtained such as 25% of the proportion that holds the standard deviation of the estimation error, of the events incurred but not reported (“IBNR”) reserve of the Thomas Mack method.

The risk adjustment is calculated on the IBNR, given the number of claims considered that are still su

ect to adjustments.

3.	Material Accounting Policies

The Group has consistently applied the following accounting policies to all periods presented in these consolidated financial statements.

A.	Basis of consolidation

i.	Business combinations

The Group accounts for business combinations using the acquisition method when control is transferred to the Group. The consideration transferred in the acquisition is generally measured at fair value, as are the identifiable net assets acquired. Any goodwill that arises is tested annually for impairment. Any gain on a bargain purchase is recognized in profit or loss immediately. Tra

nsaction

costs are expensed as incurred.

F-1

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

ii.	Subsidiaries

Subsidiaries are entities controlled by the Group. The Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases.

Also, in preparing the consolidated financial statements of the Company, the effects of all transactions between subsidiaries were eliminated.

iii.	Non-controlling interest

For each business combination, the Group elects whether to measure the

non-controlling

interests in the acquiree at fair value or at the proportionate share of the acquiree’s identifiable net assets as of the date of acquisition.

Changes in the Group’s interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions.

iv.	Common control transactions

The Company presents common control transactions at the date the transaction occurs without

re-presenting

comparative information, unless material. Material common control transactions are presented as if the transaction had occurred before the start of the earliest period presented.

v.	Associates

Associates are those entities in which the Group has significant influence, but not control or joint control, over the financial and operating policies. A joint venture is an arrangement in which the Group has joint control, whereby the Group has rights to the net assets of the arrangement, rather than rights to its assets and obligations for its liabilities.

Interests in associates and the joint venture are accounted for using the equity method. They are initially recognized at cost, which includes transaction costs. Subsequent to initial recognition, the consolidated financial statements include the Group’s share of the profit or loss and OCI of equity-accounted investees, until the date on which significant influence or joint control ceases.

vi.	Joint arrangements

Under IFRS 11, investments in joint arrangements are classified as joint operations or as joint ventures depending on the contractual rights and obligations of each investor. The Group has assessed the nature of its joint arrangements and determined that they are joint ventures.

Joint ventures are accounted for using the equity method. Under the equity method, equity in joint ventures is initially recognized at cost and subsequently adjusted to recognize the Group’s share in profits or losses and other post-acquisition movements in other comprehensive income. When the Group’s share in the losses of a joint venture is equivalent to or exceeds its share in such joint venture (including any long-term share that is substantially part of the Group’s net investment in the joint venture), the Group does not recognize additional losses, unless it has assumed obligations or made payments on behalf of the joint ventures.

Unrealized gains on transactions between the Group and its joint ventures are eliminated to the extent of the Group’s share in such joint ventures. Unrealized losses are also eliminated, unless the transaction provides evidence of an impairment of the transferred asset.

The profit resulting from the equity method is included in the consolidated statement of profit or loss and other comprehensive income.

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

vii.	Transactions eliminated on consolidation

Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated. Unrealized gains arising from transactions with companies whose investment is recognized using the equity method are eliminated from the investment in proportion to the Group’s interest in the investment. Unrealized losses are eliminated in the same way as unrealized gains, but only to the extent that there is no evidence of impairment.

B.	Financial instruments

i.	Recognition and initial measurement

Trade receivables and debt instruments are initially recognized when they are originated. All other financial assets and financial liabilities are initially recognized when the Group becomes a party to the contractual provisions of the instrument.

A financial asset (unless it is an account receivable without a significant financing component) or financial liability is initially measured at fair value plus, for an item not measured at FVTPL, transaction costs that are directly attributable to its acquisition or issue. A trade receivable without a significant financing component is initially measured at the transaction price.

ii.	Classification and subsequent measurement

•

Financial assets

On initial recognition, a financial asset is classified as measured at amortized cost or at fair value through profit and loss.

Financial assets are not reclassified subsequent to their initial recognition, unless the Group changes its business model for managing financial assets, in which case all affected financial assets are reclassified on the first day of the first reporting period following the change in the business model.

A financial asset is measured at amortized cost if it meets both of the following conditions and is not measured at FVTPL:

•

It is held within a business model whose objective is to hold assets to collect contractual cash flows; and

•

Its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

A debt investment is measured at FVOCI if it meets both of the following conditions and is not designated as at FVTPL:

•

It is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; and

•

Its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

All financial assets not classified as measured at amortized cost or FVOCI as described above are m

sured at FVTPL. This includes all derivative financial assets that are not cash flow hedge. On initial recognition, the Group may irrevocably designate a financial asset that otherwise meets the requirements to be measured at amortized cost or at FVOCI as at FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise.

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

Business model assessment

The Group makes an assessment of the objective of the business model in which a financial asset is held at a portfolio level because this best reflects the way the business is managed and information is provided to Management. The information considered includes:

•

The stated policies and objectives for the portfolio and the operation of those policies in practice. These include whether Management’s strategy focuses on earning contractual interest income, maintaining a particular interest rate profile, matching the duration of the financial assets to the duration of any related liabilities or expected cash outflows or realizing cash flows through the sale of the assets;

•

How the performance of the portfolio is assessed and reported to the key personnel of the Group’s Management;

•

The risks that affect the performance of the business model (and the financial assets held within that business model) and how those risks are managed;

•

How managers of the business are compensated – e.g., whether compensation is based on the fair value of the assets managed or the contractual cash flows collected; and

•

The frequency, value, and timing of sales in prior periods, the reasons for such sales and expectations about future sales.

Transfers of financial assets to third parties in transactions that do not qualify for derecognition are not considered sales for this purpose, consistent with the Group’s continuing recognition of the assets.

Financial assets that are held for trading or are managed and whose performance is assessed on a fair value basis are measured at FVTPL.

Assessment whether contractual cash flows are solely payments of principal and interest

For the purposes of this assessment, “principal” is defined as the fair value of the financial asset on initial recognition. “Interest” is defined as consideration for the time value of money and for the credit risk associated with the principal amount outstanding during a particular period of time and for other basic lending risks and costs (e.g., liquidity risk and administrative costs), as well as a profit margin.

In assessing whether the contractual cash flows are solely payments of principal and interest, the Group considers the contractual terms of the instrument. This includes assessing whether the financial asset contains a contractual term that could change the timing or amount of contractual cash flows so that it would not meet this condition. In making this assessment, the Group considers:

•

Contingent events that would change the amount or timing of cash flows;

•

Terms that may adjust the contractual coupon rate, including variable-rate features;

•

Prepayment and extension features; and

•

Terms that limit the Group’s claim to cash flows from specified assets (e.g., non-recourse features).

A prepayment feature is consistent solely with the payments of principal and interest criterion if the prepayment amount substantially represents the amounts of principal and interest on the principal amount outstanding, which may include reasonable additional compensation for early termination of the contract. Additionally, for a financial asset acquired at a significant discount or premium to its contractual par amount, a feature that permits or requires prepayment at an amount that substantially represents the contractual par amount plus accrued (but unpaid) contractual interest (which may also include reasonable additional compensation for early termination) is treated as consistent with this criterion if the fair value of the prepayment feature is insignificant at initial recognition.

F-22

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

Subsequent measurement and gains and losses


Financial assets at FVTPL		These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognized in profit or loss. However, see note 3.B.v for derivatives designated as hedging instruments.
Financial assets at amortized cost		These assets are subsequently measured at amortized cost using the effective interest method. The amortized cost is reduced by impairment losses. Interest income, foreign exchange gains and losses, and impairment are recognized in profit or loss. Any gain or loss on derecognition is also recognized in profit or loss.
Debt investments at FVOCI		These assets are subsequently measured at fair value. Interest income calculated using the effective interest method, foreign exchange gains and losses and impairment are recognized in profit or loss. Other net gains and losses are recognized in OCI. On derecognition, gains and losses accumulated in OCI are reclassified to profit or loss.
Equity investments at FVOCI		These assets are subsequently measured at fair value. Dividends are recognized as income in profit or loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognized in OCI and are never reclassified to profit or loss.

The Group classified its financial assets at amortized cost and FVOCI.

•

Financial liabilities

Classification, subsequent measurement and gains and losses

Financial liabilities are classified as measured at amortized cost or FVTPL. A financial liability is classified as at FVTPL if it is classified as

held-for-trading,

if it is a derivative or if it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognized in profit or loss. Other financial liabilities are subsequently measured at amortized cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss on derecognition is also recognized in profit or loss.

iii.	Derecognition

Financial assets

The Group derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred, or it neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control over the transferred asset.

The Group enters into transactions whereby it transfers assets recognized in its consolidated statement of financial position, but retains either all or substantially all of the risks and rewards of the transferred assets. In these cases, the transferred assets are not de

reco

gnized.

F-23

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

Financial liabilities

The Group derecognizes a financial liability when its contractual obligations are discharged or canceled or expire. The Group also derecognizes a financial liability when its terms are modified and the cash flows of the modified liability are substantially different, in which case a new financial liability based on the modified terms is recognized at fair value.

On derecognition of a financial liability, the difference between the carrying amount extinguished and the consideration paid (including any non-cash assets transferred or liabilities assumed) is recognized in profit or loss.

iv.	Offsetting

Financial assets and financial liabilities are offset and the net amount presented in the consolidated statement of financial position when, and only when, the Group currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously.

v.	Derivative financial instruments

The Group holds derivative financial instruments to hedge some of its foreign currency and interest rate risk exposures. Embedded derivatives are separated from the host contract and accounted for separately if the host contract is not a financial asset and certain criteria are met.

Derivatives are initially measured at fair value. Subsequent to initial recognition, derivative financial instruments are measured at fair value, and changes therein are generally recognized in profit or loss.

The Group designates certain derivatives as hedging instruments to hedge the variability in cash flows associated with highly probable forecast transactions arising from changes in foreign exchange rates and interest rates.

At the inception of designated hedging relationships, the Group documents the risk management objective and strategy for undertaking the hedge. The Group also documents the economic relationship between the hedged item and the hedging instrument, including whether the changes in cash flows of the hedged item and hedging instrument are expected to offset each other.

Cash flow hedges

When a derivative is designated as a cash flow hedging instrument, the effective portion of changes in the fair value of the derivative is recognized in OCI and accumulated in the hedging reserve. The effective portion of changes in the fair value of the derivative that is recognized in OCI is limited to the cumulative change in fair value of the hedged item, determined on a present value basis, from inception of the hedge. Any ineffective portion of changes in the fair value of the derivative is recognized immediately in profit or loss.

The Group designates only the change in fair value of the spot element of forward exchange contracts as the hedging instrument in cash flow hedging relationships. The change in fair value of the forward element of forward exchange contracts (forward points) is separately accounted for as a cost of hedging and recognized in a costs of hedging reserve within equity.

The Group designates only the intrinsic value of purchased Call Spread options as the hedging instrument in cash flow hedging relationships. The change in fair value of the time value of purchased Call Spread contract is separately accounted for as a cost of hedging and recognized in a costs of hedging reserve within equity. The time value at the date of designation of the option as a hedging instrument is amortized linearly over the period during which the hedge relationship meets the qualifying criteria to apply hedge accounting.

F-2

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

In the case of Interest Rate Swap agreements, the Group designates the complete contract as hedging instrument.

In a cash flow hedge of the forward foreign currency risk and interest rate risk of a payable or receivable, the amount accumulated in the hedging reserve and the cost of hedging reserve shall be reclassified from the separate component of the equity to profit or loss over the period the payable or receivable affects profit or loss, because changes in exchange rates will affect the amount of cash required to settle the item (as measured by reference to the entity’s functional currency).

If the hedge no longer meets the criteria for hedge accounting or the hedging instrument is sold, expires, is terminated or is exercised, then hedge accounting is discontinued prospectively. When hedge accounting for cash flow hedges is discontinued, the amount that has been accumulated in the hedging reserve remains in equity until, for a hedge of a transaction resulting in the recognition of a

non-financial

item, it is included in the

non-financial

item’s cost on its initial recognition or, for other cash flow hedges, it is reclassified to profit or loss in the same period or periods as the hedged expected future cash flows affect profit or loss.

If the hedged future cash flows are no longer expected to occur, then the amounts that have been accumulated in the hedging reserve are immediately reclassified to profit or loss.

C.	Impairment

i.	Non-derivative financial assets

Financial instruments

The Group recognizes loss allowances for expected credit losses (“ECLs”) on financial assets measured at amortized cost.

Loss allowances for trade receivables are always measured at an amount equal to lifetime ECLs. When determining whether the credit risk of a financial asset has increased significantly since initial recognition and when estimating ECLs, the Group considers reasonable and supportable information that is relevant and available without undue cost or effort. This includes both quantitative and qualitative information and analysis, based on the Group’s historical experience and informed credit assessment, loss of the value of money over time and individual analysis of the clients (considering their geographical location).

The Group considers a financial asset to be in default when the client is unlikely to pay its credit obligations to the Group in full, without recourse by the Group to actions such as realizing security (if any is held).

Credit-impaired financial assets

At each reporting date, the Group assesses whether financial assets carried at amortized cost are

credit-impaired.

A financial asset is

“credit-impaired”

when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred.

Evidence that a financial asset is

credit-impaired

includes the evaluation of all the following observable data:

•

Significant financial difficulty of the debtor or issuer;

•

A breach of contract such as a default or being more than 360 days past due;

•

It is probable that the debtor will enter bankruptcy or other financial reorganization; or

•

The disappearance of an active market for a security because of financial diff

icultie

F-2

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

Presentation of allowance for ECL in the statement of financial position

Loss allowances for financial assets measured at amortized cost are deducted from the gross carrying amount of the assets.

Write-off

The gross carrying amount of a financial asset is written off when the Group has no reasonable expectations of recovering a financial asset in its entirety or a portion thereof. For individual customers and for corporate customers, the Group individually makes an assessment with respect to the timing and amount of

write-off

based on whether there is a reasonable expectation of recovery. The Group expects no significant recovery from the amount written off. However, financial assets that are written off could still be subject to enforcement activities in order to comply with the Group’s procedures for recovery of amounts due.

ii.	Non-financial assets

At each reporting date, the Group reviews the carrying amounts of its

non-financial

assets (other than investment property, inventories and deferred tax assets) to determine whether there is any indication of impairment. If any such indication exists, then the asset’s recoverable amount is estimated. Goodwill and intangible assets with an indefinite useful life are tested annually for impairment.

For impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or CGUs. Goodwill arising from a business combination is allocated to CGUs or groups of CGUs that are expected to benefit from the synergies of the combination.

The recoverable amount of an asset or CGU is the greater of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using an

after-tax

discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or CGU.

An impairment loss is recognized if the carrying amount of an asset or CGU exceeds its recoverable amount.

Impairment losses are recognized in profit or loss. They are allocated first to reduce the carrying amount of any goodwill allocated to the CGU, and then to reduce the carrying amounts of the other assets in the CGU on a pro rata basis.

An impairment loss in respect of goodwill is not reversed. For other assets, an impairment loss is reversed only to the extent that the asset’s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized.

D.	Cash and cash equivalents

Cash and cash equivalents presented in the consolidated statement of financial position include cash on hand, demand deposits at banks and other highly marketable debt investments with maturity of three months or less that are not subject to significant risk of changes in value.

E.	Inventories

Inventories are measured at the lower of cost and net realizable value. The net realizable value is the estimated selling price of the inventories in the ordinary course of business, less discounts and other costs and expenses incurred to put the inventories to sale. Cost is determined using the weighted average method.

F-2

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

Provisions for obsolescence and net realizable value are estimated based on a specific analysis made at each reporting date of the consolidated financial statements. The reduction of the carrying amount of inventories to their net realizable value is recorded under “provision for impairment of inventories” with a charge to profit or loss in the period in which it is estimated that such reductions will occur.

F.	Intangibles

Goodwill

Goodwill arises from the acquisition of subsidiaries and represents the excess between the cost of an acquisition and the fair value of the Group’s interest in the net identifiable assets at the date of the acquisition.

Goodwill arising from a business combination is allocated to each CGU or group of CGUs that are expected to benefit from the synergies of the combination. Each CGU or group of GCUs to which goodwill is allocated represents the lowest level of cash-flow generating assets within the entity at which goodwill is monitored by Management.

The identification of the CGU requires a critical judgment of Management. The Group has defined its CGUs as each of the companies acquired because they are the smallest identifiable groups of assets that generate cash flows and that are largely independent of the cash inflows of other assets or groups of assets.

Goodwill is tested for impairment at least annually and recorded at cost less accumulated impairment losses. The carrying amount of goodwill is compared to the recoverable amount, which is the greater of value in use and fair value less costs to sell. Any impairment is recognized immediately as an expense and cannot be reversed.

Acquired trademark

The trademarks are “Oncogenomics“ in Peru, “Clínica Portoazul,” “Las Américas” and “IMAT” in Colombia, and “OCA Hospital” and “Dentegra” in Mexico (note 1.C), which were identified in the acquisitions. The trademarks with presence in Mexico and Colombia offer a broad portfolio of healthcare services to their patients through the different entities under which OCA Hospital, Clínica Portoazul and PMLA operate and the trademarks with presence in Peru offer a broad portfolio of clinical laboratory services to their patients through the laboratory Oncogenomics. The estimated market value was determined using the relief-from-royalty method. Management evaluated its recognition and growth in the Peruvian, Colombian and Mexican market, and assessed that they have an indefinite useful life.

Customer relationship

It includes the estimated market value of the contracts with insures for cardiology services and client services identified as a result of the acquisition of Hospital y Clínica OCA S.A. de C.V. (note 1.C.), Patología Oncológica S.A.C., Oncogenomics S.A.C. and Promotora Médica las Américas. The estimated useful life is 8 years for Hospital y Clinica OCA S.A. de C.V., 18 years for Pagología Oncológica S.A.C., 17 years for Oncogenomics S.A.C. and 10 years for Promotora Médica las Américas S.A.

Other intangibles assets

Intangibles other than goodwill are acquired separately, and are measured at cost less subsequent amortization and impairment losses.

Surface right agreement

Corresponds to the surface rights agreement signed between Medicser and the Pe

ruvi

an Red Cross Society, owner of the land, and acquired on 2011.

F-2

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

Amortization is charged to the consolidated statement of profit or loss and other comprehensive income on a straight-line basis as follows:


	Years
Software		2 to 10
Customer relationships		10 to 18
Surface rights agreement		40

Assets that are subject to amortization are reviewed for impairment when events or circumstances indicate that their carrying amount may not be recoverable. An impairment loss is recognized in the consolidated statement of profit or loss and other comprehensive income to reduce the carrying amount to recoverable amount.

G.	Property, furniture and equipment

i.	Recognition and measurement

Land, buildings and facilities, medical equipment, and furniture are measured at cost, less accumulated depreciation and any accumulated impairment losses. Borrowing costs related to the acquisition or construction of qualifying assets are capitalized as part of the cost of that asset.

Other disbursements for service and repair are charged to the consolidated statement of profit or loss and other comprehensive income in the period when incurred. In case significant spare parts of an item of property, furniture and equipment have different useful lives, then they are accounted for as separate items (major components) of property, furniture and equipment.

Any gain or loss on disposal of an item of land, buildings and facilities, medical equipment, and furniture is recognized in profit or loss.

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets are capitalized as part of the cost of the asset. The Group defines qualifying assets as construction projects or other assets for which a minimum period of twelve months is needed to get ready for its intended use or sale (note 11).

ii.	Subsequent expenditure

Subsequent expenditures are included in the carrying amount of the asset or they are recognized as a separate asset, as appropriate, only when it is probable that future economic benefits will flow to the Group and the cost of these assets can be measured reliably.

iii.	Depreciation

Depreciation is calculated to write off the cost of items of property, furniture and equipment less their estimated residual values using the straight-line method over their estimated useful lives and is generally recognized in profit or loss.

The estimated useful lives of property, plant and equipment for current and comparative periods are as follows:


	Years
Buildings and premises		7 to 100
Medical equipment		3 to 15
Vehicles		4 to 10
Furniture, fixtures and various equipment		3 to 20
IT equipment		3 to 10

Depreciation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.

F-2

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

H.	Public service concession arrangements

Public Service Concession Arrangements are defined in the International Financial Reporting Interpretations IFRIC 12

Service Concession Arrangements

and are accounted regarding the consideration received for the infrastructure.

In 2010, Consorcio Trecca S.A.C. (hereinafter, “Consorcio Trecca”), a subsidiary of the Group, entered into a

20-year

concession agreement with the Peruvian Social Health Insurance (hereinafter, “EsSALUD”), a decentralized public agency attached to the Ministry of Labor and Employment Promotion, focused on granting prevention, promotion, economic benefits and social benefits that correspond to the Social Security contributory system. The concession was given to Consorcio Trecca, as operator of the concession, with the obligation to renovate, operate and maintain the Torre Trecca, located in the city of Lima. The Group holds a 99.99% interest in Consorcio Trecca.

On July 15, 2011, Consorcio Trecca and EsSALUD agreed to suspend the obligations prior to the start date of the investment period. This suspension was extended until January 2018.

In November 2018, Consorcio Trecca and EsSALUD were able to make the direct deals associated with the agreements to update the investment amounts and the contractual rates, which will be in effect at the beginning of the operation period.

Since June 26, 2019, both agreed to start again with the coordination of the preparation of the engineering study and update of the schedule of the project development plan.

The Group recognizes a financial asset to the extent that it has an unconditional contractual right to receive cash or another financial asset from, or at the direction of, the grantor for the construction services. This right arises where the grantor has little or no discretion to avoid payment, usually because the agreement is enforceable by law. In the event that the fair value of the construction services provided exceeds the fair value of the recognized financial asset, the difference will be recognized as an intangible asset (note 6.i).

The Group recognizes an intangible asset arising from a service concession arrangement when it has a right to charge for use of the concession infrastructure. An intangible asset received as consideration for providing construction or upgrade services in a service concession arrangement is measured at fair value on initial recognition with reference to the fair value of the services provided (note 12).

I.	Assets held-for-sale

Non-current assets, or disposal groups comprising assets and liabilities, are classified as held-for-sale or held-for-distribution to owners if it is highly probable that they will be recovered primarily through sale rather than through continuing use.

Such assets are generally measured at the lower of their carrying amount and fair value less costs to sell. Any impairment loss on a disposal group is allocated first to goodwill, and then to the remaining assets and liabilities on a pro rata basis. Impairment losses on initial classification as

held-for-sale

held-for-distribution

and subsequent gains and losses on remeasurement are recognized in profit or loss.

Once classified as held-for-sale, the property, furniture and equipment are no longer dep

reciat

ed.

F-2

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

Leases

At inception of a contract, the Group assesses whether a contract is, or con

tain

s, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, the Group uses the definition of a lease in IFRS 16.

i.	As a lease

At commencement or on modification of a contract that contains a lease component, the Group allocates the consideration in the contract to each lease component on the basis of its relative

stand-alone

prices. However, for the leases of property the Group has elected not to separate

non-lease

components and account for the lease and

non-lease

components as a single lease component.

The Group recognizes a

right-of-use

asset and a lease liability at the lease commencement date. The

right-of-use

asset is initially measured at cost, which includes the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred.

The

right-of-use

asset is subsequently depreciated using the

straight-line

method from the commencement date to the end of the lease term, unless the lease transfers ownership of the underlying asset to the Group by the end of the lease term or the cost of the

right-of-use

asset reflects that the Group will exercise a purchase option. In that case, the

right-of-use

asset will be depreciated over the useful life of the underlying asset, which is determined on the same basis as those of property and equipment. In addition, the

right-of-use

asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Group’s incremental borrowing rate. Generally, the Group uses its incremental borrowing rate as the discount rate.

The Group determines its incremental borrowing rate by obtaining interest rates from various external financing sources and makes certain adjustments to reflect the terms of the lease and type of the asset leased.

Lease payments included in the measurement of the lease liability include the following:

•

Fixed payments, including

in-substance

fixed payments;

•

Variable lease payments that depend on an index or a rate, initially measured using the index or rate as at the commencement date;

•

Amounts expected to be payable under a residual value guarantee; and

•

The exercise price under a purchase option that the group is reasonably certain to exercise, lease payments in an optional renewal period if the Group is reasonably certain to exercise an extension option, and penalties for early termination of a lease unless the Group is reasonably certain not to terminate early.

The lease liability is measured at amortized cost using the effective interest method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the Group’s estimate of the amount expected to be payable under a residual value guarantee, if the Group changes its assessment of whether it will exercise a purchase, extension or termination option or if there is a revised

in-substance

fixed lease payment.

When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the

right-of-use

asset, or is recorded in profit or loss if the carrying amount of the

right-of-use

asset has been reduced to zero.

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

Short-term leases and leases of

low-value

assets.

The Group has elected not to recognize

right-of-use

assets and lease liabilities for leases of

low-value

assets (IT equipment) and

short-term

leases. The Group recognizes the lease payments associated with these leases as an expense on a

straight-line

basis over the lease term.

K.	Trade accounts payable

Trade accounts payable are obligations to pay for medicines or services acquired from suppliers in the ordinary course of business. Accounts payable are classified as “current liabilities” if payment is to be made in a year or less; otherwise, they are presented as

“non-current

liabilities.”

Accounts payable are initially recognized at fair value, and subsequently they are measured at amortized cost using the effective interest method.

When the Group has an arrangement in which the bank agrees to pay amounts to a participating supplier in respect of invoices owed by the Group and receives settlement from the Group at a later, the accounts payable under factoring are included within operating cash flows because they continue to be part of the normal operating cycle of the Group and the payments to a supplier by the bank are considered

non-cash

transactions.

L.	Employee benefits

Defined benefit plans

A benefit plan is defined as an amount of pension benefit that an employee will receive upon retirement, usually dependent on one or more factors such as age, years of service and compensation.

The liability recognized in the combined statements of financial position in respect of defined benefit plans is the present value of the defined benefit obligation as of the date of the combined statements of financial position less the fair value of plan assets. The defined benefit obligation is calculated annually by independent actuaries using the projected unit cost method. The present value of the defined benefit obligation is determined by discounting the estimated future cash flows using discount rates that are denominated in the currency in which the benefits will be paid, and that have maturities that approximate the terms of the pension liability.

Actuarial gains and losses arising from adjustments and changes in actuarial assumptions are recorded directly in stockholders’ equity in other comprehensive income in the year in which they occur and are not reclassified to profit or loss for the period.

The Group determines the net financial expense (income) by applying the discount rate to the net defined benefit liability.

Past service costs are recognized immediately in the consolidated statements of income and other comprehensive income statement.

Profit sharing

For the Company and its Peruvian subsidiaries and Mexican subsidiaries, the employees’ profit sharing is calculated in accordance with current legal regulations on the same net taxable base used to calculate the income tax. In the case of the Peruvian subsidiaries, the rate of profit sharing is 5%, on the net taxable base of the current year. According to the Peruvian law, there is a limit in profit sharing that an employee can receive, equivalent to 18 monthly salaries. In the case of the Mexican subsidiaries, the rate of profit sharing is 10%, on the net taxable base of the current year.

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

In Colombian subsidiaries, employees’ profit sharing is not applicable. It is replaced by a legal bonus composed of an additional month’s salary that is paid twice during the year, in June and December, respectively. This bonus is mandatory even if the company does not obtain earnings. Additionally, the Board is able to approve voluntary bonuses for certain employees with high performance during a profitable year.

Legal bonuses

The Group recognizes the expense for legal bonuses and their related liabilities under laws and regulations currently in force in Peru. The legal bonuses include an additional month’s salary that is paid in July and December, respectively.

Termination benefits

Termination benefits are recognized in accordance with Peruvian, Colombian and Mexican legislation in profit or loss when paid, i.e., when employment is terminated before the normal retirement date, or whenever an employee accepts voluntary redundancy in exchange for these benefits.

Severance payment (CTS for its Spanish acronym)

In Peru, severance payment of personnel from the Group’s companies (CTS for its Spanish acronym) includes employees’ indemnities calculated according to current legislation, which shall be deposited in May and November annually in bank accounts designated by employees. Severance payment is equivalent to 50% of a current remuneration as of the date of deposit. The Group has no obligation to make any additional payments once it has made the annual deposits of funds to which the employee is entitled.

In Colombia, severance payment of personnel from the Group’s companies includes employees’ indemnities calculated according to current legislation, which shall be transferred in the fund selected by the employee at the end of the year or when the work contract finished. Severance payment is equivalent to one current remuneration.

Vacations

Personnel’s annual vacations are recognized on an accrual basis. The provision for estimated annual vacation obligations is recognized at each date of preparation of the consolidated statement of financial position.

M.	Insurance contracts

Recognition

The Group recognizes groups of insurance contracts that it issues from the earliest of the following:

•

The beginning of the coverage period of the group of contracts;

•

The date when the first payment from a policyholder in the group is due, or when the first payment is received if there is no due date; and

•

For a group of onerous contracts, as soon as facts and circumstances indicate that the group is onerous.

The Group adds new contracts to the group in the reporting period in which that contract meets one of the criteria set out above.

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

Contract boundary

The Group includes in the measurement of a group of insurance contracts all the future cash flows within the boundary of each contract in the group. Cash flows are within the boundary of an insurance contract if they arise from substantive rights and obligations that exist during the reporting period in which the Group can compel the policyholder to pay premiums, or in which the Group has a substantive obligation to provide the policyholder with insurance contract services. A substantive obligation to provide insurance contract services ends when:

The Group has the practical ability to reassess the risks of the particular policyholder and, as a result, can set a price or level of benefits that fully reflects those risks, or:

•

Both of the following criteria are satisfied;

•

The Group has the practical ability to reassess the risks of the portfolio of insurance contracts that contain the contract and, as a result, can set a price or level of benefits that fully reflects the risk of that portfolio; and

•

The pricing of the premiums up to the date when the risks are reassessed does not take into account the risks that relate to periods after the reassessment date.

A liability or asset relating to expected premiums or claims outside the boundary of the insurance contract is not recognized. Such amounts relate to future insurance contracts.

Insurance finance income and expense

The Group does not disaggregate finance income and expenses, the effect of which are recognized through profit or loss. The Group has elected not to discount claims that are expected to be settled within one year from the date they are incurred.

Insurance revenue

The insurance revenue for the period is the amount of expected premium receipts allocated to the period. The Group allocates the expected premium receipts to each period of insurance contract services on the basis of the passage of time. However, if the expected pattern of release of risk during the coverage period differs significantly from the passage of time, then the allocation is made on the basis of the expected timing of incurred insurance service expenses. For the periods presented, all revenue has been recognized on the basis of the passage of time.

Identifying contracts in the scope of IFRS 17

IFRS 17 establishes principles for the recognition, measurement, presentation and disclosure of insurance contracts.

When identifying contracts in the scope of IFRS 17, the Group assesses whether a set of series of contracts needs to be treated as a single contract and whether embedded, investment components and goods and services components have to be separated and accounted for under another standard.

Level of aggregation

Under IFRS 17, insurance contracts are aggregated into groups for measurement purposes. Gr

oups

of contracts are determined by first identifying portfolios of contracts, each comprising contracts subject to similar risk and managed together, and dividing each group into annual cohorts. Portfolios are further divided based on expected profitability at inception into three categories: onerous contracts, contracts with no significant risk of becoming onerous, and the remainder. When a contract is recognized, it is added to an existing group of contracts or, if the contract does not qualify for inclusion in an existing group, it forms a new group to which future contracts may be added.

The Group considers the nature, risk and line of products as criteria for identifying its portfolios and has determined that all insurance contracts will be grouped as a single portfolio.

F-3

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

Insurance acquisition cash flows

For insurance acquisition cash flows, the Group recognizes that the insurance acquisitions cash flows (IACF) are capitalized and amortized over the coverage period.

Measurement

On initial recognition, for a group of contracts that is not onerous at initial recognition, the Group measures the liability for remaining coverage as the premiums received on initial recognition, minus any insurance acquisition cash flows at that date, plus or minus any amount arising from the derecognition at that date of the asset or liability recognized for insurance acquisition cash flows that the Group pays or receives before the group of insurance contracts is recognized. The liability for remaining coverage does not include an adjustment for the time value of money, as the premiums are received within one year of the coverage period.

Insurance contracts – subsequent measurement

Subsequently, the carrying amount of the liability for remaining coverage is increased by any further premiums received and the earned IACF that are deferred, and decreased by the amount recognized as insurance revenue for services provided and the IACF paid. The Group expects the time between providing each part of the services and the related premium due date will be no more than a year. Accordingly, as permitted under IFRS 17, the Group will not adjust the liability for remaining coverage to reflect the time value of money and the effect of financial risk.

If at any time before and during the coverage period, facts and circumstances indicate that a group of contracts is onerous, then the Group will recognize a loss in profit or loss and increase the liability for remaining coverage to the extent that the current estimates of the fulfillment cash flows that relate to remaining coverage exceed the carrying amount of the liability for remaining coverage.

The Group recognizes the liability for incurred claims of a group of contracts at the amount of the fulfillment cash flows relating to incurred claims. As the future cash flows are expected to be paid in one year or less from the dates the claims are incurred, the Group decided not to discount cash flows.

Insurance contracts – modification and derecognition

The Group derecognizes insurance contracts when:

•

The rights and obligations relating to the contract are extinguished (i.e., discharged, cancelled or expired).

Or:

•

The contract is modified such that the modification results in a change in the measurement model or the applicable standard for measuring a component of the contract, substantially changes the contract boundary, or requires the modified contract to be included in a different group. In such cases, the Group derecognizes the initial contract and recognizes the modified contract as a new contract.

When a modification is not treated as a derecognition, the Group recognizes amounts paid or received for the modification with the contract as an adjustment to the relevant liability for remaining coverage.

Insurance acquisition cash flows

Insurance acquisition cash flows arise from the costs of selling, underwriting and begi

nni

ng a group of insurance contracts (issued or expected to be issued) that are directly attributable to the insurance contract portfolio to which the group belongs. These cash flows include cash flows that are not directly attributable to individual contracts or groups of insurance contracts within the portfolio.

F-3

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

The Group has chosen to defer insurance acquisition cash flows using a systematic and rational method.

N.	Provisions

Provisions are recognized when the Group has a present obligation, either legal or constructive, as a result of past events, and when it is probable that an outflow of resources will be required to settle the obligation, and it is possible to reliably estimate its amount.

Provisions are measured at the present value of Management’s best estimate of the expenditure required to settle the present obligation at the end of the reporting period.

O.	Government grants

Government grants are assistance by government in the form of transfers of resources to an entity in return for past or future compliance with certain conditions relating to the operating activities of the entity. Such government grants may be given to an entity to help finance a particular asset or other expenditure.

Government grants should not be recognized until there is reasonable assurance that the entity will comply with the conditions attaching to it and that the grant will be received.

The Group recognizes an unconditional government grant in the income statement on a systematic basis over the periods in which the related costs towards which they are intended to compensate are recognized as expenses.

The loans are recognized and measured in accordance with IFRS 9 at its fair value, discounted using a market rate for a similar loan. The benefit of the below-market rate of interest, measured as the difference between the initial carrying value of the loan according to IFRS 9 and the proceeds received, is accounted for as a grant in accordance with IAS 20. The grant initially recognized as deferred income is recognized in profit or loss (compensating the finance cost) over the period of the loan covered.

P.	Income tax

Current tax

Current tax includes the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to the tax payable or receivable in respect of previous years. The amount of current tax payable or receivable is the best estimate of the tax amount expected to be paid or received that reflects uncertainty related to income taxes, if any. It is measured using tax rates enacted or substantively enacted at the reporting date. Current tax also includes any tax arising from dividends.

Deferred tax

Deferred tax is recognized in respect of temporary differences between the carrying amounts of

asset

s and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for:

•

Temporary differences on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss;

•

Temporary differences related to investments in subsidiaries, associates and joint arrangements to the extent that the Group is able to control the timing of the reversal of the temporary differences and it is probable that they will not reverse in the foreseeable future; and

•

Taxable temporary differences arising on the initial recognition of goodwill.

F-3

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

Temporary differences in relation to a

right-of-use

asset and a lease liability for a specific lease are regarded as a net package (the lease) for the purpose of recognizing deferred tax.

Deferred tax assets are recognized for unused tax losses, unused tax credits and deductible temporary differences to the extent that it is probable that future taxable profits will be available against which they can be used. Future taxable profits are determined based on the reversal of relevant taxable temporary differences. If the amount of taxable temporary differences is insufficient to recognize a deferred tax asset in full, then future taxable profits, adjusted for reversals of existing temporary differences, are considered, based on the business plans for individual subsidiaries in the Group. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized; such reductions are reversed when the probability of future taxable profits improves.

The measurement of deferred tax reflects the tax consequences that would follow from the manner in which the Group expects, at the reporting date, to recover or settle the carrying amount of its assets and liabilities. Deferred tax is measured at tax rates that are expected to be applied to temporary differences when they reverse, using tax rates enacted or substantively enacted at the reporting date, and reflects uncertainty related to income taxes, if any.

Deferred tax assets and liabilities are offset only if certain criteria are met.

Uncertain tax treatment

The Group determines whether to consider each uncertain tax treatment separately or together with one or more other uncertain tax treatments and uses the approach that better predicts the resolution of the uncertainty.

Q.	Share capital and share premium

Common shares are classified as equity and are determined using the par value of the shares that have been issued.

The share premium is the amount by which the fair value of the contribution exceeds the par value of the shares issued.

R.	Dividend distribution

In 2018, the Group approved the Dividends Policy, which establishes the distribution of the available profits, up to S/ 10,000 thousand per year. The General Shareholders Meeting will determine the distribution of dividends and the respective payment schedule. During the year 2024, 2023 and 2022, the Group did not distribute dividends.

Dividend distribution is recognized as a liability in the consolidated financial statements in the period in which dividends are approved by the Group’s shareholders.

S.	Contingent liabilities and assets

Contingent liabilities are not recognized in the consolidated financial statements. They are only disclosed in the notes to the financial statements, unless the possibility of an outflow of economic resources is remote. Contingent assets are not recognized in the consolidated financial statements and are only disclosed when an inflow of economic resources is probable.

T.	Revenue recognition

Revenue is measured at the fair value of the consideration received or receivable. The Group recognizes revenue when it identifies a contract with a customer, the performance obligations in the contract, determines the transaction price, and allocates the transaction price to the performance obligations in the contract as each performance obligation is met.

F-3

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

i.	Revenue recognition from oncologic healthcare plans

Revenues arising from oncologic healthcare plans include payments from individuals and corporate clients. The Group has 13 oncologic healthcare plans. Revenue is recognized over time in which the related plan participants are entitled to healthcare services. All oncologic healthcare plans have a

one-year

duration and are automatically renewed, unless terminated by either party. The portion of the payment received that relates to unexpired risks at the base date are recognized in the “unearned premiums reserve” in the consolidated statement of financial position. The obligation of the Company is to provide health coverage from the moment the client is diagnosed with cancer, and in turn, the client has the right to receive the treatment according to the conditions and duration of the contract.

ii.	Revenue recognition from general healthcare services plan

Revenues arising from general healthcare services plan include payments from individual clients. The Group has one general healthcare plan called “Auna Salud.” Revenue is recognized over time in which the related plan participants are entitled to the general healthcare services. This plan has a

one-year

duration with recurring monthly charges. The obligation of the Group is to provide general healthcare coverage from the moment the client requests health services, and in turn, the client has the right to receive the treatment according to the conditions of the plan.

iii.	Healthcare services

Revenue from healthcare services is recognized when services are rendered. Healthcare services revenue is recognized on the date the patient receives treatment and includes amounts related to certain services, products and supplies used in providing such treatment.

Contracts related to healthcare services include a variable consideration for which the Group estimates the amount of consideration to which it will be entitled in exchange for transferring the goods and services to the insurance payers. The variable consideration is estimated at contract inception and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with the variable consideration is subsequently resolved. The variable consideration is only related to price concession provided to insurance payers after healthcare services have been provided. The Group uses the expected value method to estimate the variable consideration given the large number of insurance payers that have similar characteristics and based on statistics of historical percentages of the issued credit notes (price concession). The Group then applies the requirements on constraining estimates of variable consideration in order to determine the amount of variable consideration that can be included in the transaction price and recognized as revenue. For the year ended December 31, 2024, the variable consideration recorded by our healthcare services subsidiaries amounted to S/ 22,433 thousand (S/ 11,382 thousand and S/ 7,803 thousand as of

Decemb

er 31, 2023 and 2022, respectively) and is recorded in the Healthcare services revenue line item in the consolidated statement of profit or loss and other comprehensive income.

iv.	Sales of medicines

The sales of medicines are recognized when the medicines are delivered and have been accepted by customers. Revenue from the sale of medicines delivered during hospitalization is recognized at the time the medicine is used by the patient. The amount of revenue is recognized at the fair value of the medicines.

F-3

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

The following table provides information about the nature and timing of the satisfaction of performance obligations in contracts with customers, including significant payment terms, and the related revenue recognition policies:


Type of service	Nature and timing of satisfaction of performance obligations, including significant payment terms	Revenue recognition under IFRS 15
Healthcare services	The patient acquires control of the use of the healthcare service with the provision of the service, because the patient receives and consumes the benefits granted by the Group as it provides the service. Invoices are generated at that point in time, as services are rendered, with the exception of patients who have medical insurance, which are issued according to the contractual terms agreed with the insurance companies. Uninvoiced amounts are presented as revenue and trade receivables. Advances are primarily received from patients who do not have medical insurance for healthcare services such as hospitalization. These advances are recognized in revenue as services are rendered over time. Generally, invoices are payable in average within 120 to 150 days for insurance companies and third parties are charged within 30 to 60 days.	Revenue is recognized when services are rendered. Revenue is recognized over time based on the cost of the services, products and supplies utilized in providing such treatment. The variable consideration is determined using the expected value with statistics of historical percentages for the last year and is updated at the end of each month. Advances received were included in trade payable. Healthcare services revenue is recognized on the date the patient receives treatment and includes amounts related to certain services, products and supplies utilized in providing such treatment. The selling price is determined based upon the company’s standard rates or at rates determined under reimbursement arrangements. These arrangements are generally with third parties such as commercial insurers. Revenue from contracts with third-party payers is recognized to the extent that it is highly probable that a significant reversal in the amount of accrued revenue will not occur. Therefore, the amount of the recognized income is adjusted by the expected claims that are estimated based on the historical data of the issued credit notes. Some contracts permit the insurers to get discounts for prompt pay. Management works with statistics which are estimated based on historical percentages and these are recognized as a lower value of revenue.

Sale of medicines	Customers acquire control of the medicines, when they are delivered and have been accepted, either as part of the hospitalization or as part of the pharmacy sale. Invoices are generated at the time the customers receive the medicines and in the case of hospitalization at the time of the medicine is delivered. In general, invoices are payable at the time of issuance and after invoicing, in the case of hospitalized patients.	Revenue is recognized when medicines are delivered and have been accepted by customers at their premises. Revenue from the sale of medicines delivered during hospitalization is recognized at the estimated net realization amount at the time the medicine is received by the patient.

F-3

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

U.	Cost and expense recognition

The cost of medical services is primarily made up of costs incurred in providing healthcare services, including the cost of medicines, personnel expenses for medical staff, medical consultation fees, surgery fees, depreciation of medical equipment, amortization of software, cost of services provided by third parties, primarily lease payments to third parties for certain of our facilities, service and repair costs at our facilities, custodial and cleaning services and utilities, cost of room services for inpatients, cost of clinical laboratories and technical reserves for healthcare services.

The cost of services provided to insured who are outside the Group’s Clinic Network is recognized as it is incurred.

Other costs and expenses are recognized on an accrual basis regardless of when they are paid and, if any, in the same period in which the related income is recognized.

V.	Finance income and finance costs

The Group’s finance income and finance costs include:

•

Interest income;

•

Interest expense;

•

The net gain or loss on financial assets at FVTPL;

•

The net gain or loss on the disposal of investments in debt securities measured at FVOCI;

•

The foreign currency gain or loss on financial assets and financial liabilities; and

•

The reclassification of net gains and losses previously recognized in OCI on cash flow hedges of interest rate risk and foreign currency risk for borrowings.

W.	Foreign currency transactions and balances

Transactions in foreign currency are those transactions carried out in a currency other than the functional currency. Transactions in foreign currency are translated into functional currency at the exchange rates at the dates of the transactions.

The foreign currency gains or losses, resulting from the payment of such transactions and from the translation of monetary assets and liabilities stated in foreign currency at exchange rates ruling at

period-end

closing, are recognized in the consolidated statement of profit or loss and other comprehensive income.

The assets and liabilities of foreign operations, including goodwill and fair value adjustments arising on acquisition, are translated into soles at the exchange rates at the reporting date. The income and expenses related to foreign operations are translated into soles at the average exchange rate for each month of the year. Foreign currency differences are recognized in OCI and presented in the “translation reserve,” except to the extent that the translation difference is allocated to

non-controlling

interest.

X.	Written Put and Call Options in Business combinations

The Group may write a put option or enter into a forward purchase agr

eem

ent with

non-controlling

shareholders in an existing subsidiary on their equity interests in that subsidiary or in a subsidiary acquired in a business combination. If the put option or forward granted to the

non-controlling

shareholders provides for settlement in cash or in another financial asset by the entity, then the Group recognizes a liability for the present value of the exercise price of the option or of the forward price.

F-3

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

Non-controlling

shareholders with present access to the returns:

If the

non-controlling

shareholders still have present access to the returns associated with the underlying ownership interest, the Group could choose an accounting policy, to be applied consistently, to use one of the following methods:

•

The anticipated-acquisition method: The contract is accounted for as an anticipated acquisition of the underlying

non-controlling

interest as if the put option had been exercised already or the forward had been satisfied by the

non-controlling

shareholders. This is independent of how the exercise price is determined and how likely it is that the option will be exercised.

•

The present-access method: Under this method,

non-controlling

interest continues to be recognized because the

non-controlling

shareholders still have present access to the returns associated with the underlying ownership interests; therefore, the debit entry is to “other” equity.

Non-controlling

shareholders with no present access to the returns:

If this is the case the Group should apply the anticipated-acquisition method.

Substantially all of the returns associated with the underlying ownership interest are transferred to the parent only if both of the following tests are met:

•

From an economic perspective, the instrument will be exercised in substantially all cases.

•

The sensitivity of the exercise price to the variations in the fair value of the ownership interest is sufficiently low that substantially all of that variation accrues to the parent.

The Group applies the present-access method for all transactions where

non-controlling

shareholders still have the present access to the returns associated with the underlying ownership interest.

Subsequent to initial recognition of the liability using the present-access method, the Group chooses an accounting policy to be applied consistently, to recognize changes in the carrying amount of the liability within profit or loss or equity. Subsequent changes in the carrying amount of the liability are recognized in equity.

Y.	Share-based payments

The Company provides share-based payments, which are equity settled, since they provide the participants the right to be compensated with a specific number of Company’s shares instead of receiving a payment based on the value of the Company’s shares.

The grant-date fair value of equity-settled share-based payment arrangements granted to

non-executive

members of the Board and employees is generally recognized as an expense on a straight-line method during the vesting period, with a corresponding increase in equity, over the vesting period of the awards.

Z.	IFRS’ new amendments of mandatory application as of the periods beginning on January 1, 2024

The following amendments to IFRS are required to be applied for annual periods beginning on January 1, 2024:

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022


Effective date		New standards or amendments
January 1, 2024		• Non-current Liabilities with Covenants – Amendments IAS 1 and Classification of Liabilities as Current or Non-current – Amendments to IAS 1
		• Lease Liability in a Sale and Leaseback – Amendments to IFRS 16
		• Supplier Finance Arrangements – Amendments to IAS 7 and IFRS 7

The Group adopted these amendments, not generating significant impacts on the consolidated financial statements as of December 31, 2024.

AA.	Standards issued but not yet effective

The following accounting pronouncements issued are applicable to annual periods beginning after January 1, 2024, and have not been applied in the preparation of these financial statements. The Company plans to adopt the corresponding accounting pronouncements on their respective dates of application.


Effective date		New standards or amendments
January 1, 2025		• Lack of Exchangeability – Amendments to IAS 21

January 1, 2026		• Classification and Measurement of Financial Instruments – Amendments to IFRS 9 and IFRS 7 • Annual Improvements to IFRS Accounting Standards – Volume 11

January 1, 2027		• IFRS 18 - Presentation and Disclosure in Financial Statements • IFRS 19 - Subsidiaries without Public Accountability: Disclosures

Available for optional adoption/ effective date deferred indefinitely		• Sale or Contribution of Assets between an Investor and its Associate or Joint Venture – Amendments to IFRS 10 and IAS 28.

IFRS 18 Presentation and Disclosure in Financial Statements

IFRS 18 will replace IAS 1 Presentation of Financial Statements and applies for annual reporting periods beginning on or after 1 January 2027. The new standard introduces the following key new requirements.

•

Entities are required to classify all income and expenses into five categories in the statement of profit or loss, namely the operating, investing, financing, discontinued operations and income tax categories. Entities are also required to present a newly-defined operating profit subtotal. Entities’ net profit will not change.

•

Management-defined performance measures (MPMs) are disclosed in a single note in the financial statements.

•

Enhanced guidance is provided on how to group information in the financial statements.

In addition, all entities are required to use the operating profit subtotal as the starting point for the statement of cash flows when presenting operating cash flows under the indirect method.

The Group is still in the process of assessing the impact of the new standard, particularly with respect to the structure of the Group’s statement of profit or loss, the statement of cash flows and the additional disclosures required for MPMs. The Group is also assessing the impact on how information is grouped in the financial statements, including for items currently labelled as ‘other’.

Other accounting standards

The following new and amended accounting standards are not expected to have a sig

nific

ant impact on the Group’s consolidated financial statements.

•

Lack of Exchangeability (Amendments to IAS 21).

•

Classification and Measurement of Financial Instruments (Amendments to IFRS 9 and IFRS 7).

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

BB.	Sustainability policy pronouncements not yet effective

The following pronouncements issued are applicable for the preparation of financial statements and sustainability reports.


New IFRS of Sustainability		Effective date
IFRS S1 General Requirements for Disclosures about Sustainability Disclosures Related to Financial Information		Annual periods beginning on or after January 1, 2024. Early adoption is permitted with the joint application of IFRS S2.

IFRS S2 Climate-related Disclosures		Annual periods beginning on or after January 1, 2024. Early adoption is permitted with the joint application of IFRS S1.

The Group is evaluating these standards, since it is not obliged to adopt it. These sustainability standards have not yet been approved in the countries where the Company and its subsidiaries are domiciled.

4.	Cash and Cash Equivalents

As of December 31, this caption includes the following:


In thousands of soles	2024		2023		2022
Checking accounts (a)		217,824		226,147		173,037
Term deposits (b)		17,545		14,346		35,214
Cash funds		376		640		443

		235,745		241,133		208,694

(a)

As of December 31, 2024, checking accounts are held at local and foreign banks in local and foreign currency amounting to S/ 91,903 thousand and an equivalent of S/ 125,921 thousand, respectively (S/ 80,163 thousand and an equivalent of S/ 145,984 thousand as of December 31, 2023, and S/ 26,699 thousand and an equivalent of S/ 146,368 thousand as of December 31, 2022).

(b)

As of December 31, 2024, it includes overnight term deposits held at local and foreign banks in local and foreign currency amounting for S/ 2,615 thousand and equivalent to S/ 14,930 thousand respectively. These deposits were held in local and foreign financial entities, earned interest at market rates, and matured at the beginning of February 2025 (S/ 1,253 thousand and equivalent to S/ 13,093 thousand as of December 31, 2023 with maturity at the beginning of February 2024 and S/ 34,408 thousand and equivalent to S/ 806 thousand as of December 31, 2022 with maturity at the beginning of February 2023).

The quality of the financial institutions where the Group deposits its cash has been rated as follows:

•

In accordance with the information provided by Apoyo y Asociados Internacionales S.A.C., an international rating agency (applicable to Peruvian financial entities):


In thousands of soles	2024		2023		2022
Bank deposits and accounts
A+		125,939		90,914		73,458
AA+		—		—		204
A-		268		3,128		—
A		3,072		9,667		3,664

		129,279		103,709		77,326

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

•

In accordance with the information provided by an international rating agency (applicable to Colombian financial entities):


In thousands of soles	2024		2023		2022
Bank deposits and accounts
AAA		58,011		109,647		61,919
AA+		10		11		8
AA-		—		5		29

		58,021		109,663		61,956

•

In accordance with the information provided by an international rating agency (applicable to Mexican financial entities):


In thousands of soles	2024		2023		2022
Bank deposits and accounts
AAA		25,420		15,426		13,073
A		43		43		19
AA		2,367		2,083		—
BBB		—		9		46,638
BBB+		676		5,229		9,194
BBB-		3,027		1,036		45

		31,533		23,826		68,969

•

In accordance with the information provided by an international rating agency (applicable to Luxembourg

financial entities):


In thousands of soles	2024		2023		2022
Bank deposits and accounts
A+		48		1,351		—
AA		16,488		—
AAA		—		1,944		—

		16,536		3,295		—

5.	Trade Accounts Receivable

As of December 31, this caption includes the following:


In thousands of soles	Note		2024			2023			2022
Trade accounts receivable				1,041,330			904,997			612,994
Trade accounts receivable from related parties		31		3,191			1,637			312

				1,044,521			906,634			613,306

Less: Loss for impairment of trade receivables				(82,064	)		(45,298	)		(38,589	)

				962,457			861,336			574,717

Current				961,886			860,916			574,166

Non-current				571			420			551

Trade accounts receivable have current maturity, do not bear interest and do not have specific guarantees. Trade accounts receivable included the unbilled amount for S/ 152,937 thousand (S/ 161,651 thousand as December 31, 2023 and S/ 141,722 thousand as of December 31, 2022). These amounts will become billable within the first quarter of the next annual period.

F-4

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

As of December 31, 2024, 2023 and 2022, the

non-current

portion corresponds to receivables agreements with individual customers related to healthcare services, mainly with maturities between 24 and 36 months, and do not have specific guarantees.

The impairment estimate of trade accounts receivable is included in the “Loss for impairment of trade receivables” item in the consolidated statement of profit or loss and other comprehensive income. Amounts charged to results of the impairment period are generally written off when there is no expectation of cash recovery.

Disaggregation of trade accounts receivable

This caption includes the following:


In thousands of soles	2024		2023		2022
Healthcare services		962,457		861,336		574,717

		962,457		861,336		574,717

By primary geographical markets

2024


In thousands of soles	Peru		Colombia		México		Total
Healthcare services		245,916		624,184		92,357		962,457

		245,916		624,184		92,357		962,457

2023


In thousands of soles	Peru		Colombia		México		Total
Healthcare services		167,963		567,672		125,701		861,336

		167,963		567,672		125,701		861,336

2022


In thousands of soles	Peru		Colombia		México		Total
Healthcare services		130,066		367,352		77,299		574,717

		130,066		367,352		77,299		574,717

Transfer of accounts receivable

As of December 31, 2024, the Group maintain factoring agreements with Citibank del Perú S.A. in order to have more liquidity. According to these agreements, the Group sold without recourse trade receivables for S/ 138,300 thousand (S/ 153,767 thousand as December 31, 2023 and S/ 128,775 thousand as December 31, 2022). These trade receivables have been derecognized from the consolidated statement of financial position, because the Group transferred substantially all of the risks and rewards.

Expected credit loss assessment for customers (ECL)

The Group uses an allowance matrix to measure the ECLs of trade receivables. Loss rates are calculated using a “roll rate” method based on the probability of a receivable progressing through successive stages of delinquency to

write-off.

Roll rates are calculated separately for exposures in different segments based on the following common credit risk characteristics: geographic region, age of customer relationship and type of product purchased.

F-4

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

The Group’s exposure to credit risk is mainly influenced by the characteristics of corporate and individual clients. The Group has established a credit policy under which the client is analyzed by group if it is individual or corporate to determine its solvency before payment and the terms and conditions of the service are offered. The Group’s evaluation includes external qualifications, information from credit agencies, and considers that the main corporate clients are insurers that are supervised by the banking and insurance regulators.

The Group limits its exposure to the credit risk of trade accounts receivable by establishing a maximum payment period of one and three months for individual and corporate clients.

The composition of accounts receivable by geographic region and aging as of December 31, 2024, 2023 and 2022 is as follows:

2024


In thousands of soles	Peru		Colombia		México		Total
Current (not past due)		148,219		222,487		80,296		451,002
1 - 90 days past due		55,959		192,844		13,865		262,668
91 - 180 days past due		30,187		103,337		1,090		134,614
181 - 360 days past due		21,118		76,379		761		98,258
More than 360 days past due		30,233		67,225		521		97,979

		285,716		662,272		96,533		1,044,521

2023


In thousands of soles	Peru		Colombia		México		Total
Current (not past due)		109,854		247,064		93,005		449,923
1 - 90 days past due		37,908		186,323		30,853		255,084
91 - 180 days past due		13,511		44,738		1,563		59,812
181 - 360 days past due		11,401		62,419		944		74,764
More than 360 days past due		26,853		39,906		292		67,051

		199,527		580,450		126,657		906,634

2022


In thousands of soles	Peru		Colombia		México		Total
Current (not past due)		80,380		229,200		69,608		379,188
1 - 90 days past due		37,843		71,886		7,430		117,159
91 - 180 days past due		12,825		30,541		118		43,484
181 - 360 days past due		5,296		26,273		117		31,686
More than 360 days past due		24,908		16,727		154		41,789

		161,252		374,627		77,427		613,306

F-4

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

The following table provides information about the exposure to credit risk and ECLs for trade receivables from corporate customers as of December 31, 2024, 2023 and 2022:

2024


In thousands of soles	Weighted- average loss rate			Gross carrying amount		Loss allowance
Current (not past due)		0.26	%		418,626		1,103
1 - 90 days past due		0.67	%		267,552		1,782
91 - 180 days past due		13.76	%		134,059		18,448
181 - 360 days past due		10.47	%		95,155		9,966
More than 360 days past due		39.30	%		80,147		31,499

					995,539		62,798

2023


In thousands of soles	Weighted- average loss rate			Gross carrying amount		Loss allowance
Current (not past due)		0.13	%		439,258		573
1 - 90 days past due		0.57	%		251,240		1,420
91 - 180 days past due		4.67	%		58,196		2,717
181 - 360 days past due		10.64	%		71,527		7,613
More than 360 days past due		38.43	%		50,483		19,400

					870,704		31,723

2022


In thousands of soles	Weighted- average loss rate			Gross carrying amount		Loss allowance
Current (not past due)		0.33	%		335,439		1,114
1 - 90 days past due		2.04	%		106,157		2,169
91 - 180 days past due		3.99	%		41,016		1,636
181 - 360 days past due		8.52	%		26,967		2,298
More than 360 days past due		57.61	%		26,901		15,497

					536,480		22,714

The following table provides information about the exposure to credit risk and ECLs for trade receivables from individual customers as of December 31, 2024, 2023 and 2022:

2024


In thousands of soles	Weighted- average loss rate			Gross carrying amount		Loss allowance
Current (not past due)		1.37	%		14,237		195
1 - 90 days past due		7.22	%		8,063		582
91 - 180 days past due		42.50	%		2,135		907
181 - 360 days past due		36.56	%		4,029		1,473
More than 360 days past due		78.51	%		20,518		16,109

					48,982		19,266

F-4

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

2023


In thousands of soles	Weighted- average loss rate			Gross carrying amount		Loss allowance
Current (not past due)		2.95	%		10,665		315
1 - 90 days past due		5.10	%		3,844		196
91 - 180 days past due		11.76	%		1,616		190
181 - 360 days past due		23.42	%		3,237		758
More than 360 days past due		73.13	%		16,568		12,116

					35,930		13,575

2022


In thousands of soles	Weighted- average loss rate			Gross carrying amount		Loss allowance
Current (not past due)		3.12	%		43,749		1,363
1 - 90 days past due		14.53	%		11,002		1,599
91 - 180 days past due		13.53	%		2,468		334
181 - 360 days past due		29.18	%		4,719		1,377
More than 360 days past due		75.24	%		14,888		11,202

					76,826		15,875

The annual movement of loss for impairment of trade accounts receivables is the following:


In thousands of soles	2024			2023			2022
Initial balance		45,298			38,589			44,830
Additions		42,413			6,979			5,255
Recovery		(1,558	)		(1,295	)		(6,835	)
Write-off		(671	)		(2,781	)		(2,828	)
Exchange difference		(3,418	)		3,806			(1,833	)

Final balance		82,064			45,298			38,589

6.	Other Assets

As of December 31, this caption includes the following:


In thousands of soles	2024		2023		2022
Tax credit from sales tax (VAT) (a)		140,615		87,187		55,794
Costs of anticipated equity transactions		—		29,957		23,242
Advance payment for purchase of shares (b)		—		—		11,373
Trust fund (c)		—		—		95,201
Prepaid expenses (d)		11,500		8,810		3,852
Payments in advance of income tax (e)		64,891		66,572		47,287
Accounts receivables from credit cards		9,713		9,755		6,732
Claims to third parties (f)		2,712		1,715		1,429
Account receivable from former shareholders (g)		758		1,149		935
Guarantees furnished (h)		1,233		1,047		868
Taxes receivable		10,553		7,579		4,900
Loans to personnel		1,128		1,849		1,427
Prepayments		8,094		8,399		1,484
Others (i)		26,519		20,282		20,877

		277,716		244,301		275,401

Current		253,283		222,728		255,595

Non-current		24,433		21,573		19,806

F-4

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

(a)	As of December 31, 2024, 2023 and 2022, it includes the tax credit (net) of value added tax (VAT).

(b)

As of December 31, 2022, it includes the payment as an advance for the acquisition of shares of the OCA Hospital through Auna Mexico, which was agreed with the former shareholder as a deposit representing the amount of S/ 11,592 thousand and decreased on this balance by S/ 219 thousand as a lower exchange difference. In January 2023, this amount was recovered in cash.

(c)	It corresponds to the deposit of S/ 95,201 thousand (COP 100,000 million) in a trust fund to guarantee the payment of the contingent consideration in accordance with the acquisition of shares of the Oncomedica S.A. (note 1.C.iii). In June 2023, this amount was recovered in cash.

(d)	It corresponds to insurance paid in advance, annual licenses of software and the incremental cost of obtaining a contract with a supplier for selling oncological healthcare plans.

(e)	It corresponds to payments in advance of income tax, which will be offset with future income tax in the next fiscal year.

(f)	It includes a receivable for salaries of employees on leave that is to be refunded by the government for S/ 793 thousand for December 31, 2024 (S/ 1,199 thousand and S/ 1,124 thousand for December 31, 2023 and 2022, respectively).

(g)	As of December 31, 2024, 2023 and 2022, it corresponds to account receivables from former shareholders for tax and labor liabilities contingencies that were determined in the acquisition of Patología Oncológica for S/ 209 thousand.

As of December 31, 2024, 2023 and 2022, it includes the account receivables from former shareholders for medical liabilities contingencies that were determined in the acquisition of PMLA. In 2024, the amount of account receivables from former shareholders is S/ 549 thousand. (S/ 940 thousand and S/ 726 thousand for December 31, 2023 and 2022, respectively).

(h)	It corresponds to funds under restriction in financial institutions mainly for the compliance with debts and guarantees for real estate rentals.

(i)

It includes accounts receivable from Consorcio Trecca for S/ 16,033 thousand for December 31, 2024 (S/ 12,395 thousand and S/ 11,301 thousand for December 31, 2023 and 2022, respectively) which corresponds to preoperative activities defined in the concession arrangement, that represents a contractual right to receive cash and the accounts receivable is accumulated when the preoperative activities are incurred.

7.	Inventories

As of December 31, this caption includes the following:


In thousands of soles	2024		2023		2022
Medicines		100,398		101,970		62,372
Medical supplies		38,550		21,563		18,220
Supplies and packaging		4,816		6,988		6,986

		143,764		130,521		87,578

F-4

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

In 2024, 2023 and 2022, inventories of S/ 1,143,359 thousand, S/ 1,022,220 thousand and S/ 622,923 thousand, respectively, were recognized as an expense during these years and included in cost of sales and services.

As of December 31, 2024, the Group has recognized an impairment of inventories for S/ 419 thousand. During 2023, the Group has recognized a reversal for impairment of inventories for S/ 1,927 thousand. As of December 31, 2022, the Group recognized an impairment of inventories for S/ 4,655 thousand, presented net in cost of sales and services.

8.	Derivative Financial Instruments

A.	Derivatives Foreign exchange operation agreements with deferred premium

As of December 31, 2024, 2023 and 2022, this caption includes the following:


In thousands of soles			Reference value		Maturity date		2024			2023			2022
Derivative assets mandatorily measured at FVTPL
Fx operation Agreement – Purchased Collar				US$ 55,500		2026		—			—			9,396
Fx operation Agreement – Purchased Collar	(e	)		US$ 80,000		2024		—			721			—
Derivative assets mandatorily measured at FVOCI
Fx operation Agreements – Long forward	(a	)		US$ 300,000		2023		—			—			69,064
Fx operation Agreements – Purchased Collar (Long Put)	(a	)		US$ 300,000		2023		—			—			(9,835	)
Fx operation Agreements – Purchased Collar (Short Call)				US$ 300,000		2023		—			—			13,981
Fx operation Agreement – Call Spread	(a	)		US$ 253,000		2029		38,849			—			—
Fx operation Agreement – Call Spread (Long Put)	(a	)		US$ 47,000		2025		(2,856	)		—			—
Fx operation Agreement – Call Spread (Short Call)	(a	)		US$ 47,000		2025		7,825			—			—
Fx operation Agreements – Purchased Collar (Long Put)	(a	)		US$ 300,000		2025		—			(33,325	)		—
Fx operation Agreements – Purchased Collar (Short Call)	(a	)		US$ 300,000		2025		—			50,870			—
Fx operation Agreement – Call Spread	(b	)		US$ 55,500		2026		4,828			6,464			—
Fx operation Agreement – Call Spread	(d	)		US$ 2,082		2028		205			254			—
Fx operation Agreement – Call Spread	(d	)		US$ 50,918		2028		5,534			6,205			—
Fx operation Agreement – Purchased Collar	(c	)		US$ 396,500		2028		—			51,024			—
Fx operation Agreement – Single Call	(c	)		US$ 30,000		2028		6,337			—			—
Interest Rate Swap – TIIE	(f	)		MXN 1,705,351		2028		6,750			—			—

								67,472			82,213			82,606

Current								8,962			721			69,064

Non-current								58,510			81,492			13,542

Derivative liabilities mandatorily measured at FVOCI
Interest Rate Swap – TIIE	(f	)		MXN 3,410,702		2028		38,471			—			—
Interest Rate Swap – SOFR	(f	)		US$ 77,500		2028		3,899			—			—
Fx operation Agreements – Purchased Collar (Long Put)				US$ 300,000		2025		—			—			(50	)
Fx operation Agreements – Purchased Collar (Short Call)				US$ 300,000		2025		—			—			15,367

								42,370			—			15,317

Current								15,273			—			15,317

Non-current								27,097			—			—

Fx: Foreign exchange

F-4

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

(a)

On November 29, 2022, the Group negotiated a new agreement with Citibank N.A. on the previous derivate structure (purchased collar and long forward for S/ 1,092,750 thousand or US$ 300,000 thousand) which was valid as of November 2023, to hedge the senior notes until November 2025. As result of this agreement, the exchange fluctuations of the derivative result in a new ranging from S/ 4.2000 to S/ 4.3000 per US$

. As a result of this negotiation, the Group recorded an increase of the derivative financial asset with the premiums payable by S/ 35,702 thousand.

On December 18, 2023, new senior notes maturing in 2029 were issued in exchange for a part of the previous senior notes that were canceled in the exchange (note 15.A), and this derivate instrument was designated as a hedge to cover both senior notes up to the reference value.

On March 22, 2024, the Group signed a novation of the US$ 253,000 thousand notional portion of the “Purchased Collar” structure was carried out to Deutsche Bank (originally Citibank) and then on the same date this nominal portion was modify to replace it with a “Call Spread” structure as a continuation of the current hedging strategy.

On December 18, 2024, the Group issued new senior notes maturing in 2029 in order to prepay the senior notes outstanding which had a maturity in 2025 and the derivative instrument of US$ 47,000 thousand was designated as a hedge to cover these senior notes up to their reference value.

(b)

On November 29, 2022, the Group signed a new foreign exchange options which included Call spread agreement with Citibank N.A. for S/ 238,650 thousand (US$ 55,500 thousand) to cover 100% of the loan agreement with JPMorgan Chase Bank, S.A. As a result of this agreement, the Group recorded an increase of the derivative financial asset with the premiums payable by S/ 13,774 thousand. This loan was paid on April 2023, and this derivative instrument was designated as a hedge to cover the Notes Purchase Agreement issued in April 2023. After, this loan was paid on December 2023, and this derivative instrument was designated as a hedge to cover a part of the new term loan signed on December 18, 2023 up to the reference value. These new instruments cover the exchange fluctuations ranging from S/ 3.8750 to S/ 4.3000 per US$

(c)

On May 5, 2023, the Group, through its subsidiary Grupo Salud Auna Mexico, signed foreign exchange options which included a Single call agreement with Santander Bank for US$ 396,500 thousand. It covered 100% of the term loan. Subsequently, this loan was paid on December 2023 and this derivate instrument was designated as a hedge to cover a part of the new term loan signed on December 18, 2023, and for the no hedged item it had an effect on results that was recorded in finance cost. On March 19, 2024, the Company restructured its debt as a result of a syndication process. As a consequence, the notional in US dollars exposed to exchange rate risk has decreased to US$ 30,000 thousand and for the no hedged item it had an effect on results that was recorded in finance cost. On April 25, 2024, the Group signed a novation for a portion of US$ 366,500 thousand of the original structure to HSBC Bank, and then on the same date that portion was unwinded. As result, a notional amount of US$ 30,000 thousand was maintained with Santander Bank. This instrument cover the exchange fluctuations greater than MXN 22.50 per US$

(d)

On June 1, 2023, the Group signed foreign exchange options which included a Call spread agreement with Citibank for US$ 53,000 thousand. It covered 100% of the new senior secured bonds. Subsequently, this loan was paid in December 2023, and this derivative instrument was designated as a hedge to cover the new term loan signed on December 18, 2023, and for the no hedged item it had an effect on results that was recorded in finance cost. These instruments cover the exchange fluctuations ranging from S/ 3.8575 to S/ 4.30 per US$

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

(e)

On July 21, 2023, the Group, through its subsidiary Auna Colombia S.A.S., signed foreign exchange options which included a Single Call agreement with Citibank N.A. for US$ 80,000 thousand. These instruments cover the exchange fluctuations greater than COP 6,000 per US$

. As of September 30, 2024 this derivative has finished.

(f)

In April 2024, the Group signed new interest rate swap agreements to cover the interest rate fluctuation related to the new term loan signed December 18, 2023. The amount covered was MXN 3,410,703 thousand and USD 77,500 thousand and such instrument fixed an interest rate of 11.80% and 4.51% respectively for the entire period of the derivative.

In September 2024, the Group signed new interest rate swap agreements to cover the interest rate fluctuation related to the new term loan signed December 18, 2023. The amount covered was MXN 1,705,351 thousand and such instrument fixed an interest rate of 8.81% for the entire period of the derivative.

As of December 31, 2024, there are outstanding premiums to Citibank, Santander Bank and Deutsche Bank of S/ 85,849 thousand (S/ 157,896 thousand as of December 31, 2023 and S/ 75,374 thousand as of December 31, 2022), which were included in Other Accounts Payable (note 17.b). The liabilities were incurred in connection with Call spread and Single Call agreements.

The effect of fair value of these derivative financial instruments, net of tax recognized in the consolidated other comprehensive income for the year ended December 31, 2024, was a loss for S/ 16,140 thousand (loss of S/ 75,423 thousand and of S/ 50,297 thousand for the year ended December 31, 2023 and 2022, respectively).

During the year 2024, the effect reclassified from other comprehensive income to profit or loss as gain of exchange difference was S/ 9,249 thousand and from other comprehensive income to profit or loss as finance cost was S/ 34,482 thousand (note 24), and neither includes S/ 7,069 thousand of tax.

During the year 2023, the effect reclassified from other comprehensive income to profit or loss as loss exchange difference was S/ 32,100 thousand and from other comprehensive income to profit or loss as finance cost was S/ 86,135 thousand (note 24), and neither includes S/ 34,051 thousand of tax.

During the year 2022, the effect reclassified from other comprehensive income to profit or loss as higher exchange difference was S/ 53,400 thousand and from other comprehensive income to profit or loss as finance cost was S/ 28,097 thousand (note 24), and neither includes S/ 24,042 thousand of tax.

9.	Other Investments

As of December 31, this caption includes the following:


In thousands of soles	2024		2023
Current investments
Sovereign debt securities - at FVOCI		100,228		93,132

		100,228		93,132

Non-current investments
Sovereign debt securities - at FVOCI		282		289

		282		289

As of December 2024, and 2023 sovereign debt securities at FVOCI earned interest rates between 2.4%

-12.6%,

and 6.0% - 11.5%, respectively.

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

10.	Investments in Associates and Joint Venture

As of December 31, this caption includes the following:


In thousands of soles	Percentage ownership interest		2024		2023		2022
Associates
Ciclotrón Colombia S.A.S. (a)		32.50		12,170		10,347		4,929
Ciclotrón Perú S.A. (c)		49.00		7,792		5,655		4,315
Joint Venture
Pet CT Perú S.A. (b)		50.00		5,443		4,582		3,852

				25,405		20,584		13,096

(a)	It is dedicated to the production and commercialization of radiopharmaceuticals used for diagnostic images of PET (positron emission tomography) and scintigraphy and its fiscal address is Calle 30 N 46 - 25 Medellín – Colombia.

(b)	It is dedicated to providing medical diagnostic imaging services and cancer treatment, using PET / CT molecular imaging technology.

(c)	It is dedicated to the production of radiopharmaceuticals used for diagnostic images of PET (positron emission tomography).

The Group has recognized the following amounts in the consolidated statement of profit or loss and other comprehensive income:


In thousands of soles	2024		2023			2022
Profit
Associate
Ciclotrón Colombia S.A.S.		5,495		4,063			2,198
Ciclotrón Perú S.A.		2,444		1,497			785
Joint Venture
Pet CT Perú S.A.		861		730			774

		8,800		6,290			3,757

Other comprehensive income
Associate
Ciclotrón Colombia S.A.S.		—		(42	)		(77	)

The interest of the Group in the profit or loss, assets, and liabilities of its associate and joint venture is the following:


In thousands of soles	Assets		Liabilities		Income		Expenses		Interest (%)
As of December 31, 2024
Ciclotrón Perú S.A.		16,656		5,910		18,389		12,894		49.0
Pet CT Perú S.A.		18,473		6,820		19,142		15,843		50
Ciclotrón Colombia S.A.S.		41,849		17,825		43,350		30,503		32.5

As of December 31, 2023
Ciclotrón Perú S.A.		15,326		4,493		11,171		8,177		49.0
Pet CT Perú S.A.		15,467		4,348		17,101		14,671		50.0
Ciclotrón Colombia S.A.S.		46,897		19,975		42,181		29,680		32.5

As of December 31, 2022
Ciclotrón Perú S.A.		12,741		4,681		9,124		7,522		49.0
Pet CT Perú S.A.		11,488		3,772		14,894		13,347		50.0
Ciclotrón Colombia S.A.S.		27,280		16,149		25,493		18,729		32.5

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

The annual movement of investments in the associate and joint venture during the year includes:


In thousands of soles	2024			2023			2022
As of January 1		20,584			13,096			14,286
Group’s share in profit or loss		8,800			6,290			3,757
Group’s share in other comprehensive income		—			(42	)		(77	)
Collection of dividends		(2,709	)		(157	)		(3,545	)
Exchange difference		(1,270	)		1,397			(1,325	)

As of December 31		25,405			20,584			13,096

F-5

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

11.	Property, Furniture and Equipment

The movement of property, furniture and equipment and the respective accumulated depreciation for the years ended December 31, 2024, 2023 and 2022 is as follows:


In thousands of soles	Note		Land (a)			Buildings and facilities (a)			Medical equipment and others (a)			Vehicles			Furniture and fixture			Works in progress (b)			Total
Cost
Balances as of January 1, 2022				232,770			766,082			319,094			1,364			19,575			158,294			1,497,179
Additions				522			27,993			25,765			4			4,581			27,676			86,541
Business combination balances		1.C.iii & iv		150,085			958,868			133,817			455			4,421			4,749			1,252,395
Reclassifications to intangible assets				—			—			—			—			—			(306	)		(306	)
Reclassifications from right-of-use asset (c)				—			—			5,143			—			—			—			5,143
Transfers				—			151,521			2,998			—			2,069			(156,588	)		—
Write-off (e)				—			(715	)		(3,343	)		—			(177	)		—			(4,235	)
Disposals				—			—			(628	)		(608	)		(115	)		—			(1,351	)
Exchange difference				(24,242	)		(111,812	)		(35,180	)		(35	)		(2,263	)		(9,625	)		(183,157	)

Balances as of December 31, 2022				359,135			1,791,937			447,666			1,180			28,091			24,200			2,652,209

Balances as of January 1, 2023				359,135			1,791,937			447,666			1,180			28,091			24,200			2,652,209
Additions (a)				—			24,634			46,207			819			6,240			45,111			123,011
Business combination balances		1.C.i & ii		—			—			185			104			69			—			358
Reclassifications to intangible assets				—			—			11			—			—			(1,344	)		(1,333	)
Reclassifications from right-of-use asset (c)				—			—			8,169			126			—			—			8,295
Transfers				—			15,708			(80	)		(4	)		59			(15,683	)		—
Write-off (e)				—			(118	)		(7,480	)		(111	)		(198	)		—			(7,907	)
Disposals				(1,127	)		(75	)		(127	)		(342	)		(353	)		—			(2,024	)
Exchange difference				36,637			199,388			45,777			2			3,236			2,567			287,607

Balances as of December 31, 2023				394,645			2,031,474			540,328			1,774			37,144			54,851			3,060,216

Balances as of January 1, 2024				394,645			2,031,474			540,329			1,774			37,144			54,850			3,060,216
Additions (a)				—			21,705			51,124			153			2,588			23,839			99,409
Reclassifications from intangible assets				—			—			63			—			—			—			63
Reclassifications from right-of-use asset (c)				—			—			6,515			—			—			—			6,515
Transfers				—			7,208			18,292			—			2,785			(28,285	)		—
Write-off (e)				—			(262	)		(8,913	)		—			(493	)		(17	)		(9,685	)
Disposals				—			—			(1	)		(195	)		(18	)		—			(214	)
Exchange difference				(38,121	)		(219,597	)		(44,603	)		(72	)		(3,522	)		(3,892	)		(309,807	)

Balances as of December 31, 2024				356,524			1,840,528			562,806			1,660			38,484			46,495			2,846,497

F-5

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022


In thousands of soles	Note	Land (a)		Buildings and facilities (a)			Medical equipment and others (a)			Vehicles			Furniture and fixture			Works in progress (b)		Total
Accumulated depreciation
Balances as of January 1, 2022			—		(111,547	)		(144,659	)		(864	)		(7,891	)		—		(264,961	)
Additions (d)			—		(29,464	)		(53,377	)		(119	)		(2,350	)		—		(85,310	)
Reclassifications from right-of-use asset (c)			—		—			(2,568	)		—			—			—		(2,568	)
Write-off (e)			—		576			2,441			—			75			—		3,092
Disposals			—		—			588			475			115			—		1,178
Exchange difference			—		3,626			12,446			(22	)		454			—		16,504

Balances as of December 31, 2022			—		(136,809	)		(185,129	)		(530	)		(9,597	)		—		(332,065	)

Balances as of January 1, 2023			—		(136,809	)		(185,129	)		(530	)		(9,597	)		—		(332,065	)
Additions (d)			—		(52,062	)		(76,236	)		(259	)		(3,885	)		—		(132,442	)
Reclassifications from right-of-use asset (c)			—		—			(5,239	)		(100	)		—			—		(5,339	)
Write-off (e)			—		23			5,628			111			79			—		5,841
Disposals			—		56			111			312			—			—		479
Exchange difference			—		(5,620	)		(17,342	)		75			(663	)		—		(23,550	)

Balances as of December 31, 2023			—		(194,412	)		(278,207	)		(391	)		(14,066	)		—		(487,076	)

Balances as of January 1, 2024			—		(194,412	)		(278,207	)		(391	)		(14,066	)		—		(487,076	)
Additions (d)			—		(51,953	)		(58,778	)		(359	)		(4,147	)		—		(115,237	)
Reclassifications from right-of-use asset (c)			—		—			(3,944	)		—			—			—		(3,944	)
Write-off (e)			—		203			4,595			—			347			—		5,145
Disposals			—		—			1			143			—			—		144
Exchange difference			—		11,176			22,605			(69	)		882			—		34,594

Balances as of December 31, 2024			—		(234,986	)		(313,728	)		(676	)		(16,984	)		—		(566,374	)

Net carrying amount
Balances as of December 31, 2022			359,135		1,655,128			262,537			650			18,494			24,200		2,320,144

Balances as of December 31, 2023			394,645		1,837,062			262,121			1,383			23,078			54,851		2,573,140

Balances as of December 31, 2024			356,524		1,605,542			249,078			984			21,500			46,495		2,280,123

F-5

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

(a)	In 2024, the Group acquired medical equipment for S/ 51,124 thousand to expand the clinical services (S/ 46,207 thousand and S/ 25,765 thousand in 2023 and 2022, respectively).

In addition during 2024, the infrastructure includes S/ 8,168 thousand of costs incurred for the expansion of the Peruvian clinics, S/ 6,998 thousand of the Colombia clinics and S/ 6,539 thousand of the OCA Hospital in Mexico (S/ 9,361 thousand of costs incurred for the Peruvian clinics, S/ 5,902 thousand of the Colombia clinics, S/ 9,371 thousand of the OCA Hospital in México during 2023 and S/ 12,322 thousand of costs incurred for the Peruvian clinics, S/ 5,489 thousand of the Colombia clinics and S/ 626 thousand of the OCA Hospital in Mexico during 2022).

Also, the additions in 2022 to infrastructure include S/ 9,556 thousand of costs incurred for the construction of the radiotherapy unit, offices and parking of the Clínica Chiclayo completed on October 2022.

(b)

As of December 31, 2024, 2023 and 2022, the additions of constructions in progress amounted to S/ 23,839 thousand. This includes cost of projects related to the remodeling of the Peruvian clinics for an amount of S/ 8,020, Colombia clinics for an amount of S/ 1,311 and OCA Hospital in México for an amount of S/ 14,508.

(c)	Corresponds to transfers from right-of-use as a consequence of the termination of the lease agreement with option to purchase.

(d)	The depreciation recognized in the consolidated statement of profit or loss and other comprehensive income includes:


In thousands of soles	Note		2024		2023		2022
Cost of sales and services		21		95,193		113,360		73,583
Administrative expenses		21		20,044		19,082		11,727

				115,237		132,442		85,310

(e)	The write-off corresponds mainly to the physical inventory of fixed assets of the Group in 2024 with a cost of S/ 1,457 thousand (S/ 4,220 thousand in 2023) and accumulated depreciation of S/ 907 thousand (S/ 3,805 thousand in 2023).

F-5

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

12.	Intangibles Assets

The movement of intangibles and the corresponding accumulated amortization for the years ended December 31, 2024, 2023 and 2022 is as follows:


In thousands of soles	Note		Goodwill			Trademark			Customer relationships			Software			Public service concessions		Total
Cost
Balances as of January 1, 2022				184,961			179,912			17,836			146,293			19,109		548,111
Additions				—			—			—			49,674			1,749		51,423
Business combination balances		1C.ii & iii		1,729,292			278,264			390,889			3,520			—		2,401,965
Reclassifications from property, furniture and equipment				—			—			—			306			—		306
Disposal				—			—			—			(3,140	)		—		(3,140	)
Exchange difference				(108,363	)		(50,893	)		(6,133	)		(8,518	)		—		(173,907	)

Balances as of December 31, 2022				1,805,890			407,283			402,592			188,135			20,858		2,824,758

Balances as of January 1, 2023				1,805,890			407,283			402,592			188,135			20,858		2,824,758
Additions				—			—			—			56,068			2,920		58,988
Business combination balances		1.C.i		21,330			3,411			—			—			—		24,741
Hospital y Clínica OCA’s purchase price adjustment		1.C.ii		(8,193	)		—			—			—			—		(8,193	)
Reclassifications from property, furniture and equipment				—			—			—			1,333			—		1,333
Disposal				—			—			—			(738	)		—		(738	)
Exchange difference				250,211			67,837			48,372			11,356			—		377,776

Balances as of December 31, 2023				2,069,238			478,531			450,964			256,154			23,778		3,278,665

Balances as of January 1, 2024				2,069,238			478,531			450,964			256,154			23,778		3,278,665
Additions				—			—			—			50,499			2,000		52,499
Reclassifications from property, furniture and equipment				—			—			—			(63	)		—		(63	)
Disposal				—			—			—			(1,123	)		—		(1,123	)
Exchange difference				(314,947	)		(65,802	)		(73,733	)		(11,766	)		—		(466,248	)

Balances as of December 31, 2024				1,754,291			412,729			377,231			293,701			25,778		2,863,730

F-5

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022


In thousands of soles	Note	Goodwill		Trademark		Customer relationships			Software			Public service concessions		Total
Accumulated amortization
Balances as of January 1, 2022			—		—		(3,910	)		(34,212	)		—		(38,122	)
Annual amortization			—		—		(1,214	)		(29,841	)		—		(31,055	)
Exchange difference			—		—		938			2,398			—		3,336

Balances as of December 31, 2022			—		—		(4,186	)		(61,655	)		—		(65,841	)

Balances as of January 1, 2023			—		—		(4,186	)		(61,655	)		—		(65,841	)
Annual amortization			—		—		(63,679	)		(13,052	)		—		(76,731	)
Disposal			—		—		—			261			—		261
Exchange difference			—		—		(4,189	)		(2,978	)		—		(7,167	)

Balances as of December 31, 2023			—		—		(72,054	)		(77,424	)		—		(149,478	)

Balances as of January 1, 2024			—		—		(72,054	)		(77,424	)		—		(149,478	)
Annual amortization			—		—		(50,392	)		(25,881	)		—		(76,273	)
Disposal			—		—		—			6			—		6
Exchange difference			—		—		16,285			2,618			—		18,903

Balances as of December 31, 2024			—		—		(106,161	)		(100,681	)		—		(206,842	)

Carrying amount
Balances as of December 31, 2022			1,805,890		407,283		398,406			126,480			20,858		2,758,917

Balances as of December 31, 2023			2,069,238		478,531		378,910			178,730			23,778		3,129,187

Balances as of December 31, 2024			1,754,291		412,729		271,070			193,020			25,778		2,656,888

F-5

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

Amortization

The amortization recognized in the consolidated statement of profit or loss and other comprehensive income includes:


In thousands of soles	Note		2024		2023		2022
Cost of sales and services		21		2,047		2,005		2,329
Administrative expenses		21		74,226		74,726		28,726

				76,273		76,731		31,055

Software

As of December 31, 2024, 2023 and 2022, intangible assets include the costs related to the installation of software (SAP), digital projects, Hospital Information System (HIS), a specialized system used at our network of facilities that, among other features, registers our patients’ contact information; manages administrative services, such as hospital admissions and billing; and houses our EMR system and Matrix system (registers our patients). Also, during 2024 it includes S/ 3,275 thousand (S/ 6,358 thousand during 2023 and S/ 11,754 thousand during 2022) related to the retail digital pharmacy with last-mile delivery, Farmauna, and the telehealth platform, Clínica 360, which provides for clinical intervention with patients through remote access to physicians and other clinicians and telemedicine solutions.

In February 2023, through the business combinations, the group acquired the right to use the trademark “Dentegra” for S/ 3,411 thousand and goodwill for S/ 21,331 thousand, note 1.C.i. In April 2022, in connection with its acquisition of IMAT, the group acquired the trademark “IMAT” for S/ 63,752 thousand, softwares for S/ 2,301 thousand and goodwill for S/ 303,825 thousand (note 1.C.iii). In October 2022, through the business combination, the Group acquired in Mexico the trademark “OCA Hospital” for S/ 214,512 thousand, software for S/ 1,219 thousand, customer relationships for S/ 390,889 thousand and goodwill for S/ 1,425,465 thousand (note 1.C.ii).

Surface rights agreement

Corresponds to surface rights agreement signed between Medicser and the Peruvian Red Cross Society.

Impairment testing

For the purposes of impairment testing, goodwill has allocated to the Group’s CGUs as follows:


In thousands of soles	2024		2023		2022
Radioncologia S.A.C. (Radioncologia)		10,237		10,237		10,237
Laboratorio Cantella S.A.C. (Cantella)		4,585		4,585		4,585
R&R Patólogos Asociados S.A.C. (R&R)		23		23		23
Servimédicos S.A.C. (Servimédicos)		3,522		3,522		3,522
Clínica Bellavista S.A.C. (Bellavista)		2,219		2,219		2,219
Patología Oncológica S.A.C.		621		621		621
Oncogenomics S.A.C.		598		598		598
Promotora Médica Las Américas S.A.		49,012		54,922		45,110
Instituto de Cancerología S.A.		48,436		54,279		44,580
Laboratorio Médico Las Américas Ltda.		44,585		49,961		41,034
Oncomedica S.A.		261,558		293,106		240,732
Hospital y Clinica OCA S.A. de C.V.		1,309,765		1,572,202		1,412,629
Dentegra Seguros Dentales S.A.		19,130		22,963		—

Total goodwill		1,754,291		2,069,238		1,805,890

F-5

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

The key assumptions used in the estimation of value in use were as follows:


In percent	2024	2023	2022
For companies located in Peru
Terminal value growth rate	2.5%	2.5%	2.5%
Discount rate – After-tax	8.8%	9.5%	9.9%
Discount rate – Pre-tax	10.9% - 25.6%	11.4% - 13.8%	12.1% - 12.7%
For companies located in Colombia
Terminal value growth rate	4%	5.0%	3.0%
Discount rate – After-tax	12.5%	13.0%	11.6%
Discount rate – Pre-tax	14.6% - 17.6%	16.7% - 17.6%	15.2% - 16%
For companies located in Mexico
Terminal value growth rate	3%	3%	2.5%
Discount rate – After-tax	11.3%	10.8%	10.9%
Discount rate – Pre-tax	11.3% - 16.0%	10.5% - 14.0%	14.5%

•

The terminal growth rate represents Management’s estimate of the long-term growth of each CGU, taking into account past and future growth and external sources of information.

•

Projected cash flows are based on Management’s operating EBITDA profit projections for a period of five years.

The ranges of projected EBITDA as a percentage of revenue by CGUs over the projected period are as follows:


		EBITDA as a percentage of revenue
Radioncologia S.A.C. (Radioncologia)		49.3% - 55.3%
Laboratorio Cantella S.A.C. (Cantella)		28.5% - 26.1%
R&R Patólogos Asociados S.A.C. (R&R)		30.1% - 26.5%
Servimédicos S.A.C. (Servimédicos)		18.5% - 28.9%
Clínica Bellavista S.A.C. (Bellavista)		4.7% - 10.8%
Patología Oncológica S.A.C.		43.6% - 38.7%
Oncogenomics S.A.C.		44.9% - 36.3%
Promotora Médica Las Américas S.A.		5.5% - 19.3%
Instituto de Cancerología S.A.		26.1% - 30.0%
Oncomedica S.A.		25.8% - 27.5%
Hospital y Clinica OCA S.A. de C.V.		36.8% - 40.1%
Dentegra Seguros Dentales S.A.		15.0% - 15.4%

•

Projected cash flows include disbursements for capital investments.

•

The discount rates used to calculate the value in use for each Group’s CGU are an estimate that involves a market assessment of the time value of money and the risks inherent in each CGU where cash flows

after-tax

are generated taking into consideration the Group’s business plans. The nominal

after-tax

discount rate used for the impairment assessment was 8.8%

(after-tax)

for the companies located in Peru, according to each Group’s CGU assessed as of December 31, 2024 (9.5% and 9.9%

after-tax

as of 2023 and 2022, respectively). For the companies located in Colombia (Promotora Médica Las Américas, Instituto de Cancerología and Laboratorio Médico Las Américas), the nominal

after-tax

discount rate was 12.5% (13.0% and 11.6% as of 2023 and 2022, respectively). For the companies located in Mexico (Hospital y Clínica OCA), the nominal

after-tax

discount rate was 11.3%. (10.8% and 10.9% as of 2023 and 2022, respectively).

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

•

Projected cash flows include estimates of the revenue increase of each of the healthcare services at each CGU (Radioncología, Bellavista, Servimédicos, Cantella, Promotora Médica Las Américas, Instituto de Cancerología and Laboratorio Médico Las Américas), rates and gross margins.

•

The trademark has been allocated to the Group’s CGUs as follows:


In thousands of soles	2024		2023		2022
Hospital y Clinica OCA S.A. de C.V.		198,162		237,867		212,579
Dentegra Seguros Dentales S.A.		3,035		3,644		—
Promotora Médica Las Américas S.A.		93,586		104,874		86,135
Instituto de Cancerología S.A.		53,341		59,774		49,094
Laboratorio Médico Las Américas Ltda.		6,110		6,847		5,623
Clínica Portoazul S.A.		3,411		3,822		3,138
Oncomedica S.A.		54,884		61,503		50,514
Oncogenomics S.A.C.		200		200		200

Total trademarks		412,729		478,531		407,283

•

The customer relationship has been allocated to the Group’s CGUs net of amortization as follows:


In thousands of soles	2024		2023		2022
Hospital y Clínica OCA S.A. de C.V.		262,616		367,775		387,369
Promotora Médica Las Américas S.A.		4,606		6,444		6,346
Patología Oncológica S.A.C.		2,425		2,943		2,943
Oncogenomics S.A.C.		1,423		1,748		1,748

Total customer relationship		271,070		378,910		398,406

With regard to the assessment of value in use of the CGUs, Management performed a sensitivity analysis and considered that no reasonably possible change in any of the above key assumptions would cause the carrying value of the entities to materially exceed its recoverable amount evaluated at the end of each financial reporting year.

The following table shows the amount by which these two assumptions would need to change individually for the estimated recoverable amount to be equal to the carrying amount:


	After tax discount rate						Terminal value growth rate
	2024		2023		2022		2024			2023			2022
Radioncologia S.A.C.		27.2		25.1		16.5		(342.7	)		Indet.			(14.3	)
Laboratorio Cantella S.A.C.		78.2		92.0		115.1		Indet.			Indet.			Indet.
R&R Patólogos Asociados S.A.C.		61.5		23.9		68.1		Indet.			(470.4	)		Indet.
Servimédicos S.A.C.		10.2		20.0		29.8		—			(41.9	)		Indet.
Clínica Bellavista S.A.C.		15.3		27.5		12.6		(9.3	)		Indet.			(3.3	)
Patología Oncológica S.A.C.		9.4		32.6		66.8		1.3			Indet.			Indet.
Oncogenomics S.A.C.		9.7		31.8		19.7		0.5			Indet.			(27.9	)
Promotora Médica Las Américas S.A.		12.9		13.02		Indet.		3.6			4.97			Indet.
Instituto de Cancerología S.A.		21.3		32.02		29.3		(30.1	)		(115.57	)		(131.4	)
Laboratorio Médico Las Américas Ltda.		—		—		27.1		—			—			(141.0	)
Oncomedica S.A.		14.7		15.60		12.7		0.2			1.15			0.9
Hospital y Clinica OCA S.A. de C.V.		15.7		16.40		15.5		(4.1	)		(6.56	)		(0.8	)
Dentegra Seguros Dentales S.A		19.42		25.56		—		(13.3	)		(45.64	)		—

As of December 31, 2024, 2023 and 2022, no provision for impairment of goodwill has been recorded in the consolidated financial statements.

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

13.

Leases

Set out below are the carrying amounts of

right-of-use

assets recognized and the movements during the fiscal year ended December 31, 2024, 2023

and

2022:


			Right-of-use assets
In thousands of soles	Note		Lands			Buildings and facilities			Medical equipment and other			Vehicles			Furniture and fixture			Total
Balance at January 1, 2022				18,149			50,728			49,304			747			78			119,006
Additions of right-of-use assets (a)				—			1,495			34,672			450			—			36,617
Acquired through business combinations		1.C.iii		—			9,162			12,517			—			—			21,679
Transfers to property, furniture and equipment				—			—			(2,575	)		—			—			(2,575	)
Annual depreciation (c)				(91	)		(9,870	)		(11,534	)		(228	)		(3	)		(21,726	)
Write-off (b)				—			(1,199	)		—			—			—			(1,199	)
Exchange difference				—			(1,887	)		(5,526	)		(72	)		—			(7,485	)

Balance at December 31, 2022				18,058			48,429			76,858			897			75			144,317

Balance at January 1, 2023				18,058			48,429			76,858			897			75			144,317
Additions of right-of-use assets (a)				—			7,022			10,870			—			—			17,892
Transfers to property, furniture and equipment				—			—			(2,956	)		—			—			(2,956	)
Annual depreciation (c)				(91	)		(11,246	)		(14,982	)		(255	)		(3	)		(26,577	)
Write-off (b)				—			(459	)		(458	)		—			—			(917	)
Exchange difference				—			1,686			5,856			85			—			7,627

Balance at December 31, 2023				17,967			45,432			75,188			727			72			139,386

Balance at January 1, 2024				17,967			45,432			75,188			727			72			139,386
Additions of right-of-use assets (a)				—			22,134			4,692			—			—			26,826
Transfers to property, furniture and equipment				—			—			(2,571	)		—			—			(2,571	)
Annual depreciation (c)				(91	)		(12,633	)		(14,679	)		(230	)		(3	)		(27,636	)
Write-off (b)				—			—			(79	)		—			—			(79	)
Exchange difference				—			(1,257	)		(3,565	)		(42	)		—			(4,864	)

Balance at December 31, 2024				17,876			53,676			58,986			455			69			131,062

(a)	In 2024, the additions of the Group mainly correspond to new lease agreements for use of commercial offices and equipment for medical use. The Group recognized S/ 26,826 thousand (S/ 17,892 thousand in 2023 and S/ 36,617 thousand in 2022) of right-of-use asset and lease liability.

(b)	In 2023, it corresponds mainly to the physical inventory of fixed assets of the Group with a cost of S/ 447 thousand and accumulated depreciation of S/ 355 thousand. In 2022, it corresponds mainly to lease agreements terminated by the Group.

(c)	The depreciation recognized in the consolidated statement of profit or loss and other comprehensive income includes:


In thousands of soles	Note		2024		2023		2022
Cost of sales and services		21		21,714		21,519		18,955
Selling expenses		21		22		13		12
Administrative expenses		21		5,900		5,045		2,759

				27,636		26,577		21,726

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

i.	Lease liabilities

Set out below are the carrying amounts of lease liabilities and the corresponding movements during the fiscal years ended December 31, 2024, 2023 and 2022:


In thousands of soles	Note		2024			2023			2022
Balance at January 1				158,045			162,922			140,583
Additions				26,837			18,233			36,617
Acquired through business combination		1.C.iii		—			—			21,551
Interest expense				12,855			13,465			11,824
Leases prepayment penalty				—			—			9
Payments				(45,593	)		(42,530	)		(34,758	)
Penalty paid for leases prepayment				—			—			(9	)
Lease contracts cancelled				—			(174	)		(1,231	)
Exchange difference				(4,256	)		6,129			(11,664	)

Balance at December 31				147,888			158,045			162,922

Current				32,459			31,867			28,084
Non-current				115,429			126,178			134,838

F-6

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

14.	Deferred Income Tax

As of December 31, this caption includes the following:


In thousands of soles	Balances as of January 1			Recorded in the profit or loss for the year			Exchange difference			Recorded in other comprehensive income			Balances as of December 31			Deferred tax assets			Deferred tax liabilities
2024
Tax losses		210,073			79,113			(18,666	)		—			270,520			210,106			60,414
Loss for impairment of trade receivables		24,903			(40	)		(1,357	)		—			23,506			18,247			5,259
Provision for unpaid vacations and annual performance bonuses		18,122			(2,501	)		(1,853	)		—			13,768			13,768			—
Trade accounts payable		(217	)		715			30			—			528			471			57
Derivative financial instruments		18,859			2,140			(2,644	)		(1,744	)		16,611			16,611			—
Provisions		3,860			(277	)		(349	)		—			3,234			92			3,142
Intangibles		(237,377	)		14,431			35,019			—			(187,927	)		42			(187,969	)
Investments in associates and others		(22,120	)		(1,138	)		8,125			—			(15,133	)		(10,420	)		(4,713	)
Loans and borrowings		38,452			(6,438	)		(6,391	)		—			25,623			21,136			4,487
Property, furniture and equipment		(361,819	)		(3,787	)		48,415			—			(317,191	)		(16,940	)		(300,251	)
Others		(21,191	)		60,489			(7,687	)		—			31,611			(59,593	)		91,204

Net tax		(328,455	)		142,707			52,642			(1,744	)		(134,850	)		193,520			(328,370	)

F-6

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022


In thousands of soles	Balances as of January 1			Recorded in the profit or loss for the year			Exchange difference			Business combination			Rec ord ed in other comprehensive income			Balances as of December 31			Deferred tax assets			Deferred tax liabilities
2023
Tax losses		157,569			35,273			16,453			778			—			210,073			150,579			59,494
Loss for impairment of trade receivables		16,609			6,568			1,726			—			—			24,903			14,527			10,376
Provision for unpaid vacations and annual performance bonuses		10,615			5,019			869			925			694			18,122			5,934			12,188
Trade accounts payable		735			(664	)		11			(299	)		—			(217	)		315			(532	)
Derivative financial instruments		13,444			9,573			841			—			(4,999	)		18,859			6,247			12,612
Provisions		1,936			1,015			89			820			—			3,860			1,151			2,709
Intangibles		(243,440	)		39,962			(32,875	)		(1,024	)		—			(237,377	)		—			(237,377	)
Investments in associates and others		(1,244	)		(18,968	)		(2,198	)		290			—			(22,120	)		(3,160	)		(18,960	)
Loans and borrowings		13,510			17,286			7,656			—			—			38,452			24,748			13,704
Property, furniture and equipment		(321,753	)		(674	)		(39,386	)		(6	)		—			(361,819	)		(41,059	)		(320,760	)
Others		4,071			(23,494	)		(1,768	)		—			—			(21,191	)		8,089			(29280	)

Net tax		(347,948	)		70,896			(48,582	)		1,484			(4,305	)		(328,455	)		167,371			(495,826	)

F-6

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022


In thousands of soles	Balances as of January 1			Recorded in the profit or loss for the year			Exchange difference			Shareholder´s downstream merger		Business combination			Recorded in other comprehensive income			Balances as of December 31			Deferred tax assets			Deferred tax liabilities
2022
Tax losses		163,090			9,589			(15,159	)		49		—			—			157,569			131,913			25,656
Loss for impairment of trade receivables		10,984			(2,350	)		(1,663	)		—		9,638			—			16,609			13,585			3,024
Provision for unpaid vacations and annual performance bonuses		4,164			823			(58	)		—		5,686			—			10,615			3,153			7,462
Trade accounts payable		258			86			(4	)		—		395			—			735			305			430
Derivative financial instruments		9,180			7,260			—			—		—			(2,996	)		13,444			13,444			—
Provisions		807			(1,312	)		8			—		2,433			—			1,936			1,651			285
Intangibles		(58,576	)		1,443			17,626			—		(203,933	)		—			(243,440	)		—			(243,440	)
Investments in associates and others		(1,729	)		157			328			—		—			—			(1,244	)		(1,244	)		—
Loans and borrowings		(438	)		19,044			(5,378	)		—		282			—			13,510			(11,955	)		25,465
Property, furniture and equipment		(73,456	)		(6,231	)		16,141			—		(258,207	)		—			(321,753	)		(33,407	)		(288,346	)
Others		5,613			(1,131	)		(411	)		—		—			—			4,071			4,766			(695	)

Net tax		59,897			27,378			11,430			49		(443,706	)		(2,996	)		(347,948	)		122,211			(470,159	)

F-6

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial St

atements

December 31, 2024, 2023 and 2022

15.	Loans and Borrowings

As of December 31, 2024, 2023 and 2022, the terms and conditions of outstanding obligations are the following:


										Outstanding balances
										2024				2023				2022
In thousands of soles	Type of obligation		Maturity		Interest rate			Currency		Face value		Carrying amount		Face value		Carrying amount		Face value		Carrying amount
Entity
Banco Davivienda		Bank loan							COP
		Bank loan		2025		45.930	%				5		5		5		5		—		—
		Government guaranteed loan		2025		IBR + 1.500	%				1,442		1,357		5,170		4,507		8,503		6,944
		Government guaranteed loan		2029		IBR + 1.500	%				701		667		1,959		1,734		2,549		2,201
				2025		IBR + 5.550	%				11,842		8,721		17,167		11,108		15,929		9,601
				2025		IBR + 3.500	%				1,516		1,435		4,079		3,546		5,478		4,497
				2027		IBR + 3.750	%				13,299		11,633		24,286		19,086		26,510		19,789
				2028		IBR + 6.800	%				11,791		8,958		18,498		12,568		—		—
				2025		IBR + 5.200	%				2,272		2,194		—		—		—		—
						IBR + 4.700	%				1,120		1,072		—		—		—		—
		Bank loan				IBR + 4.500	%				2,920		2,735		—		—		—		—
						IBR + 3.500	%				2,392		2,142		—		—		—		—
						IBR + 4.600	%				836		787		—		—		—		—
						IBR + 4.600	%				2,764		2,574		—		—		—		—
				2026		IBR + 3.500	%				1,511		1,402		—		—		—		—
				2026		IBR + 3.500	%				1,302		1,196		—		—		—		—
Banco de Bogotá		Bank loan		2025		IBR + 7.000	%		COP		2,350		2,024		1,300		1,228		—		—
				2026		IBR + 5.500	%				6,710		5,935		13,884		11,181		—		—
				2025		46.230	%				20		20		2		2		15		15
						46.230	%				8		8		3		3		4		4
						IBR + 2.200	%				—		—		—		—		11,289		11,032
						IBR + 1.680	%				544		530		—		—		—		—
						IBR + 4.000	%				—		—		183		175		1,345		1,289
Banco de Occidente		Bank loan		2024		38.520	%				—		—		3		3		4		4
				2025		IBR + 1,620	%				285		280		—		—		—		—
						IBR + 2.330	%				220		216		—		—		—		—
						IBR + 2,970	%				2,362		2,086		—		—		—		—
				2024		IBR + 3,730	%				—		—		3,921		3,350		—		—
				2028		IBR + 4.990	%				2,141		1,631		3,317		2,328		—		—

F-6

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022


								Outstanding balances
								2024				2023				2022
In thousands of soles	Type of obligation	Maturity		Interest rate			Currency	Face value		Carrying amount		Face value		Carrying amount		Face value		Carrying amount
Bancolombia			2025		46.210	%	COP		24		24		6		6		26		26
									—		—		3		3		3		3
									2		2		10		10		3		3
									5		5		2		2		3		3
					2.910	%			—		—		—		—		265		263
					IBR + 4.210	%			—		—		—		—		2,257		2,029
					IBR + 4.620	%			—		—		—		—		2,450		2,189
					IBR+ 5.520	%			—		—		—		—		2,746		2,437
			2026		DT F+ 3.010	%			—		—		—		—		2,311		2,094
	Bank loan		2033		IBR + 3.2 0	%			2,847		2,727		—		—		—		—
			2033		IBR + 6.400	%			8,819		4,753		11,599		5,936		—		—
			2026		IBR + 2.920	%			4,599		4,277		—		—		—		—
			2025		IBR + 2.900	%			4,391		4,304		—		—		—		—
					IBR + 3,300	%			5,149		4,720		—		—		—		—
					IBR + 2.024	%			2,807		2,732		—		—		—		—
			2024		IBR + 6.430	%			—		—		9,057		7,952		—		—
			2025		39.640	%			3		3		1		1		—		—
			2025		IBR + 6.672	%			—		—		6,017		5,272		—		—
			2025		IBR + 7.040	%			—		—		6,130		4,854		—		—
			2024		IBR + 6.600	%			—		—		1,576		1,483		—		—
			2026		DTF+3.010	%			1,264		1,086		2,353		1,883		—		—
			2025		33.08	%			2		2		—		—		—		—
	Other financing		2033		DTF+3.950	%			75,582		36,437		93,317		42,390		47,569		33,616
Banco Citibank Colombia	Bank loan		2023		12.310	%	COP		—		—		—		—		11,323		10,686
			2023		15.080	%			—		—		—		—		10,693		9,953
			2025		15.320	%			32,823		30,812		12,841		11,964		—		—
					15.370	%			10,641		10,641		35,979		34,119		—		—
					14.630	%			11,352		10,630		12,521		11,793		—		—
									12,380		11,626		—		—		—		—
					12.600	%			18,521		17,457		13,963		13,049		—		—
Itaú Corpbanca Colombia S.A.	Bank loan		2025		45.240	%	COP		9		9		75		75		55		55
			2024		8.640	%			—		—		4,197		3,862		3,434		3,158
					IBR + 3.650	%			—		—		—		—		17,111		16,008
			2035		IBR + 3,490	%			56,151		44,747		66,588		51,449		57,098		42,224
Boston Scientific Colombia lt			2028		10.780	%			1,574		1,279		2,139		1,646		2,045		1,425
JP Morgan Bank			2023		SOFR + 4.000	%	US$		—		—		—		—		214,827		212,263
Banco de Crédito del Perú	Bank loan		2024		9.700	%	S/		—		—		13,106		12,648		—		—
					6.930	%	US$		—		—		15,367		15,301		—		—
			2023		8.480	%	US$		—		—		—		—		14,932		14,565
			2025		7.850	%	US$		15,368		15,124		—		—		—		—
			2025		7.200	%	S/		16,274		16,025		—		—		—		—
	Government guaranteed loan		2023		0.890	%	S/		—		—		—		—		45		38
	Government guaranteed loan		2023		1.990	%	S/		—		—		—		—		61		53

F-6

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022


									Outstanding balances
									2024				2023				2022
In thousands of soles	Type of obligation		Maturity		Interest rate			Currency	Face value		Carrying amount		Face value		Carrying amount		Face value		Carrying amount
Scotiabank Perú S.A.A.		Bank loan		2024		8.500	%	S /		—		—		61,700		60,307		—		—
						8.700	%	S /		—		—		41,126		40,126		—		—
				2023		4.200	%	US $		—		—		—		—		105,541		102,232
		Other financing		2027		6.300	%	S /		60,472		52,804		73,234		61,694		85,995		70,054
		Bank loan		2025		5.900	%			20,374		20,137		—		—		—		—
						6.000	%			20,392		20,270		—		—		—		—
						6.230	%			40,814		40,711		—		—		—		—
						5.950	%			20,389		20,203		—		—		—		—
Banco BBVA Continental		Bank loan		2024		7.500	%			—		—		—		—		19,293		19,285
				2025		6.500	%			20,620		20,246		—		—		—		—
						8.200	%			9,570		9,524		—		—		—		—
						6.530	%			9,289		9,065		—		—		—		—
						6.950	%	US $		—		—		9,605		9,578		—		—
Banco ITAU				2024		4.850	%	US $		—		—		—		—		72,141		71,196
Banco Interamericano de Finanzas						6.000	%			—		—		—		—		15,586		15,558
						8.450	%	S /		—		—		9,376		9,201		—		—
						7.610	%	US $		—		—		7,520		7,464		—		—
						8.150	%	S /		—		—		5,204		5,094		—		—
						8.300	%			—		—		8,530		8,373		—		—
						7.200	%			—		—		—		—		15,647		15,356
				2025		6.650	%	S /		8,262		8,212		—		—		—		—
						6.200	%			10,718		10,566		—		—		—		—
Banco Internacional del Perú S.A.A.				2024		7.750	%	US $		—		—		7,714		7,656		—		—
						7.380	%			—		—		7,700		7,670		—		—
						6.000	%			—		—		—		—		15,598		15,366
						6.830	%	S /		8,269		8,252		—		—		—		—
		Bank loan		2025		5.950	%			8,196		8,081		—		—		—		—
Banco Pichincha				2024		7.350	%			—		—		29,851		29,650		20,470		20,381
				2025		6.100	%			14,209		14,174		—		—		—		—
				2025		5.900	%			16,222		16,054		—		—		—		—
Banco Citibank				2024		6.400	%	US $		—		—		—		—		32,326		31,913
						5.790	%	US $		—		—		—		—		18,471		18,382
						10.060	%	S /		—		—		31,383		30,285		—		—
						9.650	%			—		—		—		—		9,120		8,950
				2025		8.800	%			20,776		20,517		—		—		—		—
				2025		8.380	%	US $		39,121		37,818		—		—		—		—

F-6

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022


								Outstanding balances
								2024				2023				2022
In thousands of soles	Type of obligation	Maturity		Interest rate			Currency	Face value		Carrying amount		Face value		Carrying amount		Face value		Carrying amount
Banco GNB	Bank loan		2025		5.900	%	S /		9,683		9,559
Banco Santander México, HSBC Mexico, Multiva and Genaro Levinson Marcovich	Loan		2023		TIIE + 6.50	%	MXN		—		—		—		—		1,605,436		1,392,127
BBVA Bancomer	Bank loan				TIIE + 0.900	%			—		—		—		—		14,768		13,754
Secured bonds issues	Senior notes		2025		6.500	%	US $		—		—		237,560		210,837		1,369,470		1,145,626
			2029		10.000	%			1,757,784		1,187,816		1,503,087		942,766		—		—
Banco Santander México, HSBC and Citibank	Bank loan		2028		SOFR + 4.875	%	US $		608,680		462,665		642,769		454,486		—		—
					TIIE + 4.500	%	MXN		1,816,554		1,221,939		1,839,540		1,125,742		—		—
					SOFR + 4.875	%	US $		143,341		109,120		640,706		454,131		—		—
HSBC México	Bank loan		2025		12.430	%	MXN		33,873		33,011		—		—		—		—

Total									5,048,548		3,619,774		5,557,229		3,761,582		3,860,745		3,348,647

Current											654,233		—		385,300		—		2,040,980

Non-current											2,965,541		—		3,376,282		—		1,307,667

DTF: Term deposit rate

IBR: Bank reference indicator

TIIE: Interbank equilibrium interest rate

SOFR: Secured Overnight Financing Rate

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

(a)	Bank loans with covenants

Senior Notes

On November 20, 2020, Auna S.A. successfully issued US$ 300 million in senior notes in the international market, under Rule 144A and Regulation S of the United States Securities Act of 1933, for a maturity of 5 years with an annual interest rate of 6.50 percent.

The amount collected from senior notes issued was used to pay the existing financial debt,

re-profile

the current and

non-current

liabilities and finance future investments in fixed assets.

As of December 31, 2022, the senior notes have qualitative and quantitative covenants calculated based on the Group’s consolidated financial statements.

Since November 20, 2020 (the “Issue Date”), the Group has to comply with the following covenants when planning to incur new indebtedness:

•

The Net Leverage Ratio for the Issuer and its Restricted Subsidiaries on a consolidated basis is less than (i) 5:00 to 1:00, if such Incurrence of Indebtedness occurs before the first anniversary of the Issue Date; (ii)

4:50

to 1:00, if such Incurrence of Indebtedness occurs on or after the first anniversary of the Issue Date but before the second anniversary of the Issue Date; (iii)

4:25

to 1:00, if such Incurrence of Indebtedness occurs on or after the second anniversary of the Issue Date but before the third anniversary of the Issue Date and (iv) 3.75 to 1.00, if such Incurrence of Indebtedness occurs on or after the third anniversary of the Issue Date; and

•

The Interest Coverage Ratio for the Issuer and its Restricted Subsidiaries on a consolidated basis is at least 2.25 to 1.00.

On December 18, 2023, the Group issued US$ 253.0 million aggregate principal amount of the 2029 Notes in exchange for US$ 243.4 million aggregate principal amount of 2025 Senior Notes, which were paid upon the Exchange. The Group did not receive any cash proceeds from the issuance of the 2029 Senior Notes. The new senior notes have an interest rate of 10.00% per year, payable semiannually and due on December 18, 2029. Following the closing of the Exchange, US$ 56.6 million aggregate principal amount of 2025 Senior Notes did not accept the exchange and its terms remain unchanged. The transaction costs incurred in relation to the exchange amounted to S/ 62,193 thousand (equivalent to US$ 16,571 thousand) (note 24).

As a result of the aforementioned exchange, since December 18, 2023 (the “Issue Date”), the Group has to comply with the foll

owi

ng covenants when planning to incur new indebtedness:

•

The Net Leverage Ratio for the Issuer and its Restricted Subsidiaries on a consolidated basis is less than (i)

4:75

to 1:00, if such Incurrence of Indebtedness occurs before the first anniversary of the Issue Date; (ii)

4:25

to 1:00, if such Incurrence of Indebtedness occurs on or after the first anniversary of the Issue Date but before the second anniversary of the Issue Date; and (iii) 3.75 to 1.00, if such Incurrence of Indebtedness occurs on or after the second anniversary of the Issue Date; and

•

The Interest Coverage Ratio for the Issuer and its Restricted Subsidiaries on a consolidated basis is at least i) 1.50 to 1.00, if such Incurrence of Indebtedness occurs on or before September 30, 2024; (ii)

1:75

to 1:00, if such Incurrence of Indebtedness occurs on or before September 30, 2025; and (iii) 2.25 to 1.00, if such Incurrence of Indebtedness occurs after September 30, 2025

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

On December 18, 2024, the Group issued US$ 57.8 million aggregate principal amount of the 2029 Notes in exchange for US$ 56.6 million aggregate principal amount of 2025 Senior Notes, which were paid upon. The Group received cash proceeds from the issuance of the 2029 Senior Notes to S/ 11,047 thousand (equivalent to US$ 2,949 thousand). The new senior notes have an interest rate of 10.00% per year, payable semiannually and due on December 18, 2029.The transaction costs incurred in relation to the exchange amounted to S/ 5,595 thousand (equivalent to US$ 1,494 thousand) (note 24).

As of December 31, 2024, the Group is in compliance with the covenants above indicated.

JPMorgan Bank

On April 20, 2022, the Group signed a loan agreement with JPMorgan Chase Bank, S.A. (hereinafter, “JPMorgan”) through the subsidiary Auna Colombia for an amount of S/ 205,628 thousand (equivalent to US$ 55,500 thousand). Such a loan matures in April 2023 and bears interest at the SOFR rate + 400 bps

(1-3

months), 450 bps

(4-6

months), 500 bps

(7-9

months) and 600 bps

(10-12

months).

The loan was used to acquire the shares of Oncomedica S.A. (note 1.C.ii). The transaction costs incurred in relation to the loan amounted to S/ 6,545 thousand (equivalent to US$ 1,709 thousand) and are presented net of debt and amortized using the effective interest rate method.

This agreement has quantitative covenants calculated based on the consolidated financial statements of Auna S.A. and its subsidiaries. On September 30, 2022, the Group signed an addendum with JPMorgan Bank and updated the quantitative covenants. As of December 31, 2022, the Group complies with the quantitative terms of the following covenants:

•

The consolidated leverage ratio is less than (i) 5.50 to 1.00 for the quarter ending September 30, 2022, (ii) 5.00 to 1.00 for the quarter ending December 31, 2022 and (iii) 4.75 to 1.00 for the quarter ending March 31, 2023.

•

The consolidated interest coverage ratio is at least 2.25 to 1.00 for the end of each quarter.

In April 2023, the loan was paid and did not generate penalties.

Banco Santander México, HSBC México, Multiva and Genaro Levinson Marcovich

On September 30, 2022, the Group signed a loan agreement with Banco Santander, HSBC México and Genaro Levinson Marcovich through its subsidiaries Grupo Salud Auna México, S.A. de C.V, Hospital y Clínica OCA, S.A. de C.V. and DRJ Inmuebles, S.A. de C.V. for an amount of S/ 1,338,927 thousand. The loan amounted to S/ 1,338,927 thousand and matured in October 2023, and was used to acquire the shares of Hospital y Clínica OCA, S.A. de C.V., DRJ Inmuebles, S.A. de C.V., Inmuebles JRD 2000, S.A. de C.V. and Tovleja HG, S.A. The transaction costs incurred in relation to the loan amounted to S/ 46,118 thousand and are presented net of debt and amortized using the effective interest rate method.

This agreement had quantitative covenants calculated based on the consolidated financial statements of Auna S.A. and its subsidiaries. As of December 31, 2022, the Group complied with the quantitative terms of the following covenants:

The consolidated leverage ratio is less than (i) 5.00 to 1.00 for the quarter ending December 31, 2022 and (ii) 4.75 to 1.00 for the quarter ending March 31, 2023 and as of the end of each fiscal quarter thereafter.

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

The consolidated interest coverage ratio is at least 2.25 to 1.00 for the end of each quarter.

As of December 31, 2022, the Group was in compliance with the covenants above indicated.

On April 11, 2023, this loan was

pre-paid

by the Group with the resources obtained from the Notes Purchase Agreement. As a result of prepayment, the Group recorded a

write-off

of the remaining debt issuance costs of S/ 19,434 thousand. These expenses are presented in “finance costs” as interest expenses in the consolidated statement of profit or loss and other comprehensive income (note 24).

Notes Purchase Agreement

On April 11, 2023, the Group signed a Notes Purchase Agreement through Auna S.A. and the subsidiary Grupo Salud Auna México, S.A. de C.V. for an amount of S/ 1,920,456 thousand (equivalent to US$ 505,000 thousand). The transaction costs incurred in relation to the loan amounted to S/ 64,370 thousand (equivalent to US$ 17,202 thousand) and are presented net of debt.

The loan was used to pay existing financial debt and reshape the current and

non-current

liabilities.

This agreement has quantitative covenants calculated based on the consolidated financial statements of Auna S.A. and its subsidiaries. As of September 30, 2023, the Group complies with the quantitative terms of the following covenants:

•

The consolidated leverage ratio to be less than (i) 5.25:1.0 as of December 31, 2022, March 31, 2023, June 30, 2023 and September 30, 2023, (ii) 4.75:1.00 as of December 31, 2023, March 31, 2024, June 30, 2024 and September 30, 2024 and (iii) 4.25:1.00 as of December 31, 2024, and as of the end of each fiscal quarter thereafter, in each case calculated for the period of four fiscal quarters ending on each such date.

•

The consolidated interest coverage ratio is at least (i) 1.50:1.0 as of the end of each fiscal quarter of the fiscal year ending on December 31, 2023, (ii) 1.75:1.00 as of the end of each fiscal quarter of the fiscal year ending on December 31, 2024 and (iii) 2.25:1.00 as of the end of each fiscal quarter of the fiscal year ending on December 31, 2025, and as of the end of each fiscal quarter thereafter, in each case calculated for the period of four fiscal quarters ending on each such date.

•

The minimum net worth shall not permit, as of the end of each fiscal quarter, that the total assets minus the total liabilities of any subsidiary of Auna Colombia S.A.S. that is an “institución prestadora de servicios de salud” to be less than 50% of the

paid-in

capital of such subsidiary.

On December 18, 2023, the loan amounting to S/ 1,920,456 thousand and maturing in April 2028 was

pre-paid

by the Group with the resources obtained from the Term Loan. As a result of prepayment, the Group recorded a penalty of S/ 53,285 thousand and recorded a

write-off

of the remaining debt issuance costs of S/ 56,969. These expenses are presented in “finance costs” in the consolidated statement of profit or loss and other comprehensive income (note 24).

F-7

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

Term Loan

On December 18, 2023, the Group signed a Term Loan through Auna S.A. and the subsidiary Grupo Salud Auna México, S.A. de C.V. for an amount of S/ 1,617,116 thousand (equivalent to US$ 250,000 thousand and MXN 5,230,440 thousand). The transaction costs incurred in relation to the loan amounted to S/ 48,837 thousand (equivalent to US$ 12,889 thousand) and are presented net of debt.

The loan was used to pay existing financial debt and reshape the current and

non-current

liabilities.

This agreement has quantitative covenants calculated based on the consolidated financial statements of Auna S.A. and its subsidiaries. As of December 31, 2023, the Group complies with the quantitative terms of the following covenants:

•

The consolidated leverage ratio is less than (i) 4.75:1.00 for the fiscal quarters ending December 31, 2023, March 31, 2024, June 30, 2024 and September 30, 2024, (ii) 4.25:1.00 for the fiscal quarters ending December 31, 2024, March 31, 2025, June 30, 2025 and September 30, 2025, (iii)

3.75

1.00

for the fiscal quarters ending December 31, 2025, March 31, 2026, June 30, 2026 and September 30, 2026 and (iv)

3.25

1.00

for the fiscal quarter ending December 31, 2026 and as of the end of each fiscal quarter thereafter.

•

The consolidated interest coverage ratio is greater than (i) 1.50:1.00 for the fiscal quarters ending December 31, 2023, March 31, 2024, June 30, 2024 and September 30, 2024, (ii) 1.75:1.00 for the fiscal quarters ending December 31, 2024, March 31, 2025, June 30, 2025 and September 30, 2025 and (iii)

2.25

1.00

for the fiscal quarter ending December 31, 2025 and as of the end of each fiscal quarter thereafter.

In March 2024, the Group completed a syndication process for US$ 550 million with the participation of Banco Santander México, HSBC, and Citibank as “Joint Lead Arrangers and Joint Bookrunners” and a group of banks as lenders.

As of December 31, 2024, the Group is in compliance with the covenants above indicated.

Other financing with Scotiabank Perú S.A.A.

This corresponds to a financing agreement with Scotiabank for a credit line of S/ 70 million maturing in February 2027, and which is used for the construction of the ongoing project “Clínica Chiclayo”. In October 2021, the credit line extended to S/ 77 million. As of December 31, 2024, the credit line used net of the transaction cost amounted to S/ 52,804 thousand (S/ 61,694 thousand as of December 31, 2023 and S/ 70,054 thousand as of December 31, 2022). In the month of November 2020, the modifications of compliance with the agreements were approved as indicated below:

•

Maintain a debt service ratio equal to or greater than 1.2x.

•

Maintain a consolidated leverage ratio, defined as the ratio of our net debt / EBITDA, less than or equal to 5.00x between December 1, 2020 and December 1, 2021, 4.5x between December 1, 2021 and December 1, 2022, 4.25x between December 1, 2022 and December 1, 2023 and 3.75x from December 1, 2023 onwards.

•

Maintain an interest coverage ratio equal to or greater than 2.25x from December 1, 2020 onwards.

F-7

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

On June 30, 2021, the Group signed an addendum with Scotiabank replacing the compliance of the covenants aforementioned as indicated below:

•

Maintain a debt service ratio equal to or greater than 1.2x.

As of December 31, 2024, the Group is in compliance with the covenants above indicated.

The Group expects to comply with the quarterly covenants for at least 12 months after the reporting date.

F-7

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

(b)	Reconciliation of movement in liabilities to cash flows arising from financing activities:


In thousands of soles	Financial loan			Deferred income			Lease liabilities			Derivatives premiums payable			Accounts payable related with exchange			Share capital/ premium			Retained earnings (losses)			Translation reserve			Merge reserve			Non- controlling interest			Total
Balance as of January 1, 2024		3,761,582			619			158,045			157,896			21,735			8,820			(366,899	)		140,066			1,626,411			311,281			5,819,556
Changes in cash flows from financing
Proceeds from issuance of common stock in initial public offering, net of issuance costs		—			—			—			—			—			1,267,794			—			—			—			—			1,267,794
Payments of initial public offering costs		—			—			—			—			—			(15,908	)		—			—			—			—			(15,908	)
Proceeds from loans and borrowings		1,239,486			—			—			—			—			—			—			—			—			—			1,239,486
Payment for borrowings from financial obligations		(1,125,622	)		—			—			—			—			—			—			—			—			—			(1,125,622	)
Payment for costs of Extinguishment of debt		—			—			—			—			(16,607	)		—			—			—			—			—			(16,607	)
Payment of lease liabilities		—			—			(45,593	)		—			—			—			—			—			—			—			(45,593	)
Trust funds		—			—			—			—			—			—			—			—			—			—			—
Interest paid		(450,982	)		—			—			—			—			—			—			—			—			—			(450,982	)
Penalty paid for debt prepayment		—			—			—			—			—			—			—			—			—			—			—
Acquisition of non-controlling interest		—			—			—			—			—			—			—			18,909			(1,076,628	)		(159,910	)		(1,217,629	)
Dividends paid		—			—			—			—			—			—			—			—			—			—			—
Payment for derivatives premiums		—			—			—			(50,705	)		—			—			—			—			—			—			(50,705	)

Total changes from financing cash flows		(337,118	)		—			(45,593	)		(50,705	)		(16,607	)		1,251,886			—			18,909			(1,076,628	)		(159,910	)		(415,766	)

Effect of changes in foreign exchange rates		(268,512	)		(48	)		(4,256	)		(4,201	)		—			—			—			(391,745	)		—			—			(668,762	)

Changes arising from obtaining control of new subsidiaries		—			—			—			—			—			—			—			—			—			—			—

Changes in fair value		—			—			—			—			—			—			—			—			—			—			—
Total equity-related other changes		—			—			—			—			—			(34,733	)		93,366			—			125,106			(5,647	)		178,092

Other changes
Assets acquired through new leases		—			—			26,837			—			—			—			—			—			—			—			26,837
Acquisition of derivative with premiums financing		—			—			—			60,957			—			—			—			—			—			—			60,957
Lease contracts cancelled		—			—			—			—			—			—			—			—			—			—			—
Debt exchange		5,595			—			—			—			—			—			—			—			—			—			5,595
Interest expense		459,157			(256	)		12,855			7,451			—			—			—			—			—			—			479,207
Transaction costs related to loans and borrowings		(930	)		—			—			—			—			—			—			—			—			—			(930	)
Unwind of derivative financial instruments net of premiums payable		—			—			—			(85,549	)		—			—			—			—			—			—			(85,549	)

Balance as of December 31, 2024		3,619,774			315			147,888			85,849			5,128			1,225,973			(273,533	)		(232,770	)		674,889			145,724			5,399,237

F-7

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022


In thousands of soles	Financial loan			Deferred income			Lease liabilities			Derivatives premiums payable			Trust funds			Share capital/ premium			Retained earnings (losses)			Merge reserve			Non-controlling interest			Total
Balance as of January 1, 2023		3,348,647			880			162,922			75,375			(96,674	)		622,592			(90,982	)		699,333			493,082			5,215,175
Changes in cash flows from financing
Proceeds from loans and borrowings		4,871,380			—			—			—			—			—			—			—			—			4,871,380
Payment for borrowings from financial obligations		(4,520,827	)		—			—			—			—			—			—			—			—			(4,520,827	)
Payment of lease liabilities		—			—			(42,530	)		—			—			—			—			—			—			(42,530	)
Trust funds		—			—			—			—			94,539			—			—			—			—			94,539
Interest paid		(566,774	)		—			—			—			—			—			—			—			—			(566,774	)
Penalty paid for debt prepayment		(53,285	)		—			—			—			—			—			—			—			—			(53,285	)
Contributions from non-controlling shareholder		—			—			—			—			—			—			—			(1,016	)		1,032			16
Dividends paid		—			—			—			—			—			—			—			—			(6,841	)		(6,841	)
Payment for derivatives premiums		—			—			—			(51,141	)		—			—			—			—			—			(51,141	)

Total changes from financing cash flows		(269,506	)		—			(42,530	)		(51,141	)		94,539			—			—			(1,016	)		(5,809	)		(275,463	)

Effect of changes in foreign exchange rates		81,760			(7	)		6,129			5,237			3,172			—			—			—			—			96,291

Changes arising from obtaining control of new subsidiaries		—			—			—			—			—			—			—			—			—			—

Changes in fair value		—			—			—			—			—			—			—			—			—			—
Total equity-related other changes		—			—			—			—			—			(613,772	)		(275,917	)		928,094			(175,992	)		(137,587	)

Other changes
Assets acquired through new leases		—			—			18,233			—			—			—			—			—			—			18,233
Acquisition of derivative with premiums financing		—			—			—			124,349			—			—			—			—			—			124,349
Lease contracts cancelled		—			—			(174	)		—			—			—			—			—			—			(174	)
Debt exchange		40,581			—			—			—			—			—			—			—			—			40,581
Interest expense		507,198			(254	)		13,465			4,076			(1,037	)		—			—			—			—			523,448
Transaction costs related to loans and borrowings		(383	)		—			—			—			—			—			—			—			—			(383	)
Financial debt prepayment penalty		53,285			—			—			—			—			—			—			—			—			53,285

Balance as of December 31, 2023		3,761,582			619			158,045			157,896			—			8,820			(366,899	)		1,626,411			311,281			5,657,755

F-7

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022


In thousands of soles	Financial loan			Deferred income			Lease liabilities			Derivatives premiums payable			Share capital/ premium		Retained earnings (losses)			Merge reserve			Non- controlling interest			Total
Balance as of January 1, 2022		1,352,444			692			140,583			50,366			622,592		(45,490	)		(79,764	)		50,094			2,091,517
Changes in cash flows from financing
Proceeds from contributions from non-controlling shareholder		—			—			—			—			—		—			960,679			391,931			1,352,610
Proceeds from loans and borrowings		2,287,819			—			—			—			—		—			—			—			2,287,819
Payment for borrowings from financial obligations		(340,113	)		—			—			—			—		—			—			—			(340,113	)
Payment of lease liabilities		—			—			(34,758	)		—			—		—			—			—			(34,758	)
Interest paid		(108,303	)		—			—			—			—		—			—			—			(108,303	)
Penalty paid for debt prepayment		—			—			(9	)		—			—		—			—			—			(9	)
Payment for derivatives premiums		—			—			—			(26,461	)		—		—			—			—			(26,461	)

Total changes from financing cash flows		1,839,403			—			(34,767	)		(26,461	)		—		—			960,679			391,931			3,130,785

Effect of changes in foreign exchange rates		(99,192	)		(128	)		(11,664	)		—			—		—			—			—			(110,984	)

Changes arising from obtaining control of new subsidiaries		62,270			—			21,551			—			—		—			(161,915	)		73,901			(4,193	)

Changes in fair value		(620	)		620			—			—			—		—			—			—			—
Total equity-related other changes		—			—			—			—			—		(95,872	)		(9,216	)		(33,586	)		(138,674	)

Other changes
Assets acquired through new leases		—			—			36,617			—			—		—			—			—			36,617
Acquisition of derivative with premiums financing		—			—			—			49,476			—		—			—			—			49,476
Lease contracts cancelled		—			—			(1,231	)		—			—		—			—			—			(1,231	)
Interest expense		194,363			(304	)		11,824			1,994			—		—			—			—			207,877
Transaction costs related to loans and borrowings		(21	)		—			—			—			—		—			—			—			(21	)
Financial debt prepayment penalty		—			—			9			—			—		—			—			—			9

Balance as of December 31, 2022		3,348,647			880			162,922			75,375			622,592		(141,362	)		709,784			482,340			5,261,178

F-7

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

16.	Trade Accounts Payable

As of December 31, the trade accounts payable of the Group are stated in the following currencies:


In thousands of soles	2024		2023		2022
Soles		300,068		219,546		199,582
U.S. dollars		73,537		62,786		31,217
COP		438,871		408,018		233,627
Euros		—		461		—
MXN		121,530		62,444		48,234

		934,006		753,255		512,660

Current		931,265		749,349		512,587

Non-current		2,741		3,906		73

Trade accounts payable are mainly related to the acquisition of supplies, materials and services for the Group’s performance. These accounts payable have current maturity and do not bear interest and generally have payment terms of 108 days, 78 days and 170 days in the subsidiaries located in Peru, Mexico and Colombia, respectively, including the supplier finance arrangement of the Group.

As of December 31, 2024, 2023 and 2022, they include: (i) medical fees payable by the Peruvian, Colombian and Mexican subsidiaries amounting to S/ 46,364 thousand, S/ 28,652 thousand and S/ 23,840 thousand, respectively, and (ii) contract liabilities related to the advance consideration received from patients for healthcare services, for which revenue is recognized over time amounting to S/ 23,800 thousand, S/ 17,291 thousand and S/ 14,222 thousand, respectively. They are stated in soles, COP and MXN and have current maturity.

Likewise, the Group participates in a supplier finance arrangement under which its suppliers may elect to receive early payment of their invoices from a bank by factoring their receivables from the Group. Under the arrangement, a bank agrees to pay amounts to a participating supplier in respect of invoices owed by the Group and receives settlement from the Group later. The principal purpose of this program is to facilitate efficient payment processing and provide the willing suppliers early payment terms, compared with the related invoice payment due date. The Group has not derecognized the original trade payables relating to the arrangement because neither a legal release was obtained nor was the original liability substantially modified on entering into the arrangement. From the Group’s perspective, the arrangement does not significantly extend payment terms beyond the normal terms agreed with other suppliers that are not participating. All payables under the arrangement are classified as current as at 31 December 2024, 2023 and 2022. As of December 31, 2024, December 31, 2023 and December 31, 2022, the amounts related to supplier factoring facility are S/ 155,887 thousand, S/ 107,996 thousand and S/ 64,789 thousand, respectively. The payments to the bank are included within operating cash flows because they continue to be part of the normal operating cycle of the Group and their principal nature remains operating – i.e., payments for the purchase of goods and services. The payments to a supplier by the bank are considered

non-cash

transactions and amounted to S/ 477,849 thousand, S/ 306,660 thousand and S/ 281,788 thousand at December 31, 2024, December 31, 2023 and December 31, 2022, respectively.

As of December 31, 2024, 2023 and 2022 the

non-current

portion corresponds to payments agreements with suppliers of the Colombian subsidiaries with maturities between 12 and 36 months.

F-7

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

17.	Other Accounts Payable

As of December 31, this caption includes the following:


In thousands of soles	Note		2024		2023		2022
Current
Employee benefits (c)				108,344		120,826		62,960
Taxes payable				100,490		97,323		24,197
Derivatives Fx premiums and accounts payable for “unwind” (b)				30,512		65,377		29,223
Constructions in progress and medical equipment payable				5,150		3,421		3,794
Deposits in guarantee				1,259		1,083		1,942
Commissions payable (a)				3,682		2,755		2,998
Contingent consideration (d)		1.C.iii		—		64,008		69,470
Account payables to former shareholder (d)		1.C.ii, iii		19,832		85,265		—
Other accounts payable (e)				20,294		23,542		21,579

				289,563		463,600		216,163

Non-current
Employee benefits (c)				5,724		6,977		3,957
Derivatives Fx premiums and accounts payable for “unwind” (b)				55,337		92,519		46,152
Put liability		1.C.iii		—		121,636		136,938
Account payables to former shareholder		1.C.ii,iii		12,089		—		90,134

				73,150		221,132		277,181

(a)	Corresponds to the sales commissions payable for the sales of corporate and individual oncologic healthcare plans.

(b)	Derivatives premiums financing

As of December 31, 2024, 2023 and 2022, the balance corresponds to the liabilities payable of the premiums of the “Call Spread and Single Call” agreements with semi-annual equal payments (note 8).


In thousands of soles	Maturity		Currency of origin		Annual nominal interest rate			Current portion		Non-current portion		December 31, 2024
Citibank		2025		S/		1.67	%		2,983		—		2,983
Citibank		2028		S/		1.30	%		102		260		362
Citibank		2026		S/		1.67	%		3,459		3,535		6,994
Citibank		2028		S/		1.30	%		2,490		6,348		8,838
Deutsche Bank		2029		S/		10.88	%		19,058		43,972		63,030
Santander Bank		2026		S/		2.53	%		2,420		1,222		3,642

									30,512		55,337		85,849


In thousands of soles	Maturity		Currency of origin		Annual nominal interest rate			Current portion		Non-current portion		December 31, 2023
Citibank		2025		S/		1.67	%		18,259		18,907		37,166
Citibank		2028		S/		1.30	%		2,493		8,814		11,307
Citibank		2026		S/		1.67	%		3,416		6,983		10,399
Citibank		2028		S/		1.30	%		102		361		463
Citibank		2024		S/		0.72	%		3,460		—		3,460
Santander Bank		2026		S/		2.53	%		37,647		57,454		95,101

									65,377		92,519		157,896

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022


In thousands of soles	Maturity		Currency of origin		Annual nominal interest rate			Current portion		Non-current portion		December 31, 2022
Goldman Sachs Bank		2023		S/		3.52	%		18,198		—		18,198
Citibank		2025		S/		1.67	%		—		35,767		35,767
Citibank		2026		S/		1.67	%		3,413		10,385		13,798

									21,611		46,152		67,763

Accounts payable for novation of the old derivatives.

As of December 31, 2022, the outstanding balance corresponds to the liabilities payable to Goldman Sachs Bank as a consequence of the transfer for novation of the old derivatives call spread and swaps agreements with semi-annual equal payments (note 8).


In thousands of soles	Maturity		Currency of origin		Annual nominal interest rate			Current portion		Non-current portion		December 31, 2022
Goldman Sachs Bank		2023		S/		3.52	%		7,612		—		7,612

									7,612		—		7,612

(c)

Corresponds to compensation and other short-term benefits payable to personnel of S/ 106,762 thousand (S/ 116,395 thousand and S/ 61,657 thousand for December 31, 2023 and 2022, respectively). Also, includes a defined benefit liability of Mexican subsidiaries as of December 31, 2024 amounted to S/ 7,306 thousand (S/ 8,907 thousand and S/ 5,260 thousand for December 31, 2023 and December 31, 2022, respectively). There are no plan assets.

The following table shows a reconciliation from the opening balances to the closing balances for the defined benefit liability and its components:


In thousands of soles	Note	Seniority premium			Retirement benefits		Total
2024
Balances as of January 1, 2024			8,907			—		8,907
Included in profit or loss
Current service cost			736			—		736
Cancellation retirement benefits			—			—		—
Interest cost			680			—		680
Benefits paid			(20	)		—		(20	)

			10,303			—		10,303

Included in OCI
Remeasurement of actuarial loss (gain) arising from:
Experience adjustment			(1,166	)		—		(1,166	)
Financial assumptions			(357	)		—		(357	)
Exchange difference			(1,474	)		—		(1,474	)

			(2,997	)		—		(2,997	)

Balance at December 31, 2024			7,306			—		7,306

Current								1,582

Non-current								5,724

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022


In thousands of soles	Note		Seniority premium			Retirement benefits			Total
2023
Balances as of January 1, 2023				5,030			230			5,260
Business combination balances		1.C.i		248			—			248
Included in profit or loss
Current service cost				472			24			496
Cancellation retirement benefits				—			(292	)		(292	)
Interest cost				478			19			497
Benefits paid				(244	)		—			(244	)

				5,984			(19	)		5,965

Included in OCI
Remeasurement of actuarial loss (gain) arising from:
Experience adjustment				2,122			—			2,122
Financial assumptions				80			—			80
Exchange difference				721			19			740

				2,923			19			2,942

Balance at December 31, 2023				8,907			—			8,907

Current										1,931

Non-current										6,976

2022
Business combination balances		1.C.		4,420			298			4,718
Included in profit or loss
Current service cost				93			5			98
Interest cost				98			5			103
Benefits paid				(22	)		(25	)		(47	)

				169			(15	)		154

Included in OCI
Remeasurement of actuarial loss (gain) arising from:
Experience adjustment				393			(54	)		339
Financial assumptions				95			3			98
Exchange difference				(47	)		(2	)		(49	)

				441			(53	)		388

Balance at December 31, 2022				5,030			230			5,260

Current										1,303

Non-current										3,957

The following were the principal actuarial assumptions at the reporting date (expressed as weighted averages):


In percent	Seniority premium	Retirement benefits
2024
Discount rate	10.50% - 10.70%		—
Salary growth rate	5.00% - 5.50%		—
Rate of increase in minimum wage	5.20% - 4.00%		—
2023
Discount rate	9.10% - 9.35%		—
Salary growth rate	5.00% - 5.50%		—
Rate of increase in minimum wage	5.20% - 4.00%		—

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022


In percent	Seniority premium			Retirement benefits
2022
Discount rate		9.50	%		9.50	%
Salary growth rate		5.00	%		5.00	%
Rate of increase in minimum wage		5.20	%		5.20	%

Reasonably possible changes at the reporting date to one of the relevant actuarial assumptions, holding other assumptions constant, would have affected the defined benefit obligation by the amounts shown below:


In thousands of soles	Seniority premium			Retirement benefits			Total
2024
Discount rate sensitivity analysis
Effect of an increase of 0.50%
Defined Benefit Obligation impact		(110	)		—			(110	)
Current Service Cost impact		(9	)		—			(9	)
Effect of a decrease of 0.50%
Defined Benefit Obligation impact		119			—			119
Current Service Cost impact		11			—			11
Salary increase rate sensitivity analysis
Effect of an increase of 0.50%
Defined Benefit Obligation impact		83			—			83
Current Service Cost impact		12			—			12
Effect of a decrease of 0.50%
Defined Benefit Obligation impact		(49	)		—			(49	)
Current Service Cost impact		6			—			6
2023
Discount rate sensitivity analysis
Effect of an increase of 0.50%
Defined Benefit Obligation impact		(121	)		—			(121	)
Current Service Cost impact		(12	)		—			(12	)
Effect of a decrease of 0.50%
Defined Benefit Obligation impact		131			—			131
Current Service Cost impact		13			—			13
Salary increase rate sensitivity analysis
Effect of an increase of 0.50%
Defined Benefit Obligation impact		87			—			87
Current Service Cost impact		13			—			13
Effect of a decrease of 0.50%
Defined Benefit Obligation impact		(48	)		—			(48	)
Current Service Cost impact		6			—			6
2022
Discount rate sensitivity analysis
Effect of an increase of 0.50%
Defined Benefit Obligation impact		79			3			82
Current Service Cost impact		7			1			8
Effect of a decrease of 0.50%
Defined Benefit Obligation impact		(83	)		(3	)		(86	)
Current Service Cost impact		(7	)		(1	)		(8	)

F-8

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

(d)

As of December 31, 2024, the Group entered into agreements with selling shareholders who had the contingent consideration, generating short and long-term payment commitments; therefore, the “Contingent consideration” was reclassified to “Account payable to former shareholder” for an amount of S/ 17,178 thousand.

(e)	As of December 31, 2024, 2023 and 2022, other accounts payable include collections in favor of Citibank del Perú S.A.A. for S/ 12,962 thousand, S/ 18,399 thousand and S/ 18,800 thousand, respectively, under the factoring contracts signed with the Group’s companies.

18.	Provisions

As of December 31, this caption includes the following:


In thousands of soles	Note		Outstanding claims reserve (i)			Other provisions			Total
As of January 1, 2022				113			8,563			8,676
Annual provision				—			380			380
Paid during the year				—			(2,145	)		(2,145	)
Business combination balances		1.C.ii		—			14,119			14,119
Exchange difference				—			(1,056	)		(1,056	)

As of December 31, 2022				113			19,861			19,974

As of January 1, 2023				113			19,861			19,974
Annual provision				—			1,176			1,176
Paid during the year				(8	)		(4,320	)		(4,328	)
Exchange difference				—			2,252			2,252

As of December 31, 2023				105			18,969			19,074

As of January 1, 2024				105			18,969			19,074
Annual provision				—			1,001			1,001
Paid during the year				(69	)		(5,649	)		(5,718	)
Exchange difference				—			(2,111	)		(2,111	)

As of December 31, 2024				36			12,210			12,246

(i)	Outstanding claims reserve represent the Group’s outstanding third-party obligations and do not include amounts related to the Group’s customers that are part of the insurance premium program.

Outstanding claims reserve

These provisions include unsettled events based on the notices for claims received up to the consolidated financial statements date.

Other provisions

As of December 31, 2024, these include mainly the estimate of provision for present obligation from civil, labor and tax judicial processes amounting to S/ 2,696 thousand of Colombian subsidiaries, S/ 1,795 thousand for the Group’s Peruvian subsidiaries and S/ 7,719 thousand from Mexican subsidiaries.

As of December 31, 2023, these include mainly the estimate of provision for present obligation from civil, labor and tax judicial processes amounting to S/ 3,357 thousand of Colombian subsidiaries, S/ 2,465 thousand for the Group’s Peruvian subsidiaries and S/ 13,147 thousand from Mexican subsidiaries. As of December 31, 2022, they include mainly the estimate of provision for present obligation from civil, labor and tax judicial processes amounting to S/ 3,481 thousand of Colombian subsidiaries, S/ 3,147 thousand for the Group’s Peruvian subsidiaries and S/ 13,987 thousand from Mexican subsidiaries.

F-8

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

19.

Equity

A.	Share capital

As of December 31, 2024, the share capital is represented by 30,052,722 class “A” ordinary shares with a par value of US$ 0.01 each and 43,917,577 class “B” ordinary shares with a par value of US$ 0.10 each. The class A shares and class B shares will be entitled to participate equally in distributions made by the Group, with economic entitlement proportionate to the number of shares held (and not the voting power of a shareholder).

On March 4, 2024, the Extraordinary Shareholders Meeting approved: i) the conversion through a reverse stock split of 241,546,679 ordinary shares held by the existing shareholders of class A and B shares on a

5.5-to-one

ratio into class B shares, ii) to increase the share capital by S/ 7,453 thousand through capitalization from “Merge and other reserves” and iii) to increase the par value of the class “B” shares to a par value of US$ 0.1 each. The reverse stock split conversion is effective from March 4, 2024.

In accordance with Codification of Staff Accounting Bulletins Topic 4: Equity Accounts, section C, this reverse stock split has been recognized by the Group retrospectively for the Basic and diluted earnings per share calculation in the consolidated financial statements (note 25).

On March 21, 2024, the Company completed its initial public offering (the “IPO”) of 30,000,000 shares of our Series A common stock at a price to the public of US$ 12.00 per share and the Company sold 30,000,000 of such shares. As a consequence, the share capital increased by S/ 1,112 thousand and the share premium increased by S/ 1,204,913 thousand and it includes a deduction of S/ 29,957 thousand related to issuance costs previously recorded in “Other assets” as of December 31, 2023 and S/ 31,812 thousand related to issuance costs incurred in 2024. As of December 31, 2024, these issuance costs were reclassified to Share premium.

On August 29, 2024, the Extraordinary Shareholders Meeting approved to increase the share capital by S/ 2 thousand. This amount corresponds to the shares from the Restricted Share Awards 2023 (note 33).

As of December 31, 2024 the share capital structure of the class “B” is as follows:


Range of shareholding percentage	Number of shareholders		Participation percentage
From 0.01 to 0.79		5		2.47
From 0.80 to 2.37		4		9.50
From 2.38 to 9.13		4		29.77
From 9.14 to 58.26		1		58.26

		14		100.00

As of December 31, 2023, the share capital is represented by 241,544,679 class “A” ordinary shares with a par value of US$ 0.01 each. Each share of our common stock represents the same economic interest, except that, as provided in our

by-laws,

each year that dividends are distributed, the class A shares benefit from the right to receive a preferred dividend consisting of 100% of any dividends distributed until we have distributed US$ 1 billion in the aggregate in dividends. The excess dividends that the general shareholders’ meeting decides to distribute will be distributed proportionally to the equity interest held by shareholders in both class “A” and class “B” shares.

On July 6, 2023, the Group redomiciled to Luxembourg by way of a merger where Auna S.A.A. (absorbed entity) transferred all its assets and liabilities to Auna S.A. (surviving entity). As a result of the merger, the share capital and share premiums of Auna S.A.A. amounting to S/ 236,547 thousand and S/ 386,045 thousand, respectively, were derecognized. Furthermore, the share capital and retained losses of Auna S.A. amounting to S/ 8,820 thousand and S/ 2,012 thousand, respectively, were recognized. The difference between balances was allocated in “Merge and other reserves”.

F-8

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

On April 25, 2022, the General Shareholder´s Meeting approved the downstream merger between the Company and its shareholders Enfoca Discovery 1 S.A.C. and Enfoca Discovery Parallel S.A.C. The Company has recognized this merger as a common control transaction and it was recognized at historical cost. This transaction represents only an exchange of equivalent shares between the Company and its aforementioned shareholders, and the effect of this transaction was S/ 50 thousand recognized in equity in merger reserve as a result of the difference between the consideration paid (shares issued) and the capital of the legally disappearing companies. As a result of this merger, the former shareholders Enfoca Discovery 1 S.A.C. and Enfoca Discovery Parallel S.A.C. ceased to exist and the shareholders of these companies received shares in the Company.

B.	Other capital reserves

According to the Companies Act, the Company is required to allocate at least 5% of its annual net income to a legal reserve after deducting accumulated losses. This allocation is required until the reserve equals 10% of

paid-in

capital. The legal reserve can be used to compensate losses in the absence of

non-distributed

earnings or nonrestricted reserves and must be restored with future earnings. This reserve may also be capitalized, but it shall be subsequently restored.

As of December 31, 2024, the Group allocated S/ 13,230 thousand to a legal reserve (as of December 2023 and 2022 the Group allocated S/ 23,468 thousand and 5,074 to a legal reserve, respectively).

C.	Translation reserve

Translation reserve includes all exchange differences resulting from the translation of the financial statements of foreign operations. As of December 31, 2024, 2023 and 2022, the Group recognizes the translation differences of the consolidated financial statements of the subsidiary Auna

Colombia S.A.S.

and Auna México in translation reserve of the consolidated statement of profit or loss and other comprehensive income.

D.	Cost of hedging reserve

The cost of hedging reserve reflects gain or loss on the portion excluded from the designated hedging instrument that relates to the forward element of forward contracts and as well as the time value of purchased collar contracts. It is initially recognized in OCI and accounted for similarly to gains or losses in the hedging reserve.

E.	Hedging reserve

Hedging reserve includes the effective portion of the accumulated net change in the fair value of the hedging instruments used in cash flow hedges with subsequent recognition in profit or loss. This reserve is recognized net of deferred income tax.

F.	Merger and other reserves

In 2022, this account includes “other reserves” of S/ 161,915 thousand as a result of the initial and subsequent recognition of the “put liability” with the

non-controlling

shareholders, in accordance with the SPA of Oncomedica S.A.

On September 28, 2022, the General Shareholder’s Meeting of the subsidiary Auna Salud S.A.C approved an increase in the capital by S/ 1,352,610 thousand through cash contributions received from Heredia Investments S.A.C., an indirect subsidiary of Enfoca Group (ultimate controlling party), as follows: (i) S/ 214,431 thousand to share capital and (ii) S/ 1,138,179 thousand to share premium. This contribution by this

Non-controlling

interest diluted the participation of Auna S.A. in Auna Salud S.A.C. and its controlled subsidiaries from 100% to 78.80%.

On August 31, 2023, a transfer of shares that Auna Salud S.A.C. maintained in Grupo Salud Auna México, S.A. de C.V. was made to transfer them to Auna S.A. This transfer diluted the

Non-controlling

interests held by Auna Salud S.A.C. and its controlled subsidiaries.

F-8

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

On March 21, 2024, the Company, through its subsidiary Auna Salud S.A.C., acquired the

non-controlling

interest of Heredia Investments S.A.C., which held 21.2% of Auna Salud S.A.C., through a capital reduction of S/ 1,217,629 thousand. The Group wrote off the

non-controlling

interest for S/ 159,910 thousand, with the corresponding debit entry in “Merger and other reserves” for S/ 1,076,628 thousand and credit entry in “Translation reserve” for S/ 18,909 thousand.

As of September 30, 2024, the Group has determined that the precedent conditions of the put and call options over the shares owned by the

non-controlling

interest of Oncomédica S.A., agreed in the Share Purchase Agreement signed in the 2022, have not been, and will not be exercised. Therefore, in September 2024, the Group derecognized the put liability for S/ 118,906 thousand, as well as the “merger and other reserves” in equity for S/ 138,251 thousand (which includes S/ 7,099 thousand for the fair value update of the period) and the corresponding translation reserve for

S/ 19,345 thousand.

G.	Non-controlling interests

The following table summarizes the information related to each of the Group´s subsidiaries that has material NCI, before any intra-group eliminations.


In thousands of soles	Clínica Vallesur			Clínica Miraflores			PMLA			Clinica Portoazul			Oncomedica			Total
December 31, 2024
NCI percentage		11.77	%		2.66	%		0.16	%		39.00	%		31.19	%

Net assets		13,764			(10,188	)		762,500			124,354			303,485			1,193,915

Net assets attributable to NCI		1,620			(271	)		1,220			48,498			94,657			145,724

Profit (loss)		8,497			(2,927	)		39,737			(697	)		44,152			88,762
Other Comprehensive Income (OCI)		—			—			(42,500	)		(16,128	)		(37,329	)		(95,957	)

Total comprehensive income		8,497			(2,927	)		(2,763	)		(16,825	)		6,823			(7,195	)

Profit allocated to NCI		1,000			(78	)		64			(272	)		13,771			14,485
OCI allocated to NCI		—			—			(68	)		(6,290	)		(11,643	)		(18,001	)

Total comprehensive income allocated to NCI		1,000			(78	)		(4	)		(6,562	)		2,128			(3,516	)


In thousands of soles	Clínica Vallesur			Clínica Miraflores			PMLA			Clinica Portoazul			Oncomedica			Auna Salud			Total
December 31, 2023
NCI percentage		30.47	%		23.30	%		21.38	%		51.93	%		44.84	%		21.20	%

Net assets		5,268			(7,293	)		611,304			141,179			312,257			(154,070	)		908,645

Net assets attributable to NCI		1,605			(1,699	)		130,704			73,317			140,016			(32,662	)		311,281

Profit (loss)		3,023			(4,782	)		20,519			(2,699	)		43,470			81,566			141,097
Other Comprehensive Income (OCI)		—			—			96,957			27,064			55,867			188,499			368,387

Total comprehensive income		3,023			(4,782	)		117,476			24,365			99,337			270,065			509,484

Profit allocated to NCI		921			(1,114	)		4,387			(1,402	)		19,492			17,293			39,577
OCI allocated to NCI								20,731			14,055			25,051			39,961			99,798

Total comprehensive income allocated to NCI		921			(1,114	)		25,118			12,653			44,543			57,254			139,375

F-8

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022


In thousands of soles	Clínica Vallesur			Clínica Miraflores			PMLA			Clinica Portoazul			Oncomedica			Auna Salud			Total
December 31, 2022
NCI percentage		30.47	%		23.30	%		21.38	%		51.93	%		44.84	%		21.20	%		—

Net assets		2,243			(2,444	)		493,913			116,815			230,063			1,054,425			1,895,015

Net assets attributable to NCI		684			(569	)		105,605			60,664			103,160			223,538			493,082

Profit (loss)		1,149			802			(34,894	)		20,895			38,702			(58,988	)		(32,334	)
Other Comprehensive Income (OCI)		—			—			(111,752	)		(28,666	)		(54,977	)		100,761			(94,633	)

Total comprehensive income		1,149			802			(146,646	)		(7,771	)		(16,275	)		41,774			(126,967	)

Profit allocated to NCI		350			187			(7,461	)		10,851			17,354			(12,505	)		8,776
OCI allocated to NCI		—			—			(23,894	)		(14,887	)		(24,652	)		21,362			(42,071	)

Total comprehensive income allocated to NCI		350			187			(31,355	)		(4,036	)		(7,298	)		8,856			(33,295	)

In 2024, 2023 and 2022, the Group paid dividends to

non-controlling

shareholders for S/ 1,150 thousand, S/ 6,841 thousand and S/ 131 thousand, respectively.

20.

Revenue

A.	Revenue streams

The Group generates revenue primarily from the sale of oncologic healthcare plans and healthcare services to its customers.

This caption includes the following:


In thousands of soles	2024		2023		2022
Revenue from contracts with customers
Healthcare services (i)		3,012,454		2,695,860		1,514,639
Sale of medicines		320,700		265,865		220,905

Total revenue from contracts with customers		3,333,154		2,961,725		1,735,544

Insurance revenue		1,052,958		914,182		716,064

Total revenue		4,386,112		3,875,907		2,451,608

Insurance revenue includes the following:


In thousands of soles	2024		2023		2022
Oncology plans		799,605		723,029		664,971
General healthcare services plans		253,353		191,153		51,093

Total insurance revenue		1,052,958		914,182		716,064

Timing of revenue recognition
Products transferred at a point in time		320,700		265,865		220,905
Products and services transferred over time		3,012,454		2,695,860		1,514,639

Total revenue from contracts with customers		3,333,154		2,961,725		1,735,544

(i)	The amounts reported in the Healthcare services revenue line item do not include revenue recognized for customers that are part of the Company’s insurance premium program.

F-8

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial

Statements

December 31, 2024, 2023 and 2022

B.	Disaggregation of revenue from contracts with customers

This caption includes the following:


In thousands of soles	Oncosalud Peru		Healthcare services segments		Total
For the year ended December 31, 2024
Primary geographical markets
Peru		1,030,432		718,051		1,748,483
Colombia		—		1,443,032		1,443,032
Mexico		—		1,194,597		1,194,597
For the year ended December 31, 2023
Primary geographical markets
Peru		895,507		657,923		1,553,430
Colombia		—		1,192,089		1,192,089
Mexico		—		1,130,388		1,130,388
For the year ended December 31, 2022
Primary geographical markets
Peru		789,093		551,028		1,340,121
Colombia		—		895,366		895,366

C.	Contract balances

The following table provides information about receivables from contracts with customers.


In thousands of soles	Note	2024			2023			2022
Trade accounts receivable	5		962,457			861,336			574,717
Contract liabilities, which are included in “trade accounts payable”	16		(23,780	)		(17,291	)		(14,222	)

The contract assets primarily relate to the Group’s rights to consideration for service completed but not billed at the reporting date. The contract assets are transferred to receivables when the rights become unconditional. This usually occurs when the Group issues an invoice to the customer. There are no contract assets as of December 31, 2024, 2023 and 2022.

The contract liabilities primarily relate to the advance consideration received from patients for healthcare services, for which revenue is recognized over time. This will be recognized as revenue over the next 12 months.

F-8

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

21.	Cost of Sales and Services, Selling Expenses and Administrative Expenses

This caption includes the following:


In thousands of soles	Note	Cost of sales and services						Selling expenses						Administrative expenses						Total
In thousands of soles	Note	2024		2023		2022		2024		2023		2022		2024		2023		2022		2024		2023		2022
Medicines			1,143,359		1,022,220		622,923		—		—		—		—		—		—		1,143,359		1,022,220		622,923
Auxiliary services and clinical laboratory			88,989		70,904		37,346		—		—		—		—		—		—		88,989		70,904		37,346
Room service for inpatients			85,490		48,498		25,395		—		—		—		—		—		—		85,490		48,498		25,395
Surgery fees			205,414		188,816		142,065		—		—		—		—		—		—		205,414		188,816		142,065
Medical consultation fees			89,373		97,796		71,675		—		—		—		—		—		—		89,373		97,796		71,675
Insurance contracts			47,624		41,433		1,929		—		—		—		—		—		—		47,624		41,433		1,929
Personnel expenses (a) (c)			722,950		668,637		482,845		68,332		70,181		60,166		364,298		334,578		188,029		1,155,580		1,073,396		731,040
Services provided by third parties (b) (c)			141,723		147,185		79,189		120,469		118,076		103,656		244,166		206,476		192,598		506,358		471,737		375,443
Depreciation	11, 13		116,907		134,879		92,538		22		13		12		25,944		24,127		14,486		142,873		159,019		107,036
Amortization	12		2,047		2,005		2,329		—		—		—		74,226		74,726		28,726		76,273		76,731		31,055
Other management charges (c)			16,917		18,183		13,643		8,566		5,622		5,924		54,758		42,439		36,290		80,241		66,244		55,857
Tax expenses			26		5		27		86		51		45		25,285		22,219		17,395		25,397		22,275		17,467

			2,660,819		2,440,561		1,571,904		197,475		193,943		169,803		788,677		704,565		477,524		3,646,971		3,339,069		2,219,231

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

(a)	Personnel expenses include the following:


In thousands of soles	2024		2023		2022
Remunerations		733,614		680,560		492,354
Legal bonuses		72,769		71,372		57,491
Health insurance for employees		117,947		104,444		75,419
Bonuses		33,808		42,834		6,916
Severance payments		53,281		49,061		39,316
Vacations		45,703		42,841		36,029
Employees’ profit sharing		36,188		32,817		4,375
Board of Directors’ remuneration		5,781		5,027		4,006
Equity-settled share-based payment expenses		9,145		3,675		—
Compensation to personnel		13,647		9,211		7,004
Training		1,647		1,995		1,290
Other benefits		32,050		29,559		6,840

		1,155,580		1,073,396		731,040

The average worldwide full-time equivalent headcount was 14,804, 14,958 and 9,485, respectively, for the years ended December 31, 2024, 2023 and 2022, respectively.

(b)	Services provided by third parties include the following:


In thousands of soles	2024		2023		2022
Sales commissions		62,268		66,303		56,837
Advisory and consulting fees		74,711		61,647		79,639
Leases		63,741		58,927		30,173
Credit card commissions		31,425		27,569		22,386
Service and repair		73,353		74,805		51,866
Custodial and cleaning services		50,897		38,121		26,141
Advertisement		27,199		24,019		22,344
Utilities		55,571		60,937		34,004
Hosting		18,107		14,925		11,887
Collection expenses		1,697		889		1,516
Travel and entertainment expenses		3,163		3,399		2,373
Others		44,226		40,196		36,277

		506,358		471,737		375,443

(c)	For the years ended December 31, 2024 and 2023, personnel expenses, services provided by third parties and other management charges include the amortization of the account “insurance acquisition cash flows” of S/ 129,973 thousand and S/ 140,438 thousand, respectively (note 32).

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

22.	Other Income

This caption includes the following:


In thousands of soles	2024		2023		2022
Income for parking (a)		5,087		3,807		3,227
Indemnification for claims		1,480		800		1,551
Investment property rentals		16,406		15,759		4,374
Increase in fair value of investment property		161		116		173
Receivable recoveries (b)		7,043		8,893		10,743
Tax recoveries		—		—		20
Other income for derecognition of other accounts payables to former shareholders (d)		46,613		—		—
Other income for reversal of contingent consideration		—		4,095		—
Gain on sale of property, furniture and equipment		118		4,307		111
Debt forgiveness and donations received		—		12		—
Others (c)		10,678		12,324		1,459

		87,586		50,113		21,658

(a)	Corresponds to the administration, parking and valet parking services provided by the clinics. Income for parking is recognized once the service has been rendered.

(b)	Mainly corresponds to recoveries of receivables that were expected as uncollectable at the acquisition date of Oncomedica S.A.

(c)	Mainly corresponds to income from food services (cafeteria), income from teaching services and other miscellaneous income of the Mexican Component.

(d)

This caption includes S/ 46,613 thousand for the derecognition of a portion of other account payables to former shareholders of Hospital y Clínica OCA, S.A. de C.V. (OCA). These other account payable corresponds to the Holdback at the acquisition of OCA to compensate to Group for any subsequent indemnification (note 17).

The movement of account payables to former shareholders is the following:


In thousands of soles	Note		2024			2023
Balances as of January 1,				85,265			90,134
Interest expense				4,896			4,290
Payments				(30,011	)		(1,368	)
Reversal				(46,613	)		—
Hospital y Clínica OCA’s purchase price adjustment (*)				—			(8,193	)
Transfer from Contingent consideration		17(d)		17,178			—
Acquired through business combination				—			1,347
Exchange difference				1,206			(945	)

Balances as of December 31				31,921			85,265

(*)	In June 2023, the Group adjusted the purchase price of the acquisition of Hospital y Clínica OCA performed in October 2022 in accordance with the acquisition Share Purchase Agreement for S/ 8,193 thousand.

F-

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

23.	Other Expenses


In thousands of soles	Note		2024		2023		2022
Changes in contingent consideration		24.d		—		20,927		—
Derecognition of other assets				2,112		—		—
Loss on disposal of intangibles				—		—		1,028

				2,112		20,927		1,028

24.	Net Finance Costs

This caption includes the following:


In thousands of soles	2024		2023		2022
Finance income
Interest income under the effective interest		328		186		150
Cash flow hedges settlement - Swaps		3,285		—		—
Interest on term deposits		12,399		8,747		6,734
Exchange difference (a)		—		75,852		—
Interest income on other investments		8,358		8,030		—
Others		440		163		26

		24,810		92,978		6,910


In thousands of soles	Note	2024		2023		2022
Finance cost
Financial liabilities measured at amortized cost – interest expense (c)			471,248		522,258		196,673
Interest from leases liabilities			12,855		13,465		11,824
Exchange difference (a)			41,709		—		57,771
Cash flow hedges - reclassified from OCI for costs of hedging reserve			34,482		86,135		28,097
Change in fair value of contingent consideration (d)			2,492		2,011		6,692
Financial assets at FVTPL – net change in fair value: Derivate assets mandatorily measured at FVTPL			7,714		9,813		4,377
Extinguishment of debt	15.a		5,595		62,193		—
Financial debt prepayment penalty	15.a		—		53,285		9
Unwind of derivative financial instruments measured at FVOCI			7,550		—		—
Cash flow hedges settlement - Swaps			3,781		—		—
Others (b)			46,167		34,622		7,258

			633,593		783,782		312,701

(a)	In 2024, the net exchange difference includes an effect for S/ 9,249 thousand (S/ 32,100 thousand and S/ 53,400 thousand in 2023 and 2022, respectively) for the cash flow hedges reclassified from OCI (note 8.A).

(b)	For years 2024, 2023 and 2022, this includes mainly cost of factoring for S/ 19,132 thousand, S/ 14,465 thousand and S/ 5,191 thousand, respectively.

(c)	For years 2024, 2023 and 2022, this includes S/ 256 thousand, S/ 339 thousand and S/ 304 thousand related to government grants of interest expenses (note 3.O), respectively.

(d)	The movement of contingent consideration is the following:

F-9

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022


In thousands of soles	2024			2023			2022
Balances as of January 1,		64,008			69,470			848
Acquired through business combination		—			—			79,461
Reversal		—			(4,095	)		—
Change in fair value of contingent consideration		2,492			2,011			6,692
Payment of contingent consideration		(47,174	)		(36,143	)		(397	)
Transfer to Account payables to former shareholder, Note 17 (d)		(17,178	)		—			—
Change in fair value of contingent consideration		—			20,927			—
Exchange difference		(2,148	)		11,838			(17,134	)

Balances as of December 31		—			64,008			69,470

25.	Earnings per Share

The earnings per ordinary share were determined based on the net profit attributable to shareholders of the Group and weighted-average number of shares outstanding as follows:


In thousands of soles	2024		2023			2022
Net profit (loss) for the year attributable to owners of the Company		110,271		(253,921	)		(85,606	)
Number of shares		73,970,299		43,917,577			43,917,577
Weighted average number of ordinary shares at December 31 (Basic)		67,330,955		43,917,577			43,917,577
Weighted average number of ordinary shares at December 31 (Diluted)		67,500,074		43,917,577			43,917,577
Basic earnings per share		1.64		(5.78	)		(1.95	)

Diluted earnings per share		1.63		(5.78	)		(1.95	)

As of December 31, 2024, 3,261 options were excluded from the diluted weighted-average number of ordinary shared calculation because their effect would have been anti-dilutive. The average market value of the Company’s shares for the purpose of calculating the dilutive effect of share options was based on quoted market prices for the year during which the options were outstanding.

As of December 31, 2023 and 2022, the earnings per ordinary share were determined based on the net profit attributable to owners of the Company and the weighted-average number of shares of class B outstanding. The Group did not have dilutive potential ordinary shares as of December 31, 2023 and 2022.

There have been no other transactions involving common shares and investment shares between the reporting date and the date of the authorization of these consolidated financial statements.

F-9

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

26.	Operating Segments

A.	Basis for segmentation

The Group has determined four reportable segments. These operating segments are components of a company about which separate financial information is available that is regularly evaluated by the Board of Directors (Chief operating decision maker) in deciding how to allocate resources and assess performance.

The following summary describes the operations of each reportable segment.


Reportable segments		Operations
Oncosalud Peru		Including our prepaid oncologic healthcare plans and healthcare services related to the treatment of cancer.

Healthcare services in Peru		Corresponds to medical services within the network of clinics and health centers in Peru.

Healthcare services in Colombia		Corresponds to medical services within the network of clinics and health centers in Colombia.

Healthcare services in Mexico		Corresponds to medical services within the network of clinics and health centers, and the insurance business in Mexico.

F-9

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

B.	Information about reportable segments

Information related to each reportable segment is set out below. Segment profit (loss) before tax is used to measure performance because the chief operating decision maker believes that this information is the most relevant for the Group.


	Reportable segments
In thousands of soles	Oncosalud Peru			Healthcare services in Peru			Healthcare services in Colombia			Healthcare services in Mexico			Total reportable segments			Holding and eliminations			Total
2024
External revenues		1,030,432			718,051			1,443,032			1,194,597			4,386,112			—			4,386,112
Inter-segment revenue (i)		40,188			277,701			—			—			317,889			(317,889	)		—

Segment revenue		1,070,620			995,752			1,443,032			1,194,597			4,704,001			(317,889	)		4,386,112

External cost of service		(307,047	)		(671,370	)		(1,040,646	)		(641,756	)		(2,660,819	)		—			(2,660,819	)
Inter-segment cost of service (i)		(279,344	)		(36,596	)		—			—			(315,940	)		315,940			—

Segment cost of service		(586,391	)		(707,966	)		(1,040,646	)		(641,756	)		(2,976,759	)		315,940			(2,660,819	)

Gross profit		484,229			287,786			402,386			552,841			1,727,242			(1,949	)		1,725,293

External selling expenses		(159,619	)		(19,552	)		(5,689	)		(11,948	)		(196,808	)		(667	)		(197,475	)

Segment selling expenses		(159,619	)		(19,552	)		(5,689	)		(11,948	)		(196,808	)		(667	)		(197,475	)

External administrative expenses		(78,596	)		(107,736	)		(197,887	)		(249,202	)		(633,421	)		—			(633,421	)
Inter-segment administrative expenses		(369	)		(5,593	)		—			—			(5,962	)		5,962			—
Corporate expenses		(64,885	)		(63,407	)		(11,542	)		(6,567	)		(146,401	)		(8,855	)		(155,256	)

Segment administrative expenses		(143,850	)		(176,736	)		(209,429	)		(255,769	)		(785,784	)		(2,893	)		(788,677	)

Impairment losses on trade receivables		(511	)		(7,914	)		(28,397	)		(3,987	)		(40,809	)		(46	)		(40,855	)

Other expenses		—			—			—			—			—			(2,112	)		(2,112	)

Other income		3,196			7,386			9,438			68,818			88,838			(1,252	)		87,586
Inter-segment other income		10,859			948			—			—			11,807			(11,807	)		—

Other income		14,055			8,334			9,438			68,818			100,645			(13,059	)		87,586

Segment operating profit (loss)		194,304			91,918			168,309			349,955			804,486			(20,726	)		783,760

Share of profit of equity accounted investees, net of taxes		3,305			—			5,495			—			8,800			—			8,800
Exchange difference, net		(1,710	)		(1,189	)		(67,555	)		(20,823	)		(91,277	)		49,568			(41,709	)
Interest expense, net		(30,833	)		(46,346	)		(108,301	)		(264,340	)		(449,820	)		(117,254	)		(567,074	)

Segment profit (loss) before tax		165,066			44,383			(2,052	)		64,792			272,189			(88,412	)		183,777

Other disclosures
Depreciation and amortization		(32,651	)		(42,818	)		(42,404	)		(92,070	)		(209,943	)		(9,203	)		(219,146	)
Capital expenditure		(31,974	)		(45,180	)		(43,614	)		(36,436	)		(157,204	)		(21,530	)		(178,734	)

Segment assets		2,260,833			1,034,399			2,299,375			3,079,407			8,674,014			(1,593,294	)		7,080,720

Segment liabilities		1,105,230			663,499			1,359,899			1,881,392			5,010,020			447,760			5,457,780

F-9

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022


	Reportable segments
In thousands of soles	Oncosalud Peru			Healthcare services in Peru			Healthcare services in Colombia			Healthcare services in Mexico			Total reportable segments			Holding and eliminations			Total
2023
External revenues		895,507			657,923			1,192,089			1,130,388			3,875,907			—			3,875,907
Inter-segment revenue (i)		36,173			225,966			—			—			262,139			(262,139	)		—

Segment revenue		931,680			883,889			1,192,089			1,130,388			4,138,046			(262,139	)		3,875,907

External cost of service		(277,611	)		(645,375	)		(853,887	)		(663,688	)		(2,440,561	)		—			(2,440,561	)
Inter-segment cost of service (i)		(225,196	)		(34,297	)		—			—			(259,493	)		259,493			—

Segment cost of service		(502,807	)		(679,672	)		(853,887	)		(663,688	)		(2,700,054	)		259,493			(2,440,561	)

Gross profit		428,873			204,217			338,202			466,700			1,437,992			(2,646	)		1,435,346

External selling expenses		(163,299	)		(18,065	)		(6,313	)		(5,518	)		(193,195	)		(748	)		(193,943	)

Segment selling expenses		(163,299	)		(18,065	)		(6,313	)		(5,518	)		(193,195	)		(748	)		(193,943	)

External administrative expenses		(72,532	)		(94,553	)		(176,915	)		(211,816	)		(555,816	)		—			(555,816	)
Inter-segment administrative expenses		(908	)		(4,658	)		—			—			(5,566	)		5,566			—
Corporate expenses		(63,867	)		(60,072	)		(11,810	)		(8,772	)		(144,521	)		(4,228	)		(148,749	)

Segment administrative expenses		(137,307	)		(159,283	)		(188,725	)		(220,588	)		(705,903	)		1,338			(704,565	)

Impairment losses on trade receivables		(355	)		142			(6,352	)		1,097			(5,468	)		(216	)		(5,684	)

Other expenses		(4,479	)		—			(20,302	)		—			(24,781	)		3,854			(20,927	)

Other income		1,388			8,384			16,223			26,157			52,152			(2,039	)		50,113
Inter-segment other income		11,001			966			—			—			11,967			(11,967	)		—

Other income		12,389			9,350			16,223			26,157			64,119			(14,006	)		50,113

Segment operating profit (loss)		135,822			36,361			132,733			267,848			572,764			(12,424	)		560,340

Share of profit of equity accounted investees, net of taxes		2,227			—			4,063			—			6,290			—			6,290
Exchange difference, net		(5,741	)		(1,783	)		119,884			74,020			186,380			(110,528	)		75,852
Interest expense, net		(24,909	)		(45,770	)		(109,508	)		(385,597	)		(565,784	)		(200,872	)		(766,656	)

Segment profit (loss) before tax		107,399			(11,192	)		147,172			(43,729	)		199,650			(323,824	)		(124,174	)

Other disclosures
Depreciation and amortization		(31,968	)		(38,997	)		(40,226	)		(115,650	)		(226,841	)		(8,909	)		(235,750	)
Capital expenditure		(26,385	)		(27,256	)		(81,965	)		(49,023	)		(184,629	)		(15,262	)		(199,891	)

Segment assets		2,146,867			889,286			2,435,123			3,763,000			9,234,276			(1,544,724	)		7,689,552

Segment liabilities		1,101,354			565,754			1,514,739			2,343,238			5,525,085			387,901			5,912,986

F-9

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022


	Reportable segments
In thousands of soles	Oncosalud Peru			Healthcare services in Peru			Healthcare services in Colombia			Healthcare services in Mexico			Total reportable segments			Holding and eliminations			Total
2022
External revenues		789,093			551,028			895,366			216,121			2,451,608			—			2,451,608
Inter-segment revenue (i)		26,031			179,303			—			—			205,334			(205,334	)		—

Segment revenue		815,124			730,331			895,366			216,121			2,656,942			(205,334	)		2,451,608

External cost of service		(240,855	)		(553,885	)		(620,407	)		(156,757	)		(1,571,904	)		—			(1,571,904	)
Inter-segment cost of service (i)		(178,882	)		(24,409	)		—			—			(203,291	)		203,291			—

Segment cost of service		(419,737	)		(578,294	)		(620,407	)		(156,757	)		(1,775,195	)		203,291			(1,571,904	)

Gross profit		395,387			152,037			274,959			59,364			881,747			(2,043	)		879,704

External selling expenses		(146,016	)		(15,881	)		(5,741	)		(718	)		(168,356	)		(1,447	)		(169,803	)

Segment selling expenses		(146,016	)		(15,881	)		(5,741	)		(718	)		(168,356	)		(1,447	)		(169,803	)

External administrative expenses		(69,159	)		(76,153	)		(153,137	)		(46,193	)		(344,642	)		—			(344,642	)
Inter-segment administrative expenses		(228	)		(2,586	)		—			—			(2,814	)		2,814			—
Corporate expenses		(79,570	)		(52,910	)		(5,895	)		—			(138,375	)		5,493			(132,882	)

Segment administrative expenses		(148,957	)		(131,649	)		(159,032	)		(46,193	)		(485,831	)		8,307			(477,524	)

Impairment losses on trade receivables		2,359			4,097			(4,744	)		(132	)		1,580			—			1,580

Other expenses		—			—			—			—			—			(1,028	)		(1,028	)

Other income		(360	)		3,663			15,318			1,909			20,530			1,128			21,658
Inter-segment other income		9,393			764			—			—			10,157			(10,157	)		—

Other income		9,033			4,427			15,318			1,909			30,687			(9,029	)		21,658

Segment operating profit (loss)		111,806			13,031			120,760			14,230			259,827			(5,240	)		254,587

Share of profit of equity accounted investees, net of taxes		1,559			—			2,198			—			3,757			—			3,757
Exchange difference, net		(3,863	)		778			(131,039	)		(1,651	)		(135,775	)		78,004			(57,771	)
Interest expense, net		(40,733	)		(25,619	)		(62,142	)		(63,021	)		(191,515	)		(56,505	)		(248,020	)

Segment profit (loss) before tax		68,769			(11,810	)		(70,223	)		(50,442	)		(63,706	)		16,259			(47,447	)

Other disclosures
Depreciation and amortization		(25,375	)		(38,835	)		(27,816	)		(37,698	)		(129,724	)		(8,367	)		(138,091	)
Capital expenditure		(43,702	)		(38,342	)		(82,128	)		(2,988	)		(167,160	)		(7,423	)		(174,583	)

Segment assets		1,943,792			815,574			1,805,816			3,289,686			7,854,868			(1,261,205	)		6,593,663

Segment liabilities		952,240			525,271			1,311,333			2,009,673			4,798,517			237,085			5,035,602

F-9

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

(i)

Inter-segment cost of service (claims expense) from the Oncosalud Peru segment and intersegment revenue from our Healthcare Services in Peru segment are presented on a gross basis by adding the corresponding profit margin markup by our Healthcare Services in Peru segment and vice versa. Likewise, our Oncosalud Peru segment consolidates Oncocenter Perú S.A.C., a subsidiary providing healthcare services related to the exclusive treatment of cancer. In the separate financial statements of Oncocenter Perú S.A.C., the revenue mainly consists of the insurance claims expense recorded as cost of sales in the separate financial statements of Oncosalud S.A.C., our insurance subsidiary that is also consolidated in Oncosalud Peru segment. In the segment consolidation process, the related revenues from such healthcare services are eliminated with the corresponding claims expense of our insurance subsidiary Oncosalud S.A.C., while the external cost (third parties) of services incurred by Oncocenter Perú S.A.C. remains.

C.	Geographic information

The geographic information analyzes the Group’s revenue and

non-current

assets by the country where it operates. In presenting the geographic information, segment revenue has been based on the geographic location of customers and segment assets were based on the geographic location of the assets.


In thousands of soles	2024		2023		2022
Revenue
Peru		1,748,483		1,553,430		1,340,121
Colombia		1,443,032		1,192,089		895,366
México		1,194,597		1,130,388		216,121

		4,386,112		3,875,907		2,451,608

Non-current assets (*)
Peru		908,301		871,520		929,840
Colombia		1,432,141		1,601,604		1,274,891
México		2,784,380		3,418,414		3,058,082

		5,124,822		5,891,538		5,262,813

(*)	Non-current assets exclude deferred tax assets and derivatives.

D.	Major customer

None of the revenue derives from transactions carried out with a single customer or counterparty which is equal to or greater than

percent or more of the total revenue of the Group for the years ended December 31, 2024, 2023 and 2022.

27.	Tax Matters

Tax regime applicable to income tax

A.	Income tax is determined on a separate basis; it is not consolidated. According to Peruvian, Colombian, Mexican and Luxembourg current legal legislations, the income tax is paid based on the statutory financial statements and tax losses, additions, and deductions established.

Tax rates

B.	The Group is subject to Peruvian, Colombian, Mexican and Luxembourg Tax Regimes as of December 31, 2024, 2023 and 2022.

The current income tax rates are 29.5% in Peru, 30% in Mexico, 35% in Colombia and 24.9% in Luxembourg, calculated based on the taxable income. The income tax rate applicable to Colombian legal entities was 35% for the year 2022 onwards. As a consequence, deferred tax assets and liabilities on temporary differences from Colombia entities that reversed during those years were measured at such corresponding rates.

F-9

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

Income tax determination

C.	The Group computed its taxable income for the years ended December 31, 2024, 2023 and 2022, and determined current income tax for S/ 202,526 thousand, S/ 161,066 thousand and S/ 56,761 thousand, respectively.

Income tax expense includes:


In thousands of soles	Note		2024			2023			2022
Current				202,526			161,066			56,761
Deferred		14		(142,707	)		(70,896	)		(27,378	)

Income tax				59,819			90,170			29,383

Reconciliation of the income tax effective rate to the tax rate is presented as follows:


In thousands of soles	2024					2023					2022
Profit (loss) before income tax		183,777		100.00	%		(124,174	)	100.00	%		(47,447	)	100.00	%

Tax using the Company’s domestic tax rate (a)		45,760		24.90	%		(30,919	)	24.90	%		(13,997	)	29.50	%
Effect of tax rates of a subsidiary abroad		12,504		23.06	%		(5,095	)	4.10	%		(6,909	)	14.56	%
Non deductible expenses		3,318		(10.66	%)		34,429		(27.73	%)		13,960		(29.42	%)
Tax losses for which deferred tax asset was not recognized		12,110		6.59	%		63,234		(50.92	%)		21,727		(45.79	%)
Derecognition of previously recognized deductible temporary differences		—		—			8,411		(6.77	%)		15,241		(32.12	%)
Recognition of previously unrecognized tax losses		(32,362	)	(43.36	%)		—		—			—		—
Changes in tax rate (Colombia)		116		0.06	%		11,815		(9.51	%)		—		—
Annual adjustment for inflation		4,106		5.75	%		7,432		(5.98	%)		8,244		(17.38	%)
Changes in estimates related to prior years		14,267		26.21	%		863		(0.70	%)		(8,883	)	18.72	%

Income tax		59,819		32.55	%		90,170		(72.62	%)		29,383		(61.93	%)

Tax losses carried forward

D.	The Group has recognized a deferred income tax asset related to the tax-loss carryforward of those subsidiaries where it is more likely than not that the tax-loss carryforward can be used to compensate future taxable net income.

As of December 31, 2024, the Group recognized deferred net tax assets for S/ 270,520 thousand (S/ 210,073 thousand and S/ 157,569 thousand as of December 31, 2023 and 2022, respectively) related to tax losses carried forward of the Group.

Deferred tax assets recognized for tax losses expire as follows:


In thousands of soles	2024		Expiration date		2023		Expiration date		2022		Expiration date
Expire		168,865		2025-2036		99,089		2024-2035		47,128		2023-2034
Never expire		101,655		—		110,984		—		110,441		—

Income tax		270,520				210,073				157,569

F-

100

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

According to the Income Tax Act, as amended, the entities established in Peru can choose one of the following two methods to carry forward their tax losses:

(i)

The tax loss may be offset with future income until it is extinguished, applying said loss up to 50 percent of the taxable income per year, or

(ii)

The tax loss may be used until four years after it has been generated.

According to the Income Tax Act, as amended, the entities established in Colombia can use the following method to carry forward their tax losses:

(i)

Tax losses established until 2016 do not expire, while tax losses generated as of 2017 can be carried forward for 11 years.

According to the Income Tax Act, as amended, the entities established in Mexico can use the following method to carry forward their tax losses:

(ii)

Tax losses generated can be carried forward for 10 years.

According to the Income Tax Act, as amended, the entities established in Luxembourg use the following method to carry forward their tax losses:

(iii)

Tax losses generated can be carried forward for 17 years.

Unrecognized deferred tax assets

E.	Deferred tax assets for certain subsidiaries have not been recognized in respect of the following item, because it is not probable that future taxable profit will be available against which the Group can use the benefits therefrom.


	2024				2023				2022
In thousands of soles	Gross amount		Tax effect		Gross amount		Tax effect		Gross amount		Tax effect
Tax losses		41,051		12,110		214,354		63,234		73,650		21,727

		41,051		12,110		214,354		63,234		73,650		21,727

Temporary tax on net assets

The Group is subject to the Temporary Tax on Net Assets (ITAN, from its Spanish acronym) in Peru. The taxable base is the prior period adjusted net asset value less depreciation and amortization, admitted by the Income Tax Law. The ITAN rate is

0.4

% for 2022 and 2024 applied to the amount of net assets that exceed S/

1,000,000

. It may be paid in cash or in nine consecutive monthly installments. The amount paid may be used as a credit against payments of the general income tax regime for taxable periods from March to December of the fiscal period for which the tax was paid until maturity. As of December 31, 2024, the Group recognized S/ 13,103 thousand in Other assets (S/ 12,365 thousand and S/ 10,033 thousand as of December 31, 2023 and 2022, respectively).

F-

101

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

Transfer pricing

For the purpose of determining the Income Tax, the transfer prices of transactions with related parties and with companies domiciled in countries or territories that are noncooperating or low or zero tax countries or territories, or with entities or permanent establishments whose income, revenues or gains from said contracts are subject to a preferential tax regime, must be supported by documented information on the valuation methods used and the criteria considered for their determination. On the basis of the analysis of the operations of the Group’s subsidiaries, Management and its internal legal advisors believe that, as a consequence of the application of these standards, contingencies of the subsidiaries domiciled in Peru, Colombia, Mexico and Luxembourg will not arise as of December 31, 2024, 2023 and 2022.

Review of tax administration

The Peruvian and Colombian tax authorities are entitled to audit and, if applicable, to correct the income tax calculated by the Group’s entities within the four years following the year of the tax return filing. The Group’s income tax returns for the years 2018 through 2022 are open for review by the Peruvian and Colombian tax authority. The Mexican and Luxembourg tax authorities are entitled to audit and, if applicable, to correct the income tax calculated by the Group’s entities within the five years following the year of the tax return filing. The income tax returns for the years 2017 through 2022 are open for review by the Mexican and Luxembourg tax authorities.

I.	The Group’s sales tax returns are open for review by the Peruvian, Colombian, Mexican and Luxembourg tax authorities, in the same years indicated in the previous paragraph.

Value Added Tax (VAT)

J.	For Peruvian, Colombian, Mexican and Luxembourg companies, the value added tax (VAT) is 18%, 19%, 16% and 17%, respectively.

Uncertainty over income tax treatments

K.	The Group believes that its accrual for tax liabilities is adequate for all open tax years based on its assessment of many factors, including interpretations of tax law and prior experience.

Pillar Two

In Luxembourg, the Parliament adopted the bill of law 8292 implementing Council Directive (EU) 2022/2523 dated December 14, 2022 on ensuring a global minimum level of taxation for multinational enterprise groups and large-scale domestic groups in the EU, commonly known as Pillar Two, on December 20, 2023 and the law was published in the official gazette on December 22, 2023, therefore Lux Pillar Two is only effective as of January 1, 2024 and it has not been enacted in Peru, Colombia nor Mexico.

Management has analyzed the potential exposure of the Group to the Pillar Two, concluding that there is not any impact on the Group’s consolidated financial statements as of and for the year ended December 31, 2024 and Management also expects no significant impacts of Pillar Two in the coming years basically due to the following:

•

As of December 31, 2024, the consolidated Group’s revenue did not exceed EUR 750 million in at least two out of the last four years.

•

Management has no expectation to obtain an effective tax rate of 15% or less in Peru, Colombia or Mexico in the coming years.

F-

102

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

28.	Group Structure

The following table shows the companies that are part of the Group as of December 31, 2024, 2023 and 2022. All subsidiaries have been included in the consolidation:


In thousands of soles	Country of incorporation and operations		Percentage of common shares held by the Group (%)						Percentage of common shares held by the non-controlling interest
In thousands of soles	Country of incorporation and operations		2024		2023		2022		2024		2023		2022
Operating companies
Oncosalud S.A.C. (a)		Peru		99.99		78.79		78.79		0.01		21.21		21.21
Oncocenter Perú S.A.C. (b)		Peru		99.99		78.79		78.79		0.01		21.21		21.21
Servimédicos S.A.C. (b)		Peru		99.99		78.79		78.79		0.01		21.21		21.21
Clínica Bellavista S.A.C. (b)		Peru		99.99		78.79		78.79		0.01		21.21		21.21
Laboratorio Clínica Inmunológico Cantella S.A.C. (b)		Peru		99.99		78.79		78.79		0.01		21.21		21.21
Clínica Miraflores S.A. (b)		Peru		97.34		76.70		76.70		2.66		23.30		23.30
R&R Patólogos Asociados S.A.C. (b)		Peru		99.80		78.64		78.64		0.20		21.36		21.36
Clínica Vallesur S.A. (b)		Peru		88.23		69.53		69.53		11.77		30.47		30.47
GSP Trujillo S.A.C. (Clínica Camino Real) (b)		Peru		99.99		78.79		78.79		0.01		21.21		21.21
Medicser S.A.C. (Clínica Delgado) (b)		Peru		99.99		78.79		78.79		0.01		21.21		21.21
Patología Oncológica S.A.C. (b)		Peru		100.00		78.80		78.80		—		21.20		21.20
Oncogenomics S.A.C. (b)		Peru		100.00		78.80		78.80		—		21.20		21.20
Hospital y Clínica OCA S.A. de C.V. (a)		Mexico		100.00		100.00		78.80		—		—		21.20
DRJ Inmuebles, S.A. de C.V. (d)		Mexico		100.00		100.00		78.80		—		—		21.20
Inmuebles JRD 2000, S.A. de C.V. (d)		Mexico		100.00		100.00		78.80		—		—		21.20
Tovleja HG, S.A. (d)		Mexico		100.00		100.00		78.80		—		—		21.20
Dentegra Seguros Dentales, S.A.		Mexico		100.00		100.00		—		—		—		—
Oncomedica S.A. (a)		Colombia		68.81		55.16		55.16		31.19		44.84		44.84
Imat S.A.S. (a)		Colombia		68.81		55.16		55.16		31.19		44.84		44.84
Clínica Portoazul S.A. (b)		Colombia		61.00		48.07		48.07		39.00		51.93		51.93
Promotora Médica Las Américas S.A. (b)		Colombia		99.84		78.62		78.62		0.16		21.38		21.38
Laboratorio Médico Las Américas Ltda. (b)		Colombia		—		—		78.62		—		—		21.38
Instituto de Cancerología S.A. (a)		Colombia		99.84		78.62		78.62		0.16		21.38		21.38
Pre-operating companies
Consorcio Trecca S.A.C. (b)		Peru		99.99		99.99		99.99		0.01		0.01		0.01
Las Américas Farma Store S.A.S. (b)		Colombia		99.84		78.62		78.62		0.16		21.38		21.38
Cardio Imat S.A. (b)		Colombia		—		—		55.16		—		—		44.84
Intensivos Imat S.A. (b)		Colombia		—		—		55.16		—		—		44.84
Sociedad Radio-Oncológica de Montería S.A. (b)		Colombia		68.81		55.16		55.16		31.19		44.84		44.84
Non-operating companies
Inversiones Mercurio S.A.C. (b)		Peru		97.34		76.70		76.70		2.66		23.30		23.30
Holdings companies
Grupo Salud Auna México, S.A. de C.V. (c)		Mexico		100.00		100.00		78.80		—		—		21.20
Auna Colombia S.A.S. (c)		Colombia		100.00		78.80		78.80		—		21.20		21.20
Auna Salud S.A.C. (c)		Peru		99.99		78.80		78.80		0.01		21.20		21.20
GSP Inversiones S.A.C. (c)		Peru		99.99		78.79		78.79		0.01		0.01		0.01
Operador Estratégico S.A.C. (c)		Peru		99.99		99.99		99.99		0.01		0.01		0.01
Other subsidiaries
GSP Servicios Generales S.A.C. (d)		Peru		99.99		78.79		78.79		0.01		21.21		21.21
GSP Servicios Comerciales S.A.C. (d)		Peru		99.99		78.79		78.79		0.01		21.21		21.21
Pro Med Las Américas LLC (d)		USA		99.84		78.62		78.62		0.16		21.38		21.38

(a)	Mainly dedicated to providing oncologic healthcare services.

(b)	Mainly dedicated to providing services through health centers (inpatients and outpatients).

F-10

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

(c)	Holdings of the Group. Auna Colombia is a holding located in the Republic of Colombia and Grupo Salud Auna México, S.A. de C.V. is a holding located in the Republic of Mexico.

(d)	Mainly dedicated to providing the Group with internal administrative, commercial, real estate and management services.

As of December 31, 2024, the total

non-controlling

interest amounts to S/ 145,724 thousand (S/ 311,281 thousand and S/ 493,082 thousand as of December 31, 2023 and 2022, respectively).

29.	Financial Risk and Insurance Management

Due to its business, the Group assumes the risks inherent to its activities related to the insurance business, market, credit, liquidity and foreign currency.

Management is responsible for monitoring these risks, based on various measurement, analysis and control techniques to minimize potential effects, although the use of these mechanisms does not completely eliminate the inherent risk factors to which the Group is exposed.

Management is exposed to risks as a result of: (i) the use of financial instruments and (ii) the risks associated with the healthcare business. These risks have been categorized taking into consideration their nature and scope, as well as Management, which are described below.

A.	Insurance risk

Insurance activities expose the Group mainly to incidence risk (level of occurrence of the insured event), frequency risk (level of prevalence of the event once it has occurred) and control risk of the healthcare benefit cost.

The table below shows the actual amount of the cost of service in the Oncosalud Peru segment and includes the general healthcare plan called “Auna Salud.” It also shows a sensitivity analysis for the most relevant variables affecting this cost: the frequency (number of patients / number of plan members) and the average cost per patient.


In thousands of soles			Frequency			Frequency			Average cost per patient			Average cost per patient			Combined			Combined
2024
Change %				+5	%		+10	%		+5	%		+10	%		+5	%		+10	%
Cost of segment Oncosalud Peru	586,391			615,711			645,030			615,711			645,030			646,496			709,533
Frequency	4.29	%		4.50	%		4.72	%		4.29	%		4.29	%		4.50	%		4.72	%
Average cost per patient	10.01			10.01			10.01			10.51			11.02			10.51			11.02
# of plan members	1,365,028			1,365,028			1,365,028			1,365,028			1,365,028			1,365,028			1,365,028


In thousands of soles			Frequency			Frequency			Average cost per patient			Average cost per patient			Combined			Combined
2023
Change %				+5	%		+10	%		+5	%		+10	%		+5	%		+10	%
Cost of segment Oncosalud Peru	502,807			527,947			553,088			527,947			553,088			554,345			608,396
Frequency	4.49	%		4.71	%		4.94	%		4.49	%		4.49	%		4.71	%		4.94	%
Average cost per patient	8.82			8.82			8.82			9.26			9.70			9.26			9.70
# of plan members	1,270,930			1,270,930			1,270,930			1,270,930			1,270,930			1,270,930			1,270,930

F-10

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022


In thousands of soles			Frequency			Frequency			Average cost per patient			Average cost per patient			Combined			Combined
2022
Change %				+ 5	%		+ 10	%		+ 5	%		+ 10	%		+ 5	%		+ 10	%
Cost of segment Oncosalud Peru	419,737			440,724			461,711			440,724			461,711			462,760			507,882
Frequency	4.23	%		4.44	%		4.65	%		4.23	%		4.23	%		4.44	%		4.65	%
Average cost per patient	9.13			9.13			9.13			9.59			10.04			9.59			10.04
# of plan members	1,087,546			1,087,546			1,087,546			1,087,546			1,087,546			1,087,546			1,087,546

As of December 31, 2024, 2023 and 2022, reasonably possible changes in the most relevant variable of 5% and 10% could affect profit or loss by amounts shown below:


In thousands of soles	Fluctuations in variables (%)		2024			2023			2022
In thousands of soles	Fluctuations in variables (%)		Profit for the year			Profit for the year			Profit for the year
Frequency		5		(29,320	)		(25,140	)		(20,997	)
Frequency		10		(58,639	)		(50,281	)		(41,995	)
Average cost per patient		5		(29,320	)		(25,140	)		(20,997	)
Average cost per patient		10		(58,639	)		(50,281	)		(41,995	)
Combined		5		(60,105	)		(51,538	)		(43,044	)
Combined		10		(123,142	)		(105,589	)		(88,189	)

The Group adopts various mechanisms with the main objective of minimizing insurance risk as severity. Such mechanisms include the control of (i) price adequacy and (ii) healthcare benefit expenditures, in addition to selecting medical service providers based on various factors, such as specialization, experience, location, quality and cost of services.

The adequacy of prices relies on past actuarial analyses and more recent service levels, combined with future projections of more recently observed trends. Price risk affects only future cash flows since new rates will impact premium levels earned once cancer health contracts are renewed.

Within the Group, the type of product is an oncologic healthcare insurance contract and a general healthcare plan “Auna Salud,” both renewable annually. This enables the Group to review fees that respond fairly and quickly to the changes in service experience. The new fees are automatically applied at each renewal date; however, the client might not accept the increase, which would lead to the contract cancellation. This is a factor that significantly mitigates price risk. The Group does not enter into fixed premium contracts for a period longer than 12 months from the original date or the renewal date of the respective contracts.

Control risk of the cost of providing benefits (treatment and preventive care) is monitored through

(i) pre-authorization

of the service, (ii) use of a certain network of clinics and “agreed-upon” fees and (iii) monitoring adhesion to medical practice guides.

In general, the Group’s healthcare contracts contain terms and conditions establishing that only medical services are provided (the contracts benefits do not include refund or compensation amounts). Subject to specific circumstances, they provide reimbursement for medical expenses incurred in treatments related to chronic medical conditions.

In addition, when necessary, the Group negotiates its contracts with healthcare providers to obtain more favorable and competitive prices, to the extent possible. The Group also has a highly trained medical audit team who continually review invoices received from their service providers.

F-10

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

One of the Group’s key procedures is to use strict criteria to accept the risk of new clients for corporate and individual cancer health plans. This process involves the analysis of the policyholder’s risk profile and

pre-existing

conditions, and is subject to certain approvals and other factors, under the rules and regulations issued by the local regulator in Peru.

Technical reserves risk

This is the risk that the technical reserves for healthcare insurance contracts may be insufficient to cover the obligations under the contracts. The reserve risk is not significant for the Group due to the short-term nature of the contracts which allows the Group to adjust fees as needed, together with the effectiveness of the model used to analyze and develop the assumptions underlying the pricing of the products.

The short-term nature of the Group’s contracts means that the variability of the assumptions used in determining final claims is not generally significant and can be adjusted as required. Claim development patterns are reviewed on an ongoing basis and used to update the amount of the provisions if required, therefore reducing the variability of the provision recognized in the consolidated financial statements.

The amount of the provision to cover claims incurred but not yet reported at the end of the year is not material due to the business integrated model, which means that the claims are recorded as they arise.

B.	Market risk

i.	Exchange risk

The Group and its subsidiaries invoice the rendering of local services in the currency of the country in which they operate, which enables them to meet their obligations in their functional currency. Exchange rate risk arises mainly from loans and other liabilities held in U.S. dollars. To mitigate this risk, as of December 31, 2024, 2023 and 2022, the Group used derivative financial instruments to hedge the exposure to exchange rate risk, for more than 90% of its financial obligations.

As of December 31, the Group has the following assets and liabilities stated in U.S. dollars, COP and MXN:


In thousands of	2024									2023									2022
In thousands of	US$			COP			MXN			US$			COP			MXN			US$			COP
Assets
Cash and cash equivalents		14,629			67,383,971			156,086			19,545			68,198,988			101,537			10,026			77,781,245
Trade accounts receivable		2,501			732,206,977			506,029			2,349			592,832,974			573,760			1,214			467,080,290
Other assets		2,033			67,499,144			62,643			1,431			53,926,570			46,428			38,063			41,846,383
Derivative financial instruments		16,185			—			37,005			22,175			—			—			21,693			—

		35,348			867,090,092			761,763			45,500			714,958,532			721,725			70,996			586,707,918

Liabilities
Loans and borrowings		(484,903	)		(843,882,862	)		(6,863,633	)		(572,514	)		(713,312,165	)		(5,263,563	)		(430,734	)		(230,983,211	)
Lease liabilities		(29,068	)		(51,441,394	)		—			(18,335	)		(53,098,486	)		—			(20,111	)		(43,374,862	)
Trade accounts payable		(20,069	)		(513,900,964	)		(665,868	)		(14,122	)		(426,350,789	)		(340,669	)		(8,167	)		(297,235,534	)
Other accounts payable		(4,740	)		(136,340,317	)		(484,050	)		(26,479	)		(308,351,354	)		(948,193	)		(24,006	)		(254,525,182	)
Derivative financial instruments		(1,034	)		—			(210,787	)		—			—			—			(4,004	)		—

		(539,814	)		(1,545,565,537	)		(8,224,338	)		(631,450	)		(1,501,112,794	)		(6,552,425	)		(487,022	)		(826,118,789	)

Liability position, net		(504,466	)		(678,475,445	)		(7,462,575	)		(585,950	)		(786,154,262	)		(5,830,700	)		(416,026	)		(239,410,871	)

F-10

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

As of December 31, the exchange rate, used by the Group to translate the balances of assets and liabilities into foreign currency, has been published by the Peruvian Banking, Insurance and Pension Plan Agency (SBS), as follows:


In soles	2024		2023		2022
US$ 1 - Exchange rate - Buy (assets)		3.758		3.705		3.808
US$ 1 - Exchange rate - Sale (liabilities)		3.770		3.713		3.820
COP 1 - Exchange rate		0.000854		0.000957		0.000786
MXN 1- Exchange rate		0.182513		0.219083		0.195792

The Group recorded loss for net exchange difference of S/ 41,709 thousand in 2024, gain of S/ 75,852 thousand in 2023 and loss of S/ 57,771 thousand in 2022.

As of December 31, 2024, 2023 and 2022, a reasonably possible strengthening (weakening) of the U.S. dollar against the Peruvian Sol, COP and MXN at December 31 would have affected the measurement of financial instruments denominated in a foreign currency and affected equity and profit or loss by the amounts shown below:


In thousands of soles	Fluctuations in exchange rates (%)		2024						2023						2022
In thousands of soles	Fluctuations in exchange rates (%)		Profit or loss for the fiscal year			Other comprehensive income			Profit or loss for the fiscal year			Other comprehensive income			Profit or loss for the fiscal year			Other comprehensive income
Weakening		5		97,959			(2,847	)		112,908			(4,108	)		82,869			(3,368	)
Weakening		10		195,919			(5,694	)		225,815			(8,216	)		165,738			(6,736	)
Strengthening		5		(97,959	)		2,847			(112,908	)		4,108			(82,869	)		3,368
Strengthening		10		(195,919	)		5,694			(225,815	)		8,216			(165,738	)		6,736

ii.	Interest rate risk

The Group adopts a policy of ensuring as a minimum 80% of its interest rate risk exposure is at a fixed rate. This is achieved by entering into

fixed-rate

instruments and partly by borrowing at a floating rate and using interest rate swaps as hedges of the variability in cash flows attributable to movements in interest rates.

The Group determines the existence of an economic relationship between the hedging instrument and hedged item based on the reference interest rates, tenors, repricing dates and maturities and the notional or par amounts. The Group assesses whether the derivative designated in each hedging relationship is expected to be effective in offsetting changes in cash flows of the hedged item using the hypothetical derivative method. As of December 31, 2024, the Group have financial derivative instruments in order to cover interest rate (Note 8).

As of December 31, 2024, a reasonably possible strengthening (weakening) of interest rates as of December 31 would have affected results by the amounts shown below:


In thousands of Soles	Fluctuations in interest rates (%)		2024
In thousands of Soles	Fluctuations in interest rates (%)		Profit or (loss) for the fiscal year
Decrease		5		165,270
Decrease		10		330,642
Increase		5		(165,167	)
Increase		10		(330,232	)

F-10

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

C.	Credit risk

The Group’s financial assets are exposed to credit risk concentrations mainly comprising bank deposits and trade accounts receivable. Regarding bank deposits, the Group reduces the likelihood of credit risk concentrations because it keeps its deposits and places its cash investments at first-class financial entities and limits the amount of exposure to credit risk in any of such financial entities.

Regarding trade accounts receivable, the significant credit risk concentrations, individual or group, are mitigated since the Group’s policy is to monitor the payment behavior of customers and their financial position to comply with the respective payments on a regular basis (note 5).

As of December 31, the exposure to credit risk of trade accounts receivable was the following:


In thousands of soles	2024		2023		2022
Peru		285,716		199,527		161,252
Colombia		662,272		580,450		374,627
México		96,533		126,657		77,427

		1,044,521		906,634		613,306

D.	Liquidity risk

The prudent liquidity risk management involves maintaining enough cash and cash equivalents and the possibility of finding and/or obtaining funding through an adequate quantity of credit sources.

The Group has adequate levels of cash and cash equivalents considering:

•

Auna S.A. can finance its current assets (accounts receivable, inventories and others) with current liabilities (accounts payable, deferred revenue and others).

•

Auna S.A. analyses the maturity of its debts to identify any refinancing required to maintain an appropriate debt structure.

•

Not considering growth capex (new hospitals, acquisitions, etc.), Auna has enough cash flow from operations to finance its maintenance capex, current debt service (interest and principal), dividends and a portion of growth capex.

•

Growth capex is financed mainly by long-term debt and cash flow from operations. In some cases, by capital contribution (for example: acquisition of PMLA and Hospital y Clínica OCA).

•

In addition, Auna has revolving credit lines of S/ 600,054 thousand to use in case of cash flow needs. As of December 31, 2024, the Group had S/ 446,068 thousand drawn and S/ 153,986 thousand of availability under the revolving credit facility. As of December 31, 2023, the Group had S/ 348,178 thousand drawn and S/ 139,283 thousand of availability under the revolving credit facility.

•

These credit lines are renewed every year. The interest rate applicable for the lines in Peru is a fixed rate that is agreed upon with the bank before the reception of the cash in Auna accounts and depends on the credit terms (up to 180 days). In the case of Colombia and Mexico lines, the interest rates applicable are a floating rate. The credit revolving lines available for Auna are with the following banks in Perú: Scotiabank: S/ 100,000 thousand; Banbif: S/ 18,820 thousand; BBVA: S/ 37,640 thousand; BCP: S/ 45,168 thousand; Interbank: S/ 15,056 thousand; Citibank: S/ 57,966 thousand; Pichincha: S/ 30,112 thousand, Santander: S/ 94,100 thousand and GNB: S/ 9,500 thousand. The available credit revolving lines in Colombia are around S/ 113,212 thousand and in Mexico are around S/ 78,480.

F-10

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

In addition, the Group monitors its liquidity risk based on the plans and guidelines established by Management.

The following table analyzes the Group’s financial liabilities classified per maturity based on the remaining contractual period as of the date of the consolidated statement of financial position. The amounts disclosed are contractual cash flows.


In thousands of soles	Carrying amount		Contractual cash flows		Less than 1 year		From 1 to 2 years		From 3 to 5 years		More than 5 years
2024
Trade accounts payable		934,006		934,006		931,265		2,741		—		—
Other accounts payable (*)		148,155		174,601		83,955		36,820		53,826		—
Loans and borrowings (**)		3,619,774		5,048,548		1,041,977		650,674		3,288,042		67,855
Lease liabilities (**)		147,888		198,425		43,275		38,391		68,084		48,675
Derivative financial instruments		42,370		51,226		15,895		15,932		19,399		—

		4,892,193		6,406,806		2,116,367		744,558		3,429,351		116,530

2023
Trade accounts payable		753,255		753,255		749,349		3,906		—		—
Other accounts payable (*)		459,606		465,466		248,769		65,109		151,588		—
Loans and borrowings (**)		3,761,582		5,557,229		785,301		821,223		2,821,724		1,128,981
Lease liabilities (**)		158,045		218,196		44,295		40,231		73,425		60,245

		5,132,488		6,994,146		1,827,714		930,469		3,046,737		1,189,226

2022
Trade accounts payable		513,383		513,383		513,310		73		—		—
Other accounts payable (*)		406,691		532,748		224,522		22,113		286,113		—
Loans and borrowings (**)		3,348,647		3,845,977		2,333,506		108,937		1,333,160		70,374
Lease liabilities (**)		162,922		224,037		38,794		36,363		77,674		71,206
Derivative financial instruments		15,317		15,317		15,317		—		—		—

		4,446,960		5,131,462		3,125,449		167,486		1,696,947		141,580

(*)	They do not include taxes payable, remunerations and other benefits payable.

(**)	They include contractual interest.

Management monitors the risk related to the liabilities included in the above-mentioned categories, and considers obtaining enough credit lines and having working capital to comply with the plans established by Management.

The Group manages the excess cash flow investing in short-term investments. In addition, at the end of fiscal years 2024, 2023 and 2022, the Group has credit lines for working capital that have not been used or used partially, which are enough to comply with short- and medium-term obligations.

The Group also participates in a supplier finance arrangement with the principal purpose of facilitating efficient payment processing of supplier invoices and providing the willing suppliers early payments terms compared with the related invoice payment due date. The arrangement allows the Group to centralize payments of trade payables to the bank rather than paying each supplier individually. From the Group’s perspective, the arrangement does not significantly extend payment terms beyond the normal terms agreed with other suppliers that are not participating.

E.	Capital risk management

The Group’s objectives in managing capital is to safeguard its capacity to continue as a going concern generating return to its shareholders and benefits to other stakeholders. The Group may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares, or sell assets to reduce its debt to maintain or adjust the capital structure.

F-10

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

During the year ended December 31, 2024, 2023 and 2022, the Group’s strategy was to maintain a leverage ratio not higher than 1.0. Based on this strategy, the Group maintains a leverage ratio of 0.68 in 2024 (0.66 and 0.67 in 2023 and 2022, respectively) as shown below:


In thousands of soles	2024			2023			2022
Total loans and borrowings		3,619,774			3,761,582			3,348,647
Less: Cash and cash equivalents		(235,745	)		(241,133	)		(208,694	)

Net debt (A)		3,384,029			3,520,449			3,139,953

Plus: Total equity		1,622,940			1,776,566			1,558,061

Total adjusted equity (B)		5,006,969			5,297,015			4,698,014

Leverage ratio (A)/(B)		0.68			0.66			0.67

F-1

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

F.	Accounting classification and fair value

The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy. It does not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value.


	Carrying amount										Fair value
In thousands of soles	FVOCI – debt instruments		Fair value hedging instruments		Financial assets at amortized cost		Other financial liabilities		Total		Level 1		Level 2		Level 3		Total
As of December 31, 2024
Financial assets measured at fair value
Other investments		100,510		—		—		—		100,510		100,510		—		—		100,510
Derivative financial instruments		—		67,472		—		—		67,472		—		67,472		—		67,472

		100,510		67,472		—		—		167,982		100,510		67,472		—		167,982

Financial assets not measured at fair value
Cash and cash equivalents		—		—		235,745		—		235,745		—		—		—		—
Trade accounts receivable		—		—		962,457		—		962,457		—		—		—		—
Other assets (*)		—		—		42,063		—		42,063		—		—		—		—

		—		—		1,240,265		—		1,240,265		—		—		—		—

Financial liabilities measured at fair value
Derivative financial instruments		—		42,370		—		—		42,370		—		42,370		—		42,370

		—		42,370		—		—		42,370		—		42,370		—		42,370

Financial liabilities not measured at fair value
Loans and borrowings		—		—		—		3,619,774		3,619,774		—		3,768,101		—		3,768,101
Lease liabilities		—		—		—		147,888		147,888		—		—		—		—
Trade accounts payable		—		—		—		934,006		934,006		—		—		—		—
Other accounts payable (**)		—		—		—		148,155		148,155		—		—		—		—

		—		—		—		4,849,823		4,849,823		—		3,768,101		—		3,768,101

(*)	They do not include taxes receivable and prepayments.

(**)	They do not include taxes payable, prepayments and labor liabilities .

F-1

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022


	Carrying amount										Fair value
In thousands of soles	FVOCI – debt instruments		Fair value hedging instruments		Financial assets at amortized cost		Other financial liabilities		Total		Level 1		Level 2		Level 3		Total
As of December 31, 2023
Financial assets measured at fair value
Other investments		93,421		—		—		—		93,421		93,421		—		—		93,421
Derivative financial instruments		—		82,213		—		—		82,213		—		82,213		—		82,213

		93,421		82,213		—		—		175,634		93,421		82,213		—		175,634

Financial assets not measured at fair value
Cash and cash equivalents		—		—		241,133		—		241,133		—		—		—		—
Trade accounts receivable		—		—		861,336		—		861,336		—		—		—		—
Other assets (*)		—		—		35,798		—		35,798		—		—		—		—

		—		—		1,138,267		—		1,138,267		—		—		—		—

Financial liabilities measured at fair value
Contingent consideration		—		—		—		64,008		64,008		—		—		64,008		64,008
Put liability		—		—		—		121,636		121,636		—		—		121,636		121,636

		—		—		—		185,644		185,644		—		—		185,644		185,644

Financial liabilities not measured at fair value
Loans and borrowings		—		—		—		3,761,582		3,761,582		—		3,930,474		—		3,930,474
Lease liabilities		—		—		—		158,045		158,045		—		—		—		—
Trade accounts payable		—		—		—		753,255		753,255		—		—		—		—
Other accounts payable (**)		—		—				273,962		273,962		—		—		—		—

		—		—		—		4,946,844		4,946,844		—		3,930,474		—		3,930,474

(*)	They do not include taxes receivable and prepayments.

(**)	They do not include taxes payable, prepayments and labor liabilities .

F-1

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022


	Carrying amount										Fair value
In thousands of soles	Fair value hedging instruments		Financial assets at amortized cost		Other financial liabilities		Total		Level 2		Level 3		Total
As of December 31, 2022
Financial assets measured at fair value
Derivative financial instruments		82,606		—		—		82,606		82,606		—		82,606

		82,606		—		—		82,606		82,606		—		82,606

Financial assets not measured at fair value
Cash and cash equivalents		—		208,694		—		208,694		—		—		—
Trade accounts receivable		—		589,308		—		589,308		—		—		—
Other assets (*)		—		127,469		—		127,469		—		—		—

		—		925,471		—		925,471		—		—		—

Financial liabilities measured at fair value
Derivative financial instruments		15,317		—		—		15,317		15,317		—		15,317
Contingent consideration		—		—		69,470		69,470		—		69,470		69,470
Put liability		—		—		136,938		136,938		—		136,938		136,938

		15,317		—		206,408		221,725		15,317		206,408		221,725

Financial liabilities not measured at fair value
Loans and borrowings		—		—		3,348,647		3,348,647		3,115,560		—		3,115,560
Lease liabilities		—		—		162,922		162,922		—		—		—
Trade accounts payable		—		—		513,383		513,383		—		—		—
Other accounts payable (**)		—		—		200,283		200,283		—		—		—

		—		—		4,225,235		4,225,235		3,115,560		—		3,115,560

(*)	They do not include taxes receivable and prepayments.

(**)	They do not include taxes payable, prepayments and labor liabilities .

F-11

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

G.	Measurement of fair values

i.	Valuation techniques and significant unobservable inputs

The following tables show the valuation techniques used in measuring Level 2 fair values at December 31, 2024 and Level 2 and Level 3 fair values at 2023 and 2022 for financial instruments measured at fair value in the statement of financial position, as well as the significant unobservable inputs used. Related valuation processes are described in note 3.

Financial instruments measured at fair value


Type	Valuation technique	Significant unobservable inputs	Inter-relationship between significant unobservable inputs and fair value
Put liability (note 17)	Discounted cash flows: The valuation model considers the present value of the expected future payments, discounted using a risk-adjusted discount rate.	• Expected cash flows (December 31, 2023: COP 140,549,846 thousand). Risk-adjusted discount rate ( 8.00 % – 13.80 %).	The estimated fair value would increase (decrease) if: • the expected cash flows were higher (lower); or • the risk-adjusted discount rate were lower (higher).

Contingent consideration (note 17)	Discounted cash flows: The valuation model considers the present value of the expected future payments, discounted using a risk-adjusted discount rate.	• Expected cash flows (December 31, 2023: COP 66,884,414 thousand). • Risk-adjusted discount rate (December 31, 2023: 12.3% – 12.71%).	The estimated fair value would increase (decrease) if: • the expected cash flows were higher (lower); or • the risk-adjusted discount rate were lower (higher).

Derivatives financial instruments (note 8)	For the Options: Garman–Kohlhagen: The fair value is determined using this model that treats foreign currencies as if they are equity securities that provide a known dividend yield, which uses the following inputs: Spot rate at the valuation date, strike price, implicit volatility, and risk-free rate in both currencies. For long-forward/swap: Interest rate parity: Consists of estimating the present value of the future profit (loss) generated by the forward/swap contract. The gain or loss is calculated as the difference between the forward exchange rate estimated according to the market and the strike.	Not applicable	Not applicable

F-11

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

ii.	Sensitivity analysis

For the fair value of contingent consideration and put liability, reasonably possible changes at December 31, 2023 and 2022 to one of the significant unobservable inputs, holding other inputs constant, would have the following effects. As of December 31, 2024 the contingent consideration does not have effect.


	December 31, 2023
In thousands of soles	Increase			Decrease
Contingent consideration	Profit or loss
Expected cash flows (10% movement)		(7,005	)		7,005
Risk-adjusted discount rate (1% movement (100 bps))		(469	)		469

Put liability	Other comprehensive loss
Expected cash flows (10% movement)		(2,227	)		2,227
Risk-adjusted discount rate (1% movement (100 bps))		—			—


	December 31, 2022
In thousands of soles	Increase			Decrease
Contingent consideration	Profit or loss
Expected cash flows (10% movement)		(6,893	)		6,893
Risk-adjusted discount rate (1% movement (100 bps))		153			(154	)

Put liability	Other comprehensive loss
Expected cash flows (10% movement)		(2,507	)		2,507
Risk-adjusted discount rate (1% movement (100 bps))		888			(914	)

30.	Commitments, Guarantees and Contingencies

A.	Commitments

As of December 31, 2024, 2023 and 2022, no commitments to be reported have been identified.

B.	Guarantees

As of December 31, 2024, 2023 and 2022, the Group has the following guarantees:

•

Guarantee letters in financial institutions for S/ 20,979 thousand in favor of third parties in order to ensure compliance with providing healthcare services (2023: S/ 16,166 thousand and 2022: S/ 109,467 thousand).

•

Guarantee to cover a financial loan for a total of S/ 250,628 thousand. In favor of Scotiabank Perú S.A.A. S/ 113,000 thousand; in favor of Banco Interamericano de Finanzas S/ 39,522 thousand; in favor of Banco Interbank S/ 9,410 thousand; in favor of Banco de Credito del Peru S/ 31,056; and in favor of Citibank S/ 57,640 (2023: S/ 113,000 thousand in favor of Scotiabank Perú S.A.A., S/ 39,872 thousand in favor of Banco Interamericano de Finanzas, S/ 27,336 thousand in favor of Banco de Credito del Peru, in 2022: S/ 113,000 thousand in favor of Scotiabank Perú S.A.A., S/ 41,000 thousand in favor of Banco Interamericano de Finanzas, S/ 9,535 thousand in favor of Banco Interbank, S/ 14,303 thousand in favor of Banco de Credito del Peru and S/ 57,901 thousand in favor of Citibank.

•

The Group maintains properties in mortgage in favor of Scotiabank Perú S.A.A. for S/ 21,195 thousand related to loans received (S/ 20,886 thousand as of December 31, 2023 and S/ 21,477 thousand as of December 31, 2022) and Mexico for S/ 3,199,400 thousand as of December 31, 2024 (S/ 3,152,650 thousand as of December 31, 2023).

F-11

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

•

Colombian subsidiaries maintain guarantee trust for S/ 45,322 thousand to guarantee compliance with the proceeds of their sale (2023: S/ 50,788 thousand and 2022 S/ 41,713 thousand) and a guarantee pledge of its machinery for S/ 10,452 thousand (S/ 11,713 thousand as of December 31, 2023 and S/ 9,620 thousand as of December 31, 2022) and leasing guarantees for S/ 47,180 thousand (S/ 49,109 thousand as of December 31, 2023).

•

The 99.99% of the shares of Mexican Subsidiaries and the 70% of the shares of Oncomedica S.A. are pledged to guarantee bank loans.

•

The Company and its subsidiaries engage as issuer and guarantors, respectively, in the issuance and placement of Senior Notes at a rate of 10.00% with maturity in 2029, in the international market, under Rule 144A and Regulation S of the United States Securities Act of 1993 for up to US$ 310,837 thousand or equivalent in local currency.

•

The Company and its subsidiaries engage as

co-debtor

and guarantors, respectively, in the Credit Agreement dated December 10,2023 for up to US$ 550,000 thousand or equivalent in local currency.

C.	Contingencies liabilities

As of December 31, 2024, 2023 and 2022, the Group maintains various judicial processes (labor, regulatory, civil, tax), that Management evaluated as possible. If the defense against those actions is unsuccessful, then fines and legal costs could amount to S/ 46,464 thousand, S/ 41,143 thousand and S/ 35,936 thousand, respectively.

31.	Related Parties

As of December 31, this caption includes the following:


	Transaction value						Outstanding balances
In thousands of soles	2024		2023		2022		2024		2023		2022
Sales of oncologic healthcare services
Joint ventures		50		35		144		234		236		247
Associates		—		—		—		—		—		—
Others		6,135		1,151		33		2,957		1,234		1,895

		6,185		1,186		177		3,191		1,470		2,142

Cost of sales of oncologic healthcare services
Joint ventures		3,929		3,791		3,270		1,076		1,096		1,182
Associates		15,878		12,164		8,110		3,473		2,574		1,945
Others		13,032		10,747		7,896		3,160		3,185		3,353

		32,839		26,702		19,276		7,709		6,855		6,480

Administrative expenses
Services provided by related parties (v)		1,844		2,620		3,355		630		816		1,329
Other management charges		4,521		2,844		5,419		4,439		1,452		200

		6,365		5,464		8,774		5,069		2,268		1,529

Selling expenses
Services provided by related parties (vi)		1,761		1,106		1,036		396		123		95

		1,761		1,106		1,036		396		123		95

Finance income
Loans and related interest from related parties		71		—		—		1,952		—		—

		71		—		—		1,952		—		—

F-11

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

All outstanding balances with these related parties are priced on an

arm´s-length

basis. None of the balances is secured. No expense has been recognized in the current year or prior year of loss for impairment of trade receivables in respect of amounts owed by related parties. No guarantees have been given or received.

(i)	Compensation to key personnel

For the year ended December 31, 2024 the compensation paid to the key Management of the subsidiaries located in Peru amounts to S/ 99,505 thousand (S/ 81,674 thousand and S/ 84,978 thousand for the years ended December 31, 2023 and 2022, respectively). In Colombian subsidiaries, the amount is S/ 23,230 thousand for the year ended December 31, 2024 (S/ 14,844 thousand and S/ 14,022 thousand for the year ended December 31, 2023 and 2022) and in Mexican subsidiaries, the amount is S/ 60,132 thousand for the year ended December 31, 2024 (S/ 55,556 thousand for the year ended December 31, 2023). Also, for the year ended December 31, 2024 expenses were recognized for S/ 9,145 thousand corresponds to share based payment (S/ 3,675 thousand as of December 31, 2023) (note 21.a) to

non-executive

members of the Board and employees.

(ii)	Advances and loans granted to the Members of the Management and Supervisory Bodies

The Group has not granted any advances or commitments, loans and guarantees granted on their behalf related to pension funds, life insurances and other similar concepts and other long-term benefits other than share-based payments to its key Management personnel, including Directors of the Company and Supervisory Bodies.

(iii)

Compensation to directors

For the year ended December 31, 2024, 2023 and 2022, the compensation paid to the board of directors amounts to S/ 5,781 thousand, S/ 5,027 thousand and S/ 4,006 thousand, respectively.

(iv)	Medical services

For the year ended December 31, 2024, 2023 and 2022, certain directors provided medical services to the Group. For their medical services, they have received customary compensation and benefits commensurate with their level of responsibility within the Company, aligned with the compensation paid to other physicians and medical professionals of similar stature employed by the Group.

In addition, the Group reimbursed certain expenses incurred in connection with providing these services, such as rent for office space, phone expenses, certain taxes, purchase of medical books and travel expenses related to attendance at conferences on behalf of the Group.

(v)	Management expenses

For the year ended December 31, 2024, administrative expenses provided to the Group by Enfoca, corresponded mainly to reimbursements related to travel and other expenses of S/

thousand. For the year ended December 31, 2023 and 2022, administrative expenses provided to the Group by Enfoca corresponded mainly to management services of S/

1,229

thousand and S/

2,451

thousand, respectively, and reimbursements related to consultant fees and travel expenses of S/

445

thousand and S/

904

thousand, respectively.

(vi)	Selling expenses

For the year ended December 31, 2024, 2023 and 2022, selling expenses provided to the Group by companies related to shareholders corresponded mainly to sales commission and advertisement of S/ 1,761 thousand, S/ 1,106 thousand and S/ 1,036 thousand, respectively.

F-11

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

32.	Insurance Contract Liabilities

The movement for the years ended December 31, 2024 and 2023 is as follows:


	2024												2023
				Liabilities for incurred claims												Liabilities for incurred claims
In thousands of soles	Liabilities for remaining coverage			Estimates of present value of future cash flows			Risk adjustment for non-financial risk			Total			Liabilities for remaining coverage			Estimates of present value of future cash flows			Risk adjustment for non-financial risk		Total
Balances as of January 1		31,039			8,560			254			39,853			8,626			2,829			244		11,699
Changes in the statement of profit or loss and OCI		—			—			—			—			—			—			—		—

Insurance revenue		(1,052,958	)		—			—			(1,052,958	)		(914,182	)		—			—		(914,182	)

Insurance service expenses
Incurred claims and other insurance service expenses		—			47,631			—			47,631			—			41,423			—		41,423
Amortization of insurance acquisition cash flows		129,973			—			—			129,973			140,438			—			—		140,438
Adjustments to liabilities for incurred claims		—			—			(7	)		(7	)		—			—			10		10

Total insurance service expenses		129,973			47,631			(7	)		177,597			140,438			41,423			10		181,871

Total insurance service result		(922,985	)		47,631			(7	)		(875,361	)		(773,744	)		41,423			10		(732,311	)

Effect of movements in exchange rates		(520	)		(631	)		(2	)		(1,153	)		603			119			—		722

Total changes in the statement of profit or loss and OCI		(923,505	)		47,000			(9	)		(876,514	)		(773,141	)		41,542			10		(731,589	)

Cash flows
Premiums received		1,047,445			—			—			1,047,445			935,888			—			—		935,888
Claims and other insurance service expenses paid		—			(47,452	)		—			(47,452	)		—			(39,115	)		—		(39,115	)
Insurance acquisition cash flows		(153,234	)		—			—			(153,234	)		(139,329	)		—			—		(139,329	)

Total cash flows		894,211			(47,452	)		—			846,759			796,559			(39,115	)		—		757,444

Acquired through business combinations		—			—			—			—			(1,005	)		3,304			—		2,299

Closing assets		—			—			—			—			—			—			—		—

Closing liabilities		1,745			8,108			245			10,098			31,039			8,560			254		39,853

F-11

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

Liability for Incurred Claims (LIC)

These provisions include the reserve for events incurred but not reported (IBNR), the claims pending settlement reserve and the risk adjustment for

non-financial

risk to the condensed consolidated financial statement date. As of December 31, 2024, 2023 and 2022, the reserves of the oncology healthcare plans and the general healthcare plan called “Auna Salud” were determined using a reserving model based on a mix of several methods. As of December 31, 2024, 2023 and 2022, the key assumptions of the oncologic healthcare plans and the general healthcare plan include the evolution of past claims, which are projected in the future.

Insurance expenses

The insurance expenses incurred by Oncosalud S.A.C. are presented in its separate financial statements for the years ended December 31, 2024, 2023 and 2022.

The insurance expenses incurred by Oncosalud S.A.C. are as follows:


	Cost of sales and services (i)
In thousands of soles	2024		2023		2022
Medicines		263,613		195,114		167,278
Room service for inpatients		36,196		116,171		34,091
Medical consultation fees		88,966		34,483		41,334
Auxiliary services and clinical laboratory		114,042		26,434		122,800
Surgery fees		25,165		66,341		20,934
Insurance contracts		5,604		3,279		2,138

		533,586		441,822		388,575

(i)

These expenses are included in the cost of sales and services in our consolidated statement of profit or loss and other comprehensive income after deducting the margin markup. For the years ended December 31, 2024, 2023 and 2022, the margin applied was calculated using the same basis as what we charge third parties for these services, and the overall average margin applied in each period was 24%, 17% and 18%, respectively.

Due to the vertical integration of the Group’s companies, these insurance expenses incurred by Oncosalud S.A.C. and the corresponding trade and other accounts payable are eliminated with the transactions performed with Oncocenter Perú S.A.C. and the Company’s healthcare services subsidiaries (see note 26.b.i.)

33.	Share-Based Payments

A.	Description of share-based payment arrangements

During 2023, the Board of Directors approved the Equity incentive plans. As of December 31, 2024, the Group has share-based payments plans for

non-executive

members of the Board and employees.

i.	Restricted shares plan

The award 2024 plan granted on January 1, 2024, has a vesting period ending on January 1, 2025. The restricted shares became

non-forfeitable

as of its respective vesting date, with settlement date following this vesting period.

F-11

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

The following table illustrates the movements in Restricted Shares under the Plans as of December 31, 2024:


Grand date/ Directors entitled	Number of shares in thousands		Vesting conditions	(In thousands of soles)
Grand date/ Directors entitled	Number of shares in thousands		Vesting conditions	2024		2023
Award 2024 - Grant to Directors on January 1, 2024		43	1 year service from grant date		1,131		—
Award 2023 - Grant to Directors on December 8, 2023		53	1 month service from grant date		—		3,675

As of December 31, 2024, the Group recognized S/ 1,131 thousand to the personnel expenses (S/ 3,675 thousand as of December 31, 2023), note 21 (a).

ii.	Option and restricted stock unit plans

During 2024, the Company signed the long-term incentive plan seeks to drive the achievement of the company’s performance targets, along with providing an element of retention, allowing employees to obtain part of the shares of the company. They will be able to exercise the stock rights after a period of continuous employment and additional conditions depending on the case.

The following table illustrates the long-term incentive plans as of December 31, 2024:

Incentive plans / Vesting

Commencement Date

Number of
options / shares
in thousands

Vesting conditions

Contractual
life of options /
shares

(In thousands of
soles)

2024

Performance-Based Option Agreement on March 21, 2024

2,661

years’ service from grant date

10 years

6,655

Long-Term Incentive Management on March 21, 2024

600

years’ service from grant date

5 years

195

Restricted Stock Unit on March 21, 2024

161

years’ service from grant date

3 years

1,164

As of December 31, 2024, the Group recognized S/ 8,014 thousand to the personnel expenses note 21(a).

B.	Measurement of grant date fair values

The grant-date fair value of equity-settled share-based payment arrangements granted to employees is generally recognized as an expense with different methods during the vesting period, with a corresponding increase in equity, over the vesting period of the awards.

The following table illustrates the different methods of incentive plans for December 31, 2024:


Incentive plans	Year		Methodology of fair value	Grace period		Number of options / shares in thousands		Annual volatility			Risk- free rate			Weighted average of fair value of options / shares (in soles)		Vesting status
Performance-Based Option Agreement		2024	Binomial		21/03/2024 to 21/03/2027		2,661		33.54	%		4.83	%		9.61	Partially vested
Long-Term Incentive Management		2024	Black Scholes		21/03/2024 to 21/03/2028		600		33.54	%		3.63	%		1.25	Partially vested
Restricted Stock Units		2024	Market value		21/03/2024 to 21/03/2027		161		—			—			27.71	Partially vested

F-1

Auna S.A. and Subsidiaries

Notes to the Consolidated Financial Statements

December 31, 2024, 2023 and 2022

34.	Auditor Fees

The fees in relation to the audit and related services for the years ended December 31, 2024, 2023 and 2022 provided by Emmerich, Córdova y Asociados S. Civil de R.L. and KPMG foreign members firm, the external auditor of the Group, were as follows:


	Year ended December 31,
In thousands of soles	2024		2023		2022
Audit services fees (i)		5,445		10,417		5,402
Tax services fees		387		119		—
Other non-audit fees		88		102		42

Total		5,920		10,638		5,444

(i)	As of December 31, 2023 Audit services fees include S/ 6,927 thousand (S/ 3,114 thousand as of December 31, 2022). In 2023 corresponds to costs related to public offering efforts which were included as costs of anticipated equity transactions in Other Assets (note 6).

The fees in relation to the statutory audit in Luxembourg and related services for the year ended December 31, 2024 provided by Atwell S.à r.l. the statutory auditor of the Group was S/ 665 thousand.

35.	Subsequent Events

Between January 1, 2025 and until the date of issuance of these financial statements (April 10, 2025), no additional events or events of importance have occurred that require adjustments or disclosures to the consolidated financial statements as of December 31, 2024, except for the following events:

On January 16, 2025, the Board of Directors approved to increase the share capital by S/ 2 thousand through capitalization from “Share Premium”. This amount corresponds to the shares from the Restricted Share Awards 2024 (note 33).

In January 2025, the Group modified its Call spreads to renegotiate them into one for a total of US$ 108,000 thousand in a new range from S/ 3.713 to S/ 4.20 per US$ 1.

F-1